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Melanocytes are pigment-producing cells that colour our hair, skin and eyes. 
Melanocytes are evolutionary conserved in vertebrates, and in addition to 
contributing to pigmentation and pattern formation, can contribute to background 
adaptation (zebrafish) and protection against harmful UV irradiation (humans). Many 
of the processes involved in melanocyte development – such as migration, 
proliferation and differentiation - are misregulated in melanoma.  Here, I use 
chemical biology in zebrafish to identify targetable pathways in melanocyte 
development and regeneration, with a view to how these processes may be 
misregulated in melanoma and other pigmentation syndromes.  
 
We first wanted to address the potential for small molecules to regulate multiple 
stages of melanocyte development and differentiation. In Chapter 3, I describe my 
work involved in a small molecule screen for clinically active compounds that alter 
melanocyte biology (Colanesi et al., 2012). In this work we have identified small-
molecules that affect melanocyte migration, differentiation, survival, morphology 
and number. This is important as it highlights new pathways essential for normal 
melanocyte development and consequently provides further tools in which to study 
melanocytes. 
 
Identifying the target of small molecules in vivo is a challenge in chemical biology. 
In Chapter 4, I describe my contributions to understanding how 5-nitrofuran 
compounds act in zebrafish (Zhou et al., 2012). My work has contributed to 
understanding the activity of 5-nitrofurans is dependent upon its nitrofuran ring 
structure. I have also helped confirm a conserved interaction between 5-nitrofurans 
and ALDH2, which may contribute to the off-target effects observed in the clinic. 
These results are important as they aid further understand of the 5-nitrofuran class of 
drugs and give evidence to support combination therapy of 5-nitrofurans with 
ALDH2 inhibitors as a way to overcome clinical side effects. Additionally I show 
that NFN1 treatment limits ensuing melanocyte regeneration thereby suggesting a 
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role at the Melanocyte Stem Cell (MSC), which provides me with a key tool to study 
melanocyte regeneration in zebrafish. 
 
How tissue specific cell numbers are specified and maintained is a key question in 
developmental biology. In Chapter 5, I describe the identification of the MITF gene 
in the maintenance of cell cycle arrest in differentiated melanocytes (Taylor et al., 
2011). We show that the human melanoma mutation MITF4T∆2B promotes melanocyte 
division, thereby suggesting a role for melanocyte division in the pathogenesis of 
melanoma. This work is valuable because it highlights Mitf as a molecular rheostat 
that controls melanocyte proliferation and differentiation in living vertebrates, and 
helps us to understand the role of MITF in melanoma progression. 
 
Little is known about the pathways that control melanocyte stem cells in animals. To 
identify new melanocyte stem cell pathways, I used NFN1 as the basis for a small 
molecule screen for enhancers of melanocyte regeneration (Chapter 6). I find that 
chemical inhibition of Phosphatase of Regenerating Liver-3 (Prl-3) in zebrafish can 
enhance melanocyte regeneration. Importantly, I have found that there are an 
increased number of melanocyte progenitor cells in PRL3-inhibitor treated zebrafish. 
I propose that PRL-3 may control progenitor cell number in melanocyte 
regeneration. This is significant because it identifies PRL-3 as a novel molecular 
target controlling melanocyte progenitor cells, and identifies a new chemical tool 
with which to study melanocyte differentiation from a progenitor population.  
 
In the final chapter, I discuss how this work relates to the larger field of melanocyte 
developmental biology, and the new insight it provides into the fundamental 
processes of how organisms control cell number and pattern formation. In addition, I 
discuss how this work may have implications for understanding and treating 
melanocyte diseases, such as vitiligo (loss of melanocytes) and melanoma (cancer of 
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Schematic of zebrafish melanocyte development. 
Neural crest cell migration pathways during early development. 
During mouse development melanocytes are derived from two distinct pathways 
Hypothetical model of signalling pathways essential in melanocyte development in the zebrafish embryo 
Gene expression and soluble signals associated with diversification of the zebrafish neural crest. 
Schematic showing changes in localization of Sox10+ and Mitf+ cells during early mouse development. 
Schwann cell precursors are a bipotent progenitor cell. 
Zebrafish pigmentation mutants. 
Zebrafish pigment cell and myelinating schwann cell development 
 
Melanocyte counts were restricted to a specific region on the head 
Melanocyte cell number is reduced following roscovitine treatment 
Melanocyte development in roscovitine treated embryos 
Cox inhibitors affect melanocyte morphology 
Tyrphostin AG1296 alters melanocyte movement in zebrafish embryos 
Flk-1 inhibitors affect normal melanocyte biology. 










































5-Nitrofurans Promote Melanocytotoxicity in Zebrafish 
Loss of differentiated melanocytes in NFN1 treated embryos 
 NFN1 melanocytotoxicity is independent of tyrosinase activity 
NFN1 treatment restricts a melanocyte progenitor population 
5-Nitrofurans bind Aldh2 in zebrafish 
Morpholino knockdown of aldh2b reduces 5-nitrofuran melanocytotoxicity 
Small molecule screen to identify suppressors of the NFN1 phenotype. 
Chemical inhibition of aldh2 rescues melanocytotoxicity in zebrafish 
A role for zebrafish aldh2 in melanocyte background adaptation 
 
Melanocyte counting 
Melanocytes develop from undifferentiated precursor cells and from pigmented melanocytes 
Tyrp1-GFP expression precedes melanocyte pigmentation 
Visualization of the differentiation marker tyrp1-GFP during cell division 
Melanocyte division events are enhanced during melanocyte regeneration 
Melanocyte division events are enhanced during melanocyte regeneration 
Time of earliest visible differentiation (pigmentation) to cell division is reduced in regeneration. 
Hypomorphic Mitf activity enhances differentiated cell division 












































A small molecule screen for enhancers of melanocyte regeneration 
PRL-3 inhibition enhances melanocyte regeneration in mitfavc7 mutants 
Prl-3 inhibition does not affect normal embryo development or final zebrafish pigment pattern 
Loss of erbb mediated MSC establishment in mitfavc7 embryos can be rescued by PRL-3 
PRL-3 rescues AG1478-mediated melanocyte loss on the lateral line 
PRL-3 rescues AG1478-mediated melanocyte loss of adult pigment pattern stripes 
DAPT induces a loss of MSC derived melanocytes that cannot be rescued by PRL-3 inhibition 
PRL-3 inhibition does not alter expression patterns of neural crest genes, sox10 and foxd3 
PRL-3 inhibition enhances expression of mitfa in possible unpigmented progenitor cells 
Mutant p53 enhances melanocyte regeneration following NFN1 mediated melanocyte ablation 
 
PRL-3 inhibition enhances melanocyte regeneration from an unpigmented precursor population 
Prl-3 expression along notch dependent midbrain-hindbrain boundary 
A theoretical role for Prl-3: regulation of Mitf levels by de-phosphorylation 
Prl-3 could be activated by p53 to promote cell cycle arrest 










































Example of conventional nomenclature for gene and protein 
Zebrafish melanocyte classes present (+) or absent (−) in selected pigment pattern mutants 
 
List of Zebrafish strains 
Morpholino knockdown of genes 
List of Small molecules 
Primers for p53 genotyping 
PCR reaction volumes 
In situ hybridisation probes 
 
Derivatives of 5-Nitrofurans and Their Activity in Zebrafish 
 
Chemical compounds identified to enhance melanocyte regeneration 




























































Bovine Serum Albumin 
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Cyclin dependent kinase 
complementary DNA 
Confidence Interval 
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Polymerase chain reaction 
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1.1.	  	  Melanocytes:	  normal	  function	  and	  disease	   	  
  
Melanocytes are a conserved cell type in vertebrates and are responsible for 
producing the dark brown-black pigment, eumelanin. The function of melanocytes 
varies from species to species and is a key example of how an evolutionarily 
conserved cell type has developed evolutionary divergent roles. In mouse, 
melanocytes pigment the fur and are responsible for coat colour. In zebrafish and 
other fish species, melanocytes retain their pigment and are capable of rapid 
expansion and contraction in response to light stimulus, allowing background 
adaptation (camouflage) (Gates and Zimmermann, 1953; Logan et al., 2006). In the 
relatively hairless human species, melanin dispersal from melanocytes to 
surrounding keratinocytes is responsible for differences in skin pigmentation. The 
dark brown-black pigment melanin is an efficient absorber of harmful UV 
irradiation, and can form cap-like structures on the keratinocyte nucleus to protect 
the cell from DNA damage (Byers et al., 2003). Indeed, DNA damage in surrounding 
keratinocytes is sufficient to activate TYROSINASE gene expression in melanocytes 
resulting in subsequent melanocyte differentiation and melanin production, known as 
the tanning response (Romero-Graillet et al., 1997).  
 
Melanocytes are derived from highly motile, multipotent neural crest cells (NCC), 
which de-laminate from the neural tube during tube closure and constitute many 
different cell lineages, including melanocytes, neurons, glia, bone and cartilage 
(Serbedzija et al., 1994; Serbedzija et al., 1990). Prior to melanocyte differentiation, 
neural crest cells first differentiate into immature melanoblasts, which are 
characterised by lack of pigmentation, Dct expression, high motility and extensive 
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proliferation. Further melanocyte differentiation reduces cell motility and 
proliferation, but initiates melanin production (Jordan and Jackson, 2000a; 
Mackenzie et al., 1997; Taylor et al., 2011). These key characteristics of melanocyte 
development contribute to the aggressive, highly metastatic and drug-resistant traits 
of the most fatal pigment disorder, melanoma (cancer of the melanocyte). 
Therapeutic strategies for the treatment of melanoma have so far focussed on 
targeting proliferative pathways, such as the Mitogen Activated Protein Kinase 
(MAPK) pathway.  BRAFV600E is a constitutively active mutant form of the protein 
BRAF, which causes hyperactivation of the MAPK pathway and hence extensive 
proliferation of melanocytes (Davies et al., 2002). It is the most common mutation in 
the formation of benign human moles (nevi), which is a key step in the mole-to-
melanoma model of melanoma progression, and is the most frequent mutation in 
melanoma (Davies et al., 2002; Tsao et al., 2012). This melanoma progression model 
dictates senescent nevi acquire co-operating mutations, such as CDKN2A, that 
together are sufficient to drive melanoma. A recent new clinically effective 
chemotherapeutic against melanoma, Vemurafenib, targets the constitutively active 
mutant form of BRAF, BRAFV600E. Vemurafenib is only effective in patients with this 
specific BRAFV600E mutation, however after an initial regression period, many 
melanomas develop drug resistance eventually leading to fatality (Bollag et al., 2012; 
Flaherty et al., 2012; Yang et al., 2010). Other studies are realizing the potential of 
targeting early melanocyte specification and differentiation pathways as possible 
new therapeutic targets. The Zon laboratory identified an enrichment of neural crest 
progenitor markers during early embryo development of a zebrafish transgenic 
melanoma model (see Section 1.3 for more details) (Patton et al., 2005; White et al., 
2011). They suggested this enrichment of neural crest gene expression during 
development is analogous to melanoma initiation, and propose melanoma cells in 
this model would adopt a neural crest-like fate. The authors then used chemical-
genetic small-molecule screening to identify a class of compounds (dihydroorotate 
dehydrogenases) that suppress the neural crest lineage. Finally the authors showed 
the dihydroorotate dehydrogenase, Leflunomide is effective against melanoma 
growth and can be used in combination therapy with the BRAFV600E inhibitor, 
PLX4720 (White et al., 2011). In conclusion, further understanding of melanocyte 
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developmental pathways could lead to development of new drugs that target 
melanocyte development, differentiation or proliferation. 
 
Much can be learnt about human melanocyte developmental pathways through study 
of known human pigmentation disorders. Waardenburg syndrome (WS) is a 
hypopigmentation disorder that is characterised by piebaldism (patchy loss of skin 
pigmentation) and deafness. It is an autosomal dominant disorder that is derived 
from mutations of the melanocyte developmental pathway. There are four classes of 
Waardenburg syndrome (WS1-4) that have distinct clinical phenotypes owing to 
mutation differences. WS2 patients is characterised only by the hypopigmentation 
phenotypes associated with all WS patients. WS2 is caused by mutations in MITF, a 
transcription factor specific to the melanocyte lineage, explaining the specificity of 
WS2 phenotypes (Tachibana et al., 1994). In addition to hypopigmentation, WS1 
patients are further characterised by craniofacial disorders, and WS3 patients by 
musculoskeletal abnormalities. These two classes can both be attributed to mutations 
in PAX3, which is an early neural crest specification factor and contributes to fate 
determination of melanocytes, cartilage and bones (Tassabehji et al., 1992; 
Tassabehji et al., 1993). Finally WS4 patients show all the characteristics of WS1 but 
with additional phenotypes of Hirschsprung’s disease, a deficiency of intestine 
neurons resulting from a failure of neural crest cells to migrate completely. WS4 
patients tend to have congenital mutations in SOX10 or either EDNRB or its ligand 
EDN3 (McCallion and Chakravarti, 2001; Pingault et al., 1998; Puffenberger et al., 
1994). WS4 patient phenotypes highlight the importance of these genes in promotion 
of neuronal lineages and neural crest cell migration. In conclusion, we seek to 
understand melanocyte biology to aid development of treatments to pigmentation 
disorders, but in addition, pigmentation disorder phenotypes can also teach us about 
melanocyte developmental pathways. Likewise, the ability to model these 
pigmentation phenotypes in animals allows for in-depth molecular study of 
melanocyte development, which is not possible in the human. Importantly, many 
zebrafish melanocyte development genes are orthologous to the human ones, and 
mutations in these zebrafish genes also result in abnormal pigmentation phenotypes, 
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1.2.	  Zebrafish	  as	  a	  model	  organism	  
 
The study of complex biological networks essential for development and disease is 
greatly aided by the use of model organisms. There are numerous popular animal 
models that each have their own specific advantage for use. For example, as a 
mammal, the mouse (Mus musculus) is closely related to the human in evolutionary 
terms, thereby findings in the mouse system are likely to be translatable to the human 
system. In other more distantly related species such as the fly (Drosophila 
melanogaster) or the worm (Caenorhabditis elegans), their advantage is in the 
simplicity of their systems, for example tractable genetics and in the case of the 
worm, a simple CNS. Likewise, the zebrafish (Danio rerio) model has its own 
distinct advantages. As a vertebrate system it is  more closely related to mammals 
and humans than invertebrate models, making findings in the zebrafish system more 
easily translatable. However, the zebrafish model is still amenable to genetic studies 
and its genome has been fully sequenced (http://www.sanger.ac.uk/Projects/D_rerio/ 
Zv9_assembly_information.shtml). The zebrafish is a relatively cost effective model 
organism and aquarium facilities can house tens of thousands of fish in a relatively 
small environment. Zebrafish young are externally fertilised and one breeding pair 
can lay up to a few hundred eggs in the space of a few hours, allowing for easy 
collection of embryos and a large number of biological replicates. Once fertilised, 
zebrafish embryos are fast developing with the majority of organs being developed 
by 48 hours post fertilisation (hpf) (Kimmel et al., 1995). Externally fertilised 
embryos are water-born and can be thus handled simply with 5 ml pastettes, and can 
be collected in petri dishes, they are also large enough to be visually observed down 
a dissecting microscope. 
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The zebrafish system is amenable to genetic modification. It is a relatively simple 
procedure to microinject a transgene into a 1-cell stage embryo, and owing to the 
large numbers of young, extensive founder lines can be quickly generated. For these 
reasons, a wealth of zebrafish transgenic lines are readily available, providing useful 
tools to explore gene expression in vivo. Developing zebrafish embryos are optically 
transparent, making them an ideal organism for the use of transgenic fluorescent 
reporter technology. This allows in vivo real-time labeling of expression patterns in 
the zebrafish embryo and variations in gene expression in response to chemical 
treatment, genetic modification, amputation and regeneration can amenably be 
studied. Furthermore the zebrafish has proved an ideal model for use in forward 
genetic screens, such as random N-ethyl-N-nitrosourea (ENU) mutagenesis screens, 
which enable identification of novel genes associated with a desired phenotype 
(Haffter et al., 1996).  Furthermore, ENU mutagenesis can be utilized in a reverse 
genetic approach by target-selection of mutagenised genes (Berghmans et al., 2005; 
Wienholds et al., 2002). However this approach does not allow for exact genetic 
manipulation. Whereas specific gene knockdown can be achieved by morpholino 
oligonucleotide technology (Gene Tools). Morpholino antisense oligonucleotides can 
be synthesized, and bind to complementary RNA sequences to temporarily down-
regulate expression of a specific gene (Dutton et al., 2001a). Morpholino 
oligonucleotides provide a fast and relatively cost-effective method to test gene 
function and phenotypes associated with gene loss; however the morpholino is only 
stable in the zebrafish embryo in the first few days of embryo development, meaning 
the extent of its use is limited. Therefore it has become apparent that zebrafish 
reverse genetic technology is lacking an approach that can induce precise targeted 
genetic mutations in an efficient and permanent manner. Recent advances have led 
initially to the development of zinc finger nuclease (ZFN) technology. ZFNs can 
induce targeted double strand breaks in DNA, which are then repaired to generate 
small insertions and deletions into the gene of interest. ZFN technology relies on a 
DNA recognition domain that consists of three or more zinc finger motifs, and a 
FokI nuclease cleavage domain (Doyon et al., 2008). However this technology has 
thus far proved to cause many off-target effects. Advances in DNA targeting led to 
the development of a straightforward DNA base recognition cipher known as 
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Transcription activator-like effector (TALE), this can be used to generate targeted 
double stranded breaks when fused with the FokI nuclease (TALEN) (Clark et al., 
2011). Following this, Bedell and colleagues used TALEN technology 
(GoldyTALEN) to introduce DNA double-stranded breaks, and then made use of 
homology directed repair machinery to introduce exogenous single stranded DNA 
oligonucleotides at a specific locus (Bedell et al., 2012). Consequently this is a 
significant new development in zebrafish reverse genetic technology. 
 
As aquatic organisms, zebrafish are a useful tool with which to study chemical 
biology. Small molecule screens in the zebrafish system have been successful at 
identifying new phenotypes, new biological pathways and new targets associated 
with a known drug. Zebrafish are small enough to be screened in a single well of a 
96-well plate if necessary, or up to five embryos can easily be screened in a single 
well of a 24 well plate. Soluble drugs are taken into the embryo by absorption and 
can be applied directly to the embryo medium allowing the exact treatment dose to 
be controlled. As mentioned previously zebrafish are easily visualised under a 
dissecting microscope allowing visualisation of drug phenotypes. These phenotypes 
will be the result of complex molecular interactions within an in vivo system; this can 
uncover possible new drug functions which are not necessarily apparent in more 
simple systems, such as cell lines or yeast (Saccharomyces cerevisiae). There is a 
remarkable degree of homology between zebrafish developmental pathways, genes 
and proteins compared to humans. Because of this, many FDA-approved drugs and 
known bioactive compounds are able to act on homologous zebrafish proteins to 
their human counterparts. Thus, drug discovery in the zebrafish is a useful way to 
modify signalling pathways, and has the advantage of temporal control unlike 
permanent genetic modifications. 
 
Zebrafish have three types of pigment cells: shiny iridophores, yellow xanthophores, 
and black melanophores, and together these constitute the embryonic and adult 
pigment pattern stripes. In mammals, melanin from melanocytes is transferred to 
surrounding keratinocytes to pigment the hair, skin and eyes, whereas zebrafish 
melanophores retain their pigment, allowing for rapid expansion or contraction of the 
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cellular pigment in response to the environment (background adaptation) (Bruder et 
al., 2012; Logan et al., 2006; Okazaki et al., 1976). Zebrafish melanocytes (except 
melanocytes in the retinal pigment epithelium) are derived from late-migrating 
neural crest cells (NCCs) delaminating from the neural tube, this is analogous to 
melanocyte development in mammals (Fuhrmann et al., 2000; Johnston et al., 1979; 
Serbedzija et al., 1994; Serbedzija et al., 1990). However mammals, unlike zebrafish, 
only have one type of pigment cell, the melanocyte. My thesis explores novel 
processes in zebrafish melanophore development with a view to providing useful 
insight into the genetics in normal melanocyte development and disease in humans, 
because of this I will hereafter refer to zebrafish melanophores as melanocytes. As in 
humans, much can be learnt by the study of zebrafish pigmentation mutants. The 
zebrafish species has a variety of naturally occurring pigmentation phenotypes such 
as the striped “AB” strain, the spotted “leopard” strain, and the lightly pigmented 
“golden” strain, and these diverse pigment phenotypes first attracted pigment 
researchers to this model (Figure 1.8). More recently, site-directed mutagenesis 
studies have produced new pigmentation mutants, which has identified zebrafish 
genes essential for normal melanocyte development in both early embryos and from 
a melanocyte stem cell (MSC) population (Budi et al., 2008; Dutton et al., 2001b; 
Lister et al., 1999; Parichy et al., 2000; Parichy et al., 1999). These zebrafish genes 
are orthologous to the mammalian melanocyte development genes, and further 
details of these pathways including their conserved and divergent functions will be 
addressed later in this section.  
 
Unlike mammals, zebrafish have an extensive capacity for regeneration and are 
capable of repairing many tissues after injury such as bone, heart, cartilage, 
notochord, brain, and even pigment cells (Becker et al., 1997; Brown et al., 2009; 
Poss et al., 2002; Rawls and Johnson, 2000). Much study has centred on the genetic 
differences in zebrafish and mammalian regeneration, and what makes the zebrafish 
a “pro-regenerative” environment. Partial amputation of tail fin stimulates 
regeneration of fin tissue including the pigment cells (Rawls and Johnson, 2000). It 
is believed that regeneration of melanocytes in zebrafish occurs from differentiation 
of an otherwise quiescent melanocyte stem cell population (MSC), however 
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definitive markers of this cell population are still lacking. In the laboratory zebrafish 
melanocyte regeneration can be induced following chemical ablation (MoTP and 
NFN1), physical ablation (amputation or laser ablation), or by genetic ablation 
(hypomorphic mitfavc7 model) (Johnson et al., 2011; Rawls and Johnson, 2000; Yang 
and Johnson, 2006; Yang et al., 2004). Key advances in zebrafish melanocyte 
regeneration have implicated erbb, kita and ednrb signalling as important factors in 
zebrafish regeneration, which are also implicated in the mammalian systems (this is 
covered in further details in sections 1.3 and 1.5) (Budi et al., 2008; Dutton et al., 
2001b; Hultman et al., 2009; Hultman and Johnson, 2010; Johnson et al., 2011; 
Parichy et al., 2000; Parichy et al., 1999). While some regenerative systems are 
known to rely on differentiated cell division, such as pancreatic β-cells and 
horizontal neurons in the retina (Ajioka et al., 2007; Brennand et al., 2007), no 
evidence has previously been described a significant role for differentiated cell 
division in melanocyte regeneration. The “pro-regenerative” zebrafish system may 
be a useful tool to study the contribution of differentiated melanocyte division in 
regeneration of the pigment pattern.  
 
Many human diseases have also been successfully modelled in the zebrafish system, 
including melanoma (cancer of the melanocyte). The Zon laboratory developed the 
first animal model for BRAFV600E activity in melanoma in zebrafish. Patton and 
colleagues generated a stable transgenic of the most common BRAF mutation 
(BRAFV600E) under the mitfa promoter, and showed this alone was sufficient to 
promote nevus formation (ten per cent of mitfa-BRAFV600E injected fish developed 
nevi) (Patton et al., 2005).  Previously Berghmans and colleagues identified the 
p53M214K mutation in exon 7 of the zebrafish p53 gene from an ENU mutagenised 
stock (a process called TILLING) and showed an orthologous methionine 
(methionine-246) to lysine nonsense mutation in humans which is commonly 
mutated in tumours. Zebrafish p53M214K homozygous mutants were shown to be 
deficient at a G1-checkpoint (mdm2 and p21 signalling), subsequently losing 
apoptotic response to γ–radiation (Berghmans et al., 2005). The authors noted 28% 
of p53M214K homozygous fish developed malignant peripheral nerve sheath tumours 
(Berghmans et al., 2005). Patton and colleagues reasoned that while p53 mutations in 
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human melanoma are relatively rare, the most common genetic mutation in 
melanoma is in CDKN2A, which is thought to have an indirect effect on the p53 
pathway. Therefore, they asked if mutant p53 is sufficient to drive melanoma in nevi 
with an activating BRAFV600E mutation, and remarkably out of the 9/66 of fish that 
developed nevi, almost half of these (n= 4/66) developed melanoma (confirmed by 
histological analyses and serial transplantation) (Patton et al., 2005). Hence Patton 
and colleagues showed that genetic modification of key melanoma target genes was 
sufficient to drive melanoma progression in the zebrafish. Following this, other 
groups have developed melanoma models driven by NRAS or HRAS mutations 
(Dovey et al., 2009; Michailidou et al., 2009; Santoriello et al., 2010). Additionally, 
in our lab a novel melanoma model has been identified that is driven by the two 
cooperating mutations: BRAFV600E and a hypomorphic mitfa mutation, mitfavc7 
(covered in more depth in Chapter 5), and this model has distinct pathophysiology to 
the previously described BRAFV600E; p53M214K melanoma model (E.Patton, A.Capper, 
Z.Zeng; Unpublished data). In conclusion, the zebrafish is a valuable model to study 
the genetic factors contributing to melanoma progression, and subsequent melanoma 
models can be used to further study the pathophysiology and different aetiologies of 
distinct melanoma tumour types. 
 
1.3.	  Ontogenetic	  development	  of	  melanocytes	  	   	  
 
1.3.1.	  Neural	  Crest	  Cell	  migration	  pathways	  in	  the	  mouse	  and	  zebrafish	  
	  
During vertebrate early development NCCs delaminate from the neural tube. These 
cells are highly migratory multipotent cells from which numerous vital cell types are 
derived, including neurons, glia, pigment cells, craniofacial cartiladge, and bone 
(Raible et al., 1992; Serbedzija et al., 1994; Serbedzija et al., 1990). In this section I 
will discuss the similarities and differences between early ontogenetic melanocyte 
development in both the zebrafish and mouse. All genes and proteins are noted in 
standard nomenclature as described in Table 1.1. Where general statements are being 
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made the mouse nomenclature will be used as standard. The signalling pathways that 
induce NCC specification and fate determination are remarkably similar within 
mouse and zebrafish: Wnt signalling promotes neural crest cell migration from the 
neural tube, has a role in specifiying NCC lineage, and WNT-3a has even been 
implicated in directly inducing melanocyte specification through activation of Mitf 
expression (Dorsky et al., 1998; Dorsky et al., 2000; Garcia-Castro et al., 2002; Jin et 
al., 2001; McKeown et al., 2005; Takeda et al., 2000). SOX10 and SOX9 signalling 
also specifies cells to a NCC fate, however Sox9 expression is temporary and limited 
to the pre-migratory neural crest, whereas SOX10 signalling persists following 
neural crest specification (Dutton et al., 2001b; McKeown et al., 2005). Interestingly, 
in the zebrafish Sox9b was postulated to have an additional transitory role in 
inducing expression of late melanocyte specification genes (Greenhill et al., 2011) 
(Figure 1.4). The specific cell lineage of migrating neural crest cells is temporally 
regulated: early-migrating NCCs migrate down the ventral pathway and give rise to 
neuronal lineages, such as sympathetic neurons, sensory neurons and Schwann cell 
precursors (SCPs) (Serbedzija et al., 1989). A recent finding in early mouse 
melanocyte development showed that ventral migrating NCCs that give rise to SCPs 
contribute to development of Schwann cells and melanocytes (Figure 1.3) 
(Adameyko et al., 2009; Adameyko et al., 2012).  During development SCPs migrate 
down axons and rely upon nerve activation to maintain an immature progenitor 
lineage, via Erbb3 activation by NRG1 signalling. Upon migration away from 
innervating nerves loss of Erbb3 activation of SCPs results in subsequent 
differentiation into a melanocyte lineage (Adameyko et al., 2009; Adameyko et al., 
2012). One theory suggests that SCPs proliferate and migrate down axons during 
early development competing for physical contact with nerves to allow NRG1 
activation and maintenance of a progenitor state (Ernfors, 2010). Following SCP 
proliferation, axon contact becomes limited and following loss of NRG1 signalling 
SCPs either undergo cell death or dissociate from nerves and adopt a melanocyte fate 
(Adameyko et al., 2009; Adameyko et al., 2012). These SCPs may also have a role as 
a source of MSCs that contribute to melanocyte regeneration. Late-migrating NCCs 
give rise to a melanocyte lineage, which in the mouse migrate down the dorso-lateral 
pathway between the dermamyotome and the epidermis (Figure 1.2, 1.3) (Serbedzija 
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et al., 1990). The zebrafish pigment pattern is derived from three distinct pigment 
cells, meaning pigment cell migration in the zebrafish needs to be differentially 
regulated. As such, iridoblasts migrate down the medial pathway, xanthoblasts down 
the lateral pathway, and melanoblasts down the ventral and lateral pathways (Figure 
1.2) (Jesuthasan, 1996; Kimmel et al., 1995; Raible and Eisen, 1994; Raible et al., 
1992). The zebrafish embryonic pigment pattern is mainly derived from direct-
developing neural crest cells (Hultman and Johnson, 2010; Jesuthasan, 1996; Raible 
and Eisen, 1994; Tryon et al., 2011) (Figure 1.1). Evidence suggests that like the 
mouse, SCPs exist in the zebrafish system and that these could be important 
melanocyte progenitor cells that contribute to adult pigment pattern stripe and 
melanocyte regeneration (Budi et al., 2011). However, if or what role these SCPs 





Figure 1.1 Schematic of zebrafish melanocyte development.  
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Figure 1.1 Schematic of zebrafish melanocyte development. (A) Zebrafish melanocytes are derived 
from two waves of development. Initially in the early embryo, late-migrating neural crest cells 
differentiate into melanoblasts (unpigmented melanocyte precursor), undergo clonal expansion and 
migrate to the skin where they further differentiate into melanocytes. During the same time period, 
some neural crest cells also  establish a  MSC pool, where they remain quiescent until called upon to 
differentiate into melanocytes. (i) In Chapter 3, I address novel molecular pathways involved in direct 
melanocyte development. (ii) In Chapter 5, I explore the process of cell cycle arrest in differentiated 
melanocytes. (iii) Finally, in Chapter 6, I use small-molecule screening to identify novel pathways 
which may have a role in regulation of a MSC population or in control of differentiation from a MSC 
population. (B) Early developing zebrafish melanocytes are derived from direct developing neural 
crest cells (grey box).  A subset of late-developing embryonic melanocytes and the adult pigment 
stripe pattern are derived from a MSC  population (yellow box). (C) A schematic  of a 5 dpf zebrafish 
embryo to show the contribution of direct-developing melanocytes (black) and ErbB-dependent late-
developing melanocytes (red/blue) to the final embryonic pigment pattern (Hultman and Johnson, 
2010). A distinct population of late-developing melanocytes also contribute to the head pigment 
pattern, however these are not dependent upon ErbB signalling, so may be either late-developing 
ontogenetic (direct developing neural crest cells) or perhaps another MSC-derived population that is 





1.3.2.	  The	  role	  of	  Pax3	  in	  early	  NCC	  specification	  
 
Specification of NCC fate is dependent upon expression of the gene, Pax3 (Figure 
1.5) (Epstein et al., 1991; Watanabe et al., 1998). In mouse and humans Pax3 is 
necessary to establish enteric neuron and melanocyte cell fates, emphasised by the 
hypopigment and megacolon phoenotypes characteristic of Waardenburg (WS1 and 
WS3) patients and mice mutant for Pax3 (Epstein et al., 1991; Tassabehji et al., 
1992). In mice, Pax3 promotes Mitf expression and thus initial melanoblast 
specification. PAX3 even plays a role in the adult MSCs, co-localising with 
melanocyte stem cell (MSC) marker DCT, signifying the role of Pax3 in maintaining 
an immature progenitor cell fate. However, in zebrafish the role of Pax3 in pigment 
cell development is mainly restricted to specification of a xanthophore lineage 
(Minchin and Hughes, 2008). Zebrafish pax3 morphants have dramatically reduced 
xanthophore development, but in contrast have enhanced melanocyte development 
(Minchin and Hughes, 2008). This suggests that in zebrafish melanocyte 
development it is likely that either Pax3 or perhaps xanthophores themselves 
negatively regulate melanocyte differentiation. Notably, loss of enteric neurons is 
observed in zebrafish pax3 morphants suggesting a conserved function of pax3 in the 





Species Gene symbol Protein symbol 
Homo sapiens SOX10 SOX10 
Mus musculus Sox10 SOX10 
Danio rerio sox10 Sox10 
 






Figure 1.2.  Neural crest cell migration pathways during early development. Early migrating 
neural crest cells in the mouse migrate down a ventral pathway and develop into neuronal and glial 
cell types, whereas late-migrating neural crest cells migrate down a dorso-lateral pathway and 
contribute to the melanocyte pigment pattern. In the zebrafish neurons/glia migrate down the ventral 
pathway, iridoblasts migrate down the medial pathway, xanthoblasts migrate down the lateral 
pathway, and melanoblasts migrate down both the ventral and lateral pathways. Abbreviations: nt, 








During mouse development melanocytes are derived from two distinct pathways. (A) 
Late-migrating neural crest cells migrate down the dorsal-lateral pathway differentiate directly into 
melanoblasts, the precursors of melanocytes. Melanoblasts rapidly expand within the dermis. (B) 
NCC derived neurons and glia migrate down the ventral pathway. SCPs become nerve associated to 
maintain an immature progenitor state. Following migration away from the nerve, SCPs develop into 
melanoblasts, which proliferate and contribute to melanocyte numbers. Abbreviations: NCCs, Neural 
crest cells; MB, melanoblasts; SCP, Schwann cell precursor. Figure used with permission from 
Ernfors (2010). 
22 
1.3.3.	  Mitf:	  The	  master	  melanocyte	  specification	  factor	  
 
The key melanocyte cell fate determinant in vertebrates is the basic helix-loop-helix 
transcription factor, Microphthalmia-associated transcription factor (MITF) 
(Steingrimsson et al., 1994). MITF is known as the master melanocyte specification 
factor, and expression of MITF is thought promote a melanocyte/melanoblast fate 
(Figure 1.5) (Dutton et al., 2001b; Elworthy et al., 2003; Lister et al., 1999). MITF 
directly activates expression of pigmentation genes essential in late-stage melanocyte 
specification, including Dopachrome tautomerase (Dct), Tyrosinase (Tyr), and 
Tyrosinase-related protein-1 (Tyrp1), and also induces expression of melanocyte 
survival genes (Kit and Bcl2) (Bentley et al., 1994; Bertolotto et al., 1996; Bertolotto 
et al., 1998; Lister et al., 1999; McGill et al., 2002; Steingrimsson et al., 2004; 
Yasumoto et al., 1997). Of note, DCT is also a key marker of MSCs in the mouse 
hair follicle, however in the zebrafish system Dct only has an established role in 
melanocyte pigmentation and no such link to a MSC population has been described 
(Nishimura et al., 2002). 
 
Work by Greenhill and colleagures proposed Mitfa activation of expression in the 
zebrafish may induce further mitfa expression, thereby establishing a postitive 
feedback loop. Although, a threshold level of mitfa expression would initially be 
necessary to establish this feedback loop (Greenhill et al., 2011) (Figure 1.4). This 
group also proposed a role of Mitfa in promotion of Histone deacetylase (Hdac) 
mediated Sox10 repression in the zebafish. This suggests in zebrafish development, 
numbers of sox10+ mitfa+ co-expressing cells would decline over time (Greenhill et 
al., 2011) (Figure 1.4). These results are contradictory to the relationship between 
Sox10 and Mitf in mice, in which Sox10 expression is known to persist in Mitf 
expressing cells and is critical for expression of Tyr (Hou et al., 2006; Murisier et al., 
2007). Therefore, this is an example in which the role of Sox10 in zebrafish has 
diverged slightly from that of mammals, and what function this has is unknown 
although it may have a role to play in the establishment of a melanocyte fate over 




Figure 1.4.  Hypothetical model of signalling pathways that are essential for melanocyte 
development in the zebrafish embryo. Mitfa is known to induce expression of key genes in 
melanocyte development such as Dct, Tyrp1, Tyrosinase and Silva. Another role for Mitfa in the 
zebrafish is thought to be repression of Sox10 expression through activity of Hdac1 (purple). Mitfa 
possibly has a role in maintaining its own expression once a threshold level has been reached (blue). 
Finally Sox9b could have a transient role in activation of key melanocyte specification genes 
downstream of Mitfa (red). Factor A are the NCC specification factors such as Pax3, Foxd3, Wnt, 












Figure 1.5. Gene expression and soluble signals associated with diversification of the zebrafish neural 
crest. (A) Illustration of hierarchical relationship of neural crest derived cells and genes whose expression 
(+ sign) or loss of expression (− sign) are required for specification into indicated cell types. Soluble signals 
NRG1 and IGF and their role during glia and melanocyte lineage commitment are also indicated. Figure 
used with permission from Ernfors, (2010). (B) Illustration of hierarchical relationship of neural crest 
derived cells in zebrafish, including pigment cell development. As above, gain of gene expression (+ sign) 
or loss of expression (− sign) are required for specification into indicated cell types. Soluble signals NRG1 
and IGF and their role during glia and melanocyte lineage commitment are also indicated. Abbreviations: 
NCC, neural crest cells; N/G/M, neuronal, glia and melanoblast progenitor; N, neuronal committed cell; 
G/M, glia and melanoblast progenitor; G, glial cells; MB, melanoblasts; M, melanocytes; MB/IB, 
melanoblast and iridoblast progenitor; I, iridophores; XB, xanthoblast; X, xanthophore. 
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1.3.4.	  	  Foxd3	  expression	  represses	  a	  melanocyte	  lineage	  
 
The forkhead transcription factor, FOXD3 regulates NCC fate decisions by 
promoting a neuronal/glial cell fate at the expense of a melanocyte fate (Figure 1.5) 
(Thomas and Erickson, 2009). It has been demonstrated in vertebrate models that 
Foxd3 and Mitf expression are mostly mututally exclusive during early melanocyte 
development, and that Foxd3 expression is sufficient to repress Mitf expression 
(Curran et al., 2009; Thomas and Erickson, 2009). In chick, FOXD3 was proposed to 
repress MITF expression indirectly through repression of PAX3 binding to the MITF 
promoter, and repression of subsequent MITF gene expression (Thomas and 
Erickson, 2009). However, in zebrafish, Curran and colleagues suggest that Foxd3 
may be able to suppress Mitfa by direct binding at the Mitfa promoter (Curran et al., 
2009). The role of Foxd3 in zebrafish can be deciphered by the study of foxd3 
mutants/morphant phenotypes. Loss of foxd3 expression results in reduced numbers 
of iridophores, loss of dorsal root ganglions, loss of enteric neurons, loss of glial 
cells and loss of jaw cartilage (Lister et al., 2006; Stewart et al., 2006). Interestingly, 
loss of mitfa expression also enhances supernumerary iridophores, supporting the 
theory that under normal conditions Foxd3 may act to repress Mitfa and thus 
promote an iridophore fate (Curran et al., 2010). Corroborating this theory foxd3; 
mitfa double mutants can rescue the loss of iridphores associated with the foxd3 
mutants (Curran et al., 2010). A possible explanation is that Foxd3 does not have an 
early role in specification of iridoblasts or melanoblasts, but acquires a new function 
later during initial pigment cell development (~20 hpf) to repress mitfa expression in 
a bipotent melanoblast/iridoblast precursor, and hence promote an iridophore cell 
fate. 
 
Finally mitfa expression in pigment cell precursors was believed to strictly define a 
melanoblast/melanocyte lineage. However Curran and colleagues recently identified 
the iridoblast marker, pnp4a and have shown this to be co-expressed with mitfa, 
leading them to believe they had identified a bipotent iridophore/melanocyte 
precursor. They then went on to show by direct lineage tracing that a substantial 
fraction of mitfa-positive cells were able to subsequently differentiate into 
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iridophores (Curran et al., 2010). Intriguingly, this group also showed Mitfa+ Pnp4a+ 
bipotent progenitors co-localised with Pax3 (determined by antibody staining), which 
had never previously been associated with zebrafish melanocyte progenitors (Curran 
et al., 2010).  This indicates a degree of plasticity still remains in developing pigment 
cells, even after the onset of mitfa expression, and suggests that zebrafish could be a 
useful model with which to study the extent of melanocyte progenitor plasticity in 
vivo. 
 
1.4.	  Schwann	  cell	  precursors	  are	  bipotent	  melanocyte	  precursor	  
 
In mammals, neural crest cells delaminate from the neuroepithelium and can give 
rise to a diverse lineage of cell types, including neurons, glia, melanocytes, bone and 
smooth muscle (Serbedzija et al., 1994; Serbedzija et al., 1990). MITF specifies 
SOX10-positive neural crest cells to the melanocyte lineage and subsequent 
expression of Dct denotes a melanoblast population (unpigmented progenitors of 
melanocytes). These melanoblasts are highly migratory cells that rapidly expand in 
the dermis, then migrate and localise to hair follicles throughout the epidermis of 
mammalian skin (Jordan and Jackson, 2000b; Mackenzie et al., 1997). A subset of 
these localised melanoblasts directly differentiate into melanocytes and contribute to 
an initial phase of melanogenesis. The remaining unpigmented melanoblasts 
populate the lower permanent portion (LPP) of the hair follicle where they constitute 
a MSC pool that can be called upon during subsequent cycles of hair growth and 
pigmentation (Nishimura et al., 2002). Thus the mammalian hair follicle acts like a 
“mini-organ” cycling through stages of growth (stem cell proliferation and 
differentiation) and regression (apoptosis). Additionally pigmentation of the hair 
shaft is strictly linked to hair follicle cycle, meaning mammalian MSCs continuously 
cycle through rounds of proliferation, and differentiation into mature melanocytes 
(Nishimura et al., 2002). As a result mammalian MSC biology has proven to be a 
useful model with which to study stem cell biology, namely the processes involved 
in stem cell maintenance and differentiation. Due to a constant demand for MSC 
renewal in the growing hair, it is not surprising that the main source of MSCs in 
mouse and humans is the hair follicle. In humans, re-pigmentation in the clinic, 
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following UV therapy of depigmentation disorders such as vitiligo, results in 
pigmentation that is initially localised to hair follicles before enlargement across the 
region of depigmentation (Cui et al., 1991; Nishimura, 2011). Therefore, further 
investigation of the molecular cues essential for MSC propagation and differentiation 
in the mouse hair follicles could help the understanding of human pigmentation 
disorders. 
 
During ontogenetic development of mouse melanocytes (E10) direct developing 
melanoblasts at the midbrain-hindbrain boundary develop independently of Erbb 
signalling, but require functional Ednrb signalling for melanoblast expansion 
(Adameyko et al., 2012). In contrast, melanoblasts at cranial nerve IX-X develop in 
an ERBB-dependent process, and EDNRB is required for both expansion and 
migration of these cells. The cranial nerve IX-X melanoblasts are closely associated 
with nerves and represent a bipotent Schwann Cell Precursor (SCP) that can give rise 
to both Schwann cell and melanocyte lineages (Adameyko et al., 2012). Survival and 
proliferation of SCPs is dependent upon Neuregulin-1, and the molecular switch 
between Schwann cell and melanocyte lineages depends upon a balance of Sox2 and 
Mitf signalling (Adameyko et al., 2009; Adameyko et al., 2012) (Figure 1.6). Mitf 
signalling represses Sox2 expression and drives melanocyte differentiation, whereas 
high Sox2 expression represses Mitf and drives late SCP development, which can 
then differentiate into mature Schwann cells (Adameyko et al., 2012) (Figure 1.7). 
Activation of the ERBB3 receptor by nerve-associated NRG1 maintains an immature 
SCP state. Following rapid expansion of SCPs during development these cells need 
to compete for membrane-bound NRG1. Invariably some SCPs lose nerve 
association and hence differentiate into the “default” melanocyte fate (Adameyko et 
al., 2009; Adameyko et al., 2012). Figure 1.3 shows how these SCP derived 
melanocytes could contribute to the pigment pattern clonally, suggesting 
hypopigmentation disorders that characteristically manifest in patches could be due 
to a loss of these SCP derived melanocytes. Interestingly, mature Schwann cells are 
able to differentiate into mature melanocytes following denervation (Adameyko et 
al., 2009). This example of transdifferentiation between Schwann cell and 
melanocyte fate indicates a degree of plasticity exists between these two cell types, 
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and study of this may have profound effects on understanding stem cell biology. It 
must be noted that the above cited work bases most of its interpretations upon the 
presumption that all MITF+ cells observed in early mouse and chick development 
represent a melanocyte lineage. However MITF is also known to be present in other 
cells types, such as the heart cells, osteoclasts and mast cells (Tshori et al., 2006; 
Tshori et al., 2007; Weilbaecher et al., 1998). Therefore while DCT+ and KIT+ cells 
have been shown in nerve cells, it would be prudent for the authors to corroborate the 
results regarding SCPs as a potential melanocyte precursor with other melanocyte 
specific markers (DCT/ KIT/ TYR/ TYRP-1) (Adameyko et al., 2012). Additionally 
care should be taken when interpreting the data showing excess melanocyte numbers 
following loss of SCP nerve contact  by microsurgery of axons. Melanocytes have 
been documented to migrate to areas of wounding (Levesque et al., 2013). Thus the 
excess melanocyte numbers following loss of SCP nerve contact  could merely be 
due to melanocytes responding to wounding following microsurgery. Although it is 
compelling that many of these melanocytes were shown to be from a KROX20+ 
lineage (SCP marker) (Adameyko et al., 2009). The aforementioned studies suggest a 
population of neural crest derived melanocytes could be derived from a nerve-
associated precursor during early development of both mouse and chick. However, 





Figure 1.6 Schematic showing changes in localization of SOX10+ and MITF+ cells during early 
mouse development. Blue, Sox10+ cells; green, neurofilament staining; red, Mitf+ cells. Figure used 









Figure 1.7. Schwann cell precursors are bipotent progenitor cells. Illustration depicting gene 
expression and relevant negative feedback mechanisms that result in Schwann cell precursor 
differentiation to melanocyte or myelinating Schwann cell fates. Expression levels are stated 
(High/Low) Abbreviations: SCP, Schwann cell precursor; SC, Schwann cell. Figure used with 
permission from Ademeyko et al., (2012). 
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1.5.	  Zebrafish	  MSC	  biology	   	  
 
Much can be learnt about zebrafish pigmentation genetics through the study of the 
adult pigment stripe pattern. Zebrafish pigmentation stripes are derived from 
differentiation of melanocyte precursors during metamorphosis (Budi et al., 2008) 
(Figure 1.1). Orthologues of known pigmentation genes (e.g. mitfa, kita, ednrb1, 
erbb3b) also play a key role in zebrafish adult stripe development (Figure 1.8) (Budi 
et al., 2008; Dutton et al., 2001b; Lister et al., 1999; Parichy et al., 2000; Parichy et 
al., 1999). These mutants provide useful tools in which to study how these genes 
contribute to the zebrafish melanocyte pattern. For example differences in temporal 
activity of melanocyte stripe development at metamorphosis, or perhaps synergistic 
effects in double mutants can be studied. Melanocyte development is absolutely 
dependent upon Mitf activity, as such mitfa mutant zebrafish, “nacre”, are devoid of 
all body melanocytes, a phenotype comparable to that seen in mouse (Lister et al., 
1999; Silvers, 1956; Steingrimsson et al., 1994). Zebrafish with mutations in the 
tyrosine kinase receptor, kita (sparse) develop embryonic melanocytes but these are 
unable to migrate to their final position in the embryonic pigment pattern, and 
undergo apoptosis (Budi et al., 2011; Cooper et al., 2009). Thus, in zebrafish, kita is 
essential for melanocyte survival and migration, and zebrafish kita mutants resemble 
mouse Kit mutants, which have a white belly spot and increased melanoblast cell 
death. Furthermore, mutations in KIT in humans result in the hypopigmentation 
disorder piebald syndrome (Chabot et al., 1988; Geissler et al., 1988; Jordan and 
Jackson, 2000b; Nocka et al., 1990; Spritz et al., 1992). In contrast to the embryonic 
phenotype, adult sparse mutants have normal stripe pattern; however adult stripes 
appear to be lighter than in wildtype fish (Figure 1.8) (Johnson et al., 1995; Parichy 
et al., 1999). Additionally, melanocyte regeneration following tail amputation was 
delayed in kita mutants and likewise so was melanocyte stripe metamorphosis 
(Johnson et al., 1995; Rawls and Johnson, 2000; Rawls and Johnson, 2001). It has 
therefore been proposed that kita is essential for development of an early 
differentiating population of MSCs (Table 1.2). Following initial delay of MSC 
differentiation normal pigment pattern was established, prompting the possibility of a 
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late differentiating population of MSCs that is kita independent and is able to 
contribute to the adult pigment pattern. 
  
Some zebrafish pigmentation mutants were observed to have normal embryonic 
pigment pattern development, but abnormal adult stripe pattern (picasso, rose, puma) 
(Budi et al., 2008; Parichy et al., 2000; Parichy and Turner, 2003b; Parichy et al., 
2003).  These mutants highlight genes necessary in development of melanocytes 
from a MSC pool, but not necessary in development of neural crest cell derived 
melanocytes (Figure 1.8). Zebrafish picasso mutants have a mutation in the erbb3b 
gene encoding a member of the epidermal growth factor receptor family (Budi et al., 
2008; Lyons et al., 2005). They are missing melanocytes from the adult stripe pattern 
in a characteristic patch around the dorsal flank of the fish. This patch of 
pigmentation loss suggests erbb3b is responsible for development of a MSC pool 
specific to maintenance of this region. Further studies in these mutants and following 
chemical inhibition of erbb signalling demonstrate an impaired melanocyte 
regeneration phenotype (Budi et al., 2008; Hultman et al., 2009; Hultman and 
Johnson, 2010; Johnson et al., 2011), confirming the role of erbb signalling in 




Figure 1.8. Zebrafish pigmentation mutants. Wildtype (WT) zebrafish have characteristic pigment 
stripes consisting of dark melanocyte pigment stripes interspaced with yellow xanthophore stripes. 
Shiny iridophores occur throughout the pigment pattern. The naturally occurring pigmentation mutant, 
leopard has a spotted adult melanocyte pattern as apposed to the characteristic zebrafish stripes. A 
mutation in mitfa in the nacre transgenic results in loss of all body melanocytes. Other zebrafish 
mutants result in loss of a MSC derived melanocyte population; these are listed here with the gene 
mutated followed by the name of the mutant in brackets: kita (sparse), ednrb1 (rose), erbb (picasso), 
tuba8l3a (puma). Figure compiled from several published figures (Kelsh et al., 2009; Parichy and 














           (Rawls et al., 2001) 
 













sparse (kita) − − + − + 
rose (ednrb1) + + − + N/A 
nacre (mitf) − − − − − 
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Another pigmentation mutant with an abnormal adult pigment stripe pattern (but a 
normal embryonic pigment pattern) is the rose mutant (ednrb1) (Parichy et al., 
2000). Ednrb1 (Endothelin receptor type B) is a G-protein coupled receptor 
important in melanoblast proliferation and migration, and survival (Adameyko et al., 
2012; Budi et al., 2011). In human disease, EDNRB1 mutations result in 
hypopigmentation disorders and loss of enteric neurons (aganglionic megacolon), 
manifest as Waardenburg syndrome and Hirschsprung’s disease (McCallion and 
Chakravarti, 2001; Puffenberger et al., 1994). In the zebrafish rose mutants 
embryonic pigment pattern is normal, which implies ednrb1 does not have a role in 
direct development of melanocytes from neural crest cells. However zebrafish rose 
mutants are missing melanocytes in their adult pigment stripe pattern, suggesting 
ednrb1 is necessary for the development of a MSC pool (Johnson et al., 1995; 
Parichy et al., 2000). In the rose adult stripe pattern, pigment cell loss has a different 
morphology to that observed in picasso mutants; this could indicate that ednrb1 and 
erbb3b are essential for establishing either distinct MSC pools, or have different 
contributions to establishment of the same MSC pool (Figure 1.8) (Budi et al., 2008; 
Johnson et al., 1995; Parichy et al., 2000). Temporal analysis of adult pigment 
pattern development in rose mutants, identified melanocyte loss occurring 
specifically during late-pigment pattern stripe development, whereas early pattern 
development was normal (Johnson et al., 1995). This is contrasting to sparse mutants 
in which late melanocyte stripe development is deficient, but early melanocyte stripe 
development is intact. Subsequently the authors asked if kita and ednrb1 mediate 
different populations of MSCs in the zebrafish, and if this can account for the 
temporal differences observed. To answer this question kita; ednrb1 double mutants 
were assessed and remarkably a complete loss of melanocyte pigment pattern in the 
adult trunk was observed (Johnson et al., 1995). This additive phenotype observed in 
the double mutants indicates that kita and ednrb1 could regulate different 
populations of MSCs in the fish.  
 
Recent evidence by Budi and colleagues identified a novel population of MSCs 
located extra-hypodermally in the myotome of adult zebrafish, and showed these to 
be erbb dependent (Budi et al., 2011). Mis-expression of kitla (kit ligand) results in 
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ectopic melanocytes within the myotome verifying the existence of a melanocyte 
progenitor in this vicinity. Following this, immunohistochemical analyses revealed 
unpigmented low mitfa expressing cells localised throughout the myotome. These 
cells were shown to be nerve-associated and numbers of these progenitors were 
dramatically reduced/missing in erbb3b− and tubulin alpha 8-like 3a (tuba8l3a) 
mutants (Budi et al., 2011). The zebrafish tuba8l3a mutant (puma) has an abnormal 
pigment stripe pattern, and tuba8l3a is implicated in regulation of expansion of a 
progenitor population, or specification of these progenitors to a melanocyte fate  
(Figure 1.8) (Larson et al., 2010; Parichy and Turner, 2003b; Parichy et al., 2003). 
Further analysis of the origin, differentiation and morphogenesis of genetic 
pigmentation mutants allowed Budi and colleagues to propose a novel model of 
melanocyte development from nerve associated bipotent/multipotent progenitors 
(Figure 1.9; as reviewed by (Kelsh and Barsh, 2011) (Budi et al., 2011). This model 
proposes erbb3b and tuba8l3a signaling are required to establish a nerve-associated 
Glial-Pigment progenitor (mGP) within the myotome. These Glial-Pigment 
progenitor cells have the capacity to give rise to myelinating Schwann cells, or to a 
mitfa+ bipotent pigment progenitor cell localised within the myotome. Bipotent 
pigment progenitors then migrate to the hypodermis, proliferate in an ednrb1 
dependent manner, and have the capacity to give rise to a melanocyte or an 
iridophore lineage (Budi et al., 2011). Further, melanocyte differentiation is thought 
to be dependent upon kita signalling (Budi et al., 2011), and previous studies have 
suggested iridophore development could be dependent upon latent foxd3 and ltk 
expression (Curran et al., 2010; Lopes et al., 2008). Consequently, this noteworthy 
study provided novel evidence of nerve-associated melanocyte progenitors that are 
dependent upon erbb3b and tuba8l3a signaling for development (Budi et al., 2011). 
However it is important to note that this study was reliant on the accuracy of a mitfa-
GFP transgenic reporter line and should be verified in another manner before 
definitive conclusions can be drawn from this evidence. Additionally 
immunohistochemistry data that suggests that pigment cell precursors are associated 
with peripheral nerves and ganglia are only as accurate as the resolution of the 
image. It could be entirely possible that these Mitfa+ cells along the peripheral nerve 
are merely located close to the nerve, but not directly associated with the nerve. 
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Higher resolution imaging would need to be used to determine this. Moreover 
authors suggest that identified pigment cell precursors associated with peripheral 
nerves potentially represent a niche for precursors to adult melanocytes; however 
another interpretation could be that melanocyte precursors are in the process of 
migrating along peripheral nerves from their presumed niche to the skin, especially 
as Budi and colleagues only analysed zebrafish larvae actively undergoing pigment 
cell metamorphosis (Budi et al., 2011). It must also be noted that in this paper they 
provide evidence of a hypodermal melanocyte precursor niche only during 
metamorphosis, and this may not bear relevance to my data in the embryo prior to 
metamorphosis. Another interpretation of this data could be that in absence of 
erbb3b, migration of melanocyte precursors along nerves may be affected or be sub-
optimal, and therefore subsequent melanocyte development or establishment of a 
MSC pool may likewise be affected. Nonetheless, significant parallels can be drawn 
between zebrafish glial-pigment progenitors and the Schwann cell precursor cells 
observed in mouse and chick models (Adameyko et al., 2009; Adameyko et al., 
2012; Budi et al., 2011), thus these nerve associated melanocyte progenitors could be 
an evolutionarily-conserved cell type throughout vertebrates, or perhaps nerve cells 
are essential for allowing migration of melanocyte precursors and subsequent 








Figure 1.9. Zebrafish pigment cell and myelinating Schwann cell development. Embryonic 
pigment cells and Schwann cells originate directly from neural crest cells. A Glial-Pigment Progenitor 
cell is established by erbb3b signalling (described as mGP in Budi et al., 2011), this mGP persists into 
adulthood and  is responsible for development of adult pigment pattern and the regenerative capacity 
of pigment cells and glia in the adult. The mGP is thought to be similar to SCPs in the mouse and 
exist outside the skin (extra-hypodermal) likely associated with peripheral nerves or ganglia. Under 
the right conditions this mGP can differentiate into myelinating Schwann cells, or can migrate away 
from nervous contact into the skin (hypodermal) and give rise to iridophores (Irid.) and melanocytes 
(Melan.). Adult xanthophores (Xanth.) are derived from a different lineage. Figure used with 
permission from Kelsh and Barsh (2011). 
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1.6.	  Summary	   	   	  
 
In conclusion, zebrafish are a unique tool to further explore melanocyte 
development. The zebrafish model provides a number of advantages: it is an in vivo 
model allowing complex molecular interactions to be taken into account, it has 
tractable genetics, and is an ideal tool to study chemical biology. As a vertebrate 
model the mechanisms and genetics involved in zebrafish melanocyte development 
are remarkably similar to mouse and humans: homologous pathways have been 
implicated in both neural crest cell differentiation and MSC biology. Due to the large 
degree of homology between zebrafish melanocyte development and that of other 
vertebrates, I believe my results could have an impact into understanding 
mechanisms of human melanocyte biology and pigmentation disorders. In this thesis 
I explore chemical tools that affect pigment cell biology, differentiated melanocyte 
survival, and melanocyte regeneration pathways (Chapters 3, 4 and 6). I present a 
novel role for zebrafish mitfa in regulation of a terminally differentiated melanocyte 
state, and show how this is relevant to understanding the aetiology of some human 
melanomas (Chapter 5). Finally, I identify a novel role for the phosphatase, Prl-3 in 
regulation of a melanocyte progenitor population (Chapter 6). I show inhibition of 
this phosphatase under challenged conditions is sufficient to enhance melanocyte 
regeneration, and that this could occur through expansion of an unpigmented mitfa–












Chapter	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Materials	  and	  Methods	  	  
 
2.1	  List	  of	  Reagents	  	  
N.B Reagents are organised in alphabetical order 
 
Bleaching Solution 
Sodium hypochlorite (Sigma-Aldrich, UK)   180 μl 
Millipore H20       500 ml 
 
Blocking Solution 
1% Commercial Blocking Reagent (Roche, Germany) 1 g 
MABT        100 ml 
 
Blue Staining Solution 
100 mg/ml NBT (Roche, Germany)    22.5 μl 
50 mg/ml BCIP (Roche, Germany)    35 μl 
NBT/BCIP buffer      10 ml 
 
Distilled Water (dH2O) 
Sterile autoclaved water (MRC HGU technical services) 
 
DNA Extraction Buffer 
10 mM Tris pH 8.2 (Sigma-Aldrich, UK) 
10 mM EDTA (MRC HGU technical services) 
200 mM NaCl (MRC HGU technical services) 
0.5% SDS (Sigma-Aldrich, UK) 
10 μg/ml RNase A (Qiagen) 
200 μg/ml Proteinase K (Roche, Germany) 







60 x Embryo Medium (E3)  
NaCl (Sigma-Aldrich, UK)     17.2 g   
MgSO4.7H2O (Sigma-Aldrich, UK)    4.9 g  
CaCl2.2H2O (Sigma-Aldrich, UK)    2.9 g  
KCl (Sigma-Aldrich, UK)     0.76 g  
in dH2O up to 1 L 
 
1 x Embryo Medium (E3)  
60 x Embryo Medium (E3)      100 ml 
in dH2O up to 6 L 
2-4 drops of methylene blue  
 
Ethanol-Sodium Acetate Solution (EtOH-NaAc) 
100% Ethanol       13.5 ml 
3 M Sodium Acetate pH 5.2 (Sigma-Aldrich, UK)  750 μl 
dH2O        750 μl 
 
Hybridisation Mixture + (Hyb+) 
Formamide       25 ml 
20x SSC       12.5 ml 
Heparine 5mg/ml (Sigma-Aldrich, UK)   0.5 ml 
tRNA 50mg/ml (Sigma-Aldrich, UK)   0.5 ml  
20% Tween® 20 (Promega)     0.25 ml 
1 M Citric Acid (BDH, VWR International)   0.46 ml 
dH2O        10.7 ml 





Hybridisation Mixture - (Hyb-) 
Formamide       25 ml 
20x SSC       12.5 ml 
20% Tween® 20 (Promega)     0.25 ml 
1 M Citric Acid (BDH, VWR International)   0.46 ml 
dH2O        11.7 ml 
NB. Samples were aliquoted before storing at -20°C 
 
MAB 5x 
500 mM Maleic Acid 
450 mM NaCl 
in dH2O, adjust pH to 5.5 and autoclave 
 
MABT 
Dilute 5x MAB with dH2O 
Add 0.1% (v/v) Tween® 20 (Promega) 
NB. Keep for 1-2 days before discarding 
 
NBT/BCIP Buffer 
1 M Tris HCl pH 9.5      5 ml 
5 M MgCl2 (MRC HGU technical services)   2.5 ml 
5 M NaCl (MRC HGU technical services)   1 ml 
20% Tween® 20      250 μl 
in dH2O 
 
4% Paraformaldehyde (PFA) 
16% PFA (Electron Microscopy Sciences, USA)  10 ml 




PBS - Supplied by MRC HGU technical services  
2.7 mM KCl 
137 mM NaCl (MRC HGU technical services) 
in dH2O, and then autoclaved 
 
PBT - Supplied by MRC HGU technical services  
0.1% (v/v) Tween® 20 (Promega) 
in PBS 
NB. Keep for 1-2 days before discarding 
 
20x SSC 
3M NaCl (MRC HGU technical services) 
300 mM Sodium Citrate 
in dH2O (MRC HGU technical services) 
Adjust to pH 7.0 with drops 1M HCl and autoclaved 
NB. Samples were aliquoted before storing at -20°C 
 
2x SSC 
20x SSC       100 ml 
dH2O (MRC HGU technical services)   900 ml 
 
0.2x SSC 
20x SSC       10 ml 
dH2O (MRC HGU technical services)   990 ml 
 
10x TBE stock 
Tris base (Sigma-Aldrich, UK)    108 g 
Boric acid        55 g 
EDTA pH8 (MRC HGU technical services)   40 ml 
in dH2O up to 1 L 
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Tricaine (ethyl-3 aminobenzoate methane sulfonic acid) solution (40%) 
Tricaine  (Sigma-Aldrich, UK)     400 mg 
1M Tris pH 9 (MRC HGU technical services)  2.1 ml  
dH2O        97.9 ml 
Adjust to pH 7.0 
 
20% Tween® 20 
Tween® 20 (Promega)      20 ml 
in dH2O       80 ml 
NB. Store at room temperature and keep out of light 
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2.2	  Zebrafish	  Techniques	  
 
2.2.1	  Zebrafish	  husbandry	  
 
The zebrafish facility was supplied by Aquatic Habitats (USA), and consisted of a 
multi-rack system. RO water was generated by a RiOs™ 50 Millipore unit 
(Millipore, Germany). Mains water was purified by five UV lights, a mechanical 
filter and a carbon filter before being used in the zebrafish facility (Aquatic Habitats, 
USA). Parameters were maintained at: 28°C water temperature, 7.5 mgL-1 dissolved 
oxygen, pH 7.3, and 550 μS conductivity. Parameters were monitored by a YSI 
system (Aquatic Habitats, USA) that polls data onto a PC desktop, and a sensor 
phone alarm system is in place to warn of any significant change in parameters. 
Light was automatically regulated; light cycles consisted of a 9am – 11pm light 
cycle, and a 11pm – 9am dark cycle. Zebrafish adults were kept in 3L and 10L tanks, 
and larvae were raised in 1L tanks in the nursery. Babies were initially raised off-
system in carry tanks until two weeks of age, at which point they were transferred to 
the nursery. Carry tanks were cleaned out once every two days to maintain water 
quality. Larvae were fed three times daily with paramecium (Paramecium stock, ZM 
Ltd), and twice daily with appropriate sized dried food feeds: ZM000 (ZM Ltd) for 
small babies, ZM100 (ZM Ltd) for larger larvae. Adult fish were fed twice daily with 
brine shrimp (Artemia cysts, INVE), and once daily with dry food (Adult ziegler, 
ZM Ltd). Standard zebrafish husbandry precedures were carried out, as described in 






tyrp1-GFP Dr. S.L. Johnson Hultman et al., 2010 
mitfavc7 Dr J.A. Lister Johnson et al., 2011 
nacre Dr J.A. Lister Lister et al., 1999 
p53M214K N/A Berghmans et al., 2005 
 
 
Table 2.1. List of Zebrafish strains 
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2.2.2	  Zebrafish	  Strains	  
 
All zebrafish work was in accordance with home office licence regulations, covered 
by my personal home office licence (PIL: 60/12467), under the main project licence 
(PPL: 60/3992) of the group of Dr E.E. Patton. A number of wildtype strains were 
maintained in the fish facility (Ganga fish facility, MRC Human Genetics Unit, 
University of Edinburgh, Edinburgh, UK). Wildtype strains used were AB, Tupefel 
long fin (TL), and AB x TL. However I preferentially used AB fish in my 
experiments. Mutant strains used are listed in Table 2.1. 
 
2.2.3	  Zebrafish	  breeding	  
 
Primarily zebrafish breeding was done by pair mating. One male and one female 
adult zebrafish were distributed into pair mating tanks and were separated by 
barriers; this was done the day before breeding took place at no earlier than 3pm. At 
9am barriers were raised and fish were allowed to mate for a 1-2 hour period, so as to 
synchronise embryos. Embryos were collected as described in The Zebrafish Book 
(Westerfield, 1995), and rinsed with embryo medium. No more than 30 embryos 
were kept in a single 90 mm petri dish to avoid over crowding and subsequent 
growth retardation. If embryos were to be raised in the fish facility then embryos 
were bleached following collection (see section 2.2.7). Embryo quality was checked 
using a Nikon SMZ 1000 stereomicroscope, with embryos illuminated from below. 
 
On some occasions it was not necessary to precisely stage embryos, rather to collect 
large quantities of embryos. On these occasions a marbling breeding method was 
used: two containers were placed inside one another; the inner container has a mesh 
bottom, which is big enough to allow passage of embryos but not of adult zebrafish. 
A layer of marbles was placed in the inner container, providing a satisfactory 
breeding environment for adult zebrafish. The marbling container was put in an adult 
10 L tank the night before breeding, and embryos were collected within two hours of 
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the lights turning on the next morning. Embryo collection, bleaching and checking of 
embryo quality was done in the same manner as described above. 
 
2.2.4	  Schedule	  1	  (culling)	  of	  adult	  zebrafish	  
 
Adult zebrafish were submerged in 40% tricaine solution (see list of reagents) until 
10 minutes following cessation of respiration. Zebrafish were then disposed of 
according to Home Office regulations. 
 
2.2.5	  Anaesthetising	  adult	  zebrafish	  
 
Anaesthetising procedures were performed as recommended by Home Office licence 
regulations (procedure 19b-1). An anaesthetic solution was made by adding 4.2 ml of 
tricaine solution pH 7.0 (see list of reagents) to 96 ml of zebrafish facility system 
water. Adult zebrafish were netted and added to the anaesthetic solution, making sure 
the fish were completely submerged. Adult fish were continually monitored while 
being anaesthetised. The fish was considered sufficiently anaesthetised following 
slowing of respiration and loss of a response to touch. 
 
2.2.6	  Caudal	  tail	  fin	  amputation	  
 
An adult zebrafish was anaesthetised (see section 2.2.5). Following this the fish was 
scooped from the anaesthetising solution and placed onto a fresh 90 mm petri dish. 
The distal third of the caudal tail fin was amputated using a sterile surgical scalpel 
(Swan-Morton, UK). The fish was then immediately transferred to a carry tank 
containing fresh zebrafish system water until fully recovered from the anaesthetic. If 
the purpose of tail fin amputation was to collect tissue for genotyping, then tail fin 
tissue would be immediately transferred to a sterile microtube (Axygen, USA), and 
kept cold in ice until stored at -20°C or lysed for further use (see section 2.5.1.1). 
Amputated fish for genotyping would then be kept separate in individual tanks until 
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genotyping was complete. Importantly any fish kept off system during this time 
would be fed a diet of only brine shrimp to maintain good water quality. Any tail fin 
tissue not used in genotyping analysis was disposed of according to home office 
regulations. 
 
2.2.7	  Embryo	  bleaching	  
 
Embryos were immersed in embryo bleaching solution for 10 minutes, then washed 
with fresh embryo medium for 10 minutes, this was repeated once again, followed by 
a final 10 minute wash with embryo medium before embryos were transferred to a 90 




Borosilicate glass capillaries with an external diameter of 1 mm were used to make 
glass microinjection needles. To do this a single glass capillary was pulled under heat 
using a Sutter Intracel micropipette puller (Intracel LTD, UK), thus producing two 
microinjection needles from one capillary. Each needle was loaded with 2-5 μl of 
solution by gel loading pipette tips (Eppendorf, UK). Needles were held in place by a 
P/N standard straight holder (Intracel, UK) and a micromanipulator (Narishige 
International LTD, UK). Microinjection volume was regulated by adjusting the 
duration of a pressure pulse using a Picospritzer III microinjector (Intracel LTD, 
UK). The needle was then cut using tweezers to a sufficient size: big enough to 
penetrate the chorion without breaking, but small enough not to damage the embryo. 
An embryo injection stage was created by placing a 25 x 75 mm glass slide (VWR 
International, UK) on a 90 mm non-sterile petris dish (Fisher, UK). Embryos were 
lined up in a single row against the glass slide, excess embryo media was aspirated 
off, and embryos were injected at the 1-2 cell stage.  
 
Morpholino oligonucleotides and control morpholinos used are described in table 
2.2; optimal injection volumes and injection concentrations are also noted. In prl-3 
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morpholino experiments (see Chapter 6), the data presented were achieved by 
injection of “ptp4a3_2 TB” morpholino, alongside a random control morpholino (see 
table 2.2). For Aldh2b morpholino experiments, Z.Zeng performed microinjections 
of “Aldh2bE4/4” morpholino, which targeted the exon 4 / intron 4 splice junction of 
the zebrafish aldh2b gene (see table 2.2) (Zhou et al., 2012b).  
 
Zebrafish mitfa cDNA, and human MITF cDNA (wildtype and 4TΔ2B) 
microinjections were performed by Z.Zeng (see Chapter 5). In brief, zebrafish mitfa 
cDNA, and human MITF cDNA (wildtype or 4TΔ2B) were placed under a zebrafish 
mitfa promoter and incorporated into Tol2 transposase constructs (Z.Zeng) (Kwan et 
al., 2007). These constructs were into mitfavc7 and nacre embryos at the 1-2 cell 





Oligo Name Oligo 
target 
gene 













0.3 mM 4.19 1.4 








0.3 mM 4.19 1.4 
Random control N/A N/A N/A N/A 0.3 mM 4.19 1.4 
Aldh2bE4/4  aldh2b Splice site TCAGAACAATAGAAAATGTGTACCT (25)  3’- Fluorescein 
 
1 mM 2 2  
Standard control N/A N/A CCTCTTACCTCAGTTACAATTTATA (25)  N/A 1 mM 2 2 
 
 







Drug Name Relevant Chapter Source Target Action Stock Solution (mM) Diluent 
Tyrphostin AG1296 Chapter 3 Sigma Aldrich Kit Inhibitor 10 DMSO 
Roscovitine Chapter 3 Sigma Aldrich CDK2/7/9 Inhibitor 10 DMSO 
SU4312 Chapter 3 Enzo Life Sciences Flk-1 Inhibitor 10 DMSO 
SU1498 Chapter 3 Enzo Life Sciences Flk-1 Inhibitor 10 DMSO 
PP1 Chapter 3 Enzo Life Sciences Src Inhibitor 10 DMSO 
PP2 Chapter 3 Enzo Life Sciences Src Inhibitor 10 DMSO 
Nimesulide1 Chapter 3 Sigma Aldrich Cox Inhibitor 10 DMSO 
Indomethacin2 Chapter 3 Sigma Aldrich Cox Inhibitor 10 DMSO 
Ibuprofen1 Chapter 3 Sigma Aldrich Cox Inhibitor 10 DMSO 
PKC-412 Chapter 4 Enzo Life Sciences PKC Inhibitor 10 DMSO 
Ro 31-8220 Chapter 4 Enzo Life Sciences PKC Inhibitor 10 DMSO 
Daidzin Chapter 4 Sigma Aldich Aldh2 Inhibitor 10 DMSO 
GF109203X Chapter 4 Enzo Life Sciences PKCε Inhibitor 10 DMSO 
Nifurtimox Chapter 4 G. Sholler /  
S. Wilkinson 
Aldh2 / Nitroreductases Pro-drug 100/50/10 DMSO 
NFN1/ BTB05727 Chapter 4/ 5 / 6 Maybridge Aldh2 / Nitroreductases Pro-drug 100/10 DMSO 
B4-Rhodanine Chapter 6 Enzo Life Sciences Prl-3 Inhibitor 10 DMSO 
Tyrphostin AG1478 Chapter 6 Enzo Life Sciences/  
LC Laboratories 
Erbb Inhibitor 10 DMSO 
DAPT Chapter 6 Sigma Aldrich Notch Inhibitor 10 DMSO 
 
Table 2.3. List of Small molecules 
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2.3	  Drug	  Treatments	  
 
2.3.1	  N-­‐phenylthiourea	  treatment	  of	  embryos	  
 
30 mg N-phenylthiourea (PTU) (Sigma-Aldrich, UK) was dissolved in 1 Litre of 
embryo media, which lacked methylene blue. This solution was stirred on a magnetic 
stirrer at room temperature for 6 hours – overnight, to allow for PTU to be dissolved. 
Once dissolved PTU solution can be stored at room temperature. Embryos were 
treated with PTU solution directly (PTU solution replaced embryo media) from 24 
hpf (just prior to pigmentation). The drug was replenished daily. However following 
long-term exposure to PTU embryos would become unhealthy and develop a wavy 
notochord. 
 
2.3.2	  Small	  molecules	  
 
All compounds were made from powder into 10 mM stock solutions in Dimethyl 
sulfoxide (DMSO) (Sigma Aldrich, UK). These were then aliquoted into 0.2 ml thin 
wall tubes (Alpha Laboratories, UK) and stored at -80°C, unless otherwise stated*. A 
summary of compounds and manufacturers are listed in Table 2.3. 
 
2.3.3	  Small	  molecule	  screening	  
 
In this thesis three small molecule screens were undertaken. Chapter 3 describes 
results from one small molecule screen to identify pigmentation phenotypes. In this 
particular screen I was involved in screen design and validating melanocyte 
phenotypes on wildtype backgrounds. Screening was carried out by Dr S. Colanesi 
and Dr N. Temperley. Specifically, this screen required the treatment of 4 hpf 
wildtype embryos with drugs from compound libraries. These embryos were then 
assessed for melanocyte phenotypes using a Nikon SMZ 1000 stereomicroscope, and 
embryos were monitored daily until 3 dpf. 
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In Chapter 4 and Chapter 6, I present results from NFN1 suppressor and melanocyte 
regeneration screens, which I designed (alongside E.E.Patton and R.Kelsh), 
performed, and confirmed hits. In these screens 30 hpf embryos were treated with 20 
μM NFN1 (optimised concentration, see Chapter 4) and also co-treated with drugs 
from small molecule libraries (5/10/20 μM, see below). At 50 hpf embryos were 
assessed for a NFN1 melanocyte ablation phenotype. Compounds that rescued 
NFN1-induced melanocyte ablation were scored and removed from subsequent 
melanocyte regeneration screening to avoid incurring false positives. The remaining 
compounds were unable to suppress the NFN1 phenotype i.e. they elicited a 
characteristic melanocyte ablation phenotype. These embryos were washed in fresh 
embryo media subsequently allowing regeneration of embryonic melanocytes. 
Melanocyte regeneration was observed using a Nikon SMZ 1000 stereomicroscope, 
and was followed daily for 3 days following washout. Any compound treatments that 
enhanced melanocyte regeneration over NFN1-only treated controls were scored. 
 
The general screening protocol used required breeding of wildtype parents by 
breeding pairs to synchronise embryo development. Embryos were collected as 
described in The Zebrafish Book (Westerfield, 1995). Embryo quality was then 
checked under a Nikon SMZ 1000 stereomicroscope illuminated from below, and 
any unfertilised or unhealthy embryos were discarded (Westerfield, 1995). Using a 
wide-tipped 3ml graduated pastette (Fisher, UK), five embryos (of appropriate age) 
were distributed in each well of a 24-well plate (Corning Incorporated). Following 
removal of embryo media using a fine-tipped pastette, embryos were treated with 
compounds from small molecule libraries.  
 
Three small molecule libraries were used: the Sigma LOPAC library, the Enzo Life-
Sciences Screen-WellTM Kinase Inhibitor library and the Enzo Life-Sciences Screen-
WellTM Phosphatase Inhibitor library. All drugs in the three libraries were diluted to 
10 mM stock concentrations and stored in aliquots at -80°C. Screens took place with 
aliquots that had only undergone a maximum of 1x freeze-thaw transition to ensure 
quality of the compounds used. Drugs were screened at a 10 μM final concentration 
57 
for all libraries. However owing to the relatively small size of the Enzo Life Sciences 
kinase and phosphatase inhibitor libraries, additional 5 μM and 20 μM screening 
concentrations were also tested. Aliquot screening plates were allowed to defrost 
then were briefly centrifuged before use (Sorval Legend RT centrifuge). Drugs were 
diluted using embryo media in separate 24-well plates to a final volume of 1ml. For 
both NFN1 ablation and melanocyte regeneration screens, compound libraries were 
diluted in NFN1 solution to make a total final volume of 1ml. To treat embryos, 
embryo media was removed from the well using a fine-tipped pastette and the pre-
diluted drug was pipetted onto embryos. Importantly embryos were not de-
chorionated prior to drug treatment to maintain screening efficiency, I accept that by 
doing this I may have incurred some false negatives in which some drugs may not 
successfully penetrate the chorion. 
 
2.4	  Imaging	  Techniques	  
 
2.4.1	  Agarose	  embedding	  of	  embryos	   	  
 
For imaging of zebrafish embryonic pigment pattern, embryos were mounted in 0.6-
1.2% UltraPure™ low melting point (LMP) agarose (Invitrogen, UK) on a 90mm 
non-sterile petris dish (Fisher, UK). Agarose was dissolved in embryo media, melted 
until clear in a microwave, and stirred using a magnetic flea at 50°C on Stuart heat-
stirrer (Scientific Laboratory Supplies, UK). Agarose was aspirated using a 1ml 
graduated pastette (Fisher, UK), then cooled-to-touch on ice before being added to 
the embryos. Embryos were manipulated using fine-tipped pastettes (Fisher, UK) to 
an optimal position for imaging. Agarose was allowed to further cool and solidify 
before imaging. If the surface of the agarose droplet did not dry smooth then a 
second layer of agarose could be applied to limit possible distortion of the image. 
Importantly, the agarose droplet needed to be large enough to ensure minimal 
curvature of agarose directly above the mounted embryo to reduce the level of light 
refraction when imaging. 
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2.4.2	  Imaging	  stills	  
 
For photos, two imaging systems were used. Images of embryonic melanocytes on 
the head and dorsal stripe were taken using a Nikon E5400 camera attached by a 
Nikon MxA 5400 microscope adaptor to a Nikon SMZ1500 microscope equipped 
with a 1x WD54 Nikon HR plan Apochromat objective. Embryos were imaged on a 
white background using overhead illumination through Phototonic PL2000 swan 
neck lights. A C-SHG1 Nikon super high-pressure mercury lamp power supply was 
used for fluorescence imaging.  
 
For images of adult zebrafish, in situ hybridisation images, and lateral views of 
zebrafish embryo morphology a Nikon Macroscope AZ100 system was used. The 
imaging system comprised of a Nikon AZ100 macroscope with 0.5x, 1x, 2x, 4x and 
5x objectives, Intensilight 130W Hg light source and Nikon UV, G or B filter cubes 
(Nikon UK Ltd, Kingston-on-Thames, UK).  For fluorescence work a Qimaging 
Retiga EXi camera was used. For colour brightfield imaging a Qimaging 
Micropublisher 5 cooled colour camera (Qimaging, Burnaby, BC) was used. Image 
capture and image analysis were performed using IPLab Spectrum (Scanalytics 
Corp, Fairfax, VA). For brightfield work images were taken on a white background, 
illuminated from above using a Leica CLS 150X ring light (Leica, Germany). 
Critically, imaging of adult zebrafish was in accordance to home office licensing 
regulations in a designated and approved imaging area. To image adult zebrafish, a 
single adult fish was anaesthetised before imaging (see section 2.2.5), then 
transferred to a 90 mm petris, excess water removed before quickly imaging and 
placing in a recovery tank to wake up. The overall imaging process should take no 
longer than 60 seconds so as to not stress or harm the fish. Imaging of in situ 
hybridisation samples was done in 100% glycerol on a 90 mm petris dish, using a 
fine-tipped pastette (Fisher) to manipulate samples into an optimal position. 
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2.4.3	  Timelapse	  imaging	  
 
Timelapse imaging took place from 26 hpf or 48 hpf depending upon experimental 
design. For those embryos pre-treated with NFN1, embryos were washed out and 
allowed a recovery time of 1 hour before being immobilised in agarose for timelapse 
imaging. Embryos were immobilised in a drop of agarose (1.2%) on glass-bottomed 
6-well plates (IWAKI, Japan) as described above (Section 2.4.1). As the live cell 
imaging system imaged from beneath, embryos were arranged so their dorsal sides 
were facing the glass bottom of the plate. Additionally as the live cell imaging 
system only had a 300 μm depth-of-focus, then embryos were arranged directly 
adjacent to the bottom of the plate to ensure most embryos were in the same depth of 
field. Importantly, when plating 26 hpf embryos I arranged them at a specific angle 
to allow for maximal focus of the head during development. Using a metal wire, 
agarose was removed from around each embryo tail to allow for normal tail 
extension during development. To control rate of growth, temperature was 
maintained inside a timelapse-imaging chamber (MRC Human Genetics Unit 
workshop, UK) by a thermostat (Solent Scientific, UK). Temperature was monitored 
hourly using an ELUSB-1 temperature sensor (Lascar Electronics, Hong Kong). 
Wells were filled with embryo medium to maintain moistness, and plates were sealed 
with parafilm to limit evaporation.  
 
The Live Cell Imaging System comprised of a Zeiss Axiovert 200 fluorescence 
microscope equipped with 20✕/1.5 EC plan Neofluar, 10✕/0.45 and 5✕/0.16 plan 
apochromat objectives (Carl Zeiss, UK). The light source was a Lambda LS 300 W 
Xenon source with liquid light guide and 10-position excitation, and neutral density 
and emission filterwheels (Sutter Instrument, CA) that contained #86000 Sedat Quad 
filter set (Chroma Technology, VT). Image capture and control of the filterwheel 
were performed using MetaMorph software (Molecular Devices, CA). To allow for 
better optical resolution, z-stack images were taken through the depth of field (20 or 
30 μm apart as appropriate), allowing for the optimal plane of focus to be chosen or 
for all z-stacks to be condensed into a z-projection.  Brightfield imaging took place at 
a 20 ms exposure with a binning of 1x. GFP fluorescence was excited at a 
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wavelength of 490. Fluorescent images were captured at 500 ms exposure using a 
binning of 2x (in these cases their corresponding brightfield images were also 
obtained at binning 2x to allow for image overlay). I chose to image pigment 
development in the head of the embryo as this region could be consistently kept 
constant, and because both early and late-developing melanocytes in the head are 
constituted of direct-developing melanocytes (Hultman and Johnson, 2010). Image 
analysis was performed using IPLab Spectrum (Scanalytics Corp, VA). 
	  




2.5.1.1	  DNA	  Extraction	  
 
Tail fin tissue was placed in a sterile microtube (Axygen, USA). Proteinase K 
(Fisher) was added to the DNA extraction buffer (see list of reagents) at a final 
concentration of 200 μg/ml, and 100μl of this solution was added to the tail fin 
tissue. Samples were agitated regularly and kept at 56°C for 3 hours – overnight. 
 
2.5.1.2	  Ethanol	  Precipitation	  
 
To each microtube containing lysed tail fin tissue, 200μl of Ethanol/Sodium Acetate 
solution was added (see list of reagents) and left at room temperature for 15 minutes. 
This was then spun down in a microcentrifuge (Eppendorf, UK) for 10 minutes at 
13,200 rpm until a pellet formed. Supernatant was removed and discarded. The pellet 
was washed with 500μl of 70% ethanol, agitated and then spun down for a further 10 
minutes at 13,200 rpm. Again the supernatant was removed, and the pellet was 





Primer 5’ to 3’ sequence 
p53 fwd TTTTT AAG GGA AAG TGT GAT TTA CAA 
p53 wt1 rev AGG ATG GGC CTG CGG TTC A 
p53M214K rev AGG ATG GGC CTG CGG TTC T 
 
 




PCR stock solutions Volume per 
reaction (μl) 
10x PCR buffer 2.5 
50 mM MgCl2 0.75 
10 μM Fwd primer 0.5 




5 μM dNTP mix 0.5 
Taq polymerase (5 U/μl) 
 
0.2 






Table 2.5. PCR reaction volumes 
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2.5.1.3	  p53	  Genotyping	  
 
Sample DNA was amplified in a PCR reaction using reverse primers that were 
complementary to either wildtype p53 or p53M214K DNA (see table 2.4). Ethanol 
precipitated sample DNA was added to the PCR reaction mixture described in table 
2.5. Optimal PCR conditions were as follows: An initial denaturation step of 95°C 
for 3 minutes was followed by 38 cycles of short denaturation (95°C, 15 seconds), 
annealing (58°C, 30 seconds), and elongation (72°C, 1 minute) steps, finally a last 
elongation step of 72°C for 1 minute took place. Samples were run on a 1% agarose 
gel in TBE solution (see list of reagents). Positive gene detection produced a band at 
221 bp. 
 
2.5.2	  RNA	  extraction	  
 
I designed a microarray experiment (Mitenyi Biotec) in the zebrafish mitfavc7 
regeneration assay. Compounds were made up in embryo media (E3) (see list of 
reagents), and drug treatments were: DMSO control (1), 20 μM B4-Rhodanine (2), 6 
μM ERBB inhibitor (3), and co-treated with both 20 μM B4-Rhodanine and 6 μM 
ERBB inhibitor (4). Total DMSO concentrations were made equal in each drug 
solution. Embryos were reared at the restrictive temperature and treated daily with 
drugs. Embryos were aspirated into 1.7ml clear microtubes (Axygen, USA) and flash 
frozen in liquid nitrogen at 2 dpf. RNA was extracted from 30-40 embryos per 
treatment condition using the SV Total RNA Isolation system (Promega, USA). 
Solutions were made following manufacturer’s guidelines. When ethanol was 
required to make up stock solutions then ethanol 95% v/v (Fisher Scientific, UK) 
was added, which was kept separate from main lab stocks to minimise 
contamination. Embryo lysates were prepared following the instructions in the 
technical manual, Section 4.B, “Preparation of Lysates from Small Tissue Samples 
(≤30 mg)”. Embryos were mechanically ground at the point of thawing using a 
micropestle (Eppendorf, UK). Micropestles were rinsed, autoclaved and wiped down 
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with RNase ZAP® (Sigma, UK) between uses. RNA was purified following 
instructions in Section 4.E, “RNA Purification by Centrifugation (Spin)”. 
Nanodrop analysis was used to check RNA yield and quality was optimal (ND-1000 
Spectrophotometer, Nanodrop Technologies), this is further described in Section 5, 
“Determination of RNA Yield and Quality”. Samples were stored at -80°C before 
collection. Gene expression of different zebrafish RNA samples using Agilent Whole 
Zebrafish Genome Oligo microarrays (one-colour) were performed by Miltenyi 
Biotec (Germany). Miltenyi Biotec performed a quality control step using the 
Agilent 2100 Bioanalyzer platform (Agilent Technologies).  Miltenyi Biotec 
performed a linear T7-based amplification of RNA step using 100 ng of total RNA 
sample. Samples were amplified using Agilent Input Quick Amp Labelling Kit 
(Agilent Technologies), which produced Cy3-labelled RNA. Dye-incorporation and 
RNA yields were measured by Nanodrop (ND-1000 Spectrophotometer, Nanodrop 
Technologies). Miltenyi Biotec then performed a hybridisation step on Agilent 60-
mer oligo microarrays, using the Agilent Gene Expression Hybridization Kit 
(Agilent Technologies). Microarrays were scanned using Agilent’s microarray 
scanner system (Agilent Technologies) and data analysis was performed using the 
Agilent Feature Extraction Software (FES). Microarray expression ratios were 
analysed between all samples (1 Vs 2, 3 Vs 4, 1 Vs 3, 2 Vs 4). All Quality control, 
amplification, hybridisation, scanning and data analysis steps were performed by 
Miltenyi Biotec, and the brief description described above is as written in the 
Microarray service report (MACS Molecular).  
 
2.6	  In	  situ	  Hybridisation	  
 
The following in situ hybridisation method was adapted from the protocol presented 
by Thisse and colleagues (Thisse et al., 1993). 
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Zebrafish gene Restriction 
Endonuclease 
Polymerase Source 
mitfa EcoRI T7 Dr R.N. Kelsh, University of Bath (Lister et al., 1999) 
sox10 SalI T7 Dr R.N. Kelsh, University of Bath (Dutton et al., 2001b) 
foxd3 BamHI T7 Dr R.N. Kelsh, University of Bath (Kelsh et al., 2000a) 
her5 XhoI T3 Dr L. Bally-Cuif, Institute of Neurobiology Alfred Fessard (Tallafuss 
and Bally-Cuif, 2003) 
prl-3 HindIII T7 Dr E.E. Patton, E.Nirmala, W. Rybski. MRC Human Genetics Unit, 
Edinburgh (Unpublished data) 
 
 
Table 2.6. In situ hybridisation probes 
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2.6.1	  Probe	  Synthesis	   	  
 
Plasmid DNA was linearised using the appropriate restriction enzyme (New England 
BioLabs) (see table 2.6), in an overnight reaction at 37°C, with the appropriate buffer 
and BSA concentration (see instruction manual; New England BioLabs). DNA was 
then purified using a phenol-chloroform purification step: To 50 μl of linearised 
plasmid, 100 μl of phenol-chloroform (1:1 ratio) was added. This was then mixed, 
and spun down for 5 minutes at 13,200 rpm in room temperature. The upper phase 
was transferred to a fresh 1.7 ml microtube (Axygen, USA), and 100% ethanol added 
to this (2.5x volume of the upper phase). This solution was then left at -20°C for 20 
minutes. Following this, the samples were spun down at 13,200 rpm in a 
microcentrifuge (Eppendorf, UK) at 4°C for 15 minutes. The supernatant was 
discarded, the pellet air-dried, then dissolved in sterile Milli-Q® water (Millipore). 
Concentrations of linearised DNA were calculated by Nanodrop analysis (ND-1000 
Spectrophotometer, Nanodrop Technologies). Finally, the RNA probe was 
transcribed using an in vitro transcription step (Roche, Germany). 1 μg linearised 
plasmid was added to 2 μl of 10x transcription buffer (Roche, Germany), 2 μl of 10x 
DIG RNA labelling mix (Roche, Germany), and 2 μl of appropriate RNA 
polymerase (Roche, Germany) (see table 2.6). Finally 1 μl RNase inhibitor 
(Promega, USA) was added and the solution was made up to 20 μl with sterile water. 
This reaction mixture was then incubated for 2 hours at 37°C. To digest DNA 
contaminants, 2 μl of DNase I (Promega, USA), which was RNase-free, was added. 
The reaction mixture was incubated at 37°C for 30 minutes. Finally a RNA 
precipitation step was undertaken: 25 μl of 4 M Lithium Chloride (Ambion) and 75 
μl of pre-chilled 100% Ethanol were added. This reaction mixture was put at either 
80°C for 30 minutes, or -20°C for 2 hours. Following this, the reaction mixture was 
spun down for 15 minutes at 13,200 rpm in a pre-chilled microcentrifuge 
(Eppendorf, USA) at 4°C. Supernatant was discarded and the pellet was air-dried, 
and dissolved in RNase free water, or TE buffer (Qiagen). Nanodrop analysis was 
used to check RNA yield and quality (ND-1000 Spectrophotometer, Nanodrop 
Technologies), and stock solution was adjusted to 100 ng/μl. Finally, probe quality 




2.6.2	  Embryo	  Collection	  
 
Melanin synthesis in neural crest derived melanocytes would obscure visualisation of 
in situ hybridisation probes, therefore wildtype embryos were treated daily with PTU 
(see section 2.3.1) from 24 hpf (immediately prior to melanin synthesis), or mitfavc7 
embryos (see Chapter 5) were reared at the restrictive temperature (30 - 32°C). 
Embryos were de-chorionated as described in (Westerfield, 1995). Embryos were 
then fixed in 4% paraformaldehyde (PFA) (see list of reagents) (Electron 
Microscopy Sciences, USA) either overnight at 4°C or for 2 hours at room 
temperature. Following fixation embryos were washed once with PBT (see list of 
reagents), then dehydrated by 3x 5minutes washes in 100% methanol, and a final 10-
minute wash of 100% methanol at room temperature. Samples were then stored at 
minus 80°C for a minimum duration of overnight. 
 
2.6.3	  In	  Situ	  Hybridisation	  protocol	  
 
Serial rehydration steps were carried out: samples were washed x1 in gradually 
decreasing concentrations of methanol (75%, 50%, then 25%) diluted in PBS (see list 
of reagents) for 5 minutes each. Following this, embryos were washed 4x 5 minutes 
in PBT. Embryos were digested in a solution of 10 μg/ml proteinase K (Roche, 
Germany) in PBT for 34 minutes (48 hpf embryos), or 50 minutes (72 hpf embryos). 
Embryos were then immediately washed in PBT followed by a second 4% PFA 
fixation step for 20 minutes, before a final PBT wash (4 x 5 minutes). Embryos were 
prepared for hybridisation by a pre-hybridisation step: initially embryos were washed 
for 15 minutes with Hybridisation mix + (Hyb+) (see list of reagents); following this 
embryos were incubated at 68°C between 2 – 5 hours in a water bath (Grant 
Instruments Ltd, Cambridge). Synthesised probes (100 ng/μl) were diluted 1:100 in 
Hyb+ and pre-heated for 5 minutes at 68°C. Samples were then treated with 200 μl 
of pre-warmed probes (up to 60 embryos can be adequately treated with 200 μl of 
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probe-Hyb+ solution). Samples were incubated overnight at 68°C. Crucially, all 
steps requiring Hyb+ were carried out in a fume hood. 
 
The following day probes were aspirated from samples and were recycled, which 
improves efficiency and minimises background. Embryos were washed x1 at 68°C in 
gradually decreasing concentrations of Hyb- (100%, 75%, 50%, and 25%) diluted in 
2x SSC (see list of reagents) for 10 minutes each. All washes requiring Hyb- took 
place in a fume hood for safety. Embryos were then washed at 68°C in 2x SSC for 
10 minutes, followed by 2x 30 minute washes in 0.2x SSC (see list of reagents). 
Samples were then washed x1 at room temperature in gradually decreasing 
concentrations of 0.2x SSC (75%, 50%, and 25%) diluted in PBT for 5 minutes each. 
Next samples were washed 3x for 5 minutes in MABT (see list of reagents), again at 
room temperature. Hybridised embryos were blocked for 1-2 hours in 1% blocking 
solution (Commercial blocking reagent, Roche, Germany) diluted in MABT (see list 
of reagents). Finally embryos were incubated overnight at 4°C under gentle agitation 
in 1:5000 anti-Digoxigenin-AP (Fab fragments) antiserum (Roche, Germany), 
diluted in 1% blocking solution. 
 
The following day samples were washed briefly with MABT at room temperature, 
followed by 6x 15 minute MABT washes at room temperature. Samples were then 
washed in NBT/BCIP buffer (see list of reagents) 3x for 5 minutes each. Samples 
were then either stained with BM Purple AP directly (Roche, Germany), or with blue 
staining solution (see list of reagents). Staining was developed at room temperature 
in the dark, and took any time between 1- 6 hours depending upon the probe used. 
Importantly, for mitfa staining I wished to identify low expressing mitfa positive 
cells, and therefore prolonged exposure of samples until these cells were visible. At 
the appropriate time the reaction was stopped with a quick wash in PBT, followed by 
a longer 5 minute wash in PBT. Washed samples were fixed using 4% PFA either at 
4°C overnight, or at room temperature for 2 hours (optional). Finally embryos were 
gently agitated in gradually increasing concentrations of glycerol solution (30%, 
50%, and 80%) diluted in PBT. In situ hybridisation samples were stored at 4°C in 
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3.	   A	   Small-­‐molecule	   screen	   to	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   new	   targetable	   pathways	  




As a vertebrate species, zebrafish melanocytes have remarkably homologous biology 
to mammalian melanocytes, including in humans. Like mammals, zebrafish 
melanocytes are derived from late-migrating neural crest cells, which differentiate 
into melanoblasts and migrate through the dorsolateral and ventral pathways, 
subsequently differentiate into mature melanocytes and constitute the pigment 
pattern (Raible and Eisen, 1994; Raible et al., 1992; Serbedzija et al., 1989; 
Serbedzija et al., 1990). In the zebrafish, melanoblasts can additionally migrate down 
the ventral pathway to make up the embryonic pigment pattern, which consists of a 
dorsal, lateral ventral, and yolk sac stripe. Uniquely, zebrafish melanocytes retain 
their melanin rather than dispersing it throughout the surrounding keratinocytes 
(mouse and human) (Byers et al., 2003; Logan et al., 2006). Thus melanin can 
function as an inherent lineage tracer in zebrafish melanocytes, making zebrafish 
melanocyte biology tractable to study in vivo. Homologous transcription factor 
pathways are involved in vertebrate melanocyte development, for example in 
vertebrates Sox10-expressing neural crest cells are specified into the melanocyte 
lineage through Mitf expression. Additionally Dct and Tyr are involved in late-stage 
pigmentation of melanocytes, and also Kit is necessary for melanocyte/melanoblast 
migration (Dutton et al., 2001b; Hou et al., 2006; Johnson et al., 1995; Kelsh et al., 
1996; Lister et al., 1999; Murisier et al., 2007; Parichy et al., 1999). Subsequently 
findings in zebrafish melanocyte biology are often translatable to human biology. 
Likewise studies of zebrafish pigmentation mutants show comparable phenotypes to 
mice/humans with homologous mutations, e.g. nacre, albino, sparse (Johnson et al., 
1995; Kelsh et al., 1996). Additionally the pigmentation disorder melanoma has been 
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successfully modelled in the zebrafish system (Dovey et al., 2009; Michailidou et al., 
2009; Patton et al., 2005; Santoriello et al., 2010). 
 
Libraries of bioactive drugs of known function (in humans) are now commercially 
available, meaning that small-molecule screening can provide a relatively cost-
effective method of screening for new molecular targets that are causative of a 
specific phenotype (Taylor et al., 2010). Zebrafish are an ideal tool for use in small-
molecule screening: one mating pair can produce hundreds of embryos that are 
externally fertilised. Zebrafish embryos are small and tractable to handle. They are 
water-derived and during early development absorb nutrients from the surrounding 
liquid, meaning drugs can simply be applied directly into the embryo media. Early 
zebrafish embryos are optically transparent, meaning some organs; pigmented cell-
types or fluorescently marked cells can be easily discerned within the embryo. 
Moreover large libraries of zebrafish transgenic mutants or fluorescently labelled 
transgenics are now available (Carney et al., 2006; Gilmour et al., 2002; Hultman 
and Johnson, 2010; Seger et al., 2011). Taken together zebrafish are an ideal tool to 
observe phenotypic changes in a specific cell type or expression pattern. Zebrafish 
have rapid development: gastrulation occurs between 5-10 hpf, neural crest is 
derived from 10 hpf, the segmentation period takes place between 10-24 hpf during 
which the somites and the primary organs develop, pigmentation pattern is 
established (24-48 hpf), and by 72 hpf the zebrafish larvae has completed most of its 
morphogenesis (Kimmel et al., 1995). This means zebrafish are also a quick and 
tractable model for studying organogenesis and development. 
 
When designing a small molecule screen establishing the screen parameters is a key 
step. Factors to consider are: drug concentrations, treatment windows, readout 
(phenotype) and age at which to assess readout. Drug concentrations vary depending 
upon the model and the developmental stage studied. Concentrations need to be 
sufficient to induce some developmental phenotypes in a significant proportion of 
the samples, ensuring adequate drug penetration. For zebrafish embryos a good 
starting concentration is 10 µM (Colanesi et al., 2012). Specific drug treatment 
windows depend upon the phenotype or cell type screened. If screening for early 
72 
developmental defects then embryos should be treated with drugs during early 
embryo development (from 4 hpf) e.g. screening for pigment disorders in zebrafish 
embryos require drug treatment before neural crest specification until pigment 
pattern has been established (48- 96 hpf) (Kimmel et al., 1995; Raible and Eisen, 
1994; Raible et al., 1992). By 72 hpf the majority of the zebrafish larval pigment 
pattern has been laid down by ontogenetic pathways, however a few late-developing 
melanocytes further contribute to the pigment pattern after this, and generally these 
are thought to be MSC derived (except late-developing melanocytes on the head) 
(Hultman and Johnson, 2010). Screening for phenotypes in more sophisticated 
processes, such as background adaptation in melanocytes or zebrafish embryo 
behaviour would limit the screening treatment window and assessment to older 
embryos. Background adaptation of melanocytes occurs from 72 hpf, and it is 
recommended to put the embryo through a round of dark-light exposure first to 
normalise the response in all embryos (Logan et al., 2006). By 120 hpf zebrafish 
embryos are actively seeking food, respond to tail-touch tests, and have functional 
optics (Kimmel et al., 1995; Taylor et al., 2010).  
 
I was directly involved in the design and validation of results in a small molecule 
screen to identify targetable pathways in pigment cell development in the zebrafish. 
The goal of this screen was to identify new pathways involved in pigment cell 
development and chemical modifiers of these pathways (Colanesi et al., 2012). As 
we screened with drugs from libraries of known bioactives and an FDA-approved 
drug library, any findings could be translated to homologous pathways involved in 
mammalian pigment biology (Colanesi et al., 2012). 
 
3.2.	  Screen	  design	  
 
Screen design was achieved through collaborating efforts between Dr. E. E. Patton, 
Dr R.N. Kelsh, Dr S. Colanesi, Dr N. Temperley and myself. To study 
developmental pigmentation phenotypes we chose to treat embryos from early 
development (4 hpf) with drugs from the Sigma LOPAC library, the Enzo Life-
Sciences Screen-WellTM Kinase Inhibitor library and the Enzo Life-Sciences Screen-
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WellTM Phosphatase Inhibitor library. Screens assessed pigment biology of all three 
zebrafish chromatophores that are responsible for producing distinct pigment 
colours: melanocytes (black; melanin), iridophores (iridescent; crystalline guanine), 
xanthophores (yellow; pteridine) (Kimmel et al., 1995; Raible and Eisen, 1994; 
Raible et al., 1992). Additionally the screen made use of wildtype embryos, parade 
mutants, and mitfa hypormophic embryos (Johnson et al., 2011; Kelsh et al., 1996). 
However my work involved validating melanocyte-specific pigment phenotypes in 
wildtype embryos, therefore these are the results I will focus on for the remainder of 
the chapter. Screening parameters involved plating 5 “sphere stage” embryos (4 hpf) 
per well of a 24-well plate (Corning) (Kimmel et al., 1995). Drug libraries were 
prepared at 10 µM in 1 ml in separate plates, embryo medium was then removed off 
plated embryos with a fine-tipped pastette and drug solutions added. This technique 
controlled for uniform drug concentrations in the well. Melanocyte phenotypes were 
assayed at 48, 72 and 96 hpf and in categories as previously described by Kelsh et al 
(1996). Melanocyte phenotypes assessed were: reduced numbers, abnormal 
distribution, reduced pigmentation, and abnormal cell morphology (Kelsh et al., 
1996). 
  
3.3.	  Results	   	  
 
3.3.1.	  Roscovitine	  treatment	  reduces	  melanocyte	  number	  	  
 
In our screen for modulators of zebrafish pigmentation pathways, roscovitine was 
identified as a compound that reduced overall embryonic melanocyte number. 
Roscovitine (Enzo Life Sciences; Seliciclib) is a potent and selective inhibitor of the 
cyclin dependent kinases (CDK2, CDK7, and CDK9), which are important for 
progression of the cell cycle. Roscovitine has also been shown to be a potent 
activator of p53, which can mediate senescence and programmed cell death pathways 
(David-Pfeuty et al., 2001; Lu et al., 2001). Roscovitine treated embryos had a 
15.8% reduction in melanocytes by 4 dpf when compared to DMSO controls, and 
then again a 14% loss in melanocyte numbers by 5 dpf  (melanocytes were counted 
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in a defined head region) (Figures 3.1, 3.2). Melanocyte loss was also observed over 
the entire body of 4 dpf zebrafish embryos [28% reduction in melanocyte number: 
control mean: 300.8 (SD = 53.53, n = 5); roscovitine 20 μM mean: 217.2 (SD = 
15.90, n = 6) two-sample unpaired t-test P = 0.0051] (Colanesi et al., 2012) (N. 
Temperley).  
 
I hypothesised that the reduced numbers of melanocytes in roscovitine-treated 
embryos could be due to one of three possible alternatives: either enhanced apoptosis 
of melanocytes or their precursors, loss of proliferation of melanocytes or their 
precursors, or clustering together of melanocytes so they cannot be easily 
distinguished from each other.  We noticed roscovitine treated embryos had unusual 
melanocyte morphology; they characteristically have short dendrites compared to 
DMSO controls and tend to group together in the embryonic pigment pattern (Figure 
3.2). No evidence was observed of melanocyte death in roscovitine fish, such as 
melanocyte fragmentation or extrusion from the epidermis (O'Reilly-Pol and 
Johnson, 2008; Parichy et al., 1999; Zhou et al., 2012a; Zhou et al., 2012b) (data not 
shown). However in future experiments it would be prudent to use TUNEL staining 
to confirm this, and also to assess if a melanocyte precursor population could be 
being affected. Previously I established that zebrafish differentiated melanocytes 
were capable of undergoing differentiated cell division upon loss of mitfa (Taylor et 
al., 2011) (see Chapter 5). As roscovitine is a CDK inhibitor, it could be possible the 
reduced numbers of embryonic melanocytes in this cohort is due to loss of 
melanocyte proliferation. To address this question I performed timelapse imaging of 
roscovitine-treated mitfavc7 hypomorphic embryos, which have enhanced melanocyte 
proliferation events due to hypomorphic levels of mitfa (See Chapter 5) (Taylor et 
al., 2011). Importantly I observed no marked reduction in melanocyte division events 
(data not shown), interestingly I observed melanocytes were still able to divide but 
seemed unable to migrate away from their sister cells (Figure 3.3). These results 
suggest that roscovitine does not reduce melanocyte numbers by inhibiting 
melanocyte division. However to address this more accurately I would like to assess 
proliferation through EdU incorporation studies as this would allow me to accurately 
assess any effects of roscovitine treatment on either melanocyte proliferation or 
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proliferation of a melanocyte precursor population.  In this study we showed that 
following roscovitine treatment numbers of late-stage embryonic melanocytes in the 
zebrafish are reduced. The proportion of missing melanocyte is consistent with the 
proportion of late-developing melanocytes that contribute to total embryo pigment 
pattern (Hultman and Johnson, 2010).  Hultman and colleagues showed that the 
majority of these late-developing melanocytes were derived from a melanocyte 
precursor population rather than from ontogenetic development of neural crest cells 
(Hultman and Johnson, 2010). Therefore it could be a possibility that roscovitine 







Figure 3.1.  Melanocyte counts were restricted to a specific region on the head. (A) Wildtype 
embryos treated with 20 μM roscovitine from 24 hpf to 5 dpf (roscovitine replenished daily). 
Roscovitine treated embryos formed characteristic “couplets” of melanocytes that are difficult to 
distinguish from each other, melanocytes are irregular in their shape, and a subtle loss in melanocyte 
numbers is also observed. (B) Counts of melanocytes were made in a defined region: from half-way 
down the eyes down to the “pinched” region of the neck (defined by red-dotted lines).  Diameter of 
the red dot represents the minimum size of a melanocyte before it was scored as a real melanocyte. 






Figure 3.2.  Melanocyte cell number is reduced following roscovitine treatment. A-B 5 dpf 
embryos treated with 20μM roscovitine or DMSO daily from 24 hpf. Characteristic roscovitine 
phenotype includes reduced number of melanocytes, short dendrites and grouping together of 
melanocytes into “doublets” (arrow). At the time of analysis, melanocytes were contracted by 
exposure to light and embryos were immediately fixed (4% PFA). Counts of melanocytes were made 
in the previously defined head region (Figure 3.1). C-D Box and Whisker plots of melanocyte number 
in the head of 4 dpf (C) and 5 dpf (D) treated embryos. Outliers are represented by an asterisk. Figure 






Figure 3.3.  Melanocyte development in roscovitine treated embryos.  
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Figure 3.3.  Melanocyte development in roscovitine treated embryos. Timelapse image analysis 
of roscovitine treated mitfavc7 hypormophs shows a remarkable difference in differentiated melanocyte 
behaviour compared to DMSO controls. Embryos were reared at the restrictive temperature (32°C) 
and treated with 20 μM roscovitine or DMSO control from 24 hpf. At 2 dpf, embryos were down-
shifted to the permissive temperature (<24°C) and melanocyte development was assayed by timelapse 
imaging. Drug was replenished daily. (A) In control samples, single melanocytes are able to undergo 
differentiated division (87.5 hpf; red arrowhead, 98.5 hpf; red arrow), and sister melanocytes then 
migrate away from each other (93.1 hpf; red arrowhead, 99.1 hpf; red arrow). (B) In roscovitine 
treated samples melanocytes are able to undergo division (108.5 hpf-118.2 hpf; green arrows), 
however these sister melanocytes remain clustered together (118.5 hpf; green arrows). Additionally 
two melanocytes have developed separately (90.8 hpf; green arrowheads), but afterwards form a tight 
couplet (109.2 hpf- 118.5 hpf; green arrowheads), and were never observed to separate. 
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3.3.2.	  Cox	  inhibitors	  affect	  melanocyte	  morphology	  
 
Three cyclooxygenase (Cox) inhibitors were identified independently to affect 
melanocyte morphology (Nimesulide, Ibuprofen, and Indomethacin). Cox inhibitors 
are non-steroidal anti-inflammatory drugs (NSAIDs) commonly used to treat pain 
and heart disease. Additionally activation of the Cox pathway by treatment of 
dimethyl-prostaglandin E2 (dm-PGE2) has been shown to enhance haematopoietic 
stem cells (HSC) in zebrafish, and is currently under clinical trials for use in 
conjunction with cord blood transplants (Goessling et al., 2011; Lord et al., 2007; 
North et al., 2007). Consequently the Cox pathway has real clinical importance, and 
it is therefore important to determine as much about the biology of this pathway and 
its in vivo effects as possible.  
 
In this screen we have identified COX inhibitors to cause aberrant melanocyte 
morphology in zebrafish embryos. We observed low concentrations of COX 
inhibitors (5-10 µM, treated from 4 hpf) resulted in melanocytes with “spindly” 
morphology (Figure 3.4). Spindly melanocytes characteristically have a small cell 
body and long thin protrusions, which appear distinct to the dendritic morphology of 
normal melanocytes (Figure 3.4). Moreover embryos treated with higher 
concentrations of COX inhibitors (15-20 µM) had small “dot-like” punctate 
melanocytes, indicating enhanced severity of the COX inhibitor phenotype. I asked if 
melanocyte morphology phenotypes in the COX inhibitor treated embryos were the 
result of melanocytoxicity, however I observed no characteristic evidence of 
melanocyte death, such as extrusion of melanocytes through the epidermis, 
fragmented melanocyte detritus, or cumulative loss of melanocyte numbers (Parichy 
et al., 1999). This suggests that the melanocyte morphology phenotype in the COX 
inhibitor treated embryos is not due to melanocytotoxicity. Another possibility is that 
Cox could have a role in melanocyte differentiation and the morphologies observed 
are the result of deficient differentiation of melanocytes. Previous studies have 
already demonstrated a link between COX signalling and activation of the late-stage 
melanocyte differentiation enzyme, TYROSINASE. Following UV treatment of 
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human erythrocytes, PGE2 stimulates TYROSINASE activity and subsequently 
melanin synthesis of melanocytes. This mechanism has been proposed to mediate the 
tanning response of melanocytes in response to UV irradiation (Gledhill et al., 2010). 
Consequently our results likely corroborate a known Cox - Tyrosinase axis in late-
stage melanocyte specification. This gives credence to our screening results and 
suggests that small molecule screening in zebrafish could be useful to discover novel 
drugs that affect melanocyte specification, and that these results would be relevant to 
zebrafish and possibly mammalian melanocyte development. Additionally it is 
important to confirm if the COX inhibitor phenotype observed in zebrafish is the 
result of deficient melanocyte differentiation, and if so what extent zebrafish Cox 






Figure 3.4.  Cox inhibitors affect melanocyte morphology. Treatment of COX inhibitors during 
early development causes spindly phenotype (black arrows) or dot-like phenotype (red arrow) 
melanocytes at 48 hpf. All three COX inhibitors, nimesulide (B, B’), indomethacin (C, C’, C’’), and 
ibuprofen (D’), result in comparable melanocyte phenotypes. Figure used with permission from 
(Colanesi et al., 2012). 
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3.3.3.	  Aberrant	  melanocyte	  migration	  after	  AG1296	  treatment	  	  
 
Tyrphostin AG1296 inhibits both KIT and PDGFR’s in humans. In our screen 
following AG1296 treatment from 4 hpf until 48 hpf, abnormal melanocyte 
migration was noted. Specifically melanocytes were able to specify, differentiate and 
pigment as normal, but accumulated behind the ears and more dorsally on the tail. 
Melanocytes seemed unable to populate the head, over the yolk sac and through the 
medial pathway to populate the ventral stripe. Mutations in Kit are known to affect 
melanocyte migration in mammals. Heterozygote mouse Kit mutants have abnormal 
melanoblast migration resulting in a white belly spot phenotype (homozygotes lack 
pigmentation) (Chabot et al., 1988; Geissler et al., 1988; Jordan and Jackson, 2000a); 
also human KIT mutations cause piebaldism (Spritz et al., 1992). Zebrafish kita 
mutants (sparse) have severe embryonic melanocyte migration and survival 
abnormalities that are comparable to survival and migration phenotypes seen in 
mammals (Mellgren and Johnson, 2004; Parichy et al., 1999). Thus highlighting a 
degree of homology in the role of Kit between these different organisms. Zebrafish 
sparse mutants have severe melanocyte migration abnormalities that mirror the 
phenotype observed in AG1296 treated embryos, suggesting the AG1296 melanocyte 
migration phenotype in zebrafish is likely caused by inhibition of kita signalling. 
Additionally in sparse fish, early ontogenetic melanocytes undergo cell death from 
~4 dpf, and a delay in development of MSC derived melanocytes was also observed 
(Kelsh et al., 1996; Parichy et al., 1999; Rawls and Johnson, 2001; Rawls and 
Johnson, 2003). It would be interesting to establish if AG1296 treatment can also 






Figure 3.5. Tyrphostin AG1296 alters melanocyte movement in zebrafish embryos. (A, B) A 
prim-25 stage (36 hpf) zebrafish embryo treated with DMSO as a control or 20 μM of Tyrphostin 
AG1296 from the 2 to 4 somite stage (10.7–11.3 hpf). Treated embryos develop melanocytes, but the 
melanocytes are clustered behind the ear (asterisk; A′, B′) and have been retarded in their migration 
along the medial migration pathway (red arrow; A″, B″). Melanocytes also fail to populate the yolk 
sac and yolk sac extension (black arrows). (C) Embryos treated with 12 μM Tyrphostin AG1296 (C′) 
show reduced numbers of melanocytes at yolk extension and ventral stripe compared with embryos 
treated with 20 μM Tyrphostin AG1296 (C″; arrows). Figure used with permission from (Colanesi et 
al., 2012). 
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3.3.4.	  Flk-­‐1	  inhibitors	  affect	  melanocyte	  biology	   	  
 
Two distinct Flk-1 (Fetal Liver Kinase-1) inhibitors were identified to affect 
melanocyte biology in the screen, SU1498 and SU4312. Flk-1 (also known as Kdr, 
Kinase insert Domain Receptor) is a vascular endothelial growth factor (VEGF) 
receptor kinase (VEGFR-2), which has been extensively implicated in tumour 
angiogenesis and therefore tumour growth (Maniotis et al., 1999), moreover, Flk-1 
has been shown to up-regulated in some melanomas (Rawlings et al., 2003). The Flk-
1 inhibitor SU5416 reached phase II clinical trials for treatment of advanced 
melanoma (Peterson et al., 2004). As such, further understanding about the in vivo 
activity of Flk-1, and a potential role in normal melanocyte development may 
provide further insight to the role of Flk-1 in melanoma and applications for Flk-1 
inhibitors in melanoma treatment. 
 
I was involved in validating and characterising the melanocyte phenotype in the Flk-
1 treated embryos. Embryos were treated with flk-1 inhibitors daily from 4 hpf – 72 
hpf. SU1498-treated embryos were observed to have a pale melanin and/or a small 
“dot-like” melanocyte phenotype (Figure 3.6). SU4312-treated embryos were scored 
as having a reduced number of melanocytes, however this maybe attributed in part to 
the shortening of the body axis of the fish (Figure 3.6). Whereas one Flk-1 inhibitor 
appeared to affect melanocyte morphology, the other affected melanocyte number. 
The differing melanocyte phenotypes observed between these two Flk-1 inhibitor 
compounds, could be suggestive that one or both of the compounds are eliciting off-
target effects. It would be prudent to validate these results by morpholino 
knockdown of the Flk-1 gene in zebrafish to establish which of these phenotypes can 
be attributed to loss of Flk-1 activity. Likewise different temporal treatments of the 
Flk-1 inhibitor can be utilised to establish timings of the phenotypes observed, and 
perhaps to minimise general developmental defects (by treatment of inhibitors later 
in melanocyte development). In conclusion we may have identified Flk-1 as a novel 
target critical to normal melanocyte biology in the zebrafish, and if validated this 
result could have significant impact on understanding of the role of Flk-1 inhibitors 





Figure 3.6. Flk-1 inhibitors affect normal melanocyte biology. Embryos were treated from 6 hpf 
with Flk-1 inhibitors, SU1498 and SU4312, drugs were replenished every 24 hours. Images are of 72 
hpf embryos. (A) At high concentrations (20μM) both drugs cause shortened body axis. (B). Embryos 
treated with SU1498 have characteristic punctate, dot-like melanocytes  (red arrow) when compared 




3.3.5.	  Src	  kinase	  inhibitors	  affect	  melanocyte	  distribution	  and	  number	  
 
The two Src family tyrosine kinase inhibitors, PP1 and PP2, were initially identified 
as affecting melanocyte number and melanocyte migration within the embryo. Src 
signalling has long been established to have a role in tumourigenesis, and Src family 
kinase inhibitors have an established role in cancer chemotherapeutics. Interestingly, 
considerable evidence has shown upregulation of Src pathways in melanoma, and 
one such Src inhibitor, dasatinib, has even been taken to phase I clinical trials in 
combination therapy alongside dacarbazine (an established antineoplastic drug 
already used in melanoma chemotherapy) to treat metastatic melanoma (Algazi et al., 
2012). Understanding the role of Src signalling in melanocyte biology may enable 
further understanding of the role of Src in melanoma, and aid development of 
melanoma treatment strategies. Both PP1 and PP2 caused loss of melanocytes and 
deficient melanocyte migration with melanocytes accumulating within the medial 
pathway in embryos (Figure 3.7). Additionally a pale-melanin phenotype was also 
noted in embryos. This could be suggestive of a role of Src family kinases in 
melanocyte proliferation and migration, and perhaps in late-stage differentiation. 
Interestingly, Src binding sites were previously identified on Kit (mediates 
melanoblast proliferation and migration in mammals), and activation of Mitf by Kit 
has been shown to be dependent on functioning Src activation and intact Src binding 
sites (Phung et al., 2011). Kit is known to be critical for embryonic melanocyte 
survival and migration in zebrafish (Mellgren and Johnson, 2004; Parichy et al., 
1999). Therefore our results linking Src inhibition with abnormal melanocyte 
migration and numbers could be suggestive of a relationship between Src and Kit in 
zebrafish, drawing parallels with evidence from mammalian systems. However it is 
important to note that both drugs caused severe developmental phenotypes within the 
fish even at relatively low concentrations (2 µM – shortening of body axis). 
Consequently it is hard to distinguish melanocyte-specific phenotypes from 
secondary effects on melanocytes due to general toxicity, therefore in future 
investigations it may be useful adjust treatment windows in order to minimise 




Figure 3.7. Src inhibitors affect melanocyte morphology and migration. Embryos were treated 
from 6 hpf with Src inhibitors, PP1 and PP2, drugs were replenished every 24 hours. (A) At high 
concentrations (10μM) both drugs cause severe developmental defects. Shortened body axis can be 
observed from as little as 2μM in both drugs (B). Both drugs incurred aberrant melanocyte 
morphology and pigment phenotypes. Melanocytes are small, punctate and dot-like (red arrow) when 
compared to contracted normal melanocytes (black arrow). Fainter pigment and spindly melanocytes 
are also observed (red arrowhead) when compared to normal controls (black arrowhead) (C) Both Src 
inhibitors resulted in a build-up of melanocytes across the medial line. 
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3.4.	  Future	  Work	  &	  Discussion	  
 
3.4.1.	   Small	   molecule	   screening	   is	   an	   effective	   method	   to	   identify	  
melanocyte	  developmental	  pathways	  
 
Small molecule screening was used to identify compounds that affected melanocyte 
biology in the zebrafish. I validated a number of hits and could characterise the 
melanocyte phenotypes into four distinct classes: reduced pigmentation, aberrant 
melanocyte morphology, aberrant number of melanocytes, and deficient melanocyte 
migration. These four distinct phenotypes provide useful insight into drugs that affect 
key processes in melanocyte development (Kelsh et al., 1996). This work therefore 
highlights novel compounds for use in dissecting the processes of melanocyte 
development. 
 
Some small molecules identified elicited phenotypes that complement what is 
already known about the pharmacology of the compound. A prime example is 
AG1296, a Kit inhibitor, which caused clustering of melanocytes behind the ear and 
accumulation of melanocytes along the medial pathway. This phenotype is 
remarkably similar to that of sparse mutant embryos. The sparse phenotype has 
previously been attributed to a mutation in zebrafish kita receptor, an orthologue of 
the Kit receptor in mouse (previously known as c-Kit) (Parichy et al., 1999). 
Therefore this proof-of-principle result demonstrates the power of small molecule 
screening to successfully identify biologically significant hits.  
 
3.4.2.	  Drug	  screening	  can	  identify	  novel	  functions	  in	  established	  drugs	  
 
Importantly, unlike genetic mutations, many drugs are promiscuous and affect more 
than one target pathway. Some phenotypes observed could therefore be the result of 
inhibition of a combination of different pathways. This is also true of drugs used in 
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the clinic. Therefore small molecule screening in zebrafish can potentially identify 
novel phenotypes or functions of already established drugs, thereby providing further 
insight into in vivo activity of known drugs. In this screen we identified a novel 
melanocyte phenotype associated with roscovitine treatment. Roscovitine is an 
established drug known to inhibit CDKs and to activate p53 signalling, and is 
subsequently under development as a cancer chemotherapeutic (Le Tourneau et al., 
2010). We showed that roscovitine treatment induced loss of melanocyte numbers, 
specifically during late-stage melanocyte development in the embryo. Three possible 
lineages contribute to late-stage melanocyte development: late developing neural 
crest cells, differentiation of MSCs, or differentiated melanocyte division (Hultman 
and Johnson, 2010; Taylor et al., 2011). As roscovitine does not cause a noticeable 
loss of melanocytes during early melanocyte development (neural crest derived), 
then it is likely that roscovitine is not affecting late-stage neural crest (ontogenetic) 
derived melanocytes. Additionally, timelapse analysis of melanocyte division events 
did not reveal any effect of roscovitine treatment on division events, although further 
study would be necessary to rule this out. Finally the role roscovitine treatment may 
have on development of late-stage melanocytes from differentiation of a MSC 
population has not been addressed.  
 
3.4.3.	  Molecular	  targets	  of	  roscovitine	  	  
 
Although roscovitine is known to inhibit CDKs and also to indirectly activate p53 
signalling, we do not know which/ if any/combination of these known downstream 
targets of roscovitine mediates its melanocyte specific phenotype. Further 
investigation of this could reveal a novel function of CDK or p53 signalling in vivo. 
Importantly CDK2 is a MITF target gene in melanocytes, and CDK2 expression in 
melanoma cells correlates with susceptibility to roscovitine treatment (Du et al., 
2004; Hoek et al., 2008b). Therefore it is not unreasonable to propose that the 
roscovitine mediated melanocyte phenotype in zebrafish embryos could be 
dependent upon CDK2 activity. Additionally later in this thesis (Chapter 6) I will 
present evidence that suggests a possible role of p53 in regulation of a MSC 
population. Therefore it may be possible that roscovitine could provide a chemical 
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tool to modulate p53 signalling in the zebrafish embryo. In conclusion, further 
characterisation of roscovitine targets and what biological functions they are 
essential in, will allow dissection of critical melanocyte pathways, and development 
of new/more specific applications for roscovitine therapy in disease, such as 
melanoma. In future experiments I would first test if the roscovitine phenotype is p53 
dependent, by establishing if the roscovitine phenotype is still apparent in p53 
mutant embryos (p53M214K/M214K; see Chapter 6 for further details). Following this I 
would address the role of CDKs, and if any specific CDKs mediate the roscovitine 
phenotype. I could do this by testing a panel of CDK inhibitors that target other 
specific subsets of CDKS, alternatively I could use morpholino knockdown of 
specific subsets of CDKS to try to phenocopy the roscovitine phenotype. 
 
3.4.4.	  Concluding	  remarks	  
 
To conclude, zebrafish are a useful model with which to screen for new phenotypes 
of established drugs. Zebrafish melanocyte development is homologous to mammals, 
and with the advantage of melanin retention they are an obvious cell type to assay in 
chemical screens. Our zebrafish small molecule screen has identified novel 
compounds, which affect zebrafish melanocyte morphology, number, pigmentation 
and migration. However it should be noted that some melanocyte phenotypes were 
difficult to classify and in these cases further study would help to distinguish 
ambiguous results. Also in some instances drugs caused general developmental 
defects, which can sometimes cause inadvertent effects on melanocyte biology, such 
as paler melanocytes. Therefore it is possible some false positives were incurred. In 
summary, we have highlighted new targetable pathways that could be essential in the 
development of drugs for melanocyte disease such as melanoma (Colanesi et al., 
2012). Finally we have identified new, easily accessible chemical tools with which to 
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4.	   5-­‐Nitrofuran	   treatment	   kills	   zebrafish	   differentiated	   melanocytes	  




Full understanding of the in vivo targets of clinically used drugs is essential to enable 
better drug design and the development of effective combination therapies. Recent, 
large-scale drug testing in multiple species has shown that the drug targets are often 
conserved. Zebrafish have become important tools to identify new chemical-genetic 
interactions, and to understand drug targets. Peterson and colleagues were the first 
group to carry out a small molecule screen in the zebrafish to identify drugs that 
affected zebrafish early development, and showed that small molecule treatment is a 
useful method to dissect important developmental timings (Peterson et al., 2000). 
Small molecule screening is also an effective method to discover new targets for 
already established drugs. In this manner the Zon laboratory were able to repurpose 
drugs already in use in the clinic (Goessling et al., 2011; Lord et al., 2007; North et 
al., 2007). 
 
Our laboratory is part of a collaborative effort with Professor Mike Tyers 
(Edinburgh, Montreal) to directly compare the effects of over 1600 compounds in 
multiple species, including mammalian cells, zebrafish, worms, flies, yeast and 
bacteria. Over 10,000 small molecules from the Maybridge screening collection were 
screened for effects on budding yeast growth. From this, 1600 were tested on 
zebrafish (H. Ishizaki, E.E. Patton, M. Tyers; manuscript in preparation). A subset of 
compounds was found to alter melanocyte development and pigmentation. Out of 
these, 45 compounds were found to directly interfere with melanocyte pigmentation 
by chelating copper, an essential co-factor for tyrosinase activity (Ishizaki et al., 
2010). However four other compounds were identified that were part of a 5-
nitrofuran class of drugs (NFN1-4 [Maybridge compounds: BTB05727, SEW00138, 
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BTB13657, and BR00087]) and were identified as causing loss of zebrafish 
melanocytes through an unknown mechanism (tyrosinase independent). I 
participated in work to understand how these compounds function in zebrafish 
melanocytes (Zhou et al., 2012b). 
 
5-nitrofurans are a class of pro-drugs used worldwide to treat Chagas disease, a 
trypanosome infection of the trypanosoma cruzi parasite, which can be potentially 
life threatening. The mechanism of action of 5-nitrofurans is known to be via 
reduction of the 5-NO2 moiety to a cytotoxic anion radical, a process that is 
dependent upon parasite-specific nitroreductases (NTR) (Castro et al., 2006; Zhou et 
al., 2012b). Despite the species-specific mechanism of 5-nitrofuran activity, there are 
still considerable side effects associated with these drugs, such as polyneuropathy, 
headaches, forgetfulness, depression and alcohol intolerance (Castro et al., 2006). 
These can often be so severe they often lead to premature cessation of drug-
treatments (Castro et al., 2006). Thus we reasoned 5-nitrofurans must have additional 
targets in humans that would account for at least some of the toxic side effects 
observed. Furthermore, the 5-nitrofuran nifurtimox is currently being investigated in 
clinical trials for use as a treatment against relapsed/refractory neuroblastoma 
(Saulnier Sholler et al., 2011; Saulnier Sholler et al., 2006). Therefore further 
understanding of 5-nitrofuran pharmacokinetics may help us to understand other 





4.2.1.	  5-­‐Nitrofuran	  melanocytotoxicity	  in	  zebrafish	  is	  dependent	  on	  its	  5-­‐
NO2	  moiety	  
 
In a chemical screen for modulators of melanocyte development in zebrafish, Dr H. 
Ishizaki identified four different 5-nitrofuran compounds that cause a loss of 
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melanocytes, (Maybridge), NFN1 (BTB05727), NFN2 (SEW00138), NFN3 
(BTB13657), and NFN4 (BR00087) (Figure 4.1) (Zhou et al., 2012b). Evidence 
suggests these compounds cause a reduction in melanocytes via melanocyte-specific 
cell death, and subsequent melanocyte fragmentation, detritus, and extrusion of 
melanocytes through the epidermis were observed, these are characteristic features of 
melanocyte death in zebrafish (Parichy et al., 1999). To assess if the 5-Nitrofuran 
phenotype in zebrafish is dependent upon the 5-NO2 moiety, the 5-NO2 group was 
chemically replaced by a hydrogen atom in a series of NFN derivatives (Zhou et al., 
2012b). I then tested these derivatives on 2 dpf wildtype embryos, and found 
derivatives lacking the 5-NO2 could not elicit a melanocyte cell death response in 
zebrafish (Figure 4.1, Table 4.1) (Zhou et al., 2012b). This result indicates that the 
nitro moiety is essential for activity in zebrafish, and suggests that NFN1 is 
processed in a similar manner as clinically active 5-nitrofurans, such as nifurtimox.   
 
4.2.2.	  Differentiated	  melanocytes	  are	  targeted	  by	  5-­‐Nitrofurans	  	  
 
Melanin is synthesised by differentiated melanocytes, and production of melanin 
synthesising proteins is a final stage of melanocyte differentiation (Lister et al., 
1999). Loss of pigment cells and pigment cell detritus suggests NFN1 is toxic to 
differentiated melanocytes. To directly address if NFN1 is toxic to differentiated 
melanocytes or if rather, NFN1 simply interferes with pigmentation, I made use of 
another marker of melanocyte differentiation, tyrp1-GFP transgenic embryos, a 
zebrafish j900 line that express GFP through the fugu tyrp1 promoter in neural crest 
derived melanocytes (Figure 4.2) (Hultman and Johnson, 2010). Tyrosinase-related 
protein-1 (tyrp1) is expressed in late-stage melanocyte specification, prior to 
pigmentation and is a key factor involved in melanin synthesis (Bertolotto et al., 
1998; Hultman and Johnson, 2010; Taylor et al., 2011). I treated 2 dpf tyrp1-GFP 
embryos with 1 µM NFN1 or a DMSO control for 5-days until pigmented 
melanocytes had fragmented and “died”.  I found that loss of melanocytes 
corresponded with loss of tyrp1 expression, suggesting that NFN1 activity did not 







Figure 4.1.  5-Nitrofurans Promote Melanocytotoxicity in Zebrafish. (A) Pigmented zebrafish 
embryos were treated at 2 dpf with a DMSO control, 5 μM NFN1, or 5 μM of its no-nitro 
derivative, NFN1.1 (B) Alternatively 2 dpf embryos were treated with 50 μM nifurtimox or a 
corresponding DMSO control. (A-B) Normal melanocytes are depicted by red arrows, whereas 
fragmented melanocytes and melanocyte detritus are depicted by blue arrows. (C) Nitrofuran 
derivatives all characterised by 5-NO2 group (red). NFN1-4 [Maybridge compounds BTB05727, 
SEW00138, BTB13657, and BR00087] were identified as melanocytotoxic agents in a small molecule 
screen in zebrafish (H.Ishizaki). NFN1.1 is identical to NFN1 except that its 5-NO2 functional group 






Compound 0.2 μM 0.4 μM 0.8 μM 1.6 μM 
NFN1 No activity No activity + +++ 
NFN1.1 No activity No activity No activity No activity 
NFN5 No activity + ++ ++++ 
NFN5.1 No activity + ++ ++ 
NFN5.2 No activity + ++ ++++a 
+ Some melanocytes become dendritic, few are fragmented. 
++ Some punctate and fragmented melanocytes. 
+++ All melanocytes are punctate, many clearly fragmented, pigment remains in eye. 
++++ All melanocytes are fragmented, with almost complete loss of pigment in body 
and eye. 
a Additional nonspecific toxicity. 
 
Table 4.1. Derivatives of 5-Nitrofurans and Their Activity in Zebrafish 







Figure 4.2.  Loss of differentiated melanocytes in NFN1 treated embryos. Zebrafish expressing 
GFP at a melanocyte specific tyrp1 promoter, show localisation of pigmented melanocytes and GFP 
expression. Following NFN1 treatment pigmented melanocytes are lost, and so too is the GFP 
expression. Most small black melanin detritus in not associated with GFP expression suggesting 
melanocyte loss/death (white arrow). However some melanocytes do survive (orange arrow).  Figure 
used with permission from Zhou et al., (2012). 
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4.2.3.	   5-­‐Nitrofuran	   melanocytotoxicity	   is	   independent	   of	   tyrosinase	  
activity	  
 
Melanocytotoxic agents are useful tools to study melanocyte biology, specifically 
melanocyte regeneration. A few such agents have been shown to be active in 
zebrafish melanocytes previously, however these are all predominantly through 
action on the Tyrosinase enzyme, during late-stage melanocyte specification 
(pigmentation) (O'Reilly-Pol and Johnson, 2008; Yang and Johnson, 2006). To test if 
NFN1 acts through tyrosinase, Dr H.Ishizaki treated pigmented 2 dpf wildtype 
zebrafish embryos with N-phenylthiourea (PTU), a compound that inhibits 
Tyrosinase (and therefore de novo pigmentation). After a 6-hour pre-treatment, 
embryos were then challenged with 0.5 µM NFN or DMSO as a control (Figure 4.2). 
The NFN1 melanocytotoxic phenotype is not abrogated by co-treatment with PTU, 
thus we can deduce NFN1 (and subsequently other 5-nitrofurans) are not dependent 
upon Tyrosinase for their activity in vivo. This is interesting as it identifies 5-
nitrofurans as a novel tool in which to study melanocytotoxicity that is independent 








Figure 4.3.  NFN1 melanocytotoxicity is independent of tyrosinase activity. 2 dpf embryos were pre-treated with PTU (30mg/ litre) for six hours to inhibit 
tyrosinase activity. Following this embryos were treated with 0.5 μM NFN1. PTU-NFN1 double treated embryos had equal levels of melanocyte toxicity to NFN1 only 
treated controls. PTU acts to inhibit melanogenesis reversibly without killing the melanocyte, PTU only treated embryos therefore had no loss of melanocytes, equal to 
the DMSO controls. Work was carried out by Dr H.Ishizaki, figure was used with permission from Zhou et al., (2012). 
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4.2.4.	  NFN1	  treatment	  restricts	  a	  melanocyte	  progenitor	  population	  
 
In order to further study melanocyte regeneration following NFN1-induced 
melanocytotoxicity, I identified an optimal NFN1 treatment window that results in a 
“white phenotype” i.e. loss of all melanocytes (retinal pigmented epithelium and 
neural crest derived).  I treated 30-50 hpf zebrafish embryos with a concentration 
gradient of NFN1, assayed for a ‘white phenotype”. Of note uniform loss of 
melanocytes was observed at all concentrations immediately prior to washout (Figure 
4.4, A). At 2 dpf drug was washed from embryos with fresh embryo media, and 
ensuing melanocyte regeneration was observed. Interestingly, treatment of embryos 
with higher concentrations of NFN1 caused a marked reduction in the embryos’ 
capacity to regenerate their melanocytes by 2 days post washout (4 dpf) (Figure 4.4, 
B). Indeed after prolonged treatment of NFN1 in embryos, some pigmentation 
phenotypes persist into adulthood, of which eye abnormalities and missing tail and 
fin stripes were the most common (data not shown). These data suggest that whilst 
NFN1 primarily acts to kill differentiated melanocytes in zebrafish, at higher 
concentrations NFN1 may also act upon a secondary target to affect a melanocyte 
progenitor population (MSC). As such, NFN1 is a unique tool with which to study 






Figure 4.4. NFN1 treatment restricts a melanocyte progenitor population. Embryos treated with 
increasing concentrations of NFN1 during an optimal treatment window (30-50 hpf). (A) All 
treatment concentrations resulted in considerable loss of total melanocytes by 50 hpf. (B) At 2 days 
post washout of the drug with fresh E3 medium there was a concentration-dependent effect on 
melanocyte regeneration: high NFN1 treatment dose (20 μM) limits regenerative capacity. Figure was 
used with permission from Zhou et al., (2012). 
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4.2.5.	  5-­‐Nitrofurans	  bind	  Aldh2	  in	  zebrafish	  
 
To investigate potential molecular interactors with 5-nitrofurans in vivo, 5-nitrofuran 
derivatives were designed which contained a phenyl ring tag to allow for affinity 
purification (Zhou et al., 2012; chemical synthesis by L.Zhou). These tagged 5-
nitrofuran derivatives were confirmed to be active melanocytotoxic agents in 
zebrafish (work by L. Zhou), thus 5-nitrofuran binding to its in vivo target in 
zebrafish should still be intact in this tagged derivative. Following this L. Zhou 
bound the tagged 5-nitrofuran compound on to streptavidin beads and performed an 
immunoprecipitation pull-down assay on 3 dpf wildtype zebrafish extract. The 57-
kD protein, aldehyde dehydrogenase-2b (Aldh2b) was subsequently identified by 
mass spectrometry (Figure 4.5). Aldehyde dehydrogenase (ALDH) in humans 
metabolises toxic aldehydes in the liver after alcohol consumption, in the heart after 
ischaemia, and in dopamine metabolism (Chen et al., 2008; Crabb et al., 1989; 
Druesne-Pecollo et al., 2009; Yao et al., 2010).  Zebrafish have a duplication of this 
gene (aldh2a and aldh2b), and aldh2b is known to be expressed in neural crest 
derived cells including possible melanocytes (Thisse et al., 2001). To validate this 
result, western blot analysis using an anti-zebrafish Aldh2 antibody was performed. 
Proteins from 3 dpf zebrafish extracts were immunoprecipitated using a 5-nitrofuran 
probe, a control furan probe (identical except the 5-NO2 moiety), and a no-probe 
control (Zhou et al., 2012b). More Aldh2 bound to the 5-Nitrofuran probe in 
comparison to the furan-only control, and no Aldh2 bound to the no-probe control 
(work by L. Zhou). This work identifies Aldh2b as a specific target for 5-nitrofurans 
in the zebrafish, and we hypothesise that aldh2b activity in melanocytes mediates the 







Figure 4.5. 5-Nitrofurans bind Aldh2 in zebrafish. (A) Chemical structures showing the design of a 
biotinylated (blue) probe fused to a nitrofuran (red) or its no nitro derivative (red). (B) Silver stain of 
protein bands pulled down by the tagged NFN1 versus a no-probe control. An extra band was 
identified at 57 KDa (red box), which was then shown to be Aldh2b by mass spectrometry analysis. 
(C) Western blot using a zebrafish Aldh2 antibody shows stronger interaction of Aldh2 with the NFN-
fused probe as opposed to the no nitro probe or a no probe control. All work for this figure was done 
by L.Zhou. Figure was used with permission from (Zhou et al., 2012). 
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4.3.6.	   Morpholino	   knockdown	   of	   aldh2b	   reduces	   5-­‐nitrofuran	  
melanocytotoxicity	  	  
 
Morpholino oligonucleotides are an antisense technology (~25 base pairs long) that 
block translation of a specific RNA nucleic acid sequence. By doing so they inhibit 
effective translation or splicing of the pre-mRNA, and subsequently down-regulate 
target gene expression (Dutton et al., 2001a). We wanted to test the effects of NFN1 
activity in aldh2b morphants. Both injections and PCR confirmation were done by 
Dr. Zhiqiang Zeng. I analysed NFN1 melanocytotoxic phenotypes in aldh2b 
knockdown embryos. Both translation block and splice-site morpholinos were 
designed (Gene Tools), and microinjected into 1-2 cell stage wildtype embryos. 
Standard control morpholino (Gene Tools) was used as a control, and aldh2b 
morphant embryos elicited no obvious developmental/melanocyte phenotype (Figure 
4.6). However, following NFN1 treatment, aldh2b morphants embryos showed a less 
severe melanocytotoxic phenotype than control morpholino injected embryos. I 
categorized the NFN1 melanocyte phenotype into two classes: Class I (strong) 
phenotype is characterised by severely contracted/punctate melanocytes with a large 
amount of fragmentation and detritus. Some pigment pattern is missing and eyes are 
only partially pigmented. In Class II (mild) phenotype, pigment pattern remains 
intact but melanocytes have a severe dendritic phenotype, with limited 
fragmentation/detritus. Eyes appear mostly pigmented. In a blind-score, the control 
morphant injected cohort had a significantly greater proportion of Class I (strong) 
phenotypes than both splice-site and translation block aldh2b morphants [p = 0.007; 
95% CI (0.139, 0.528); Fisher’s exact test]. These results provide strong evidence 
that the melanocytotoxic phenotype of 5-Nitrofurans (specifically NFN1) is through 







Figure 4.6. Morpholino knockdown of aldh2b reduces 5-nitrofuran melanocytotoxicity (A) Both 
control morpholino and aldh2b morpholino injected embryos were normal in development with 
normal numbers of darkly pigmented melanocytes. Following NFN1 treatment embryos could be 
scored as class I (strong) phenotype or class II (mild) phenotype. Class I phenotype embryos 
characteristically have small punctate melanocytes, loss of melanocytes with evidence of 
fragmentation and detritus, whereas class II phenotype embryos have spindly, dendritic or “shrunken” 
melanocytes. (B) Following NFN1 treatment at 3dpf, aldh2b morphant embryos were less sensitive to 
NFN1 treatment compared to control morphants [p = 0.007; 95% CI (0.139, 0.528); Fisher’s exact 
test, binomial test of proportions]. Morpholino injections were carried out by Dr. Zeng. Figure was 
used with permission from Zhou et al., (2012). 
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4.3.7.	   Chemical	   inhibition	   of	   Aldh2	   rescues	   melanocytotoxicity	   in	  
zebrafish	  
 
We used a chemical-genetic approach to further test the Aldh2- 5-nitrofuran axis in 
zebrafish. Daidzin is a natural extract found in the Kudzu Vine (Pueraria lobata), 
native to Southern Japan and South-eastern China. The Kudzu vine is traditionally 
used as an antidipsotropic agent to treat alcoholism. Antidipsotropic drugs act to 
reduce the body’s ability to metabolise noxious chemicals like alcohol, thereby 
prolonging the side effects of alcohol consumption (nausea, headache, dizziness). 
The active antidipsotrophic component in the Kudzu vine was recently isolated and 
identified as daidzin, a selective ALDH2 antagonist (Keung and Vallee, 1993a; 
Keung and Vallee, 1993b). We reasoned that if 5-nitrofurans rely upon Aldh2 for 
their bioactivation, inhibition of zebrafish Aldh2 by treatment with daidzin would 
rescue the zebrafish 5-nitrofuran phenotype (melanocytotoxicity). 
 
 I pre-treated 2 dpf zebrafish embryos with daidzin or a DMSO control to allow 
sufficient absorption of the drug, and then treated these embryos with low doses of 
the 5-nitrofurans, NFN1 and the clinically-used Nifurtimox. Daidzin/5-nitrofuran 
double-treated embryos had either normal-looking melanocytes or a remarkably 
milder melanocytotoxic phenotype compared to DMSO/5-nitrofuran double treated 
controls (Figure 4.8). This additional piece of evidence confirms the Aldh2 - 5-
Nitrofuran axis is essential to promote melanocyte cell death in zebrafish. 
Importantly, it also identifies daidzin as a potential drug for combination therapy 





Figure 4.7. Small molecule screen to identify suppressors of the NFN1 phenotype.  Adult 
zebrafish were pair mated and embryos were collected and distributed 5/well into a 24-well plate. At 
30 hpf embryos were treated with 20 μM NFN1 alongside drugs from small molecule libraries 
(5/10/20 μM). At 50 hpf embryos were assessed for melanocytotoxic phenotypes, and any suppressors 
of melanocyte toxicity were scored as hits. Schematic adapted from work by Nicola Grant. 
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4.3.8.	   Design	   of	   a	   small	   molecule	   screen	   to	   identify	   5-­‐Nitrofuran	  
suppressors	   	  
 
Chemical suppressors of NFN1, such as daidzin, help us to understand the 
mechanism of NFN1 action in vivo. Thus I designed a small molecule screen to 
identify novel bioactive compounds that showed suppression of the 5-nitrofuran 
melanocytotoxicity phenotype in zebrafish (Figure 6.1). Zebrafish embryos  (30 hpf) 
were treated with 20 µM NFN1, an optimised dose to produce a strong 
melanocytotoxic effect i.e. a “white phenotype” in the embryo. Embryos were co-
treated with compounds from small molecule libraries (Sigma LOPAC library, the 
Enzo Life-Sciences Screen-WellTM Kinase Inhibitor library and the Enzo Life-
Sciences Screen-WellTM Phosphatase Inhibitor library), and the NFN1 phenotype was 
assessed at 50 hpf. Small molecule libraries were treated at a standard dose of 10 
µM, however for small libraries such as the Enzo Phosphatase and Kinase Inhibitor 
libraries (~120 compounds in total), three treatment doses were used 5 µM, 10 µM, 
20 µM.  All drugs that suppressed NFN1-induced melanocyte toxicity were scored. 
 
4.3.8.1.	  PKC	  inhibitors	  suppress	  5-­‐Nitrofuran	  activity	  in	  zebrafish	  
 
I screened 753 compounds for NFN1-suppressor activity and identified 4 
compounds: a glutamate-gated chloride channel inhibitor (Ivermectin: LOPAC 
library), a CaMKII inhibitor (KN-62; Enzo Life Sciences Kinase Inhibitor library), 
and two PKC inhibitors (PKC-412 and Ro 31-8220; Enzo Life Sciences Kinase 
Inhibitor library). The probability of identifying two PKC inhibitors lends 
authenticity to a 5-nitrofuran - PKC axis. Moreover, PKCε is a well-known ALDH2 
activator in humans. PKCε has been shown to translocate to the mitochondria in 
response to oxidative damage caused by alcohol consumption or ischaemia, PKCε 
then phosphorylates and activates ALDH2 (Yao et al., 2010; Yao et al., 2008). 
Accordingly we chose to validate these two PKC inhibitor hits, PKC-412 and Ro 31-
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8220.  I pre-treated 2 dpf zebrafish embryos with 20 µM of either PKC-412, Ro 31-
8220, or a DMSO control. Embryos were then treated with NFN1 for 2 days and the 
ensuing melanocyte toxicity was scored. NFN1-only treated controls showed a 
severe loss of melanocyte number, fragmentation and cell death of melanocytes. In 
comparison, NFN1 treated embryos co-treated with either PKC-412 or Ro 31-8220 
showed a remarkable rescue of melanocyte toxicity (Figure 4.8). Most melanocytes 
in these PKC inhibitor treated embryos had a normal phenotype or showed only a 
mild toxicity phenotype (slight dendricity and few instances of melanocyte 
fragmentation). 
 
As PKC activates ALDH2 we reasoned a PKCε-specific inhibitor could be a potent 
inhibitor of the 5-nitrofuran phenotype in zebrafish. GF 109203X is a potent, 
selective inhibitor of PKCε. After pre-treatment with GF 109203X and thereafter co-
treatment with NFN1, 35/40 embryos showed a rescue of the NFN1 melanocyte 
phenotype, suggesting that PKC activity is indeed necessary for the activity of 5-
nitrofurans in vivo (Figure 4.8). Additionally GF 109203X was also able to rescue 
the melanocyte phenotype after treatment with 50μM Nifurtimox, a clinically used 5-
nitrofuran (Figure 4.8). This is further compelling evidence to support an Aldh2b- 5-
nitrofuran axis in zebrafish; we hypothesise this is relevant to human off-target 
effects of 5-nitrofurans such as nifurtimox. Zhou and colleagues corroborated this 
theory by demonstrating human ALDH2 could bind 5-nitrofurans in vitro (Zhou et 
al., 2012b). We thus propose PKC is an additional target with which to control 
ALDH2 activation, and suggest drugs that target PKC could be useful in 






Figure 4.8. Chemical inhibition of aldh2 rescues melanocytotoxicity in zebrafish. (A) 2 dpf 
pigmented embryos were pre-treated with 20 μM daidzin, or either PKC inhibitor (PKC-412 or Ro-
318220) for 1 hour. Following this embryos were treated with 5 μM NFN1. Embryos treated with 
NFN1 showed considerable melanocyte loss, including melanocyte fragmentation and detritus. 
Double treated embryos all showed a remarkable rescue of NFN1 induced melanocytotoxicity, with 
normal melanocytes or only slightly affected melanocytes (dendritic). Three technical replicates each 
with n> 10 (B) 2 dpf embryos were pre-treated with 30 μM daidzin (Aldh inhibitor) or GF 109203X 
(PKCε inhibitor) for 1 hour. Following this they were then treated with 50 μM nifurtimox. After just 7 
hours of treatment, nifurtimox only treated embryos had a mild melanocytotoxic phenotype, 
characterised by “shrinking” of melanocytes to a punctate phenotype (red arrow), this was absent in 
double-treated embryos. Three technical replicates with 5-10 embryos per condition. Figure used with 
permission from (Zhou et al., 2012b). 
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4.3.9.	  A	  role	  for	  zebrafish	  aldh2	  in	  melanocyte	  background	  adaptation	  
 
We wanted to understand the melanocyte specific nature of the 5-nitrofuran 
cytotoxicity in zebrafish and asked what melanocyte specific function zebrafish 
Aldh2 mediates. ALDH2 in humans has a known role in metabolising by-products of 
dopamine synthesis (Yao et al., 2010). Zebrafish melanocytes rely on the dopamine 
pathway to control melanin dispersal throughout the melanocyte in response to 
light/dark stimulus (background adaptation) (Logan et al., 2006). Background 
adaptation allows zebrafish to respond to their environment and camouflage 
themselves. Following dark exposure, melanin is dispersed throughout melanocytes, 
covering more surface area of the fish with pigment and making the fish appear 
darker. Following light exposure, melanin distribution aggregates within the 
melanocyte, and “contracted” looking melanocytes make the overall fish appear 
paler. Increased cAMP levels following dopaminergic signalling caused zebrafish 
melanocytes to disperse (Logan et al., 2006). If background adaptation in the 
zebrafish relies upon dopaminergic signalling then we hypothesised that chemical 
inhibition of Aldh2 would have a knock-on effect on dopaminergic signalling in the 
zebrafish, and hence on background adaptation. 5 dpf embryos were treated with 10 
µM daidzin or a DMSO control and were subjected to a series of dark-light or light-
dark cycles. DMSO control embryos contracted their melanocytes in response to 
light and expanded their melanocytes in response to dark environments [p < 0.001, n 
= 20 for each condition; ANOVA, 95% confidence interval 11.081(5.966, 16.195)]. 
However, whereas daidzin treated embryos could successfully contract their 
melanocytes in response to light, their melanocytes remained contracted after 
exposure to dark (Figure 4.9) (work done by N.Temperley) [95% CI 0.563(4.552, 
5.677)]. As a result, chemical inhibition of zebrafish Aldh2 impairs background 
adaptation in zebrafish. Thus we hypothesise Aldh2 has a unique role in background 
adaptation of zebrafish melanocytes, thus suggesting why zebrafish melanocytes 
have an enhanced 5-nitrofuran sensitivity. Of note, human melanocytes are sensitive 
to 5-nitrofuran treatment in culture (E.E.Patton, H.Ishizaki; data not shown), 
however patients treated with nifurtimox do not show any symptoms of melanocyte 






Figure 4.9. A role for zebrafish aldh2 in melanocyte background adaptation. Zebrafish embryos (>72 hpf) are able to respond to light stimulus in order to contract 
or expand their melanocytes as necessary. 5 dpf were pre-treated with 10 μM daidzin and shifted from a dark environment to a light environment (light), and another 
subset were shifted from a light environment to a dark environment (dark). Embryos were immediately fixed in 4% PFA, and following imaging the average 
percentage of melanin cover was calculated in a defined head region (IPLAB). In DMSO-treated embryos, melanocytes are significantly contracted in the light and 
expanded in the dark [p < 0.001, n = 20 for each condition; ANOVA, 95% confidence interval 11.081(5.966, 16.195)]. However those embryos treated with daidzin 
contracted their melanin in response to light but did not significantly expand their melanin in response to dark environments [95% CI 0.563(4.552, 5.677)]. The 
experiment was repeated three separate times with embryos at 5 dpf (n = 5–20 embryos per condition) and once with embryos at 4 dpf (n = 10 embryos per condition). 
Work done by Dr N.Temperley, figure used with permission from Zhou et al., (2012). 
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4.4.	  Future	  Work	  &	  Discussion	  
  
In summary, Dr Ishizaki screened 1576 compounds in a phenotype-based small 
molecule screen; from this he identified a class of 5-Nitrofuran drugs that cause loss 
of differentiated melanocytes in the zebrafish. A challenge of phenotype-based drug 
screening can be the identification of the drug target (Taylor et al., 2010). In this 
paper, L. Zhou used classical biochemical affinity approaches to identify the enzyme 
aldehyde dehydrogenase 2 (Aldh2) as the zebrafish target protein. We therefore 
hypothesise that 5-nitrofurans act as a pro-drug in zebrafish, and that Aldh2 in 
zebrafish melanocytes can metabolise the 5-NO2-furan group into a cytotoxic form. 
To support this hypothesis I could show that treatment of zebrafish with no-nitro 
derivatives of 5-nitrofurans (e.g. NFN1.1), in which the 5-NO2 furan group has been 
replaced by a hydrogen atom, is sufficient to abolish melanocytotoxic activity in 
zebrafish.  
 
In human (and mammalian) liver cells, breakdown of alcohol can lead to an 
accumulation of cytotoxic acetylaldehyde, which is subsequently converted into non-
toxic acetate by ALDH2. The ALDH2 inhibitor, disulfram is utilised in the clinic as 
an antidipsotropic agent, and results in unwanted side effects associated with alcohol 
consumption due to accumulation of toxic acetylaldehyde. In addition to the vital 
role ALDH2 plays in human liver cells (Crabb et al., 1989), ALDH2 also has a key 
role in the dopamine synthesis pathway (Yao et al., 2010; Yao et al., 2008). 
Dopamine metabolism leads to the production of DOPAL (3,4-
dihydroxyphenylacetaldehyde), which has a role in negative regulation of further 
dopamine synthesis. ALDH2 is responsible for conversion of DOPAL to DOPAC 
(3,4-dihydroxyphenylacetic acid), thus attenuating DOPAL negative feedback.  
Cocaine addiction results from increased extracellular levels of dopamine. Thus 
ALDH2 inhibitors (disulfram) are thought to limit cocaine addiction, presumably by 
increased DOPAL mediated negative feedback of dopamine synthesis (Schroeder et 
al., 2010; Weinshenker, 2010; Yao et al., 2010). Subsequently, these cell-specific 
functions of ALDH2 within the human may explain many of the common side 
effects (intolerance to alcohol, gastrointestinal problems, headaches) associated with 
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5-nitrofuran treatment in the clinic (nifurtimox) (Castro et al., 2006). It is possible 
that 5-nitrofurans are converted to their toxic form by ALDH2 in these specific cell 
types. To corroborate this theory, 5-nitrofurans have been shown to be substrates for 
human ALDH2 in vitro (Zhou et al., 2012). The next steps would be to assay human 
liver cells and dopaminergic neurons to test for potential 5-nitrofuran sensitivity. If 
our hypothesis is correct and ALDH2 mediates 5-nitrofuran off-target effects in 
humans, then the implications of this would be huge: nifurtimox is a 5-nitrofuran in 
widespread use for the treatment of Chagas disease, and the severe side-effects 
associated with nifutimox treatment often result in the cessation of treatment (Castro 
et al., 2006). We propose that ALDH2 inhibitors in the clinic could be used in 
combination with nifurtimox treatment to alleviate 5-nitrofuran-associated side 
effects in humans.  Of note Zhou and colleagues showed that co-treatment of daidzin 
with nifurtimox had no effect on trypanocidal activity (Zhou et al., 2012b), therefore 
we can postulate that co-treatment of ALDH2 inhibitors would not affect clinical 
activity of 5-nitrofurans.  
 
In this study, screening for drugs that affect melanocyte biology led us to further 
understand the pharmacokinetics of a widely used class of drugs in the clinic, 5-
nitrofurans. This result was wholly unexpected, but sheds new light on a fundamental 
class of drugs for the treatment of Chagas disease, and may help to limit the toxic 
side effects associated with nifurtimox treatment. Additionally ALDH inhibitors are 
already in use in the clinic as antidipsotropic drugs, and as drugs to limit cocaine 
addiction. Recent evidence also suggests high ALDH activity is a marker for cancer 
stem cells (tumourigenic cells that can self renew and differentiate into multiple cell 
types), including melanoma stem cells (Huang et al., 2012; Luo et al., 2012). As such 
there is an increasing need to further understand ALDH biology in vivo. Zebrafish 
may provide a useful new tool with which to further identify novel drugs that target 
Aldh2 and the dopamine synthesis pathway, in order to dissect these ALDH 
pathways. This study is a prime example of how zebrafish small molecule screening 
can help uncover novel biological understanding of previously studied molecular 












Chapter	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One of the key questions in developmental biology is to understand the processes 
that control total cell number. Tissue-specific cells are often repopulated by 
differentiation of a progenitor or “stem cell” population such as haematopoietic stem 
cells (HSC), which differentiate into terminally differentiated red blood cells. Blood 
cell number is maintained by expansion of the Haematopoietic Stem Cell (HSC) 
population by proliferation and subsequent differentiation; the blood cells themselves 
do not have the capacity to divide (Hellman et al., 1978; Purton et al., 2006). Another 
example of stem cell renewal of a specific tissue type is in the intestinal epithelium, 
the most rapidly self-renewing organ in mammals. In this system self-renewing stem 
cells located in the crypts give rise to a transient amplifying population, which then 
rapidly proliferates and differentiates into enterocytes, goblet cells and 
enteroendocrine cells (Sato et al., 2009). Conversely there are other differentiated 
cell types whose main mechanism of repopulating their cell numbers is by 
differentiated cell division, such as pancreatic β-cells and horizontal neurons in the 
retina (Ajioka et al., 2011; Ajioka et al., 2007; Brennand et al., 2007). Additionally 
renewal of astrocytes and ependymal cells in the adult spinal cord are restricted to 
self-duplication, but these cells can also function as oligodendrocyte precursors and 
are thought to represent an adult neural stem cell population (Barnabe-Heider et al., 
2010). It is unknown why some tissues are predominantly renewed through 
differentiation of a stem cell population, whereas others renew mainly through 
differentiated cell division. In mammalian melanocyte biology the main mechanism 
of melanocyte renewal at the hair follicle is known to be by differentiation of MSCs. 
Additionally in the zebrafish, melanocyte development was previously thought to be 
entirely through differentiation of neural crest cells or of a progenitor population 
(MSCs). The role of differentiated melanocyte division in both early melanocyte 
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development or melanocyte homeostasis has not yet been fully characterised in an in 
vivo model. 
 
Mechanisms of mouse melanocyte development have been well established. As the 
hair follicle undergoes many successive rounds of hair growth and pigmentation, 
extensive renewal of melanocyte numbers is necessary (Nishimura et al., 2002). 
Therefore the hair follicle has become a useful model to study stem cell 
development. It is known that initial ontogenetic melanocyte development occurs by 
neural crest cell development into unpigmented melanoblasts, which are highly 
migratory and proliferating melanocyte precursors. Melanoblasts proliferate 
primarily in the dermis before migration, expansion and localisation to hair follicles 
in the epidermis (Jordan and Jackson, 2000b; Mackenzie et al., 1997). The first wave 
of melanocyte development at the hair follicle occurs independently of a MSC 
population (Mackenzie et al., 1997). However during successive rounds of hair 
growth and pigmentation melanocyte numbers need to be maintained to sustain hair 
pigmentation. Melanocyte renewal occurs via unpigmented melanoblasts that reside 
in the hair follicle bulge (NB. these melanoblasts are undifferentiated precursor cells 
that are responsible for renewing melanocyte populations, therefore they satisfy the 
definition of a stem cell and I will thus refer to them as MSCs). MSCs at the hair 
follicle bulge undergo extensive rounds of self-renewal (transit-amplifying period), 
and then migrate down to the hair follicle bulb, where they differentiate into 
melanocytes and pigment the hair (Nishimura, 2011; Nishimura et al., 2002). 
Differentiation seems to be mutually exclusive from proliferation in the MSCs and 
inhibition of differentiation at the hair follicle bulge appears to be a mechanism to 
maintain the stem cell pool (Aubin-Houzelstein et al., 2008; Inomata et al., 2009; 
Nishimura et al., 2002). Evidence suggests differentiated melanocyte division may 
play a role in mammalian melanocyte biology. Radioactive thymidine incorporation 
studies in human skin sections inferred the existence of differentiated melanocyte 
division (Jimbow et al., 1975). Additionally timelapse imaging has captured division 
events in both melanocyte and melanoma cell cultures (Bennett, 1983; Bennett, 
1989). Finally evidence suggests that melanocyte proliferation may play a role in 
pigmentation at the site of skin wounding, or in re-pigmentation of vitiligo (Hirobe, 
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1988). However the majority of literature about melanocyte homeostasis describes 
differentiation of unpigmented progenitor cells, both in the mouse hair follicle, and 
during zebrafish melanocyte regeneration. Much less is known about the molecular 
processes that contribute to melanocyte proliferation. 
 
In the zebrafish, it is unknown if differentiated melanocyte division contributes to the 
melanocyte pigment pattern. What was firmly established in the zebrafish model was 
that neural crest cells delaminating from the neural tube were the main cell type to 
constitute the embryonic pigment pattern, through a process of direct ontogenetic 
melanocyte development (Raible and Eisen, 1994; Raible et al., 1992). This process 
is analogous to neural crest derived melanocyte development in mammals, and 
requires signalling through homologous pathways for its progression (Johnson et al., 
1995; Kelsh et al., 1996). Zebrafish melanocyte renewal is believed to occur via 
development of melanocytes from a presumed MSC population (Budi et al., 2008; 
Budi et al., 2011; Hultman et al., 2009). Zebrafish have two distinct pigment 
patterns: first during embryonic development, which is mainly derived from direct 
developing neural crest cells (Hultman and Johnson, 2010). Following this, during 
metamorphosis zebrafish develop their adult pigment pattern stripes, which are 
constituted of de novo developing melanocytes, these are presumed to develop from 
a MSC lineage (Budi et al., 2011; Johnson et al., 1995). While no markers for MSCs 
exist yet in zebrafish, it is presumed MSCs contribute to melanocyte development 
during metamorphopsis and renewal during regeneration. Evidence to support this is 
the dramatic addition of melanocytes to the pigment pattern during metamorphosis 
(from 15 dpf) (Johnson et al., 1995). Additionally mutations have been identified 
which only affect the adult pigment pattern but have no effect on the embryonic 
pigment pattern (Budi et al., 2008; Johnson et al., 1995; Kelsh et al., 1996; Parichy et 
al., 2000; Parichy and Turner, 2003a; Parichy and Turner, 2003b), suggesting these 
mutations affect a distinct melanocyte lineage to direct developing neural crest 
melanocytes. Finally, in zebrafish erbb signalling has been shown to have a role in 
the establishment of these “MSCs”. Zebrafish erbb dependent melanocyte precursors 
have been implicated in development of the adult pigment pattern at metamorphosis, 
and during melanocyte regeneration following chemical or genetic ablation of 
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melanocytes (Budi et al., 2008; Budi et al., 2011; Hultman et al., 2009; Hultman and 
Johnson, 2010; Johnson et al., 2011). In mammals, ERBB receptor activation is 
required for development of Schwann cell precursor cells (SCPs), which act as 
nerve-associated stem cells that are able to constitute both Schwann cell and 
melanocyte lineages (Adameyko and Lallemend, 2010; Adameyko et al., 2009). 
Evidence in the zebrafish suggests an analogous Erbb sensitive melanocyte precursor 
population may exist (Budi et al., 2011). 
 
The zebrafish system provides us with a unique platform with which to study 
melanocyte biology in vivo. Zebrafish are a unique tool that are ideal for timelapse 
imaging: as embryos they are small, optically transparent, and early embryos can 
develop as normal immobilised in a drop of agarose for relatively long periods of 
time (~5 days) (Taylor et al., 2011). I wished to use this unique tool to study normal 
melanocyte development, and melanocyte regeneration in the zebrafish to answer the 
following questions: (1) does differentiated melanocyte division contribute to 
ontogenetic melanocyte development? (2) What role does melanocyte division play 
in regeneration from a progenitor population? (3) How can differentiated melanocyte 





5.2.1.	   Timelapse	   imaging	   of	  melanocyte	   development	   in	   the	   zebrafish	  
embryo	  
 
Timelapse imaging of early zebrafish development can be used to investigate 
melanocyte development in vivo. Through this method I can specifically observe 
timings of melanocyte development, melanocyte lineage, melanocyte migration, and 
possible interactions with other cell types. Embryos were imaged from 24 hpf 
through to ~92 hpf in nine embryos, and from 72 hpf to ~116-144 hpf in another 10 
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embryos. To control rate of growth, temperature was maintained at a standard 
incubation temperature of 28.5°C inside a timelapse-imaging chamber. A key feature 
of this technique was to remove agarose from around the tail of the embryos to allow 
for normal tail extension during development. To allow for better optical resolution, 
z-stack images were taken through the depth of field (7 images, 20 µm apart), and 
could then be condensed into a z-projection of all the data. By doing this I was 
accurately able to track melanocyte development through a large (300 μm) range. I 
chose to image pigment development in the head of the embryo as this region could 
be consistently kept constant, and because both early and late-developing 
melanocytes in the head are constituted from direct-developing melanocytes (Figure 
5.1) (Hultman and Johnson, 2010). Through the power of timelapse imaging, we can 
track the lineage of a differentiated melanocyte back to its initial development. 
Newly developing melanocytes can be visualised as small round faintly pigmented 
cells, which rapidly darkened. I observed melanocytes were highly motile until ~72 
hpf at which point they rounded and became static. This suggests that some specific 
molecular cue, or perhaps an environmental cue, enables early developing 
melanocytes to undergo extensive migration, and likely this cue is possibly not 
present in mature differentiated melanocytes or an older environmental cue. The 
majority of de novo melanocyte development occurred during an initial wave of 
development between 24-36 hpf (Figure 5.2) (Taylor et al., 2011).  
 
Crucially, I also identified a rare population of melanocytes that were derived from 
differentiated melanocyte division. Melanocyte division events were observed in five 
of the nine embryos followed until 90 hpf, but these only contribute to a small 
proportion of the final melanocyte pigment pattern (8/164; 4.6%). Division events 
were visualised by analysing images over time, through z-stacks and using enhanced 
contrast techniques. Immediately prior to melanocyte division during normal 
development, the parent cell becomes rounded in morphology, large and highly 
pigmented then divides and separates, a process that takes about an hour (Figure 5.2 
B).  Melanocyte division only occurs during late-stage pigment pattern development 
(72 hpf onwards), but parent cells constitute both late and early developing 
melanocytes. In summary, in vivo evidence shows that differentiated melanocyte 
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division plays only a minor role in establishing the pigment pattern in the zebrafish 
embryo. In these observations I have used melanin as a marker for differentiated 
melanocytes, however it would be interesting to analyse if dividing cells are positive 





Figure 5.1. . Melanocyte counting. All melanocyte counts took place on a defined head region, 
which extended from halfway between the eyes down to ears (yellow dotted line). Scale bar: 100 





Figure 5.2. .Melanocytes develop from undifferentiated precursor cells and from pigmented 
melanocytes. 
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Figure 5.2. .Melanocytes develop from undifferentiated precursor cells and from pigmented 
melanocytes. (A) Still images taken from timelapse microscopy movies of wildtype zebrafish 
melanocyte development, taken of a dorsal view of the head region. De novo melanocytes were 
observed emerging as pigmented dendritic cells. Most of these de novo melanocytes did not divide 
(b,c). However a few pigmented melanocytes were observed to undergo division (a). Scale bar 100 
μm. (B) Magnified view of the melanocyte division event observed (a).  Melanocyte division took 
place within 1.3 hours, with the parent melanocyte becoming static and rounded before division. The 
yellow dotted lines depict the outline of the cells as determined by analysis z-stack focuses through 
the image. (C) Quantification of melanocyte development. Nine wildtype melanocytes were tracked 
by timelapse imaging throughout development from 1-4 dpf. De novo developing melanocytes are 
marked as grey diamonds (n=166), and division events are depicted as yellow diamonds (n=8).  A 
further ten embryos were analysed between 72 – 144 hpf by timelapse imaging, this highlighted a 
further two late dividing melanocytes, and only one de novo developing melanocyte. Thick grey lines 




5.2.2.	  Pigmented	  cell	  division	  occurs	  in	  differentiated	  melanocytes	  
 
Through timelapse imaging of early melanocyte development in zebrafish embryos I 
identified a small population of pigmented cells that were capable of division, and 
suggest that these are melanocytes undergoing differentiated cell division. I wanted 
to confirm these cells were in fact differentiated melanocytes. To do this I analysed 
another marker of melanocyte differentiation. Tyrosinase-related protein-1 (Tyrp1) 
is an enzyme directly involved in pigment synthesis and is a late-stage marker of 
differentiated melanocytes (Braasch et al., 2009). We made use of a transgenic line 
that labels neural crest derived differentiated melanocytes (the j900 zebrafish 
transgenic line expresses GFP at the fugu tyrp1 promoter) (Hultman and Johnson, 
2010). Through timelapse imaging I analysed melanocyte lineage using tyrp1-GFP 
as a marker for melanocyte differentiation and confirmed that tyrp1-GFP expression 
directly precedes melanisation in the melanocyte (Figure 5.3) (Hultman and Johnson, 
2010). One caveat of this transgenic line is that cellular GFP expression is obscured 
by melanin in the cell, therefore characteristically we observe contracted 
melanocytes with surrounding GFP signal at the edges (Figure 5.4 A). The figure 
shows an example of a late stage developing melanocyte undergoing differentiated 
melanocyte division. I clearly noted tyrp1-GFP expression immediately prior to 
melanisation of the melanocyte (83.3 hpf). Once melanised this cell rounded and 
went through a stage of mitosis giving rise to two distinct daughter cells (89 hpf), 
which then migrate away from each other (93 hpf). Melanocyte division was 
observed to take about an hour (Braasch et al., 2009). 
 
Melanin absorbs GFP signal, therefore pigment in melanocytes of the tyrp1-GFP line 
may obscure visualisation of intracellular features in the melanocyte. To counter this 
problem I analysed melanocyte development in tyrp1-GFP embryos that were 
crossed on to an albino background (Streisinger et al., 1986). Albino zebrafish 
develop normal melanocytes but cannot produce melanin (Kelsh et al., 1996; Kelsh 
et al., 2000b). Intracellular GFP expression can thus clearly be seen within the 
melanocyte cytoplasm (Figure 5.4 B) Immediately prior to melanocyte division, cells 
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became rounded, (Figure 5.4 B; 73.7 hpf). During subsequent cell division GFP 
expression was also pulled apart into separate daughter cells in an equal fashion 
(Figure 5.4 B; 74.0 hpf). GFP expression from the tyrp1 promoter is indicative of 
late-stage melanocyte differentiation. Therefore I conclude that I am able to capture 
genuine differentiated melanocytes undergoing mitosis, and have confirmed this with 
two markers of melanocyte differentiation (melanin and tyrp1-GFP expression). 
However, timelapse imaging of stable differentiation markers such as GFP and 
melanin is not suitable to detect transient loss of expression or pigment. Thus I 
cannot discount the possibly of transient dedifferentiation of melanocytes taking 





Figure 5.3. Tyrp1-GFP expression precedes melanocyte pigmentation. (A) Tyrp1-GFP embryos 
express GFP at a melanocyte specific tyrp1 promoter. Stills from timelapse movies show a dorsal 
view of the head region during normal melanocyte development. (B) Magnification of the boxed 
region in (A), highlighting a developing unpigmented melanocyte that is initially GFP positive (32.7 
hpf). Following this the melanocyte undergoes onset of pigmentation (33.3 hpf) and develops into a 




Figure 5.4. Visualisation of the differentiation marker tyrp1-GFP during cell division. Timelapse 
imaging of developing melanocyte division in tyrp1-GFP embryos. GFP expression can be observed 
prior to melanisation (83.3 hpf). This melanocyte then pigments (85.3 hpf), and becomes rounded 
(88.7 hpf) immediately before melanocyte division (89 hpf). The two daughter cells then migrate 
away from each other (93 hpf). (B) Tyrp1-GFP embryos crossed on to an albino background allow 
clear visualisation of the melanocyte cytoplasm. The melanocyte becomes rounded in shape (73.7 
hpf), followed by melanocyte division (74 hpf) and separation of the two daughter cells (76.3 hpf). 
Figure used with permission from Taylor et al., (2011). 
129 
  
5.2.3.	   Differentiated	   cell	   division	   is	   enhanced	   during	   melanocyte	  
regeneration	  after	  NFN1	  treatment	  
 
I have shown that differentiated melanocyte division plays a role in normal 
development. Next I wanted to explore if differentiated melanocyte division was 
specific to a regenerating melanocyte population from a MSC pool. Chemical 
ablation of melanocytes after melanocytotoxic drug treatment promotes melanocyte 
regeneration from a MSC population (Hultman et al., 2009; Yang and Johnson, 
2006). 5-Nitrofurans are a class of drug that cause differentiated melanocyte cell 
death through activation at the Aldh2 enzyme (Zhou et al., 2012b) (See Chapter 4). I 
have previously shown that treatment of 30 hpf embryos with NFN1 (20 µM) kills 
zebrafish differentiated melanocytes, resulting in a “white phenotype”. Treatment of 
30 hpf embryos with this dose (20 μM) is sufficient to impair ensuing melanocyte 
regeneration, which suggested NFN1 could also deplete a MSC population (see 
Chapter 4). I used NFN1 as a tool to ablate melanocytes in the zebrafish embryos 
prior to timelapse imaging. I hypothesised that regenerating melanocytes from a 
MSC lineage may behave differently to ontogenetic melanocytes from a neural crest 
lineage. Additionally I hypothesised that if NFN1 is acting to deplete a MSC 
population, then ensuing melanocyte regeneration may depend upon a greater 
contribution of differentiated melanocyte division. NFN1 was washed out of treated 
wildtype embryos with E3 medium at 50 hpf, and melanocyte regeneration was 
monitored over the ensuing days using timelapse imaging. Melanocyte division 
events were observed in seven out of nine fish imaged. Importantly, a larger 
proportion of melanocytes were derived from differentiated cell division during 
melanocyte regeneration (n=21/132; 15.9%) than compared to normal development 
(8/164; 4.6%) [P=0.001; 95% CI (0.043, 0.18); binomial test of comparison of 
proportions]. We hypothesise that increased melanocyte division events may be 
because MSC-derived cells have a greater capacity to undergo differentiated 
melanocyte division or perhaps differentiated melanocyte division events are 
enhanced within the embryo to counteract possible MSC depletion following NFN1 
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treatment. Alternatively a change in molecular environment in the regeneration 
model could promote differentiated melanocyte division. Interestingly the rate of 
melanocyte regeneration varied between embryos. Onset of regeneration occurred 
any time between 54-73 hpf, and melanocytes tend to regenerate gradually over time 
instead of the initial wave of development as observed during ontogeny (Figure 5.5). 
NFN1 targets both differentiated melanocytes and presumably a MSC population, 
therefore variability in melanocyte regeneration could be because NFN1 is targeting 
multiple populations, and this is likely dependent upon NFN1 drug penetrance or 





Figure 5.5 Melanocyte division events are enhanced during melanocyte regeneration. (A) 
Schematic shows embryos were treated with NFN1 (Maybridge compound BTB05027) from 30-50 
hpf, which caused ablation of differentiated melanocytes (B). Embryos were washed out and allowed 
a 1-hour recovery before timelapse image analysis (black bar) of ensuing melanocyte regeneration. 
(C, D) Quantitative representation of regenerating melanocytes derived from de novo development 
(grey diamonds; n=111) and of numbers of melanocyte division events (yellow diamonds; n=21) in 
nine different zebrafish (i-ix). Figure used with permission from Taylor et al., (2011). 
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5.2.4.	   Differentiated	   cell	   division	   is	   enhanced	   during	   melanocyte	  
regeneration	  in	  mitfavc7	  embryos	  	  
 
We wanted to investigate the role of melanocyte division in another melanocyte 
regeneration model. Microphthalmia-associated transcription factor (MITF) is the 
master melanocyte specification factor. It is highly conserved amongst species from 
humans through to zebrafish. MITF is absolutely required for neural crest derived 
melanocytes to develop; severe mutations in Mitf in mice are characterised by white 
coat colour and pink eyes (Tachibana et al., 1994). Zebrafish have a duplication of 
the mitf gene, mitfa and mitfb (Lister et al., 2001). Zebrafish mitfa specifies neural 
crest derived melanocyte development, whereas zebrafish mitfb is required for 
development of the retinal pigment epithelium (RPE) (eyes) (Lister et al., 2001). The 
mitfavc7 hypomorphic transgenic line is a unique tool that it allows temperature 
sensitive control of functional mitfa expression. At low, permissive temperatures 
(<26°C) functional mitfa can be expressed and a “normal” melanocyte pattern can 
develop. Importantly the “normal” pigment pattern of mitfavc7 embryos contains 
slightly fewer melanocytes than wildtype pigment pattern (Johnson et al., 2011), and 
mitfa expression levels have been shown to be marginally lower than in wildtype 
embryos (E.E.Patton, A.Capper & Z.Zeng; Unpublished Data). On up-shift of the 
embryos to the restrictive temperatures (≥30°C), functional mitfa cannot be 
expressed in the mitfavc7 embryos, due to mis-spliced mitfa transcripts that 
predominate at higher restrictive temperatures (E.E.Patton, A.Capper & Z.Zeng; 
Unpublished Data). Embryos raised at these restrictive temperatures have a 
characteristic white body devoid of melanocytes but maintain pigment in their eyes 
(Figure 5.6). It was established that following release to permissive temperatures, 
subsequent delayed melanocyte development occurs by differentiation of MSCs 
(Johnson et al., 2011). 
 
I raised mitfavc7 embryos from fertilisation at a high restrictive temperature (32°C) for 
2 days. At the point of release embryos had developed normal body morphology with 
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the characteristic white body phenotype and pigmented eyes. Embryos were agarose 
embedded in glass-bottomed 6-well plates (IWAKI) and imaged by timelapse 
microscopy. A permissive temperature of 23-24°C was maintained during imaging, 
which was regularly recorded by a temperature monitor. Significantly a greater 
number of melanocyte division events were observed in these regenerating embryos 
than during normal melanocyte development [n=29/243; 11.9%; P= 0.009; 95% CI 
(0.022, 0.12); binomial test]. Taken together with the NFN1 results, I have used 
timelapse image analysis to show in a second model of regeneration that melanocyte 
division events are enhanced. This suggests that melanocytes derived from the MSC 
pool may have a greater capacity for differentiated melanocyte division than normal 
ontogenetic developing melanocytes. Another interpretation is perhaps the molecular 
environment is altered in a regeneration model, which can promote differentiated 
melanocyte division. Importantly, in the mitfavc7 regeneration model, melanocyte 
regeneration is not impaired and no evidence suggests MSC pools are altered 
(Johnson et al., 2011). Therefore enhanced melanocyte division events in this model 
cannot be stimulated by a loss of MSCs. 
 
Following release of mitfavc7 embryos to permissive temperatures, melanocyte 
pigmentation was not observed until 24-44 hours later. This suggests the time from 
initial mitfa specification through to melanocyte pigmentation is at least 24 hpf in 
vivo, assuming that mitfa becomes fully functional immediately upon downshift to 
the permissive temperature. The majority of melanocyte regeneration in the mitfavc7 
model occurs within 36 hours of each-other, in an “initial wave” of melanocyte 
regeneration. This is comparable to the developmental model (Figure 5.6), but unlike 
the NFN1 regeneration model in which melanocyte differentiation was more 
sporadic. This difference is likely to be because the mitfavc7 mutation specifically 
affects mitfa expressing developing melanocytes, whereas the NFN1 model is likely 





Figure 5.6 Melanocyte division events are enhanced during melanocyte regeneration. 
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Figure 5.6 Melanocyte division events are enhanced during melanocyte regeneration. (A-B) 
Schematic depicts treatment conditions, mitfavc7 embryos were raised at 32°C for 2 dpf resulting in a 
lack of development of neural crest derived melanocytes. (A-B) Following release to the permissive 
temperature (23.5°C) melanocytes could fully regenerate and were analysed by timelapse microscopy 
(black bar). (C, D) Quantitative representation of regenerating melanocytes derived from de novo 
development (grey diamonds; n=214) and of numbers of melanocyte division events (yellow 




5.2.5.	   Time	   between	   earliest	   visible	   differentiation	   (pigmentation)	  
through	  to	  melanocyte	  division	  is	  reduced	  during	  regeneration.	  
 
Next, I asked if the time from initial melanocyte differentiation (pigmentation) 
through to melanocyte division was critical, and if this time is altered between 
developing and regenerating melanocyte populations. I analysed the timelapse 
movies and followed melanocyte lineage from the time of earliest visible 
differentiation (TEVD) i.e. the time from first pigmentation (Bennett, 1983). I then 
scored the time elapsed from TEVD through to differentiated melanocyte division 
for each melanocyte that underwent mitosis (Figure 5.7). In normal development, 
direct-developing melanocytes do not go through mitosis until the embryo is at least 
3 dpf, with an average time from TEVD until division of 43 hours. In the mitfavc7 
regeneration model, due to treatment times, embryos are older at the first TEVD, 
however much less time elapses between initial differentiation of a given melanocyte 
and its subsequent mitosis (12 hours) [95% CI; 31.05 (20.73; 41.37)]. Finally, in the 
NFN1 regeneration model melanocyte mitosis occurs at a similar age as seen in 
normal development (~70 hpf), however as with the mitfavc7 model, the time between 
TEVD and melanocyte mitosis is significantly shorter than in normal development 
(15 hours) [95% CI; 26.81 (16.11; 37.52)]. Therefore unlike ontogenetic melanocyte 
development, regenerating melanocytes from a MSC lineage may undergo 
differentiated division. I therefore suggest differentiated melanocyte division has a 







Figure 5.7 Time of earliest visible differentiation (pigmentation) to cell division is reduced in 
regeneration. Time of earliest visible differentiation (TEVD) until cell division was calculated for 
dividing melanocytes in development and regeneration conditions. During development, the average 
time of pigmentation to division is 43 hours (n=9 cell divisions). In regenerating melanocytes cell 
division occurred in younger melanocytes, with an average of 12 hours or 15 hours post pigmentation 
in mitfavc7 or NFN1 embryos respectively. Bars represent the mean with error bars representing the 
standard error from the mean. Time from TEVD to melanocyte division is significantly greater in 
wildtype embryos than either mitfavc7 or NFN regeneration models, [95% CI; 31.05 (20.73; 41.37)] or 




5.2.6.	   Enhanced	   differentiated	   cell	   division	   in	   a	   mitfa	   hypomorphic	  
mutant.	  
 
Microphthalmia-associated transcription factor (MITF) is the master melanocyte 
specification factor and is known to drive melanocyte specification and 
differentiation (Dutton et al., 2001b; Elworthy et al., 2003; Lister et al., 1999). MITF 
has been shown to promote expression of proteins involved in late-stage melanocyte 
differentiation, such as the pigmentation enzymes, Tyrosinase-Related Protein 1 
(TYRP1), Tyrosinase (TYR) and DCT, and the cell cycle promoters, CDK2 and p21 
(Bentley et al., 1994; Bertolotto et al., 1996; Bertolotto et al., 1998; Lister et al., 
1999). Whereas in melanocytes MITF is thought to drive progression of melanocyte 
differentiation, in melanoma cells MITF expression levels are responsible for 
fluctuation between differentiation states. High levels of MITF expression drive 
terminal differentiation in melanoma cells, whereas hypomorphic expression levels 
drive proliferation in melanoma cells. Still lower MITF expression levels in 
melanoma cells induce stem-cell-like invasive characteristics. This MITF dependent 
fluctuation between differentiation states is termed the “MITF rheostat” model 
(Carreira et al., 2005; Carreira et al., 2006; Hoek et al., 2008a; Hoek and Goding, 
2010; Wellbrock and Marais, 2005). We speculated that melanocytes might employ a 
similar MITF rheostat model, and hypothesised that hypomorphic levels of mitfa in 
the zebrafish may drive melanocyte proliferation. As MITF is absolutely required for 
melanocyte development, the effect of modulating MITF expression during 
development has not previously been explored. However the zebrafish mitfa 
temperature-sensitive line provides a unique genetic tool that enables temporal 
control of mitfa expression during melanocyte development. This allows me to 
address the role of varying mitfa levels in differentiated melanocytes. I used 
timelapse-imaging analysis to follow ontogenetic melanocyte development in mitfavc7 
mutant embryos from 30 hpf through to 151 hpf. Embryos raised at 28.5°C 
(restrictive temperature) did not develop neural crest derived melanocytes, consistent 
with published data (Johnson et al., 2011; Lister et al., 2001). Embryos were raised at 
low and high permissive temperatures (<24°C and 25-26.5°C respectively), resulting 
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in variable expression of mitfa splice variants. At high permissive temperatures (25-
26.5°C) mitfa mis-splicing occurs at a greater frequency than at lower permissive 
temperatures (<24°C) (E.E.Patton, A.Capper & Z.Zeng; Unpublished data). At low 
permissive temperatures mitfavc7 mutants had a higher proportion of melanocytes 
derived from differentiated cell division (n=7; 82/210 total melanocytes; 39%), than 
during normal ontogenetic development (n=9; 16/174 total melanocytes; 9%) 
[P<0.001; 95% CI (0.22, 0.38); binomial test of comparison of proportions]. It was 
also noted that on rare occasions sister cells from melanocyte divided again 
(consecutive division) (Figure 5.8). Crucially, melanocyte development at high 
permissive temperatures results in a strikingly higher proportion of melanocytes 
derived from differentiated cell division (n=13; 168/256 total melanocytes) than both 
mitfavc7 embryos incubated at low permissive temperatures and wildtype embryo 
melanocyte development and [P<0.001; 95% CI (0.18, 0.36); binomial test of 
comparison of proportions] and [P<0.001; 95% CI (0.49, 0.64); binomial test of 
comparison of proportions]. Remarkably, I noted a number of melanocyte 
consecutive division events in mitfavc7 embryos at high permissive temperatures. In 
one example 12 melanocytes constituting the final embryo pigment pattern were 
derived from multiple consecutive divisions of a single differentiated melanocyte 
that developed de novo from an unpigmented progenitor. In this same example, 32 
melanocytes constituting the total pigment pattern on the zebrafish head were 
derived from multiple consecutive divisions of only seven de novo developing 
melanocytes. It is possible that enhanced numbers of melanocyte division observed 
in the mitfavc7 embryos is caused by background specific variation, perhaps due to 
additional unknown mutations rather than intracellular melanocyte mitfa expression. 
However differentiated melanocyte division appeared to be coupled to loss of 
functional mitfavc7 at higher permissive temperatures, and extensive serial 
consecutive division events were only observed at these higher temperatures. The 
proportion of mitfavc7 melanocytes that undergo serial division at below 24°C (n=7; 
27/82) was significantly less when compared with those grown at over 24°C (n=13; 
84/168). P=0.014, binomial test of comparison of proportions; 95% CI (0.04, 0.30). 
Because mitfavc7 is a temperature sensitive mutation, I suggest that intracellular mitfa 
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Figure 5.8 Hypomorphic Mitf activity enhances differentiated cell division 
142 
Figure 5.8 Hypomorphic Mitf activity enhances differentiated cell division. (A) Schematic 
representation of melanocyte development in embryos imaged by timelapse microscopy. Two 
embryos are represented for each treatment condition. Wildtype or mitfavc7 mutant embryos were 
grown at 28.5°C for ∼20 hours, embedded in agarose, shifted to temperatures below 24°C (23-24°C) 
or over 24°C (25°C, 25.5°C or 26.0°C), and imaged by time-lapse microscopy until ∼108-151 hpf. All 
melanocytes begin as undifferentiated (grey) melanoblasts that become differentiated (black). Lineage 
is represented by broken lines: vertical broken lines indicate relative time between division events. 
The approximate order of melanocyte development is represented along the horizontal axis. Final total 
number of melanocytes in imaged region is indicated. (B) Stacked bar graph indicating the proportion 
of melanocytes that arise from differentiated or undifferentiated cells in wild type (n=9; 16/174 
melanocytes) and mitfavc7 mutants grown at temperatures below 24°C (n=7; 82/210 total melanocytes) 
or over 24°C (n=13; 168/256 total melanocytes). The proportion of melanocytes arising from a 
differentiated cell is significantly greater in mitfavc7 mutants incubated below 24°C and over 24°C 
compared with wildtype embryos; P<0.001; 95% CI (0.22, 0.38) and P<0.001; 95% CI (0.49, 0.64) 
respectively; binomial test of comparison of proportions. Additionally, the proportion of melanocytes 
arising from a differentiated cell differs significantly between mitfavc7 mutants at below 24°C and over 
24°C; P<0.001; 95% CI (0.18, 0.36); binomial test of comparison of proportions. Datasets include 
only mitfavc7 time-lapse analysis that is longer than 108 hpf. (C) Bar graph indicating the proportion of 
mitfavc7 melanocytes that undergo serial division at below 24°C (n=7; 27/82) compared with those 
grown at over 24°C (n=13; 84/168). P=0.014, binomial test of comparison of proportions; 95% CI 
(0.04, 0.30). Datasets include only mitfavc7 time-lapse analyses that were longer than 108 hpf. Figure 




5.2.7.	   Human	   melanoma	   allele	   MITF4TΔ2B	   promotes	   differentiated	  
melanocyte	  division	  in	  zebrafish	  
 
We reasoned it was possible that melanocytes may be responding to environmental 
cues to promote differentiated cell division. For example, if a melanocyte 
develops/regenerates in a melanocyte-deficient region it might receive 
developmental signals from the surrounding tissue to promote expansion of the 
melanocyte population through differentiated cell division. To test this in the 
zebrafish system we injected wildtype zebrafish mitfa DNA (Z.Zeng) into 1-cell 
stage mitfavc7 embryos. Embryos were subsequently raised at 30°C for five days, and 
un-injected embryos were used as a control. Un-injected controls did not develop 
melanocytes in the body of the fish. However embryos injected with wildtype 
zebrafish mitfa DNA showed a low level of melanocyte development. Total body 
counts of eight mitfa-injected embryos by Dr. Zeng showed 2/8 embryos rescued > 3 
melanocytes, with a highest count of 17 melanocytes (Figure 5.9) (Taylor et al., 
2011). I followed melanocyte development in mitfa-injected embryos by timelapse 
analysis of the head region (M:11, n=7); this showed that all melanocytes were 
derived from undifferentiated precursors. No evidence of differentiated melanocyte 
division was observed in this model. Consequently rescued melanocytes in this 
melanocyte-deficient model are not induced to undergo differentiated melanocyte 
division. Therefore I suggest that increased numbers of melanocyte division events in 
mitfavc7 embryos, are likely due to hypomorphic levels of mitfa in developing 
melanocytes rather than a reduced number of total melanocytes in the embryo. 
 
Next, we wanted to establish if differentiated cell division might be relevant to 
melanoma biology. We therefore developed an in vivo system to test the effect 
human MITF alleles had upon melanocyte biology. Remarkably, injection of normal 
human MITF DNA could rescue pigmentation in the zebrafish embryo. Total body 
counts of eight embryos (Dr. Zeng) showed 2/8 embryos were rescued with > 3 
melanocytes, with a highest count of 13 melanocytes (Figure 5.9) (Taylor et al., 
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2011). Again timelapse imaging of the head region (M: 27, n=8) revealed no 
evidence of differentiated melanocyte division in these embryos. Thus I suggest the 
main mechanism of human melanocyte development is through differentiation of 
unpigmented progenitor cells. However I cannot rule out the possibility of a minor 
role for differentiated cell division in human melanocyte development (Bennett, 
1983). Thus we have successfully shown human MITF DNA can be used to rescue 
zebrafish pigmentation.  
 
I next asked if injection of a human melanoma MITF allele was able to rescue 
melanocyte development in mitfavc7 embryos at the restrictive temperature, and if 
rescued melanocytes elicited different in vivo behaviour. I hypothesise differences in 
melanocyte development between wildtype MITF and MITF4TΔ2B melanoma alleles 
could be indicative of melanoma pathogenesis. Cronin and colleagues showed that 
the human MITF4TΔ2B melanoma allele caused enhanced expression of melanocyte 
differentiation genes (Tyrosinase and DCT), and lowered expression of the cell cycle 
arrest gene, p21 (Cronin et al., 2009). Thus I hypothesised that injection of MITF4TΔ2B 
DNA may enhance not only differentiation of unpigmented precursors, but also 
proliferation of differentiated melanocytes. The numbers of rescued melanocytes 
were significantly greater in embryos injected with MITF4TΔ2B melanoma allele 
cDNA than in those injected with either zebrafish or human wildtype cDNA: Total 
body counts of eight embryos by Dr. Zeng showed 31/35 embryos rescued > 3 
melanocytes, with a highest count of 56 melanocytes, in comparisons to human 
MITF injected cDNA in which only 2/8 embryos rescued > 3 melanocytes, and to 
injected zebrafish mitfa cDNA which only rescued 2/8 embryos with > 3 
melanocytes (Figure 5.9) (Taylor et al., 2011). A significant difference was observed 
between zebrafish mitfa cDNA and human MITF4TΔ2B cDNA injected datasets [95% 
CI; 14.42 (2.03, 26.81)], and between human MITF cDNA and MITF4TΔ2B cDNA 
injected datasets [95% CI; 16.04 (3.65, 28.43)].  Timelapse image analysis of the 
head region (M: 75, n=10) identified MITF4TΔ2B derived melanocytes to have a high 
propensity for differentiated melanocyte division. In total 43 division events 
contributed to the 75 total melanocytes imaged (Figure 5.9 C). This corroborates 
published data suggesting MITF4TΔ2B enhances expression of known cell cycle 
145 
progression genes (Cronin et al., 2009). I therefore suggest differentiated melanocyte 
division could be a key feature of MITF4TΔ2B positive melanomas, and this could be 
exploited in drug development of chemotherapeutics to treat MITF4TΔ2B melanomas. 
Moreover this study describes a novel in vivo model with which to explore the effect 






Figure 5.9 Human MITF 4TΔ2B promotes differentiated cell division. 
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Figure 5.9 Human MITF 4TΔ2B promotes differentiated cell division. (A) 5 dpf wildtype and 
mitfavc7 zebrafish embryos. Embryos were raised at restrictive 30°C for 5 days so no neural crest 
derived melanocytes can develop. Dr Z.Zeng incorporated either zebrafish mitfa cDNA, or human 
MITF cDNA, or human melanoma MITF4TΔ2B cDNA on a Tol2 transposase constuct. Dr Z.Zeng then 
injected these into 1-cell stage mitfavc7 or nacre embryos. Images show representative examples of 
rescued zebrafish embryos. Importantly no uninjected mitfavc7 or nacre embryos at the restrictive 
temperature were able to develop melanocytes (n=50). (B) Box plot of a representative experiment 
showing the range of melanocytes on individual zebrafish expressing zebrafish mitfa (n=8), human 
MITF (n=8) or human MITF4TΔ2B (n=35) from the mitfa promoter in mitfavc7 mutants grown at 30°C. 
Each dataset has been repeated at least three times. Significance is observed within the dataset 
(P<0.001), analysis of variance (ANOVA), with Tukey’s post-hoc analysis. A significant difference 
was observed between zebrafish mitfa cDNA and human MITF4TΔ2B cDNA injected datasets [95% CI; 
14.42 (2.03, 26.81)], and between human MITF cDNA and MITF4TΔ2B cDNA injected datasets [95% 
CI; 16.04 (3.65, 28.43)]. (C) Schematic of melanocyte development (as described in Figure 5.8) in 
rescued embryos injected with the human melanoma allele MITF4TΔ2B. The extent of melanocyte 
rescue varied between embryos, the four examples shown are representative of this range. Figure and 
legend used with permission from Taylor et al., (2011). 
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5.3.	  Future	  Work	  &	  Discussion	   	  
 
In this chapter I showed differentiated melanocytes in zebrafish embryos have the 
potential to divide, and that Mitfa is required to maintain cell cycle arrest in 
differentiated cells. I also established that differentiated melanocyte division 
contributes to a small proportion of the embryonic pigment pattern during normal 
development and melanocyte regeneration. Proliferating melanocytes were analysed 
during development and displayed two distinct features of differentiated 
melanocytes: melanin synthesis and expression of GFP under the tyrp1 promoter 
(tyrp1-GFP transgenic line) (Bennett, 1989; Hultman and Johnson, 2010). In the 
tyrp1-GFP line I observed strong expression of GFP before, during and after 
melanocyte division, suggesting that dividing melanocytes were differentiated cells. 
However I cannot discount the possibility of temporary dedifferentiation of 
melanocytes. Loss of MITF expression has been shown to result in a loss of 
pigmentation and a rounded “amoeboid” phenotype in melanoma cell lines (Carreira 
et al., 2006). However I would expect that a short-term loss of mitfa in the 
melanocyte microenvironment would not elicit any obvious melanocyte phenotypic 
effects in my assay. Thus future experiments should address if these proliferating 
melanocytes are undergoing dedifferentiation in vivo. Consequently my work 
provides substantial evidence that differentiated melanocytes in zebrafish are capable 
of cell division, although I cannot rule out the possibility that zebrafish melanocytes 
are capable of temporary dedifferentiation immediately prior to division. 
 
I then went on to show that differentiated melanocyte division events could be 
promoted by reduction of functional mitfavc7. A much greater proportion of 
melanocytes were derived from differentiated melanocyte division at high permissive 
temperatures (25-26.5°C) than lower permissive temperatures (24°C). Moreover 
extensive serial consecutive division events were only observed at higher permissive 
temperatures (25-26.5°C). One interpretation is that during normal development 
mitfa acts to maintain melanocyte arrest. One possible mechanism by which Mitf 
could promote differentiated melanocyte arrest is through activation of the CDK 
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inhibitors, p21 and p16INK4a (which act promote cell cycle arrest), these have both 
been shown to be upregulated following Mitf expression (in the case of p16INK4a this 
is by direct binding of Mitf to the p16INK4a promoter) (Carreira et al., 2005; Loercher 
et al., 2005). However timelapse imaging analysis also shows that Mitf deficiency in 
melanocytes promotes cell cycle progression. Three possible mechanisms may 
account for this function of Mitf: Firstly, data from melanomas suggest a close 
relationship between Mitf expression and CDK2 (which acts to promote the cell 
cycle) (Du et al., 2004) therefore it is possible that this relationship also exists in 
normal melanocytes. Secondly, Tbx2 is known to be a target of Mitf (Carreira et al., 
2000), and Tbx2 can repress p19ARF  (CDKN2A) induced cell cycle arrest (Jacobs et 
al., 2000), ergo Tbx2 promotes cell cycle progression . Finally, it could be possible a 
minimum threshold level of Mitf is necessary to activate CDK inhibitor expression, 
and melanocytes deficient in Mitf do not sufficiently promote cell cycle arrest. 
 
My results are comparable to the MITF rheostat model, which suggests altered MITF 
levels drive differences in differentiation state in melanoma cells (Carreira et al., 
2005; Carreira et al., 2006; Hoek et al., 2008a; Hoek and Goding, 2010; Wellbrock 
and Marais, 2005). Goding and colleagues showed high expression of MITF 
promotes a terminally differentiated-like state in melanoma cells, whereas gradual 
lowering of MITF expression promotes melanoma cell proliferation, and still further 
loss of MITF expression gives rise to an invasive stem cell-like state. Finally 
complete loss of MITF results in melanoma cell senescence (Carreira et al., 2005; 
Carreira et al., 2006; Hoek et al., 2008a; Hoek and Goding, 2010; Levy and Fisher, 
2011; Wellbrock and Marais, 2005). Evidence implies that the MITF rheostat model 
could also be true of normal melanocyte development (Wellbrock and Marais, 2005). 
Consequently I have provided evidence to show that, as in the MITF rheostat model 
for melanoma cells, mitfa expression drives cell cycle arrest during zebrafish 
melanocyte development. Taken together this suggests that Mitf may be a key 
regulator of melanocyte differentiation and proliferation in normal melanocyte 
development as well as in melanoma. However my studies suggest that unlike the 
MITF rheostat model, proliferation and differentiation are not necessarily uncoupled 
in zebrafish melanocyte development. Although I would like to validate this further 
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by analysis of any subtle changes in melanocyte differentiation state during zebrafish 
melanocyte division. 
 
In this study I have shown that MSC derived melanocytes have an increased 
capability for differentiated cell division compared to ontogenetic developing 
melanocytes. Previous work has shown that erbb3b signalling is important in MSC 
development in the zebrafish (Budi et al., 2008; Budi et al., 2011; Hultman et al., 
2009; Hultman and Johnson, 2010; Johnson et al., 2011). Therefore to further 
validate this result I would analyse melanocyte development in picasso mutant 
embryos, which have a mutation in the erbb3b gene (Budi et al., 2008). I would 
subsequently expect to see a reduction of differentiated melanocyte division in 
picasso embryos compared to wildtype embryos. While I have established that mitfa 
expression drives cell cycle arrest in developing ontogenetic melanocytes, I have not 
ascertained if mitfa levels also regulate melanocyte division in regenerating 
melanocytes. I observe no differences in the overall contribution of melanocyte 
division to the pigment pattern between NFN1 or mitfavc7 regenerative assays. This 
suggests that other mechanisms also contribute to loss of cell cycle arrest in 
regenerating melanocytes. It would therefore be interesting to determine what other 
mechanisms could contribute maintaining cell cycle arrest in regenerating 
melanocytes. One possible candidate for future investigation could be kit signalling 
(Rawls and Johnson, 2003). 
 
Finally we were able to show that injection of human MITF4TΔ2B DNA (melanoma 
allele) was able to rescue melanocyte development in mitfa deficient embryos, and 
that this rescue was significantly greater than in embryos injected with wildtype 
human MITF DNA (Z.Zeng). I was able to use timelapse imaging to show this 
difference is due to enhanced differentiated melanocyte division in MITF4TΔ2B 
rescued melanocytes, and therefore suggest loss of cell cycle arrest in MITF4TΔ2B 
derived melanocytes may bear some relevance to the process of oncogenesis in 
MITF4TΔ2B mutant melanoma. I therefore suggest timelapse imaging could be a new 
tool to study in vivo characteristics of known melanoma mutations and how these can 
be related to melanoma oncogenesis. 
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In conclusion, in this Chapter I have used zebrafish timelapse imaging to provide 
unequivocal evidence of in vivo differentiated melanocyte division in the zebrafish 
embryo. I further used a temperature sensitive mitfavc7 transgenic line to show that 
reduction in normal levels of mitfa can drive differentiated cell cycle arrest in 
melanocytes, and showed that uncoupling of differentiation and cell cycle arrest 
could be relevant to melanoma oncogenesis. Due to extensive similarities between 
vertebrate melanocyte development pathways I propose these findings may also be 
relevant to melanocyte regeneration therapy to treat hypopigmentation disorders such 
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In the zebrafish system there are two waves of melanocyte development. In the first 
wave, direct development of sox10 expressing neural crest cells constitutes an 
ontogenetic melanocyte lineage (Hultman and Johnson, 2010; Kelsh et al., 1996; 
Raible and Eisen, 1994; Raible et al., 1992). These highly motile, late-migrating cells 
delaminate from the neural crest and migrate through the dorsolateral and medial 
pathways (Raible and Eisen, 1994; Raible et al., 1992). These cells are specified by 
mitfa (homologous to Mitf) and express late-stage melanocyte differentiation markers 
such as dct, tyrosinase and tyrp1 before producing pigment and differentiating into 
mature melanocytes (Bentley et al., 1994; Bertolotto et al., 1998; Dutton et al., 
2001b; Elworthy et al., 2003; Lister et al., 1999). We have previously shown that 
mitfa activity is critical to maintain cell cycle arrest in differentiating melanocytes 
(Taylor et al., 2011). The zebrafish embryonic pigment pattern is made up of four 
pigment stripes: dorsal, lateral, ventral and yolk sac stripes. The majority of 
melanocytes that contribute to this embryonic pigment pattern are direct-developing 
melanocytes (Hultman and Johnson, 2010; Raible and Eisen, 1994). However, in a 
secondary wave of melanocyte development many melanocytes that constitute the 
lateral stripe, and some of the melanocytes that constitute the dorsal stripe are late 
developing melanocytes derived from the melanocyte stem cell (MSC) population 
(Budi et al., 2008; Budi et al., 2011; Hultman and Johnson, 2010). MSCs are 
established during early development (9-48 hpf) alongside direct-developing 
melanocytes, and these MSCs remain dormant until they are called upon to generate 
the late-stage melanocytes, the adult pigment pattern (during metamorphosis) at 
approximately 15 dpf, and also during melanocyte regeneration (Budi et al., 2008; 
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Budi et al., 2011; Hultman et al., 2009; Hultman and Johnson, 2010).  MSC 
establishment is an erbb-dependent process, and zebrafish embryos treated with a 
potent ErbB inhibitor (AG1478) during MSC establishment show a remarkable 
reduction in melanocyte number along the lateral line (Hultman et al., 2009; Hultman 
and Johnson, 2010; Johnson et al., 2011), corroborating that these late-developing 
melanocytes along the lateral line are MSC derived. 
 
Cells expressing low levels of mitfa in the zebrafish myotome are thought to be a 
melanocyte progenitor population, and these cells are specified downstream of erbb 
signalling and of MSC establishment. (Budi et al., 2011; Johnson et al., 2011). These 
mitfa expressing cells can differentiate into mature melanocytes, and overexpression 
of kitla can induce ectopic melanocytes within the zebrafish myotome, confirming 
the existence of melanocyte progenitors in this region (Budi et al., 2011). Notably 
whilst a mitfa-expressing melanocyte progenitor population has been identified, mitfa 
is not absolutely necessary for MSC establishment. Embryos lacking functional mitfa 
in the first few days of development are still able to develop and regenerate 
melanocytes normally once functional mitfa expression is restored (Johnson et al., 
2011). I propose that at the restrictive temperature in mitfavc7 mutants, these mitfa 
expressing cells are halted at the unpigmented progenitor phase due to functional 
mitfa being absolutely required for late melanocyte differentiation.  
 
Melanoblast activation is thought to be tightly regulated by stimulation from 
keratinocytes through cell-cell interactions and activation of Notch signalling. Upon 
activation, the Notch Intracellular Domain (NCID) is cleaved by γ-secretase. NCID 
in turn associates with the transactivation complex, RBP-J, which causes subsequent 
downstream activation of target genes, most predominantly Hes1 in mouse (Aubin-
Houzelstein et al., 2008; Jarriault et al., 1995; Moriyama et al., 2006; Schouwey et 
al., 2007; Tamura et al., 1995). Ablation of notch signalling in mutant mice, or 
treatment with a γ-secretase inhibitor (DAPT), causes loss of mouse melanoblasts 
and subsequent hair greying, which is associated with reduced Hes1 expression 
(Moriyama et al., 2006; Schouwey et al., 2007). Notably, constitutive overexpression 
of Hes1 is sufficient to promote melanoblast survival and rescue hair greying in 
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mouse models (Moriyama et al., 2006).  Loss of Notch signalling in a conditional 
RBP-J knockout mouse (cRBP-J KO) (a key transcription factor involved in notch 
signalling) or deletions of Notch 1 and Notch 2 receptors leads to progressive hair 
greying, resulting from a dramatic loss of Dct expressing melanoblasts over 
successive hair cycles (Aubin-Houzelstein et al., 2008; Moriyama et al., 2006; 
Schouwey et al., 2007). Notch signalling in mouse has been implicated in controlling 
melanoblast differentiation and location, indeed cRBP-J KO mice have been 
associated with ectopic melanoblast differentiation and aberrant location at the hair 
follicle, and an inability for melanoblasts in the hair bulb to pigment the hair shaft 
(Aubin-Houzelstein et al., 2008). These data establish a critical role for Notch 
signalling in MSC biology in the mouse mammalian system. 
 
During zebrafish embryogenesis the bHLH Hairy/E (spl)-related factor her5 is an 
early marker for the midbrain-hindbrain boundary (MHB), preceding the onset of 
neurogenesis (Bally-Cuif et al., 2000). The midbrain-hindbrain boundary in early 
embryo development is characterised as a neuron-free transverse stripe and is a 
regulator of midbrain-hindbrain growth and patterning (Bally-Cuif et al., 2000; 
Geling et al., 2004; Tallafuss and Bally-Cuif, 2003). Geling and colleagues show that 
her5 acts to restrict neural differentiation in favour of promoting proliferation of a 
neural progenitor population perhaps via transcriptional control of p27 (Geling et al., 
2003). Contrary to her5 expression, neurogenin 1 (ngn1) promotes neural 
differentiation at the expense of neural stem cell proliferation. Indeed this balance 
between ngn1 and Notch signalling has been shown to control cell-fate decisions 
between neural crest cell lineage formation and Rohon-Beard (RB) primary sensory 
neuron cell fate (Cornell and Eisen, 2002). RB cell development is promoted by 
ngn1 expression whereas Notch signalling induces a neural crest cell lineage 
(Cornell and Eisen, 2002). Zebrafish mutants shown to have disrupted Notch 
signalling (mindbomb mutants) have a large excess of RB cells with an associated 
loss in neural crest derived cells, such as melanocytes, that can be rescued by 
downregulation of ngn1 signalling (Cornell and Eisen, 2002). Furthermore, in the 
adult zebrafish brain her5 expression defines a region of proliferation in the MHB, 
termed the Isthmic proliferative zone (IPZ) (Chapouton et al., 2006). The IPZ 
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denotes a possible niche of multipotent neural stem cells within the zebrafish adult 
brain, and has been shown to be able to give rise to neuronal, radial glial, astrocytic 
and oligodendrocyte lineages. Interestingly her5 was shown to co-express with sox2, 
a known neural crest stem cell marker. Furthermore, in the mouse Sox2 was shown 
to be a key regulator of SCP cells that have the capacity to differentiate into a 
melanocyte lineage (Adameyko et al., 2009; Adameyko et al., 2012). In the zebrafish 
embryo and adult her5 expression promotes proliferation of a multipotent neural 
stem cell population. Strong evidence in both the mouse and the zebrafish links 
neural and melanocyte lineages and suggests that some neural precursors (SCPs) can 
give rise to a melanocyte lineage (Adameyko et al., 2009; Adameyko et al., 2012; 
Budi et al., 2011; Curran et al., 2010; Dutton et al., 2001b; Pingault et al., 1998). It is 
therefore possible that the MHB could represent a novel reservoir for neural crest 
stem cells that have the capacity to recapitulate melanocyte populations.  
 
Phosphatase of Regenerating Liver-3 (PRL-3) is a member of the protein tyrosine 
phosphatase family (PTP4A3) (Alonso et al., 2004). The first protein identified in 
this family was PRL-1, initially discovered to be upregulated in regenerating livers, 
thereby giving the class of phosphatases its name (Mohn et al., 1990). There are 
three members of the PRL family, -1, -2, and -3, which have a high level of amino 
acid homology and are dual specific phosphatases (Alonso et al., 2004). PRL 
phosphatases are prenylated proteins, whose prenylation states determine nuclear or 
cell membrane localisation, which in-turn mediates activity of the phosphatases 
(Zeng et al., 2000). PRL-3 upregulation has been strongly associated to cancer 
progression and metastases in many cancer types (Kim et al., 2011; Laurent et al., 
2011; Liu et al., 2012; Saha et al., 2001; Ustaalioglu et al., 2012; Zhou et al.; Zhou et 
al., 2012a). Furthermore, overexpression of PRL-3 in melanoma cell lines can 
initiate a morphological transition from epithelial-like cells to fibroblast-like cells, 
and can facilitate lung and liver metastasis in mouse xenograft models (Wu et al., 
2004). However, nothing is known about the normal role of PRL-3 during 
development. In vitro data identifies Prl-3 as a p53-inducible gene in mouse 
embryonic fibroblasts (MEFs) (Basak et al., 2008). Notably, p53 transcriptional 
binding sites have been identified in both mouse and human Prl-3 promoters, which 
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suggests the p53-Prl-3 axis is conserved. Prl-3 mediates G1 cell-cycle arrest via Akt 
and Cdk2 in mouse MEFs, suggesting a role for Prl-3 in maintenance of cellular 
integrity (Basak et al., 2008). Importantly a basal level of Prl-3 was also shown to be 
absolutely required for cell cycle progression (Basak et al., 2008). Thus Prl-3 has an 
essential role in the maintenance of cell integrity and G1-mediated cell cycle arrest. 
In this chapter I identify a chemical inhibitor of PRL-3 as an enhancer of melanocyte 
regeneration in zebrafish, and suggest that zebrafish prl-3 could have a role to control 





6.2.1	  Double-­‐chemical	  screen	  to	  identify	  novel	  enhancers	  of	  melanocyte	  
regeneration	  
 
Small molecule screening in zebrafish is a powerful approach to identify new 
pathways involved in development and other responses such as hearing, behaviour 
and regeneration (Taylor et al., 2010). The zebrafish model lends itself to high-
throughput small molecule screening: embryos are small enough to grow in 96-well 
plates, live in water, and have homologous developmental pathways to humans. 
Many protein active sites are conserved throughout vertebrates meaning that drugs 
initially designed to target human proteins can also function within a zebrafish 
model. This rationale has led to zebrafish drug screens to identify new phenotypes of 
known bioactives. For example, North and colleagues successfully used a zebrafish 
in situ hybridisation screen to identify chemical modulators of haematopoietic stem 
cells (HSC) in vivo (Lord et al., 2007; North et al., 2007). The authors showed 
treatment with 16,16‑dimethyl‑PGE2 (dmPGE2), a long-acting derivative of the 
prostaglandin pathway, could enhance HSC formation, and proposed this would be 
useful in HSC transplantation therapy (cord blood transplants) (Goessling et al., 
2011; Lord et al., 2007; North et al., 2007).  
 
Zebrafish melanocytes are derived from the neural crest through homologous 
pathways to those in mammals (including humans); however, zebrafish melanocytes 
retain their melanin to allow for background adaptation. This is an advantage for 
melanocyte research as it enables pigmented melanocytes to be visualised easily 
under a dissecting microscope, and also gives zebrafish melanocytes an inherent 
lineage tracer. Finally, many pigmentation mutants have been generated and 
identified in the zebrafish, and many chemical tools that affect pigment are being 
identified (Budi et al., 2008; Hultman et al., 2008; Johnson et al., 1995; O'Reilly-Pol 
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and Johnson, 2008; Yang and Johnson, 2006). Therefore the zebrafish is an ideal 
system with which to mine for new pigmentation and melanocyte biology pathways 
that may be relevant to human disorders such as melanoma and vitiligo. 
 
Previously in the lab we identified and characterised a class of 5-Nitrofuran 
compounds that are toxic to zebrafish melanocytes through aldh2 activation (Zhou et 
al., 2012b). One such compound, NFN1, is a potent melanocytotoxic agent that 
impairs melanocyte regeneration in the zebrafish, presumably through action on a 
progenitor population (Chapter 4). Using this tool I designed a double-chemical 
screen to assay for novel drug enhancers of melanocyte regeneration in the zebrafish, 
distributing five zebrafish embryos per well in 24-well plates (Corning). Screening 
libraries were co-treated at 10 μM alongside 20 µM NFN1 (final concentration) in 
embryo medium and embryos were treated in a 30-50 hpf time window. The 
screening libraries used were the Sigma LOPAC library (1500 compounds), the Enzo 
Life-Sciences Screen-WellTM Kinase Inhibitor library (80 compounds) and the Enzo 
Life-Sciences Screen-WellTM Phosphatase Inhibitor library (33 compounds). For ease 
of screening I chose not to de-chorionate embryos before treatment, and accepted 
that this may result in a few false-negatives if drugs cannot penetrate the chorion. At 
50 hpf I assayed for the characteristic NFN1 “white phenotype”, washed the NFN1 
drug from the embryos once using fresh embryo medium and visually scored 
melanocyte regeneration over the ensuing days. Regenerating melanocytes were 
categorised as “small and punctate” or “large and differentiated”. One day post 
washout (72 hpf), lateral melanocyte regeneration was scored. In particular, 
differences were commonly noted around the base of the neck/otolith region, and 
around the eyes. By two days post washout the head region was a useful indicator of 
melanocyte regeneration: melanocyte regeneration in the head is slower, which can 
serve to make differences in timing of melanocyte regeneration more pronounced. In 
total 753 compounds were screened, including 640/1500 from the LOPAC library, 
and all of the compounds in the Enzo Life Sciences phosphatase and kinase inhibitor 
libraries. Due to the relatively small sizes of the phosphatase and kinase inhibitor 
libraries, I chose to screen these at three concentrations: 5, 10 and 20 µM. Screening 
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at three different concentrations allowed me to identify any phenotype gradients 
correlating to drug treatments and also limit any false positives.  
 
Of the 640 LOPAC library compounds screened none were identified as melanocyte 
regeneration enhancers. Of the 80 compounds from the Kinase inhibitor library, 
seven were identified as melanocyte regeneration enhancers (Table 6.1). Of these, 
three EGFRK inhibitors, two PKC inhibitors, one MEK inhibitor and one CRAF 
inhibitor were identified. Crucially, we had previously identified and verified three 
PKC inhibitors as suppressors of the melanocytotoxic NFN1 phenotype. Thus, I 
propose that identification of PKC inhibitors in the melanocyte regeneration 
enhancer screen represents a weak NFN1 suppression phenotype. Remarkably the 
remaining kinase inhibitor hits (EGFRK, MEK and CRAF) all interact in the same 
signalling pathway. EGFR activates MAPK signalling, in which CRAF is important 
for activating MEK signalling (Boone et al., 2011; Deb et al., 2001; Zhang et al., 
2000). The three protein kinases identified have previously been shown to play a role 
in tumour progression including melanoma progression (Boone et al., 2011; Dumaz 
et al., 2006; Heidorn et al., 2010), and all three are possible targets for the 
development of drugs for chemotherapeutics. While the role for MAPK signalling is 
firmly established in the pathogenesis of melanoma, less is known about the role of 
MAPK signalling to promote melanocyte differentiation from a stem cell population. 
However in the lab MEK inhibitor treatment (PD325901) induced enhanced 
melanocyte regeneration following release of mitfavc7 embryos from the restrictive 
temperature (E.E.Patton, L.Dailly; Unpublished data) (see section 6.2.2 for further 
details on the mitfavc7 regeneration assay). Thus the MAPK pathway could be a novel 
target pathway with a key role in MSC development.  
 
The phosphatase inhibitor library was a useful source to identify novel pathways 
essential for melanocyte differentiation from a progenitor population. A CDC25 
inhibitor was visually identified in the screen as an enhancer of melanocyte 
regeneration, however by two days post washout, regenerating melanocytes were still 
lightly pigmented indicating a less differentiated state (Figure 6.1). Cell division 
cycle 25 (Cdc25) promotes cell cycle through activation of cell cycle progression 
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regulators, Cyclin-dependent kinases (CDKs) (Blomberg and Hoffmann, 1999; 
Furnari et al., 1997; Gabrielli et al., 1996; Hoffmann et al., 1994).  As such, Cdc25 
phosphatases are key targets for checkpoint machinery, such as Chk1 kinase, which 
acts to phosphorylate Cdc25 in the event of DNA damage and thus inhibit the cell 
cycle (Gabrielli et al., 1996; Peng et al., 1997; Sanchez et al., 1997; Zhao et al., 
2002). A role for Cdc25 in normal melanocyte development has not been previously 
identified. I hypothesise that chemical inhibition of Cdc25 in zebrafish limits 
proliferation of a melanocyte progenitor population, which in turn promotes 
differentiation in this progenitor population. However these regenerating 
melanocytes were lightly pigmented at two days post washout, which is indicative of 
“younger” stage in melanocyte development, perhaps due to a later time of initial 
MSC differentiation. Alternatively the CDC25 inhibitor may be affecting terminal 
differentiation of the melanocyte, and maintaining melanocyte development in a 
permanent “de-differentiated” state. Finally it could also be possible that CDC25 
inhibitors may also have an effect on the melanin synthesis pathway in zebrafish. 
Thus it would be important to analyse later stages of melanocyte regeneration in 
these CDC25 inhibitor treated embryos to assess if normal pigmentation can return. 
 
My final hit was the Phosphatase of Regenerating Liver 3 (PRL-3) inhibitor, B4-
Rhodanine, identified from the Enzo Life Sciences Phosphatase Inhibitor library. Of 
all the drug hits, it was noted that the B4-Rhodanine showed the most pronounced 
and the most reproducible melanocyte regeneration phenotype. Embryos were co-
treated with NFN1 (20 µM) alongside the B4-Rhodanine, and following washout I 
observed enhanced melanocyte regeneration at all three of the B4-Rhodamine 
screening concentrations (5, 10, 20 µM). The number of regenerating melanocytes 
was significantly enhanced after B4-Rhodanine co-treatment than versus NFN1 only 
treated controls [95% CI; 20.77(14.04, 27.50)]; differences were assessed to be 
significant (P<0.001) by ANOVA analysis. (Figure 6.1) Additionally regenerating 
melanocytes appeared to be fully differentiated following B4-Rhodanine treatment: 
melanocytes were large, dendritic in morphology and darkly pigmented (Figure 6.1). 
PRL-3 is an interesting protein, which has recently associated in cancer progression 
(including melanoma), and up-regulation of PRL-3 is associated with increased 
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metastasis (Kim et al., 2011; Laurent et al., 2011; Liu et al., 2012; Saha et al., 2001; 
Zhou et al., 2012a). However, little is known about the normal biological role of 
PRL-3 or indeed its molecular targets. A possible role for Prl-3 in p53-mediated cell 
cycle control implies that Prl-3 could be critical to control cell cycle 
integrity/progression (Basak et al., 2008). I suggest that Prl-3 is a key factor 
controlling proliferation and differentiation of a melanocyte progenitor population, 





Figure 6.1.  A small molecule screen for enhancers of melanocyte regeneration.  
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Figure 6.1.  A small molecule screen for enhancers of melanocyte regeneration. (A, B) Schematic 
of screen design. Wildtype embryos were treated from 30 hpf through to 50 hpf with 20 μM NFN1 to 
induce total melanocyte cell death, and were co-treated with with drugs from small molecule libraries 
at 5, 10 and 20 μM (Enzo Life Sciences, LOPAC). At 50 hpf embryos were washed out and ensuing 
melanocyte regeneration was monitored. Hits were identified by visually assessing embryos. 
Schematic by Nicola Grant. (C-D) Counts of regenerating melanocytes took place on the head region 
(as specified in Figure 3.1). NFN1 significantly impairs melanocyte regeneration [95% Confidence 
Interval; -30.0(-37.92, -22.08)]. The PRL-3 phosphatase inhibitor was identified as a strong enhancer 
of melanocyte regeneration following NFN1-induced melanocyte ablation [95% CI; 20.77(14.04, 
27.50)]. Differences were assessed to be significant (P<0.001) by ANOVA analysis. (C) An example 
of a weak melanocyte regeneration enhancer is depicted by the cdc25 inhibitor, BN-82002. 
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Compound Library Target 
B4-Rhodanine Phosphatase Inhibitor Library (Enzo Life Sciences) PRL-3 
BN-82002 Phosphatase Inhibitor Library (Enzo Life Sciences) CDC25 
Rottlerin Kinase Inhibitor Library (Enzo Life Sciences) PKC delta 
Hypericin Kinase Inhibitor Library (Enzo Life Sciences) PKC 
U-0126 Kinase Inhibitor Library (Enzo Life Sciences) MEK 
GW 5074 Kinase Inhibitor Library (Enzo Life Sciences) CRAF 
Tyrphostin 25 Kinase Inhibitor Library (Enzo Life Sciences) EGFRK 
Tyrphostin 47 Kinase Inhibitor Library (Enzo Life Sciences) EGFRK 
Tyrphostin  51 Kinase Inhibitor Library (Enzo Life Sciences) EGFRK 
 
Table 6.1 Chemical compounds identified to enhance melanocyte regeneration 
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6.2.2.	   Prl-­‐3	   inhibition	   enhances	   melanocyte	   regeneration	   in	   mitfavc7	  
mutants	  
 
To confirm the role of PRL3 in melanocyte regeneration, I wished to assess the 
effect of B4-Rhodanine in a different regeneration assay. In mitfavc7 hypomorphic 
mutants, mitfa expression can be controlled by a change in temperature. At high, 
restrictive temperatures (>30°C) mitfa is mis-spliced and produces a non-functional 
product. While at lower permissive temperatures (<26°C) mitfa is correctly spliced 
and functional but marginally hypomorphic (Z.Zeng, E.Patton; Unpublished Data). 
Embryos were reared at a high restrictive temperature (32°C) for 2 dpf, resulting in 
fully developed embryos that lacked neural crest derived melanocytes (Johnson et 
al., 2011; Lister et al., 1999). Melanocytes in the Retinal Pigmented Epithelium 
(RPE) are controlled by the mitfb gene and thus are unaffected (Lister et al., 2001). 
Notably, the rate of zebrafish melanocyte development is temperature-dependent, 
thus at 48 hpf these embryos were actually staged as 56 hpf. Upon release of mitfavc7 
embryos from the restrictive temperature (≥30°C) to the permissive temperature (≤ 
27°C) melanocytes have been shown to regenerate from an unpigmented melanocyte 
progenitor population (Chapter 5) (Johnson et al., 2011; Taylor et al., 2011). I treated 
developing mitfavc7 embryos at the restrictive temperature with B4-Rhodanine (20 
µM) or a DMSO control. Following washout and release to the permissive 
temperature, enhanced melanocyte regeneration was observed in the B4-Rhodanine-
treated embryos (P=0.005, Student’s t-test) (Figure 6.2). The optimal time from 
embryo downshift to sufficient melanocyte regeneration was approximately 40 
hours.  
 
As with all small molecules, it is possible that the effects of the PRL3 inhibitor are 
due to off-target effects. I wanted to validate Prl-3 as the target of our inhibitor. In 
order to do this, a translation-blocking morpholino oligonucleotide was designed 
against the zebrafish Prl-3 gene (ptp4a3) that binds the ATG, so that translation can 
not be initiated (Gene Tools). The Prl-3 morpholino was co-injected with a 
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fluorescein dye to ensure accurate morpholino uptake, and was injected into single-
cell stage mitfavc7 embryos. A scrambled control morpholino was injected as a 
control. All embryos were reared for two days at the restrictive temperature (32°C), 
upon release I observed a significant increase in regenerating melanocytes by 
approximately 40 hours post release in ptp4a3 knockdown embryos compared to 
scrambled morpholino control injected embryos (P=0.0006, Student’s t-test) (Figure 
6.2). As such I verified that reduced prl-3 (ptp4a3) expression in the zebrafish 
embryo is sufficient to enhance melanocyte regeneration, and thus suggest Prl-3 is 
indeed the target of B4-Rhodanine in zebrafish. Consistent with this data I have also 
observed an enhanced melanocyte regeneration phenotype following injection of prl-
3 translation block morpholino in the NFN1 melanocyte ablation assay. Additionally 
splice site morphants, injected with morpholino designed to produce a premature 
stop codon after exon 3 of the prl-3 gene, were also able to induce enhanced 






Figure 6.2. PRL-3 inhibition enhances melanocyte regeneration in mitfavc7 mutants. (A) mitfavc7 
embryos were raised at the restrictive temperature (4-56 hpf) to genetically prevent melanocyte 
development, and then down-shifted to a permissive temperature allowing subsequent melanocyte 
development. (B, D) Embryos were treated with 20 μM PRL-3 inhibitor or an equivalent DMSO 
control through 4-56 hpf, drugs were replenished daily. PRL-3 inhibitor treated embryos displayed a 
marked increase in melanocyte regeneration two days post-washout. Embryos treated with B4-
Rhodanine had enhanced numbers of regenerating melanocytes in a total dorsal count when compared 
to DMSO control (P=0.005, Student’s t-test). (C, D) mitfavc7 embryos were injected at the 1-cell stage 
with a translation block morpholino oligonucleotide designed against the ptp4a3 gene (Gene Tools), 
and controls were injected with a standard scrambled control morpholino. Injected embryos were 
raised at restrictive temperature until 56 hpf then downshifted to the permissive temperature for 2 
days, ptp4a3 morpholino injected embryos had an enhanced melanocyte regeneration phenotype 
(P=0.0006, Student’s t-test). All t-tests assumed normal distribution and equal variance of datasets. 
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6.2.3.	   Prl-­‐3	   inhibition	   does	   not	   affect	   normal	   embryo	   development	   or	  
final	  zebrafish	  pigment	  pattern	  
 
The zebrafish embryonic pigment pattern is mainly derived from direct-developing 
neural crest cells. I have shown that the PRL-3 phosphatase is a key factor that 
controls melanocyte regeneration, presumably from a MSC population. I then asked 
if zebrafish Prl-3 also had a role in normal melanocyte ontogenetic development. 
Zebrafish treated with B4-Rhodanine from 4 hpf through to 120 hpf were observed 
to have a normal developmental phenotype and displayed no obvious melanocyte 
phenotype (Figure 6.3). Embryos were regularly analysed during early melanocyte 
development and the rate of early embryo pigmentation was not enhanced following 
B4-Rhodanine treatment. Crucially, Prl-3 inhibition did not affect total melanocyte 
number. Thus, Prl3 inhibition affects melanocyte regeneration, without losing 
intrinsic control of normal melanocyte numbers (Figure 6.3). Furthermore, in embryo 
melanocyte regeneration studies (NFN1 assay and mitfavc7 assay) and in the adult 
zebrafish tail clip assay (Chapter 7; preliminary work and future experiments), Prl-3 
inhibition enhances melanocyte regeneration but does not alter total number of 
melanocytes contributing to the final pigment pattern (Chapter 7; data not shown). 
These results confirm that prl-3 has no critical role in zebrafish embryo development 
and that Prl-3 functions during stress to melanoblasts or a melanocyte progenitor, 





Figure 6.3.  Prl-3 inhibition does not affect normal embryo development or final zebrafish 
pigment pattern. (A) Wildtype embryos were treated daily with 20μM B4-Rhodanine or DMSO 
controls. (B-C) At 96 hpf embryos were exposed to a bright light for 30 mins to contract melanocytes, 
then fixed in 4% PFA. Melanocytes were counted in a defined head region (as specified in Figure 
3.1). Error bars represent Standard deviation. No difference in was observed between numbers of 
melanocytes (P=0.14, student’s t-test). T-test assumes normal distribution and equal variance of 
datasets. (D) No abnormal developmental differences were noted in B4-Rhodanine treated embryos 
up until 120 hpf. Embryos were analysed daily, notably timing of ontogenetic melanocyte 
development also was not affected (data not shown). 
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6.2.5.	  Loss	  of	  erbb	  mediated	  MSC	  establishment	  can	  be	  rescued	  by	  B4-­‐
Rhodanine	  treatment	  
 
Budi and colleagues (2008) showed that erbb signalling was required for MSC 
establishment in the zebrafish (Budi et al., 2008). Chemical inhibition of erbb during 
varied treatment time windows identified the critical developmental stage for MSC 
establishment (9-8 hpf) (Budi et al., 2008; Hultman et al., 2009; Hultman and 
Johnson, 2010). Importantly, both MSC-derived regenerating melanocytes in the 
mitfavc7 hypomorphs and late-developing melanocytes that populate the lateral line in 
wildtype embryos were shown to be erbb-dependent (Hultman and Johnson, 2010; 
Johnson et al., 2011). Reduced numbers of melanocytes were observed in both these 
MSC-derived populations following treatment with an ERBB inhibitor (AG1478) 
during MSC establishment. Therefore I wanted to use AG1478 to examine the 
relationship of erbb and prl-3 in the zebrafish embryo. I asked if B4-Rhodanine 
could rescue erbb-dependent melanocytes in the zebrafish embryo. Using a dose 
curve, I identified 6 µM as an optimal AG1478 treatment dose for inhibition of MSC 
establishment in the mitfavc7 melanocyte regeneration assay (data not shown). 
Following this, I treated a cohort of mitfavc7 embryos with AG1478 and co-treated 
another cohort with AG1478 and B4-Rhodanine, during MSC establishment. Upon 
embryo release to the permissive temperature, I confirmed a reduction in the number 
of regenerating melanocytes after AG1478 treatment, corroborating published results 
[95% CI; -64.00(-95.65, -32.35); ANOVA] (Johnson et al., 2011). Co-treatment of 
the B4-Rhodanine with AG1478 rescued the impaired melanocyte regeneration 
phenotype in the AG1478-treated cohort [95% CI; 111.50(79.85, 143.15); ANOVA] 
(Figure 6.4). I can therefore conclude that Prl-3 inhibition is sufficient to rescue 
melanocyte regeneration in Erbb-depleted zebrafish embryos. It is important to note 
that PRL3 inhibitor/ERBB3 inhibitor double treated embryos were not observed to 
have an excess number of regenerating melanocytes over DMSO controls (Figure 
6.4). Thus Prl-3 inhibition is capable of enhancing melanocyte regeneration but does 
not lose normal regulation of melanocyte numbers, this is in contrast to over 
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expression of kitla which results in hyperpigmentation (Hultman et al., 2007). 
Therefore it most likely seems that Prl-3 inhibition expands either a pool of erbb-
independent stem cells, or remaining unaffected stem cells following AG1478 
treatment. In conclusion, I suggest that prl-3 is sufficient to rescue erbb-dependent 
melanocyte regeneration either by activity downstream of erbb signalling, or through 
expansion of an alternative erbb-independent MSC population. Notably, even in 
experiments by Johnson and colleagues (2011), in mitfavc7 embryos treated with 
AG1478, melanocyte loss was not absolute (Johnson et al., 2011). This could be due 
to either an insufficient penetrance of AG1478, a contribution of direct-
developmental melanocytes, or the existence of an erbb-independent MSC pool 
(Figure 7.5). 
 
I then asked if PRL-3 inhibition has a role in MSC-derived developmental 
melanocytes. Late developing melanocytes on the lateral line have been shown to be 
derived from a MSC population, and ERBB inhibitor (AG1478) treatment results in 
melanocyte loss along the lateral line [95% Confidence Interval; -17.8(-29.3, -6.25)] 
(Lyons et al., 2005). (Hultman and Johnson, 2010). I tested whether co-treatment 
with B4-Rhodanine could rescue Erbb-mediated melanocyte loss on the lateral line, 
and observed a significant rescue in co-treated embryos [P <0.001; 95% CI; 
16.4(4.85, 27.94); ANOVA].  (Figure 6.5) (work done by myself and E. 
Postlethwaite). Notably, treatment of wildtype embryos with B4-Rhodanine alone 
did not increase the number of lateral line melanocytes, which again confirms prl-3 
inhibition has no effect on direct developing melanocytes. 
 
Zebrafish erbb3b mutants (picasso) do not have an early embryonic pigment cell 
phenotype, but melanocytes are missing from part of the dorsal and medial stripes in 
the adult pigment pattern (Figure 6.6). Importantly, wild type embryos treated with 
AG1478 during MSC establishment show the same loss of melanocytes in the 
pigment pattern stripe as observed in the picasso fish (Budi et al., 2008). This 
confirms that AG1478 treatment is sufficient to inhibit erbb signalling in the 
zebrafish embryo. We wanted to ask whether Prl-3 inhibition during MSC 
establishment (9-48 hpf) could rescue this AG1478 mediated phenotype. All 
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embryos treated with AG1478 during MSC establishment lost a patch of 
melanocytes along the dorsal and medial stripes (n=6), whereas embryos co-treated 
with both AG1478 and B4-Rhodanine during MSC establishment showed a gradient 
of rescue phenotypes (Figure 6.6) (work done by E. Postlethwaite). Full rescue of the 
melanocyte stripe pattern was observed in a small proportion of the double treated 
cohort (2/13). “Medium” rescue was characterised by partial “filling in” of 
melanocyte stripes (4/13). Thus 46% of fish were rescued in AG1478/B4-Rhodanine 
double treated fish versus 0% in AG1478 only treated fish (P-value=0.001, bivalent 
comparison of proportions. 95% Confidence Interval (0.19, 0.73)], assuming normal 
distribution. B4-Rhodanine rescue of the AG1478 mediated phenotype was not 
absolute, over half of the fish at metamorphosis were not rescued and had significant 
loss of melanocytes in the adult pigment pattern stripes (7/13). It is important to note 
that the extent of B4-Rhodanine rescue is reduced in this assay than either the lateral 
line or mitfavc7 regeneration assays, possibly due to greater demand on MSC 
differentiation in population of adult pigment pattern stripes. The Johnson lab 
suggest that erbb3b is necessary for MSC establishment in the early embryo, and 
subsequent loss of erbb signalling results in loss of MSC derived developmental 
melanocytes (Budi et al., 2008; Hultman et al., 2009; Hultman and Johnson, 2010; 
Johnson et al., 2011). However adult picasso fish (erbb3b mutants) only have limited 
loss of melanocytes in the dorsal and medial stripes, therefore melanocyte 
development at metamorphosis must also occur through an erbb-independent 
mechanism. Thus, AG1478 treatment may only affect a subset of melanocyte 
progenitor cells. Furthermore, AG1478-mediated melanocyte loss at metamorphosis 
is limited to a particular region of the adult stripe (Figure 6.6; arrowheads). It would 
be interesting to determine if erbb-dependent MSCs have a specific niche within the 
adult zebrafish, and if this niche only contributes to melanocyte pigmentation in a 
specific part of the pigment pattern stripe.  
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Figure 6.4.  Loss of erbb mediated MSC establishment in mitfavc7 embryos can be rescued by 
PRL-3 inhibitor treatment. 
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Figure 6.4.  Loss of erbb mediated MSC establishment in mitfavc7 embryos can be rescued by 
PRL-3 inhibitor treatment. (A) mitfavc7 embryos were raised at the restrictive temperature (4- 56 
hpf) and were untreated or treated with: DMSO, 20 μM PRL-3 inhibitor, 6 μM AG1478, or co-treated 
with 6 μM AG1478 and 20 μM PRL-3 inhibitor. AG1478 is a known Erbb inhibitor, and affects MSC 
establishment. At 56 hpf embryos were washed out and down-shifted to the permissive temperature. 
Two days post down-shift total dorsal melanocytes were counted in each embryo. (B,C) As a positive 
control, the PRL-3 inhibitor enhances melanocyte regeneration when compared to untreated and 
DMSO controls [95% Confidence Interval; 49.29(16.77, 81.80)] and [95% CI; 47.50(15.85, 79.15)] 
respectively. Likewise as a negative control, AG1478 treatment inhibits melanocyte regeneration in 
embryos [95% CI; -64.00(-95.65,-32.35)]. Remarkably co-treatment of PRL-3 inhibitor significantly 
rescues the AG1478-induced melanocyte regeneration phenotype [95% CI; 111.50(79.85, 143.15)], to 
a level of regeneration that resembles DMSO controls [95% CI; 2.30(-29.35, 33.95)]. All significant 
differences stated have a p-value <0.0001, as tested by ANOVA. Experiment was repeated 4 times 






Figure 6.5.  PRL-3 rescues AG1478-mediated melanocyte loss on the lateral line. (A) Wildtype 
embryos were raised at 30°C to speed up embryo growth. (B, C) Following 2 μM AG1478 treatment 
(4-48 hpf) loss of a subset of erbb-dependent melanocytes on the lateral line was confirmed [95% 
Confidence Interval; -17.8(-29.3, -6.25)] (Lyons et al., 2005). These erbb-dependent melanocytes 
were rescued by co-treatment with PRL-3 inhibitor. Melanocyte numbers on the lateral line are 
significantly enhanced (to control levels) in 2 μM AG1478 and 20 μM PRL-3 inhibitor co-treated 
embryos as compared to AG1478 alone treated embryos [95% CI; 16.4(4.85, 27.94)]. Significant 
differences were determined by ANOVA analysis using Tukey’s post-hoc test; all significant 
differences have a P value <0.001. Error bars represent standard error of mean. This is a 
representative experiment from three technical replicates. Importantly, an AG1478 melanocyte loss 
was observed throughout a range of concentrations (2, 4.5, and 6 μM), and the optimal AG1478 
differed between batches of compound. However treatment of 20 μM B4-Rhodanine was able to 
rescue the lateral line in all three doses of AG1478. 
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Figure 6.6.  PRL-3 rescues AG1478-mediated melanocyte loss of adult pigment pattern stripes. 
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Figure 6.6.  PRL-3 rescues AG1478-mediated melanocyte loss of adult pigment pattern stripes. 
(A) Wildtype embryos were treated with 20μM PRL-3 inhibitor or an equivalent DMSO control from 
4-72 hpf. As erbb has an important role in neural crest development, embryos were treated with 
decreasing doses of AG1478 in order to maximise inhibition of erbb-mediated MSC establishment but 
minimise effects on normal embryo development [4-28 hpf at 6μM AG1478, 28- 52 hpf at 3μM, 52 – 
76 hpf at 1.8μM]. (B) No obvious effect on pigment stripe metamorphosis could be discerned in the 
PRL-3 inhibitor treated cohort. AG1478 inhibitor treated fish show a loss of melanocytes in the dorsal 
and medial stripes (red arrow head), as previously identified by Budi et al., (2008). Co-treatment of 
AG1478 embryos with PRL-3 inhibitor gives rise to a range of phenotypes in the adult fish ranging 
from no rescue (red arrow head) and medium rescue (blue arrow head) of the dorsal stripe through to 
a full rescue. 46% of fish are rescues in AG1478/B4-Rhodanine double treated fish versus 0% in 
AG1478 only treated fish (P-value=0.001, bivalent comparison of proportions. 95% Confidence 




6.2.6.	   Microarray	   analysis	   identifies	   novel	   prl-­‐3	   pathways	   in	   the	  
zebrafish	  system	  
 
In an effort to explore new Prl-3 mediated pathways, I designed a microarray screen 
(Miltenyi Biotec, Germany) in the zebrafish mitfavc7 regeneration assay. Embryos 
were reared for 2 dpf at the restrictive temperature and treated (4-50 hpf) with 
DMSO control, B4-Rhodanine, AG1478, and co-treated with both B4-Rhodanine 
and AG1478. RNA expression analysis was performed by Miltenyi Biotec. All 
statistical analysis was performed by Miltenyi Biotec. Four different comparisons 
between datasets were made: DMSO Vs B4-Rhodanine, DMSO Vs AG1478, B4-
Rhodanine Vs AG1478 + B4-Rhodanine, and AG1478 Vs AG1478 + B4-Rhodanine. 
The rationale behind these comparisons was to identify changes in gene expression 
in B4-Rhodanine-treated samples, and to see if these changes can also help to 
understand B4-Rhodanine rescue of the AG1478-induced melanocyte phenotype. 
Additionally I wanted to see if I could identify gene expression changes induced by 
AG1478 treatment that could be subsequently reversed by co-treatment of AG1478 
with B4-Rhodanine. This could help to understand the mechanism by which Prl-3 
inhibition could rescue the melanocyte phenotype caused by loss of ErbB. 
 
Applying a significant p-value to microarray data can be troublesome due to the 
large number of gene comparisons. Usually a p-value of <0.05 is considered 
significant, however in the case of my microarray data this would give 
approximately 25000 hits per comparison. Therefore I chose only to consider the 5% 
most significant p-values out of 43661 reads assessed in each comparison. I then 
went on to use an un-biased approach to highlight genes that appeared frequently 
between the four comparisons. I specifically identified genes that could help to 
understand the relationship between the four comparisons, discounting any genes 
that were expressed in an illogical manner. Finally I discounted any hits whose 
function could not be related to the melanocyte phenotype. Using this method, I 
short-listed the five most promising hits from my microarray data (Table 6.2). 
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Interestingly, comparison of datasets between DMSO treated controls and B4-
Rhodanine treated samples showed a 26.7-fold enhancement in her5 (notch) 
signalling in B4-Rhodanine treated embryos. Additionally her5 was also shown to be 
down-regulated 12-fold in the AG1478 + B4-Rhodanine treated embryos as 
compared to the B4-Rhodanine only treated embryos. It may be possible that her5 is 
up-regulated in response to Prl-3 inhibition, but that it requires adequate ErbB 
activation to function. This is an intriguing hit as it has been previously shown in 
mouse that Notch signalling through Hes1 mediates melanoblast survival. 
Furthermore, zebrafish Notch (Ninkovic et al., 2005) signalling has been linked to 
generation of a neural crest cell lineage and to a population of neural stem cells in the 
adult brain (Bally-Cuif et al., 2000; Chapouton et al., 2006; Geling et al., 2003; 
Geling et al., 2004; Tallafuss and Bally-Cuif, 2003). However, there was no change 
in her5 expression in the AG1478 Vs AG1478+ B4-Rhodanine comparison. 
Suggesting that Her5 may not be the mechanism by which Prl-3 inhibition rescues 
melanocyte phenotypes caused by loss of ErbB (see Section 6.2.6.1).  Despite this 
possibility, I decided to further investigate the potential Prl-3 – Her5 axis in 
zebrafish. This decision was based mainly upon the data from the literature, 
describing a function of Her5 in zebrafish neural stem cells, and a function of HER5 
in MSCs in mice (see section 6.2.6.1). 
 
Another interesting hit is the 16-fold up-regulation of fzr1 (fizzy/cell division cycle 20 
related 1, or also known as cdh1) following B4-Rhodanine treatment. Fzr1 up-
regulation may also be dependent on intact ErbB signalling as B4-Rhodanine treated 
embryos a 28.6-fold reduction in fzr1 expression compared to the AG1478 + B4-
Rhodanine co-treated embryos. Fzr1 has been linked to cell cycle control and 
response to genotoxic stress at the G2/M checkpoint (Ishizawa et al., 2011). It has 
also been suggested that Fzr1 has a role in the switch between cycling and 
quiescence in haematopoietic stem cells (HSCs) (Ishizawa et al., 2011), suggesting 
that it could be a promising candidate gene to further study the role of Prl-3 in 
regulation of a MSC population. 
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The up-regulation of esr2b expression (12.7-fold) in B4-Rhodanine treated embryos 
(compared to DMSO controls) is a curious hit becasuse esr2b is expressed in the 
neuromasts (mechanosensory cells) of the lateral line (Tingaud-Sequeira et al., 
2004). In fact loss of erbb in picasso mutants led to a reduction (but not total loss) of 
lateral line ganglion neuromasts (Honjo et al., 2011). Likewise my microarray data 
shows a 8.12-fold reduction in esr2b expression in AG1478 treated embryos 
(compared to DMSO controls). It has also been postulated that neuromasts are a 
source of “sensory compensation” to the loss of dorsal root ganglia (DRG) in picasso 
mutants (Honjo et al., 2011). However no change in esr2b expression was detected in 
the AG1478 embryos Vs AG1478 + B4-Rhodanine co-treated embryos.  Thus it is 
unlikely that esr2b expression is the mechanism by which Prl-3 inhibition rescues 
AG1478-mediated melanocyte phenotypes. 
 
The only short-listed hit with a difference in gene expression between the AG1478 
treated embryos Vs the AG1478 + B4-Rhodanine treated embryos (2.8-fold 
reduction in co-treated embryos) was somatostatin 2 (sst2). Somatostatin is an 
inhibitory hormone coded by a single gene in mammals, whereas zebrafish have 
three distinct sst genes. Zebrafish sst2 is expressed transiently during early embryo 
development, and then after development in the endocrine pancreas (Li et al., 2009). 
It is unknown how Sst2 might elicit an AG1478-mediated response in zebrafish, 
although it is interesting to note that in human cells SST inhibits cell proliferation by 
opposing ErbB activation. AG1478 (ErbB inhibitor) treatment was shown to enhance 
SST-mediated cell cycle arrest in cells (Kharmate et al., 2011). For this reason, the 
27- 38.5 –fold increase in sst2 gene expression in response to AG1478 treatment 
(when compared to DMSO controls) could represent a cell-cycle arrest response in 
these embryos. Moreover, the 2.87-fold reduction in sst2 expression in AG1478 + 
B4-Rhodanine treated embryos (compared to AG1478 treated embryos), may 
indicate a subset of cells that are rescued from cell cycle arrest through Prl-3 
inhibition. Thus the relationship between Prl-3, Sst2 and the cell cycle may be 






Gene DMSO	  Vs	  B4-­Rhodanine DMSO	  Vs	  AG1478 B4-­Rhodanine	  Vs	  AG1478	  +	  
B4-­Rhodanine AG1478	  Vs	  AG1478	  +	  B4-­Rhodanine 
 Fold	  Change P-­value Fold	  Change P-­value Fold	  Change P-­value Fold	  Change P-­value 
her5 26.68 4.66*10-­‐18 N.S N.S -­‐12 2.59*10-­‐17 N.S N.S 
ryk -­‐2.6 3.86*10-­‐7 2.1 5.22*10-­‐26 1.9 6.11*10-­‐21 N.S N.S 
fzr1 16 8.85*10-­‐21 N.S N.S -­‐28.6 5.40*10-­‐22 N.S N.S 
sst2 N.S N.S 27-­‐38.5 3.86*10-­‐22 44.85 7.19*10-­‐22 -­‐2.87 8.55*10-­‐10 
esr2b 12.7 4.15*10-­‐20 -­‐8.12 5.77*10-­‐17 -­‐75.9 5.84*10-­‐23 N.S N.S 
 
Table 6.2. Potential pathways important in Prl-3 biology identified from a microarray screen. Promising hits were selected as described in the main text. Only 
expression changes in the top 5% of hits (as ordered by P-value) were considered significant. Table describes the fold change in each treatment condition. Up-
regulation is marked in red and down-regulation in blue. N.S; Non-significant values. Where a fold change is indicated this is the fold change of the sample 




6.2.6.1.	  Validation	  of	  a	  notch-­‐prl-­‐3	  axis	  in	  the	  zebrafish	  
 
In notch signalling in the mouse, γ-secretase cleaves the Notch Intracellular Domain 
(NICD), which allows NICD to associate with RBP-J forming a transactivation 
complex that can translocate to the nucleus to mediate transcriptional changes 
(Tamura et al., 1995). DAPT is a chemical inhibitor of notch signalling which 
inhibits γ-secretase activity, and has been shown to induce hair greying in mouse 
(Moriyama et al., 2006). DAPT has also previously been shown to be effective at 
inhibiting notch signalling in zebrafish neural stem cell studies (Cornell and Eisen, 
2002). To address what effect DAPT had on the zebrafish fish MSC lineage, I treated 
developing zebrafish embryos with a dose curve of DAPT and assayed the number of 
melanocytes along the lateral line. Strikingly, I observed a 34% reduction in lateral 
line melanocytes in DAPT treated embryos compared to DMSO controls midline 
[95% CI; -13.69(-20.93, -6.45)] as determined by ANOVA (P<0.001). Thus I have 
identified a novel population of late-developing melanocytes on the lateral line that 
are dependent upon an intact Notch pathway (Figure 6.7) Thus I propose that Notch 
signalling in the embryo has a role in development of a MSC population, likely to be 
distinct from erbb-dependent MSCs, as lateral line melanocyte loss is not as severe 
as in AG1478 treated embryos. It would be interesting to test if co-treatment of 
AG1478 and DAPT results in a cumulative loss of melanocytes on the lateral line 
that is greater than either drug’s effect individually. A cumulative drug effect 
following AG1478/DAPT double treatment would corroborate that both drugs act in 
separate pathways/ on distinct cellular populations. The effect of DAPT on MSC-
derived melanocytes may be explained by the role of notch signalling in mediating 
neural crest cell fate over Rohon Beard sensory neuron lineages. Following this, I 
asked if B4-Rhodanine was sufficient to rescue the DAPT induced lateral line 
melanocyte phenotype (work by D. Liu) (Figure 6.7). Wildtype developing embryos 
(32°C) treated with DAPT during MSC establishment (4-48 hpf) develop on average 
34% less melanocytes on the lateral line than DMSO controls by 4 dpf. Double 
treatment of DAPT/B4-Rhodanine is insufficient to rescue melanocyte loss on the 
lateral line [95% CI; -1.28(-10.11, 7.56)], indicating that zebrafish Prl-3 acts in a 
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separate pathway to Notch signalling, or that DAPT acts to inhibit Notch signalling 
downstream of Prl-3. As observed previously, B4-Rhodanine treatment alone does 
not enhance melanocyte numbers on the lateral and thus normal control of 
melanocyte numbers is maintained. In summary, I have identified the Notch pathway 
in the zebrafish as a contributor to late-stage melanocyte development. This pathway 
may be independent of PRL3, or downstream of PRL3 as the PRL3 inhibitor was 
unable to rescue the notch-mediated lateral line.  
 
We interpret this to mean that Notch signalling is independent of Prl-3 signalling in 
zebrafish melanocyte development. At this stage, we still don’t understand why a 
downstream target of Notch was upregulated in our PRL3 inhibitor treated fish. The 
link between Notch and PRL3 activity may be independent of melanocytes. 
Alternatively, we could test if overexpression of her5 could phenocopy the prl3 
inhibitor treatment. Interestingly, we have recently found that like her5, prl-3 is 
upregulated at the midbrain hindbrain boundary (see Chapter 7.1; preliminary data 
and future work). Although we don’t yet understand the significance of this result, 
there may yet be a functional link between Prl-3 and Notch signalling that we need to 




Figure 6.7. DAPT induces a loss of MSC derived melanocytes that cannot be rescued by PRL-3 
inhibition 
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Figure 6.7. DAPT induces a loss of MSC derived melanocytes that cannot be rescued by PRL-3 
inhibition. (A) Wildtype embryos were raised at 32°C to speed up embryo growth. Embryos were 
treated with the 20 μM DAPT (notch inhibitor) from 4-48 hpf (drugs were replenished daily), at 48 
hpf drugs were washed-out and lateral line melanocytes were analysed at 4 dpf. (B, D) DAPT treated 
embryos had an average 34% reduction in melanocyte on the midline [95% CI; -13.69(-20.93, -6.45)] 
as determined by ANOVA using Tukey’s post-hoc test (P<0.001). This could not be rescued by co-
treatment with 20 μM PRL-3 inhibitor, indeed there is no significant difference in number of 
melanocytes on the lateral line melanocytes between DAPT treated embryos and DAPT/B4-
Rhodanine co-treated embryos [95% CI; -1.28(-10.11, 7.56)]. Graph is a representative of four 
technical replicates, error bars represent standard error from the mean. 
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6.2.7.	  Prl-­‐3	  enhances	  a	  mitfa-­‐positive	  unpigmented	  population	  but	  not	  
other	  neural	  crest	  associated	  genes	  
 
My data establish the role of Prl-3 in a melanocyte progenitor population, however 
two key questions remain: first, what target cell does Prl-3 affect; and second, what 
is the molecular target of Prl-3 in zebrafish? To address these questions I asked if 
treatment with B4-Rhodanine would affect expression of a series of key transcription 
factors involved in development of neural crest derived melanocytes (sox10, foxd3 
and mitfa) under regenerating conditions. I treated mitfavc7 embryos at the restrictive 
temperature with a DMSO control or B4-Rhodanine. In addition, I also treated 
mitfavc7 embryos at the restrictive temperature with AG1478, or a co-treatment of 
both AG1478 and B4-Rhodanine. By doing this I hoped to identify cell types that are 
affected by Erbb inhibition, and assess if these cell types are rescued by B4-
Rhodanine treatment. Late-migrating neural crest cells delaminating from the neural 
tube, expressing sox10 specify a non-ectomesenchymal cell fate, such as neurons, 
glia, and pigment cells (Dutton et al., 2001b; Raible and Eisen, 1994; Raible et al., 
1992). In situ analysis of sox10 expression between DMSO controls and B4-
Rhodanine treated embryos revealed no difference in sox10 expression patterns 
(Figure 6.8.1). Specifically, numbers of sox10 expressing cells were counted 
dorsally, the total numbers of DRG were counted, and width and length of 
expression down the midline was measured. Interestingly, sox10 expression at the 
dorsal root ganglion (DRG) cells in the zebrafish trunk was ablated following 
AG1478 treatment (Figure 6.8.1 (A); arrows). Additional sox10 expression situated 
ventrally to the lateral line (red arrowheads) is lost following AG1478 treatment 
(black arrowheads). I also assessed expression of another neural crest gene, foxd3, 
which is expressed downstream of sox10 and works in opposition to kita to inhibit 
melanocyte cell fate and promote a glial cell fate (Cooper et al., 2009; Curran et al., 
2010; Curran et al., 2009). I found that there was strong foxd3 expression in the 
trunk, characteristically observed in the glial cells (arrowhead) and innervating 
motorneurones (Figure 6.8.1 (B); arrows). No difference in foxd3 expression was 
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observed between DMSO control and B4-Rhodanine treated embryos. However, 
following AG1478 treatment foxd3 expression was dramatically ablated in both glial 
cell and motorneuron cell types. B4-Rhodanine treatment did not rescue AG1478 
induced expression patterns.  
 
In vertebrates, melanocyte specification and differentiation is initiated by Mitf 
expression, homologous to zebrafish mitfa (Lister et al., 1999; Steingrimsson et al., 
1994). Recent studies suggest low-expressing mitfa unpigmented cells depict a 
possible melanocyte precursor population and that these were shown to be erbb 
dependent (Adameyko et al., 2009; Adameyko et al., 2012). Subsequently I used in 
situ analysis (Budi et al., 2011) to investigate the effect of PRL-3 inhibitor treatment 
in mitfavc7 embryos. Embryos were blind-scored (n= 60) and expression was scored 
as “strong” (greater numbers of mitfa-expressing cells and darker expression) or 
“weak” staining, as shown in Figure 6.8.2 (A-B) An enhancement of mitfa 
expressing cells in the myotome, head, dorsal stripe and lateral stripe in B4-
Rhodanine treated embryos was observed. Critically, it was essential to develop in 
situ staining for a prolonged time in order to allow visualisation of low-expressing 
mitfa cells. To accurately assess if numbers of mitfa expressing cells are increased or 
if mitfa expression levels are stronger per cell, I would need to perform cryosections 
of the in situ samples.  
 
I also performed in situ staining of mitfa in AG1478 treated, and AG1478 and B4-
Rhodanine co-treated embryos (data not shown). To date I have not observed a 
rescue of mitfa expressing cells in AG1478/B4-Rhodanine double-treated embryos. 
However to assess this fully I would wish to analyse mitfa expression in a time 
course over the ensuing days following release from the restrictive temperature. I 
would also like to perform cryosections of my whole mount in situ samples, as this 
would enable accurate in-depth analysis of numbers of cells and cell types affected. 
 
In conclusion, the neural crest genes, sox10 and foxd3 were unchanged following B4-
Rhodanine exposure in melanocyte regenerating conditions. I confirmed that erbb 
inhibition induces abnormal expression of these neural crest genes (Lyons et al., 
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2005), but was unable to identify any population of sox10 or foxd3 expressing cells 
that were rescued or altered following co-treatment with B4-Rhodanine.  It would be 
important to assess how expression of sox10 and foxd3 change over time post release 
to the permissive temperature i.e. does expression of these transcription factors 
change during melanocyte regeneration, or are AG1478 treated embryos able to 
recover normal expression patterns following washout, and is this enhanced 
following co-treatment of B4-Rhodanine? Remarkably, expression of the late-stage 
melanocyte specifying transcription factor, mitfa, was greatly enhanced following 
B4-Rhodanine treatment during early development. Due to mis-splicing of the 
mitfavc7 transcript at the high restrictive temperatures, these cells were unable to go 
on to develop into differentiated melanocytes, however they are likely to indicate a 
melanocyte precursor population. It will be interesting to determine the exact nature 
of these precursor cells, specific questions I would like to address are: 1) Following 
release from restrictive temperature do these cells deplete over time as melanocyte 
regeneration occurs? 2) Are these unpigmented mitfa expressing cells capable of 
division? 3) Using lineage tracing analysis can I confirm that these cells can give rise 
to a melanocyte lineage? 4) Are these cells able to contribute to other cell lineages 
e.g. Schwann cells or iridophores? 5) Can I confirm these unpigmented mitfa 
expressing cells are present in wildtype embryos, and are their numbers enhanced by 









Figure 6.8.1. PRL-3 inhibition does not alter expression patterns of neural crest genes, sox10 
and foxd3. mitfavc7 embryos were raised at the restrictive temperature from 4-48 hpf and were treated 
with either DMSO control, 20 μM PRL-3 inhibitor,  6 μM AG1478, or co-treated with 6 μM AG1478 
and 20 μM PRL-3 inhibitor. (A) Expression of sox10 was analysed using in situ hybridisation 
staining. Following close examination of dorsal staining, midline staining, ventral staining, no 
difference was observed between DMSO controls and PRL-3 inhibitor treatment. Expanded view 
shows sox10 is expressed in the dorsal root ganglia (DRG) on the midline of the trunk in zebrafish 
(arrows), and following AG1478 treatment sox10 mis-expression occurs throughout this region. Sox10 
expression immediately ventrally to the lateral line is also severely reduced following AG1478 
treatment (arrowheads). Neither of these AG1478-induced phenotypes were rescued by co-treatment 
of PRL-3 inhibitor (three technical replicates, n-numbers were between 5-30). (B) foxd3 expression 
revealed no obvious difference between DMSO controls and PRL-3 inhibitor treated fish. foxd3 is 
characteristically expressed in glial cells along the lateral line (arrowhead) and in innervating 
motorneurons (arrows). Following AG1478 treatment foxd3 expression in these regions were lost, and 
this phenotype is not rescued with co-treatment of PRL-3 inhibitor (three technical replicates, n-




Figure 6.8.2. PRL-3 inhibition enhances expression of mitfa in possible unpigmented progenitor 
cells. (A-B) mitfavc7 embryos raised at the restrictive temperature for 4-48 hpf and treated with 20 μM 
PRL-3 inhibitor or an equivalent control. Embryos were probed deeply for mitfa using in situ 
techniques. Differences in mitfa expression were noted in the head (yellow arrow), dorsally (red 
arrow), throughout the myotome (black arrow) and along the lateral line (arrowhead). (A) PRL-3 
inhibitor treated embryo shows an example of strong expression in head, dorsal stripe and myotome 
(arrows), whereas DMSO control shows weaker expression in these areas. (B) Examples of strong and 
weak expression along the lateral line. (C-D) Expression was scored as strong or weak for the head, 
lateral line, dorsal stripe and myotome in embryos (n=60). PRL-3 inhibitor treated fish show a greater 
proportion of strongly mitfa expression in all regions when compared to DMSO controls. Four 
technical replicates, n-numbers between 5-60. 
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6.2.8.	  p53	  mutant	  embryos	  phenocopy	  the	  B4-­‐Rhodanine	  phenotype	  	  
 
The bulk of research on PRL-3 describes its role in transformed cells and during 
tumour progression and metastases (Kim et al., 2011; Laurent et al., 2011; Saha et 
al., 2001; Zeng et al., 2003), nothing is known about the role of PRL-3 in normal 
development. A key study identifies a relationship between Prl-3 and p53 in 
regulation of cell cycle progression (Basak et al., 2008). I hypothesise that this 
relationship could be a possible mechanism through which Prl-3 could regulate a 
MSC population during melanocyte regeneration. I therefore tested the capacity for 
zebrafish homozygous p53 mutant (p53M214K/M214K) embryos to regenerate 
melanocytes following NFN1 treatment (30-50 hpf). NFN1 induced melanocyte 
toxicity in p53M214K/M214K embryos was comparable to that of wildtype embryos, as 
confirmed by a “white phenotype” following treatment. Following NFN1 treatment 
and washout, ensuing melanocyte regeneration was observed. As expected, NFN1 
treated wildtype embryos had significantly limited melanocyte regeneration, whereas 
wildtype embryos co-treated with both NFN1 and B4-Rhodanine confirmed a 
significantly enhanced melanocyte regeneration phenotype [95% Confidence 
Interval; 15.53 (7.27; 23.78); ANOVA, P < 0.001]. Remarkably NFN1 treated p53 
mutant embryos showed a significant enhancement of melanocyte regeneration 
following embryo washout than wildtype embryos treated with NFN1 [95% CI; 9.06 
(0.92; 17.19); ANOVA, P <0.001] (Figure 6.9). This suggests that p53 signalling 
contributes to MSC regulation in the zebrafish, possibly through a conserved p53 – 
Prl-3 axis. However, the question remains if the enhanced melanocyte regeneration 
phenotype in p53 mutant embryos is specific to the NFN1 treatment assay. We do 
not know by what mechanism NFN1 treatment limits melanocyte regeneration. It 
could be possible that NFN1 treatment initiates loss of a MSC population through a 
p53-mediated pathway, in which case the enhanced melanocyte regeneration 
phenotype of p53M214K/M214K embryos could be restricted to the NFN1 assay. It is 
therefore important to test if p53 mutant embryos are capable of enhanced 
melanocyte regeneration in other melanocyte regeneration assays. This would help 
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establish if a p53 – Prl-3 axis has a normal role in regulation of MSC 






Figure 6.9. Mutant p53 enhances melanocyte regeneration following NFN1 mediated melanocyte 
ablation. (A-B) NFN1 treatment of wildtype and p53M214K/M214K embryos (30-50 hpf) causes loss of 
differentiated melanocytes equally in both genotypes. (B-C) Two days post washout embryos were 
fixed and melanocyte regeneration on the head region is counted. (C) Box plot depicts numbers of 
regenerating melanocytes on the head region, each symbol portrays a separate embryo. Box represents 
interquartile ranges of the data, with the median represented by the intersecting line. Wildtype 
embryos treated with 20 μM NFN1 had limited melanocyte regeneration (mean = 13). As expected 
PRL-3 inhibitor co-treatment in wildtype embryos enhanced melanocyte regeneration (mean = 30) 
significantly in the head region [95% Confidence Interval; 15.53 (7.27; 23.78)]. Importantly 
melanocyte regeneration following NFN1 treatment in p53M214K/M214K embryos is significantly 
enhanced when compared to wildtype embryos [95% CI; 9.06 (0.92; 17.19)]. There is no significant 
difference between melanocyte regeneration in p53M214K/M214K embryos Vs in wildtype embryos co-





In this chapter I have identified a chemical inhibitor of Prl-3 that enhances MSC-
derived melanocytes under challenged conditions. I showed this in two melanocyte 
regeneration assays (NFN treatment and mitfavc7 mutants) and two MSC-derived 
melanocyte developmental assays (erbb mediated loss of lateral line and adult 
stripe). Importantly prl-3 inhibition only displayed a phenotype following 
melanocyte ablation, or after MSC loss through erbb inhibition. By using 
morpholino knockdown of ptp4a3 (prl-3 gene) I was able to mimic the enhanced 
regeneration phenotype in mitfavc7 embryos, thereby confirming that inhibition of 
PRL3 is the main function of the PRL3 inhibitor in melanocyte regeneration. Most of 
what is known about Prl-3 function in vivo is limited to cancer biology. My findings 
identify a novel developmental role of prl-3 in the regulation of a stem cell 
population, and could indicate an intriguing new target for stem cell biology. One 
key publication described Prl-3 as a downstream effector of p53 that functions to 
regulate cell-cycle progression via both Cdk2 and Akt pathways (Basak et al., 2008), 
thus suggesting a possible mechanism through which Prl-3 could regulate a stem cell 
population. Curiously, Cdk2 co-expresses with Dct in a mouse melanoblast 
population at the hair follicle (E. Nirmala; unpublished data). Notably, both low and 
high levels of Prl-3 induced cell cycle arrest, whereas intermediary levels were 
sufficient to drive cell cycle progression (Basak et al., 2008). Paradoxically, 
overexpression of PRL-3 phosphatase enhances metastases in a variety of cancer 
types, including uveal melanoma and melanoma (Kim et al., 2011; Liu et al., 2012; 
Ustaalioglu et al., 2012; Zeng et al., 2003). It is suggested that in combination with 
oncogenic mutations that drive the cell cycle PRL-3 overexpression acquires new 
cellular functions such as: induction of molecular signalling that drives the Epithelial 
to Mesenchymal transition (EMT), and increased MMP mediated degradation of the 
extracellular matrix (ECM) and basement membrane (Peng et al., 2009), these 
functions combine to promote metastasis in transformed cells.  
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PRL-3 inhibitor treatment was shown to rescue erbb-mediated loss of a melanocyte 
progenitor population. This suggests that prl-3 may be active downstream of erbb 
within the same progenitor population. Alternatively prl-3 could be affecting an 
erbb-independent population, whose expansion through B4-Rhodanine treatment 
could be sufficient to offset AG1478 mediated loss of an erbb-dependent MSC 
population. I favour the latter hypothesis following in situ analysis of the neural crest 
cell markers, sox10 and foxd3, which have a characteristic AG1478 mediated 
expression pattern that cannot be rescued by co-treatment of B4-Rhodanine. 
Furthermore, treatment of embryos with AG1478 during MSC establishment (9-48 
hpf) results in a pigment phenotype observed at metamorphosis. While this 
phenotype can be rescued by co-treatment of B4-Rhodanine during MSC 
establishment, the extent of this rescue is less dramatic than in embryonic assays. I 
hypothesise that prl-3 inhibition expands an erbb-independent population capable of 
compensating for AG1478 mediated MSC loss. However during metamorphosis a 
much greater demand is required of MSCs to recapitulate the pigment pattern, 
therefore a smaller proportion of “full rescued” fish are observed. I previously 
suggested that due to the specific location of erbb-dependent melanocytes at 
metamorphosis, perhaps MSCs occupy specific niches throughout the fish, and these 
niches have a tendency to serve specific regions of the zebrafish. If true then it would 
be reasonable to suggest that different niches are dependent upon different molecular 
signals for their maintenance (i.e. erbb-dependent or -independent), this would allow 
innate resilience in zebrafish melanocyte development. To further this point I would 
next ask if prl-3 overexpression in the zebrafish results in a loss of a MSC 
population, and if this loss is additional to AG1478 mediated MSC loss. Accordingly 
I have shown that chemical inhibition of erbb and prl-3 provide two potential tools 
with which to manipulate populations of MSCs, and hypothesise these two tools may 
be biologically distinct from one-another. Thus AG1478 and B4-Rhodanine may be 
useful compounds with which to study cross talk between MSC populations/niches, 
and the molecular signals that stimulate melanocyte regeneration within the embryos. 
 
B4-Rhodanine treatment in the mitfavc7 assay enhances mitfa expression in 
unpigmented cells in the dorsal and lateral stripes, and throughout the myotome and 
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head. Budi and colleagues previously described the existence of low mitfa expressing 
cells throughout the zebrafish myotome, and suggested that these represent a 
melanocyte precursor population that is akin to Schwann Cell Precursor cells in the 
mouse, and are able to give rise to both Schwann cell lineages and melanocyte 
lineages (Adameyko et al., 2009; Adameyko et al., 2012; Budi et al., 2011). It 
remains to be seen if enhanced mitfa positive cells following B4-Rhodanine 
treatment represent this same SCP population. As SCPs were shown to be dependent 
on Erbb signalling (in both zebrafish and mouse), it would be informative to test to 
what extent these mitfa expressing cells are sensitive to AG1478 treatment and what 
effect B4-Rhodanine co-treatment has on this population. It is important to assess if 
B4-Rhodanine mediated enhancement of mitfa expressing cells is maintained in a 
wildtype background, as to date this question remains unanswered.  
 
In conclusion, I have established that prl-3 can enhance melanocyte regeneration in 
four different assays. I have not definitively identified the molecular or cellular target 
of prl-3 in zebrafish development, but can deduce that prl-3 regulates an 
unpigmented progenitor population, and can rescue loss of erbb dependent MSCs 
























7.1.	  Preliminary	  Work	  and	  Future	  Experiments	   	  
  
In this thesis I have investigated key molecular processes involved in melanocyte 
development and regeneration using small molecules and genetics. I have discovered 
a phosphatase, prl-3, with a novel function in the regulation of a melanocyte 
precursor population. Additionally, I have identified a role for differentiated 
melanocyte division in the development of the embryonic pigment pattern. I asked if 
PRL-3 inhibitor (B4-Rhodanine) treatment enhances melanocyte regeneration 
through differentiation from an unpigmented precursor or by differentiated cell 
division, and found through timelapse imaging that melanocyte regeneration after 
NFN1 melanocyte ablation was through an unpigmented precursor population. 
Crucially, de novo developing melanocytes were first observed at the same time 
point post washout in both NFN1 treated, and NFN1 and B4-Rhodanine co-treated 
embryos (data not shown), suggesting that while the rate of melanocyte 
differentiation is unaffected the numbers of regenerating melanocytes are enhanced. 
This is preliminary data and needs to be validated but it suggests the PRL-3 inhibitor 
phenotype is due to an expansion of MSCs. Another possibility could be PRL-3 
induces unregulated differentiation of MSCs without sufficient stem cell 
proliferation, possibly at the expense of the MSC pool. Therefore B4-Rhodanine 
treated fish would rapidly lose capacity for melanocyte regeneration (akin to the 
“hair-greying” effect in mice) after serial melanocyte ablation challenges e.g. adult 
tail clips (Johnson and Weston, 1995; Moriyama et al., 2006). 
 
Microarray data suggests PRL-3 inhibitor treatment in the mitfavc7 regeneration assay 
induces a 26.7- fold increase in her5 expression. To validate this result I used in situ 
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hybridisation analysis to assess her5 expression levels in zebrafish embryos (her5 
probe was kindly provided by Dr Laure Bally-Cuif) (Tallafuss and Bally-Cuif, 
2003). mitfavc7 embryos at the restrictive temperature were treated with DMSO 
control, B4-Rhodanine, AG1478 and co-treated with B4-Rhodanine and AG1478 
(n=30). No obvious difference in her5 expression at 48 hpf was observed between all 
treatment conditions (Figure 7.2). Considering the microarray data indicated a 26.7-
fold increase in her5 expression, an increase at this level should be possible to 
visualise by in situ hybridisation. Nonetheless I was unable to establish a relationship 
between prl-3 and her5 signalling in the zebrafish embryo. Contradictorily, 
preliminary data in the lab (Ella Nirmala) shows prl-3 expression in zebrafish at 
72hpf is located at the presumed midbrain-hindbrain boundary (MHB) in both 
wildtype and mitfavc7 embryos (n=5) (Thisse and Thisse, 2005). This preliminary data 
could indicate a normal role of prl-3 at the zebrafish MHB (Figure 6.3), however if 
this observed expression pattern is relevant to the role of prl-3 in melanocyte 
regeneration is yet to be determined. Studies have shown the MHB in adult zebrafish 
is a proliferative niche for multipotent neural stem cells, and that her5 (notch 
signalling) has an important role to play in regulating neural stem cell proliferation 
and differentiation (Chapouton et al., 2006; Geling et al., 2003; Geling et al., 2004; 
Ninkovic et al., 2005; Tallafuss and Bally-Cuif, 2003). It could be possible that 
during embryo development (and possibly in the adult), the MHB also provides a 
proliferative niche for the maintenance of a melanocyte precursor population, and 
proliferation of this population could be regulated by prl-3 induced her5 expression. 
Or perhaps, multipotent neural stem cells at the MHB are able to propagate a 
melanocyte lineage under challenged conditions, analogous to Schwann Cell 
Precursors (SCP) (Adameyko et al., 2009; Adameyko et al., 2012; Budi et al., 2011). 
In conclusion, despite being unable to establish a link between prl-3 and notch 
signalling in the zebrafish, I still believe further study of a relationship between these 
two pathways would be valuable. Notch signalling has been shown to be critical in 
the maintenance and survival of mouse MSCs (Aubin-Houzelstein et al., 2008; 
Moriyama et al., 2006; Schouwey et al., 2007). Thus it is important to establish if a 




Figure 7.1. PRL-3 inhibition enhances melanocyte regeneration from an unpigmented precursor 
population. Embryos were treated with 20 μM NFN1 from 30–50 hpf to ablate differentiated 
melanocytes.  Embryos were co-treated with 20 μM PRL-3 or a DMSO control. Upon washout 
embryos were left for 2-4 hours to recover, then embedded in agarose and subsequent melanocyte 
regeneration was analysed by timelapse imaging. Times depicted are the number of hours from 
washout. Representative examples of melanocyte regeneration are depicted (n=3). Embryos were 
imaged on a sox10-GFP background to allow for easy visualisation of newly developing pigmented 
melanocytes. Embryos co-treated with PRL-3 inhibitor show enhanced numbers of de novo 
differentiating melanocytes (small black specks) at 30 hours post washout, which subsequently mature 
into an increased number of differentiated melanocytes at 76 hours post-washout. No obvious 





Figure 7.2. Prl-3 expression along notch dependent midbrain-hindbrain boundary. (A) 48 hpf 
mitfavc7 embryos at the restrictive temperature were treated either with 20μM PRL-3 inhibitor, 6 μM 
AG1478, co-treatment of 20 μM PRL-3 inhibitor and 6 μM AG1478, or an equivalent DMSO control 
(n=30). Drugs were replenished daily. Embryos were probed for her5 (in situ probes kindly donated 
by Dr L. Bally-Cuif). Her5 is expressed in the midbrain-hindbrain boundary in mitfavc7 embryos, 
equivalent to wildtype expression (Geling et al., 2004; Ninkovic et al., 2005). In situ staining did not 
reveal any observable difference in her5 expression between cohorts. (B) Preliminary results by Ella 
Nirmala in the lab show ptp4a3 expression at the midbrain-hindbrain boundary (MHB) in wildtype 
and mitfavc7 72 hpf embryos (n=5).  
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7.2.	   Differentiated	   melanocyte	   division	   in	   melanoma	   and	   stem	   cell	  
biology	  
 
In this thesis I provided evidence for the existence of differentiated melanocyte 
division in an in vivo model. I then went on to show that functional mitfa levels 
played an essential role in regulation of melanocyte division in the zebrafish. I could 
induce hypomorphic levels of mitfa in the mitfavc7 transgenic zebrafish, and used this 
to show that reducing functional mitfa during melanocyte development enhances the 
frequency of differentiated melanocyte division events. I suggest that mitfa in the 
zebrafish may be able to alter differentiated melanocyte state in a manner similar to 
the “MITF molecular rheostat” model Goding and colleagues proposed in melanoma 
(Carreira et al., 2005; Carreira et al., 2006; Hoek et al., 2008a; Hoek and Goding, 
2010; Wellbrock and Marais, 2005). Goding’s rheostat model suggests that high 
levels of MITF drive terminal differentiation in melanoma cells, but lower MITF 
levels can drive melanoma cell proliferation. Still lower MITF levels reduce 
proliferation and pigmentation of melanoma cells but enhances migration or 
“metastasis”; finally total loss of MITF leads to melanoma senescence (Giuliano et 
al., 2010; McGill et al., 2002). Essentially this model describes a plastic situation in 
which melanoma cells can fluctuate between differentiated cell states and 
progressively “de-differentiated” cell states in response to MITF. It is likely that 
cooperating mutations promoting melanoma cell survival help to drive cell plasticity 
in response to MITF, but to what extent the MITF rheostat model reflects normal 
melanocyte biology is yet to be answered.  
 
During normal melanocyte development, differentiation was previously believed to 
be predominantly one-directional: neural crest cells are specified to the melanocyte 
lineage by MITF, these unpigmented melanoblasts are highly migratory cells that 
rapidly expand (divide) in the dermis. Next, high Mitf expression levels promote 
expression of pigmentation enzymes and drive differentiation, at which point 
melanocytes localise in the epidermis and motility lessens (Jordan and Jackson, 
2000a; Jordan and Jackson, 2000b; Mackenzie et al., 1997; Taylor et al., 2011). In 
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this thesis I have shown that the balance between proliferation and cell cycle arrest in 
differentiating melanocytes is regulated by mitfa in zebrafish, however I have not 
been able to provide any evidence of melanocyte dedifferentiation. This 
interpretation relies heavily on timelapse imaging techniques using either melanin or 
GFP expression (in tyrp1-GFP transgenic embryos) as markers for melanocyte 
differentiation. However both melanin and GFP are relatively long-lived in their host 
cell, consequently fluctuations between cell differentiation states may not be 
accurately determined in this system. To further explore melanocyte plasticity in the 
zebrafish system I would suggest a two-pronged approach: First, timelapse imaging 
of transgenic reporter lines such as foxd3-GFP, pax3-GFP, or sox10-GFP may 
determine an immature “pre-melanocyte” cell lineage (Carney et al., 2006; Gilmour 
et al., 2002; Seger et al., 2011). Thus generation of a mitfavc7; foxd3-GFP double 
transgenic line may provide a tool to study any possible dedifferentiation in response 
to loss of mitfa in the zebrafish. Secondly, because RNA has a relatively high 
turnover rate in cells, RNA expression analysis may provide a more accurate tool to 
investigate changes in molecular markers that could indicate dedifferentiation of 
melanocytes. Possible RNA in situ probes that would indicate immature melanocyte 
or melanocyte progenitor lineages could be: foxd3, erbb3, sox2, sox10, pax3 (Budi et 
al., 2008; Budi et al., 2011; Curran et al., 2010; Greenhill et al., 2011; Hultman et al., 
2009; Minchin and Hughes, 2008). Progressive loss of mitfa can be induced in the 
mitfavc7 hypomorphic model by changing the temperature of the embryo medium 
(Johnson et al., 2011). If mitfa loss can stimulate dedifferentiation in vivo then I 
would expect to see increased co-expression of possible melanocyte progenitor 
markers in pigmented melanocytes or in mitfa positive cells. 
 
In conclusion, I have shown in zebrafish that low levels of mitfa in developing 
melanocytes can uncouple differentiation from cell cycle arrest, suggesting that a 
mitfa rheostat model could exist in regulation of normal melanocyte development in 
zebrafish. Control of zebrafish melanocyte differentiation state by mitfa draws 
parallels to cell-type switching in melanoma cells. We showed that following 
injection of zebrafish mitfa DNA in mitfa-restricted embryos, melanocyte 
development could be rescued. Remarkably, injection of human MITF DNA is also 
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sufficient to rescue nacre or mitfavc7 embryos at the restrictive temperature, 
highlighting the homology between zebrafish and human melanocyte development. 
Finally, by the use of timelapse imaging I could confirm injection of the human 
melanoma allele MITF4TΔ2B enhances melanocyte division events during 
development. Thus timelapse imaging in zebrafish is a useful functional assay to 
assess the biological significance of known melanoma mutations in vivo. 
 
Regulation of zebrafish melanocyte differentiation and proliferation by mitfa is an 
example of how features of normal developmental biology are often found in 
melanoma biology. I therefore would expect other aspects of melanocyte biology to 
play a role in melanoma progression/ cell-type switching. A recent example 
describes how ERBB3 activation suppresses MITF activity in melanoma cell lines, 
causing subsequent loss of pigmentation and enhanced metastasis (Buac et al., 2009). 
It would therefore be compelling to assess if I could drive 
dedifferentiation/proliferative state by ectopically expressing transcription factors, 
soluble signals, or receptors associated with melanocyte precursor, or glial, or 
neuronal cell fates. Interesting candidates for ectopic expression would be: foxd3 
which is known to be important in glial and iridophore cell fates, pax3 which is 
essential for early neural crest specification and also a mouse MSC marker, nrg1 and 
erbb3 are both necessary for development of SCPs, notch which is necessary for 
MSC survival in mouse and has a possible role in a melanocyte precursor population 
in zebrafish, and finally neurogenin (ngn) which drives development of neural cell 
types (Adameyko et al., 2009; Budi et al., 2008; Budi et al., 2011; Cooper et al., 
2009; Curran et al., 2010; Curran et al., 2009; Hultman et al., 2009; Hultman and 
Johnson, 2010; Ignatius et al., 2008; Johnson et al., 2011; Minchin and Hughes, 
2008).  
 
Neural crest development of pigment cells, glial cells and neuronal lineages are all 
closely linked during early development (Serbedzija et al., 1994; Serbedzija et al., 
1990). New evidence suggests SCPs are nerve-associated bipotent progenitors that 
can differentiate into both melanocyte and Schwann cell lineages and rely upon 
nerve stimulation (via nrg1) to maintain this precursor-like state (Adameyko et al., 
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2009; Adameyko et al., 2012). In vivo evidence has even shown that following 
denervation, Schwann cells differentiate into a melanocyte lineage (Adameyko et al., 
2009). Consequently a degree of plasticity exists within pigment cell and neuronal 
lineages, which may be utilised to develop therapies for pigment disorders, such as 
vitiligo (loss of melanocytes) or hair greying. In conclusion, I have shown that mitfa 
in zebrafish drives melanocyte differentiation and that reduction in mitfa uncouples 
differentiation and cell cycle arrest. In zebrafish, mitfa is absolutely required for 
melanocyte development. Up-shift of temperature sensitive mitfavc7 embryos to the 
restrictive temperature results in loss of functional mitfa expression. Following this, 
Johnson and colleagues showed dendritic melanocytes took on a small, rounded 
appearance (Johnson et al., 2011); however, if this signifies possible melanocyte 
dedifferentiation remains to be seen. 
 
7.3.	  What	  more	  can	  we	  learn	  about	  MSCs?	  
 
Melanocyte biology is a useful model with which to study stem cell biology. While 
much progress has been made in this area, much knowledge is lacking about the 
complex molecular interactions that drive stem cell development and differentiation. 
Greater knowledge of the key regulatory pathways involved in MSC biology will aid 
development of new therapies to treat pigmentation disorders as well as melanoma. 
Also because melanocyte and neural developmental pathways are closely related 
then new findings in melanocyte biology could be relevant to understanding 
development of neural cell lines e.g. neurons, oligodendrocytes, Schwann cells. 
 
Recent evidence has shown that erbb3 signalling is necessary for the development 
and maintenance of nerve-associated SCPs, a bipotent progenitor cell that can give 
rise to both Schwann cell and melanocyte lineages (Adameyko et al., 2009; 
Adameyko et al., 2012; Budi et al., 2008). Sox2 signalling is known to be essential in 
maintaining this immature progenitor state. SCPs rely upon nerve association and 
signalling by the growth factor nrg1 to inhibit melanocyte differentiation and 
maintain an immature cell type: denervation of SCP associated nerves is sufficient to 
drive melanocyte differentiation in vivo (Adameyko et al., 2009; Adameyko et al., 
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2012). In melanoma cell lines activation of erbb signalling drives “dedifferentiation” 
of melanoma cells, causing loss of pigmentation, and acquisition of proliferative and 
highly migratory (metastatic) cellular characteristics, suggesting that normal 
differentiated melanocytes may maintain erbb responsiveness (Buac et al., 2009).  
 
In zebrafish, SCPs have been postulated to be a source of MSCs, however it is 
unknown if these represent the only source of zebrafish melanocyte progenitor cells. 
If another MSC population distinct to erbb dependent SCPs exist then what 
molecular signals are critical for their development, and where are they located? The 
dramatic difference between zebrafish embryonic and adult pigment patterns 
suggests de novo melanocytes are likely to be derived from a self-renewing stem cell 
population. However, with no definitive zebrafish MSC marker evidence for this is 
only circumstantial. Nevertheless pharmacological inhibition of erbb during 
zebrafish early development (14-22 hpf) does not produce an embryonic pigment 
phenotype but can result in melanocyte loss at metamorphosis and during 
melanocyte regeneration (Budi et al., 2008; Hultman and Johnson, 2010). This 
evidence suggests that erbb inhibition affects an unpigmented precursor population 
that would normally remain in an undifferentiated state until called upon to replenish 
the melanocyte pigment pattern, suggestive of a stem cell like population. 
Intriguingly, loss of erbb signalling (picasso mutant or AG1478 treatment) results in 
only a partial loss of adult melanocyte pigment pattern (Budi et al., 2008), suggesting 
another source of zebrafish MSC progenitors independent of erbb signalling must 
also contribute to the adult stripe pattern. Identification of a novel MSC pool in the 
zebrafish may provide insight into new sources of MSCs in mammals. SCPs are 
dependent on nerve innervation to maintain a proliferative and immature cell state, 
however it is feasible that an alternative melanocyte precursor population exists that 
is not dependent upon nerve association, and subsequently could be erbb 
independent.  
 
In mouse, Notch signalling was shown to be essential for MSC survival and also for 
maintenance of an undifferentiated state (Aubin-Houzelstein et al., 2008; Moriyama 
et al., 2006; Schouwey et al., 2007). Loss of Notch signalling in a conditional RBP-J 
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knockout mouse (cRBP-J KO) resulted in dramatic reduction in melanoblasts 
number, ectopic differentiation and aberrant location of melanoblasts. Of those 
melanoblasts that migrated to the hair bulb in the cRBP-J KO mice, most were 
unable to pigment the hair shaft, suggesting notch signalling may also have a role in 
controlling terminal differentiation of melanoblasts at the hair bulb (Aubin-
Houzelstein et al., 2008). Despite a characterised role of Notch signalling in mouse 
melanocyte development, it is still unknown if notch plays a role in zebrafish 
melanocyte or MSC development. Previous data has shown zebrafish notch 
signalling to be essential to drive a neural crest cell fate over a Rohon Beard (RB) 
sensory neuron fate (Cornell and Eisen, 2002). Additionally, I have shown that loss 
of notch signalling through treatment with the γ–secretase inhibitor DAPT resulted 
in a 34% loss of melanocytes on the lateral line (Figure 6.7). Therefore, my work 
supports a role for notch signalling in melanocyte development from a MSC 
population. However, how exactly notch signalling contributes to this is yet to be 
determined. 
 
During direct melanocyte development in the mouse, erbb independent melanoblasts 
develop at the midbrain-hindbrain boundary (MHB) (Adameyko et al., 2012). 
Whether the MHB could also be a source of melanocyte precursors in the adult is a 
question that has not been addressed. Interestingly, in the zebrafish the MHB has 
been identified as a novel niche for neurogenesis in the adult brain. Notch signalling 
(her5) was shown to play a key role in maintaining an immature proliferative state in 
neural precursor cells at the MHB (Chapouton et al., 2006; Geling et al., 2003; 
Geling et al., 2004; Ninkovic et al., 2005; Tallafuss and Bally-Cuif, 2003). However, 
no evidence exists to suggest this region of neurogenesis could also be a source of 
melanocyte precursor cells. Melanocyte and neural precursors are closely linked 
during early development, and SCPs can give rise to both Schwann cell and 
melanocyte lineages, therefore it is not unreasonable to suggest the MHB merits 
further investigation as a possible source of melanocyte stem cells. 
 
7.4.	  A	  novel	  role	  of	  Prl-­‐3	  in	  melanocyte	  stem	  cell	  biology	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Both chemical and genetic loss of prl-3 resulted in enhanced melanocyte 
regeneration, indicating a novel role of the prl-3 phosphatase may be to regulate a 
MSC or melanocyte precursor population. I hypothesise that melanocyte 
regeneration may be enhanced by one of two possible mechanisms: Firstly, loss of 
Prl-3 may induce expansion (proliferation) of a melanocyte progenitor population 
(MSC). Secondly prl-3 inhibition could promote differentiation of an immature (stem 
cell) progenitor population. As yet it is not clear which of these two hypotheses is 
correct. Future work will be able to elucidate the exact mechanisms of prl-3 mediated 
MSC regulation: If prl-3 inhibition enhances differentiation of a precursor population 
into mature melanocytes, then I would expect a loss of MSC numbers and thus 
impaired melanocyte regeneration following serial tail clip experiments in B4-
Rhodanine treated fish. However, if prl-3 inhibition results in an expansion of a MSC 
pool then I would expect to see MSC/progenitor proliferation in these embryos 
(measured by EdU incorporation), and enhanced numbers of MSC/progenitors. 
Importantly for accurate analysis of MSC numbers, a marker for MSCs in the 
zebrafish needs to be determined. Crucially, B4-Rhodanine treatment resulted in an 
expansion of unpigmented mitfa positive cells in mitfavc7 embryos, and this could be 
indicative of expansion of MSCs or melanocyte precursors. Recent evidence 
suggests unpigmented mitfa expressing cells in the zebrafish myotome represent a 
novel melanocyte precursor population (Budi et al., 2011). However, I still need to 
ascertain if the observed expansion of mitfa positive cells is specific to the mitfavc7 
assay in which melanocyte development has been halted at the mitfa level. Mitf can 
be targeted for degradation following phosphorylation (Buac et al., 2009; Wu et al., 
2000), a process that is enhanced following NRG1 activation of ERBB3 (Buac et al., 
2009). A theoretical function of Prl-3 phosphatase could be maintenance of a de-
phosphorylated form of Mitf, restricting Mitf targeted degradation and therefore 
promoting melanocyte differentiation. Hypothetically inhibition of Prl-3 could 
enhance targeted degradation of Mitf, subsequently lowering cellular Mitf levels and 
limiting melanocyte differentiation, this would by proxy promote a stem-cell like 







Figure 7.3. A theoretical role for Prl-3: regulation of Mitf levels by dephosphorylation (A) 
Phosphorylation of Mitf targets it for degradation, whereas dephosphorylation of Mitf by Prl-3 
phosphatase causes cellular accumulation of Mitf, promoting melanocyte pigmentation and 
differentiation (B) Chemical inhibition of Prl-3 phosphatase (B4-Rhodanine) increases 
phosphorylated Mitf, which is targeted for degradation. Loss of Mitf signalling maintains cells in an 





Figure 7.4. Prl-3 could be activated by p53 to promote cell cycle arrest (A) In normal conditions cellular stress activates p53 and inducing a cell signalling cascade 
in which prl-3 activates cell cycle arrest through p21, CDK2 and Akt signalling, or cell death by apoptosis (Basak et al., 2008). (B) B4-Rhodanine inhibits prl-3 
activity, thus p53 is unable to activate G1 checkpoint machinery, as a result the cell cycle can continue. (C) Mutant p53 is unable to bind to DNA p53 binding 







Figure 7.5. Possible melanocyte precursor populations that could be affected by prl-3 signalling 
(A) Schematic of a lateral view of a zebrafish embryo identifying key neural networks that may be 
relevant to melanocyte stem cell development. (B) Schematic of transverse section of zebrafish neural 
tube and dorsal root ganglion are identified. Precursor cells are found along the axis of innervating 
neurones. (B’) Expansion of melanocyte precursor cells following prl-3 inhibition. (B’’) Expansion of 
bipotent Schwann cell precursors following prl-3 inhibition. Schematic modified from (Sommer, 
2011). 
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By chemical-genetics I confirmed AG1478 treatment limited melanocyte 
regeneration and caused loss of MSC derived developmental melanocytes (Budi et 
al., 2008; Hultman et al., 2009; Hultman and Johnson, 2010; Johnson et al., 2011), I 
was then able to rescue this phenotype with co-treatment of B4-Rhodanine (PRL-3 
inhibitor). Thus, PRL-3 inhibitor treatment can rescue loss of erbb dependent MSCs, 
as yet it is unclear if this is by a direct or indirect mechanism. As such I hypothesise 
that Prl-3 is either active downstream of erbb signalling, or that Prl-3 inhibition can 
expand a different population of MSCs, which are able to counteract the AG1478 
phenotype. To assess if this rescue is direct or indirect I first need to identify a 
suitable marker for erbb dependent MSCs, and then test if this is rescued following 
co-treatment of B4-Rhodanine. Previous studies have shown unpigmented mitfa 
positive cells in the zebrafish are sensitive to loss of erbb signalling (Budi et al., 
2011; Johnson et al., 2011). Thus in future experiments it will be important to 
determine co-treatment of PRL-3 inhibitor can rescue the loss of unpigmented mitfa 
positive cells associated with AG1478 treatment. To quantify these low-expressing 
mitfa cells I suggest in situ samples will need to be wax embedded and sectioned 
transversally.  
 
Microarray analysis identified a 26.7 fold activation of her5 (notch) signalling 
following prl-3 inhibition, suggesting that her5 could be a target gene of prl-3. To 
explore this relationship I used a chemical inhibitor of γ-secretase to inhibit notch in 
the zebrafish embryo and found that MSC derived developmental melanocytes were 
reduced following DAPT treatment. By doing this I identified a potential role of her5 
signalling in zebrafish MSC development. This draws parallels to mouse MSC 
biology, in which conditional knockouts of notch signalling result in consecutive hair 
greying and loss of MSCs (Aubin-Houzelstein et al., 2008; Moriyama et al., 2006; 
Schouwey et al., 2007). However, I was unable to rescue the DAPT-mediated MSC 
phenotype by co-treatment with prl-3 inhibitor. This suggests that prl-3 acts either 
upstream of notch signalling in the zebrafish, or in a totally unrelated pathway and 
isn’t sufficient to rescue DAPT MSC loss. Interestingly erbb inhibition does not 
affect her5 expression, suggesting the MSC phenotype following DAPT treatment 




It is important to note that prl-3 inhibition enhances the rate of melanocyte 
regeneration, but does not cause excessive melanocyte numbers or ectopic 
melanocytes. This implies that regulation of total melanocyte numbers and pattern is 
still intact following prl-3 inhibition. Namely, once appropriate numbers of 
melanocytes have repopulated the pigment pattern stripe, molecular cues are still 
intact that can switch off melanocyte regeneration. This is in contrast with activated 
Kitla signalling which causes a dramatic hyperpigmentation of zebrafish embryos. 
Hultman and colleagues showed overexpression of kitla (kit ligand) in zebrafish 
resulted in over 50% increase in dorsal melanocyte counts (Budi et al., 2011; 
Hultman et al., 2007). Additionally transient overexpression of kitla in a post-
embryonic fish causes melanocyte differentiation deep within the myotome (Budi et 
al., 2011). The PRL-3 inhibitor phenotype was only observed under “challenged” 
conditions i.e. following NFN1 mediated melanocyte ablation, mitfavc7 development 
at the restrictive temperature, or loss of erbb dependent MSCs. To be specific there 
needs to be a stimulated loss of melanocytes in order for prl-3 inhibition to enhance 
melanocyte regeneration. No obvious difference was observed during metamorphosis 
in embryos pre-treated with PRL-3 inhibitor or a DMSO control, suggesting that co-
treatment during challenged conditions is a requirement of the PRL-3 inhibitor 
phenotype. It is possible that “challenging” zebrafish melanocytes/MSCs could 
induce cell stress responses to promote apoptosis or cell cycle arrest. Basak and 
colleagues suggested that Prl-3 is directly activated by p53 to mediate cell cycle 
arrest response signals, such as activation of p21 or repression of CDK2 through 
cyclin dependent kinase inhibitors (CDKI) (Basak et al., 2008). Therefore, I 
hypothesise that inhibiting prl-3 would repress the p53 mediated cell cycle response, 
and subsequently promote cell cycle progression (Figure 7.4). Additionally p53 
mutant embryos (p53M214K/M214K) phenocopied the enhanced melanocyte regeneration 
phenotype following NFN1 melanocyte ablation. Mutant p53M214K/M214K cannot 
effectively bind DNA consensus sequences to transmit downstream target effects and 
is specifically defective at mediating a G1 checkpoint response (Berghmans et al., 
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2005).  Therefore, I suggest that as in the B4-Rhodanine treated fish, this p53 mutant 
promotes cell cycle progression. 
 
7.5.	  Final	  thoughts	  and	  conclusions	   	  
 
 In this thesis I have presented novel work that has a significant impact on 
understanding the mechanisms of melanocyte development and regeneration. 
Importantly, I presented in vivo evidence of differentiated melanocyte division in the 
zebrafish, and showed how this is relevant to understanding human melanoma 
mutations. I suggest that melanocytes previously thought of as “terminally 
differentiated” can undergo differentiated cell division implying a degree of 
plasticity. Further research of melanocyte plasticity could be a valuable insight for 
development of future stem cell therapies. I also identified a novel role for the prl-3 
phosphatase in regulating a melanocyte precursor population, which provides useful 
insight into MSC biology in vivo. As yet I have not determined by what mechanism 
prl-3 acts at MSCs, however evidence indicates one of three possible alternatives is 
likely: (1) Prl-3 inhibition allows proliferation and expansion of a Schwann cell 
precursor population that is bipotent for melanocyte and Schwann cell lineages 
(Figure 7.5 B’’). (2) Prl-3 regulates an erbb independent MSC pool at the MHB 
(Figure 7.5 A) (3) Prl-3 inhibition causes rapid expansion of melanocyte precursors.  
This could possibly occur either by paracrine signalling or by a direct effect on mitfa 
phosphorylation state (Figure 7.5 B’). PRL-3 is notoriously over-expressed in 
metastatic cancer (Laurent et al., 2011; Li et al., 2012; Saha et al., 2001; Wang et al., 
2007; Wu et al., 2004; Zeng et al., 2003), and is a potential target for development of 
new cancer therapies, such as drug inhibition or antibody therapy (Guo et al., 2012; 
Han et al., 2012). However despite the increasing awareness of the role of PRL-3 in 
cancer metastasis, the normal biological role of PRL-3 was previously unknown. I 
have established a novel role for the prl-3 phosphatase in regulation of a MSC pool 
in zebrafish. Due to the striking similarities between vertebrate melanocyte 
developmental pathways I suggest that the role of human PRL-3 in MSC biology 
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Abstract
In the past two decades, zebrafish genetic screens have identified a wealth of mutations that have been essential to 
the understanding of development and disease biology. More recently, chemical screens in zebrafish have identified 
small molecules that can modulate specific developmental and behavioural processes. Zebrafish are a unique 
vertebrate system in which to study chemical genetic systems, identify drug leads, and explore new applications for 
known drugs. Here, we discuss some of the advantages of using zebrafish in chemical biology, and describe some 
important and creative examples of small molecule screening, drug discovery and target identification.
Genetic and chemical screens in zebrafish
Zebrafish (Danio rerio) have a unique status in experi-
mental biology. As vertebrates used for forward and
reverse genetics, they have provided novel insight into
development and disease genetics. More recently,
zebrafish research has pushed forward the exploration of
chemical biology in a whole animal system. The advan-
tages of using zebrafish as an experimental system for
chemical biology mirror those already well established for
their use in genetics. Only a few centimetres long as
adults, thousands of zebrafish can be housed in a labora-
tory with relatively low husbandry costs. Breeding pairs
can produce over 200 embryos each week that are fertil-
ized outside of the mother and can be easily collected
from the breeding tank. Embryonic development from a
single cell, and the rapid formation of discrete tissues and
organs with physiological similarity to their human coun-
terparts, can be viewed in real time under a light micro-
scope [1]. Organ progenitors can be observed by 36 hpf
(hours post-fertilization), hatching occurs at 48-72 hpf
and independent feeding by 5 dpf (days post-fertiliza-
tion). Whole-mount in situ hybridization and antibody
staining allows for detection of specific RNA or protein
expression (or modification) in the developing whole ani-
mal, and transgenic technology provides the tools to fol-
low the expression of a specific gene (or series of genes) in
the living fish [2]. The zebrafish genome is sequenced,
and genetic mutants affect a wide range of biological pro-
cesses including development, behaviour, metabolism,
vision, immunity and cancer.
Genetic screens in zebrafish proceed in two main
approaches: forward and reverse genetics [3]. Forward
genetics, characterized as 'phenotype to genotype', first
involves the identification and characterization of a spe-
cific phenotype, followed by the identification of the
underlying genetic mutation. The zebrafish system has
been especially powerful in the identification of develop-
mental phenotypes, caused by N-ethyl N-nitrosourea
(ENU) and insertional mutagenesis, and many of the
underlying genetic mutations have been identified [4-8].
Reverse genetics, 'genotype to phenotype', takes advan-
tage of molecular biology techniques. In these cases, a
gene of interest is selected and targeted by morpholino
oligonucleotide (MO) knockdown, TILLING (Targeting
Induced Local Lesions IN Genomes), or zinc-finger
nucleases to discover the function of the genetic muta-
tion within the fish [9-14].
Chemical genetics complements traditional genetic
approaches [3]. First, many small molecule libraries are
made up of compounds with known biological function,
allowing rapid elucidation of biological pathways within
the organism. Second, chemical treatment can occur at
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Page 2 of 14any point during development or in the adult organism,
allowing for the study of latent effects of genes during
development. Third, chemical dosage can be controlled,
which can be advantageous when studying essential func-
tions, or tissue specificity. Small molecule screening iden-
tifies relevant targets within the physiological context of
the organism, biasing the screen for compounds that are
more likely to be cell permeable, less toxic, effective and
with an aceptable pharmacokinetic and pharmacody-
namic profile [15]. Like genetics, chemical genetics can
achieve both forward and reverse approaches [3,15]. In
forward chemical genetics, 'phenotype based small mole-
cule discovery', a library of inhibitors can be screened for
a specific phenotype in the animal, and from this the tar-
get(s) can be identified (Figure 1). Here, we describe some
of the phenotype based chemical screens in zebrafish that
are pushing forward our knowledge of stem cells, behav-
ior, development and disease treatment (Figure 2A, B, D,
E). Conversely, reverse chemical screening entails testing
chemical inhibitors with known molecular targets for
specific phenotypes in the zebrafish. Examples of this
application of the zebrafish system include identifying
and optimizing new bioactive compounds, applying a
cancer drug to developmental disease, and revealing the
teratogenic mechanisms that hinder valuable clinical
drugs (Figure 2C, F).
Considerations of chemical libraries and 
methodology
In genetic screens, the type of mutagen (e.g. ENU, x-ray,
insertional mutagen) will determine the range of possible
genetic mutations and phenotypes, as well as the ease of
Figure 1 Phenotype based chemical screening in zebrafish. Male and female pairs are bred to produce hundreds of single cell embryos that are 
fertilized ex vivo. For high throughput screening, groups of males and females can be bred within in a larger tank (group breeding), producing high 
numbers of embryos for screening. Breeding is synchronized by the light/dark cycles, and the fish tend to breed within the first two hours of light in 
the morning. In this example, embryos are arrayed in 96-well plates, each with a different chemical compound, and observed for a specific phenotype. 
The chemical in well A2 causes a loss of melanocytes, like MoTP [18]. MoTP can specifically kill differentiated melanocytes, and has become a valuable 
chemical tool to explore melanocyte stem cell biology [42-44]. Other small molecule screens in zebrafish have also identified pigmentation pheno-
types [85,86,96]. In another example of a small molecule screen, compounds are screened for inhibition of tail fin regeneration. The tail fin is clipped 
and grows back within a few days. A zebrafish embryo treated with the compound from well B3, a glucocorticoid, does not correctly regenerate its 
tail fin [97].
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Figure 2 Creative examples of chemical biology in zebrafish. The zebrafish system can be used in a wide range of chemical biology experiments 
and screens. A. Zebrafish as young as four dpf have active and sleep-like states. Continuous tracking of movement behaviours of the embryos during 
rest and wake states, established by light and dark cycles, can be recorded by a camera and computer. High throughput screening for behavioural 
changes has identified new uses for poorly characterized compounds [80,82]. B. Genetic polymorphisms may underlie differences in sensitivity to poor 
nutrition. In this example, ENU mutagenized zebrafish (parental (P) generation) were screened for genetic mutations that showed sensitivity to sub-
optimal copper nutrient conditions. Zebrafish embryos fertilized with UV-inactivated sperm can live as haploid embryos until about 3 dpf [2]. Haploid 
embryos of the heterozygous mother (F1 generation) were screened for loss of pigmentation, but only in the presence of the small molecule copper 
chelator, neocuproine [41]. C. Intensive efforts by the pharmaceutical industry to develop drugs that target the MAPK pathway to treat cancer patients 
may also be useful for the management of developmental diseases caused by mutations in the MAPK pathway. In the zebrafish model, expression of 
BRAF or MEK cardio-facio-cutaneous (CFC) mutant alleles interferes with early development. A one-hour treatment within a specific developmental 
time window with a MEK inhibitor is sufficient to allow normal development for a CFC zebrafish embryo [75]. D. The cardio-vasculature system is con-
served in fish, mice and humans. A small molecule screen for changes in hematopoietic stem cells (HSC) development identified the prostaglandin 
pathway as critical for HSC establishment [59]. A long-acting compound, called dmPGE2, can stimulate HSC development in the embryo and adult 
zebrafish, as well as in the mouse. dmPGE2 can be safely administered to people, and a clinical trial is underway to see if dmPGE2 treatment of umbil-
ical cord blood prior to transplant can benefit transplant patients (L.I. Zon, personal communication). E. The acute myelogenous leukemia oncogenic 
fusion AML1-ETO (AE) promotes a change from an erythrocytic fate to a granulocytic cell fate. Erythrocytes express the gata1 gene in the posterior 
blood island of the developing zebrafish (red dotted line). Heat-shock inducible expression of AE causes a cell fate change that can be visualized by 
loss of gata1 expression. A chemical screen identified that COX-2 inhibitors can suppress the AE cell fate change, and the embryos maintain gata1 
expression in the presence of AE [72]. F. Zebrafish can play a valuable role in testing for drug toxicity and teratogenisity, as well as for testing direct 
chemical targets in vivo. Thalidomide is a valuable drug for multiple myeloma and leprosy, but caused severe developmental birth defects when taken 
by pregnant mothers in the late 1950s and early 1960s. Zebrafish are also sensitive to thalidomide, and treatment in early development prevents the 
proper development of embryonic fins [88]. Thalidomide binds CRBN, and knockdown of crbn in the developing zebrafish also causes a loss of fin 
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Page 4 of 14identifying the mutation [2,10]. For example, ENU muta-
genesis can generate hypomorphic, temperature sensi-
tive, and gain- and loss-of-function mutations that
require genetic mapping to identify the genetic lesion.
Insertional mutagenesis is more likely to cause gene dis-
ruptions, and allows for the rapid identification of the
insertion in the genome. Likewise, in chemical biology,
the choice of chemical library directs the type of molecu-
lar processes that are disrupted, as well the approach of
target pathway identification [16]. Traditionally, the dis-
covery of new drugs has been achieved through the isola-
tion of natural products from plants and microbes [17].
Screening a library of natural products will be rich in
chemical diversity and may identify novel active com-
pounds, but identifying the active compound(s) and sub-
sequent targets may require extended fractionation
procedures and biochemical techniques. Conversely,
screening a library designed to target specific classes of
enzymes, such as kinases, allows for rapid identification
and direct testing of the chemical target in vivo, but rep-
resents a much smaller range of chemical diversity. Simi-
larly, screening a library of compounds of
pharmacologically active molecules of known bioactivity,
while again covering a reduced chemical space, may allow
for a rapid transition to pre-clinical mammalian models.
As in genetic screens, an important feature of chemical
screening is consideration for the screening assay, that is,
the phenotypic feature that is the basis for the screen. The
zebrafish system allows for diverse screening assays
including development and function of internal tissues
and organs in living animals that can be illuminated by
florescent reporter genes or molecules, or disrupted by
genetic mutations. Whole-mount RNA in situ hybridiza-
tion and antibody staining provide details of cellular
changes in fixed embryos. No other vertebrate is as well
positioned for high throughput phenotyping as the
zebrafish embryo [3]. For high-throughput screening,
computerized detectors can rapidly screen thousands of
treated embryos in a small treatment volume (e.g. in a 384
well or 96 well plate), while lower throughput screening
can often involve a single investigator screening multiple
characteristics in larger treatment volumes (e.g. in a 24
well plate).
In the first chemical screen in zebrafish, Peterson and
colleagues (2000) screened 1,100 compounds selected
from the DIVERSet E Library (Chembridge) in 96-well
plates for small molecules that caused developmental
phenotypes during the first three days of development
[18]. This was an important proof-of-concept study
showing that small molecule screening in zebrafish could
identify chemicals that, like genetic mutations, disrupt
specific developmental processes. In addition, the identi-
fied chemicals could be used at different doses and at dif-
ferent developmental intervals to identify the timing of
the chemical action during development. Recently, a
thorough review of the zebrafish chemical screens per-
formed and libraries used has been published [16]. Here,
we describe selected screens and chemical-genetic analy-
ses performed in zebrafish to highlight the range of
experimental screen designs and outcomes (Figures 1 and
2).
Chemical screening to rescue disease phenotypes: 
aortic coarctation
Many genetic mutations identified in zebrafish are analo-
gous to disease genotypes in humans, or cause pheno-
types that share clinical features with human diseases
[19,20]. The zebrafish gridlock mutant suffers from a mal-
formed aorta that prevents circulation to the trunk and
the tail, similar to coarctation of the aorta in humans. The
gridlock phenotype results from a mutation in the hey2
gene, a transcriptional repressor that determines angio-
blast differentiation [21,22]. To screen for chemical sup-
pressors of aortic coarctation, Peterson and colleagues
treated gridlock mutant embryos with small molecules
from the DIVERSet E library (Chembridge) from early
gastrulating embryos until 48 hpf [23]. From over 5000
chemicals screened, two structurally related compounds
suppressed the gridlock phenotype. Altering the treat-
ment time during development revealed a critical chemi-
cal treatment window for correcting the aorta phenotype
to be between 12 and 24 hpf. Importantly, the correction
mechanism was identified to be via upregulation of vas-
cular endothelial growth factor (VEGF), and the subse-
quent promotion of blood vessel development. Small
molecule inhibitors of the vascular endothelial growth
factor receptor (VEGFR) can inhibit blood vessel forma-
tion during zebrafish development, and tail fin regenera-
tive angiogenesis in the adult [24,25]. The chemically
induced upregulation of VEGF was also effective at stim-
ulating endothelial cell tubule formation [23]. Thus, phe-
notypic-based screening can identify suppressors of a
genetic disease phenotype that have relevant biological
activity in mammalian cells. Importantly, in this example,
the target compounds did not affect the disease gene or
protein directly. Rather, a pathway critical to the rescue of
the phenotype was successfully identified, and can now
be considered for new therapeutic approaches.
Chemical screening to reveal new insight into 
retinal blood vasculature
A highly metabolic tissue, the retina is fed oxygen and
nutrients by an intricate vascular network. In humans,
disruption of the retinal vasculature network, through
damage to the existing network or inappropriate neovas-
cularization, can lead to loss of vision and severe forms of
blindness. Understanding the basic biology of retinal vas-
culature is critical to understand the aetiology and
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has been done through the identification and detailed
characterization of genetic mutants which have a disrup-
tion of the retinal vasculature network [26]. These studies
are facilitated by the generation of transgenic zebrafish
lines, expressing green florescent protein (GFP) under the
promoter of the endothelial vessel specific fli1 gene
[26,27]. As a complementary approach to genetics, and to
learn about retinal vascularization, the fli1-GFP trans-
genic line was used in a screen for small molecules that
could modulate the retinal vascular network during days
3-6 of development [28]. Approximately 2000 small mole-
cules from the bioactive Spectrum library were added to
the developing embryos at the pectoral fin stage (approx-
imately 60 hpf ), and embryos were then embedded in
methyl cellulose and visualized under an inverted micro-
scope. Of the 2000 compounds screened, five displayed a
reproducible effect on retinal vessel morphology: two
affected vessel diameter without affecting vessel number,
one affected vessel diameter and number, and two caused
severe collapse and loss of over 80% of the vessels.
Extending these studies, Kennedy and colleagues
screened a panel of known small molecule regulators of
angiogenesis, and found that LY294002, an inhibitor of
PI3 kinase signalling, can prevent the ocular angiogenesis
in wild type fish and partially correct the extraneous
angiogenesis in the out of bounds zebrafish mutant [29].
Treatment with LY294002 within specific developmental
time-windows, showed that the chemical could affect the
development of new vessels, without affecting existing
intraocular vessels or retinal function. Importantly, direct
and localized delivery of the drug was effective at inhibit-
ing intraocular angiogenesis without additional system
effects or altering visual function. Additional studies have
shown that chemical modulation in the adult zebrafish
can reduce hypoxia induced neovascularization [30].
Studies such as these provide a groundwork for identify-
ing chemicals and chemical methodologies that can spe-
cifically target aberrant retinal vascularization, which
affects the sight of millions of people worldwide.
Parallel in vitro and in vivo chemical screening: 
identifying new and known cell cycle regulators
Many small molecules that affect the cell cycle have been
identified through screening for compounds that alter the
cell cycles of cancer cells in culture. Such high-through-
put screens allow for large numbers of compounds to be
screened on multiple cell lines in a rapid and efficient
manner [31]. In the 1960s, cell based screening of natural
products by the National Cancer Institute identified taxol
as a potent mitotic inhibitor [32]. Derived from the
Pacific yew tree, taxol is now considered one of the most
important chemotherapeutics to treat breast, lung, and
ovarian cancer [33]. Many mammalian cell cycle genes
are conserved in zebrafish [34], and the majority of cell
cycle inhibitors used in mammalian cells share sufficient
conservation with the drug targets to be effective in
zebrafish embryos or cell lines [35]. The zebrafish crash &
burn (crb) mutant for the bmyb gene, is a MYB family
transcription factor involved in cell cycle progression and
cancer. The crb mutant was identified in a genetic screen
for changes to the cell cycle, as revealed by an increased
number of mitotic cells marked by a phospho-histone H3
antibody [36]. crb mutants also reveal abnormal spindle
and centrosome formation, and polyploidy. Notably,
adult zebrafish heterozygous for crb have an increased
incidence of carcinogen-induced cancer [36]. Using the
DIVERSet E library (Chembridge) of 16320 compounds,
Zon and colleagues screened for small molecules that
could specifically rescue the crb phospho-histone H3
mitotic defect [37]. One compound, called persynth-
amide, was identified that suppressed the mutant pheno-
type. In wild type embryos persynthamide transiently
delays S-phase via an ATR dependent checkpoint. Com-
parison with other known S-phase inhibitors, such as
hydroxyurea and amphidicolin, showed that it was the
chemically induced S-phase delay that was sufficient to
rescue the crb defect. In human cells, loss of B-MYB leads
to reduced levels of cyclin B1 [38], and expression of
cyclin B1 is sufficient to rescue crb mutant zebrafish
embryos [36]. The persynthamide-induced S-phase
checkpoint also causes an increase in cyclin B1 expression
and thereby rescues the crb mutant. This is another
example of phenotypic based chemical screening that res-
cues a genetic phenotype by targeting the altered path-
way, and not the mutated protein product directly.
A common question in chemical screening is whether
the identified compounds are specific to zebrafish, and
how the results of zebrafish chemical screening compare
with mammalian cell line based chemical screens. In the
small molecule screen for suppressors of crb, additional
compounds were identified that disrupted mitosis in wild
type zebrafish [35]. While the chemical library had been
previously screened extensively for cell cycle inhibitors in
mammalian cells, 14 novel compounds that affected the
cell cycle were identified via screening on zebrafish
embryos. Six of the 14 hits were effective in mammalian
cell lines, confirming the conservation of the affected tar-
get pathways across vertebrate species. Of the remaining
seven hits, three were serum-inactivated which accounts
for their lack of activity in cell culture systems. Four hits
were only active in the zebrafish embryo, but not cell
lines, possibly due to activation by yolk sac proteins. One
hit was active in zebrafish embryos and zebrafish cell cul-
ture, but not in mammalian cell culture, suggesting the
target of the compound was specific to the zebrafish and
not conserved in mammalian cells. Thus, in vivo and in
vitro chemical screens are complementary approaches,
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to identifying a more complete set of chemically bioactive
tools.
Using chemicals to identify gene-nutrient 
interactions
The ability to limit the timing and regulate the dose of
small molecules has allowed for unique insight into the
tissue-specific requirements for copper in the developing
embryo. Copper is an essential nutrient, and sub-optimal
copper nutrient conditions in humans can lead to severe
clinical symptoms including disorders of the nervous sys-
tem, hair, and skin [39]. While copper is essential for all
cells, some cells and tissues have a specialized copper
requirement. Gitlin and colleagues treated developing
zebrafish embryos with the small molecule copper chela-
tor, neocuproine, and found that loss of cuprodependent
enzyme activity specifically affected some tissues, includ-
ing melanocytes, the notochord, and the developing
hindbrain [40]. Supported by a genetic mutant in the cop-
per transporter atp7a (that was cloned in part by virtue of
phenotypic features indentical to the effect of the copper
chelator neocuproine), Gitlin and colleagues revealed the
time, dose and tissue specific requirements for copper
dependent enzymes during embryogenesis [40].
Humans with mutations in ATP7A develop Menke's
disease, a rare X-linked disorder of copper metabolism,
characterized by neurodegeneration, hypotonia, and
hypopigmentation. Less well understood are other
genetic conditions that lead to sensitivity to sub-optimal
copper nutrient conditions in otherwise healthy individu-
als. To address this problem, the Gitlin group used low
doses of neocuproine and screened for genetic mutations
that revealed a copper deficiency phenotype under mild
copper deficiency conditions (Figure 2B). Two genetic
mutants were found: a hypomorphic allele of atp7a and
mutation of the vacuolar atpase atp6. Vacuolar Atp6 is
required for proton transport in the secretory pathway,
an important process in intracellular copper transport
[41]. Thus, genetic polymorphisms that otherwise have
normal developmental features can be combined with
chemicals to reveal selected sensitivities to sub-optimal
nutrient conditions.
Chemical-genetic and chemical-chemical screens to 
probe melanocyte regeneration pathways
MoTP (4-(4-morpholinobutylthio)phenol), identified in
the original small molecule screen by Peterson and col-
leagues (2000), caused a dramatic loss of melanocytes by
cell death [18]. Tyrosinase is a copper dependent rate lim-
iting enzyme for melanin pigmentation in melanocytes,
and MoTP exerts melanocyte-specific cell death via its
conversion to a cytotoxic form in cells that express high
levels of tyrosinase [42]. With a melanocytotoxic com-
pound in hand, the Johnson group has been able to use
MoTP to gain significant understanding of melanocyte
regeneration in zebrafish. Many tissues and cells, includ-
ing melanocytes, can regenerate in zebrafish, providing
important insight into tissue-specific stem cells and pro-
genitor development. Using MoTP to ablate embryonic
melanocytes, ENU mutagenized zebrafish were screened
for mutants that fail to regenerate melanocytes after
treatment [43]. Two mutants were identified, eartha and
julie, that only regenerated about 10% of the normal com-
plement of melanocytes, affecting late stages of melano-
cyte differentiation in the regeneration process, and
proliferation of melanoblasts during early melanocyte
regeneration respectively. Thus, by using a chemical to
precisely control a specific cell type and process, genetic
mutations necessary for distinct aspects of melanocyte
regeneration can be identified.
In a further small molecule screen for compounds that
specifically blocked melanocyte regeneration following
MoTP-induced melanocyte ablation, Johnson and col-
leagues identified ICI-118,551, a chemical that specifi-
cally blocks melanocyte regeneration, while having no
effect on ontogenetic melanocyte development and other
developmental processes [44,45]. One target of ICI-
118,551 is the β2-adrenergic receptor, but it is not clear if
this is the mechanism by which it blocks melanocyte
regeneration. Nonetheless, it is still a useful tool to probe
the origin of melanocytes. For example, transgenic
zebrafish expressing kit ligand have an increased number
of ontogenetic melanocytes, that are suppressed by ICI-
118,551 treatment, indicating that kit ligand exerts its
effects on the stem cell lineage of the developing zebrafish
[44,45].
The genetic mutant, picasso develops normal larval
melanocytes (ontogenetic melanocytes), but shows defi-
cits in forming new melanocytes at the onset of meta-
morphosis. Positional cloning identified the mutation
causing the picasso phenotype to be in the erbb3b gene,
an epidermal growth factor receptor (EGFR)-like tyrosine
kinase [45]. Sequential death and regeneration cycles by
successive MoTP treatments in picasso embryos showed
that they had a defect in their capacity to regenerate mel-
anocytes [44]. Treatment of wildtype embryos with a
commercially available Erbb inhibitor mimics the picasso
phenotype of abnormal adult melanocyte development
and melanocyte regeneration after MoTP ablation.
Thus, through a combination of chemical screens and
genetics, Johnson and colleagues have identified two
existing populations of melanocytes that contribute to
zebrafish pigmentation: ontogenetic erbb3b-indepen-
dent melanocytes that develop within the first 72 hpf, and
an erbb3b-dependent melanocyte progenitor population
that is laid down before the first 48 hours of development
and provides the adult melanocytes, as well as the adult
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In humans, melanocyte stem cells maintain hair color,
and cancer stem cells may support melanoma develop-
ment and chemoresistance. A series of chemical tools
that control distinct aspects of melanocyte biology in
zebrafish will be valuable tools to test in zebrafish and
mammalian models of melanoma [46-48].
Gene-drug interactions that modulate 
mechanosensory hair cell death
Hearing loss caused by the death of inner ear sensory hair
is a common medical problem. Over a third of ageing
people have significant hearing loss, and younger people
can also suffer irreversible hearing loss after antibiotic or
chemotherapeutic treatments. In zebrafish, the lateral
line helps the fish to detect changes in water pressure and
water movement, and shares structural and functional
similarities with mammalian inner ear hair cells [49]. The
developing lateral line system in zebrafish consists of
mechanosensory hair cells supported by rosette-like
structures of neuromasts [50,51]. Like mammalian ear
hair cells, treatment with aminoglycoside antibiotics,
such as neomycin and gentamicin, can cause mecha-
nosensory hair cell death [52,53]. Using vital dyes that
allowed for visualization of the living neuromasts, Raible
and colleagues screened over 10,000 small molecules
from the DIVERSet E Library (Chembridge) for com-
pounds that protected the mechanosensory hair cells
from neomycin toxicity [52]. Two compounds, PROTO-1
and PROTO-2 (benzothiophene carboxamides) were
identified, that showed significant protection from the
ototoxic effects of neomycin. Importantly, when com-
bined with neomycin in microbiological testing, PROTO-
1 and PROTO-2 did not interfere with neomycin's anti-
bacterial activity. Aminoglycoside drug uptake depends
on ion channel activity which can be significantly blocked
by altering extracellular calcium concentrations [54].
Thus, a class of small molecules has been identified that
appear to specifically protect the mechanosensory hair
cells from death in the presence of aminoglycosides.
These compounds have relevance for the mammalian
inner ear because they show some protection against
neomycin induced hair cell loss in an in vitro mouse utri-
cle preparation [52].
As with neocuproine and MoTP, one of the exciting
avenues for chemical biology in zebrafish is the potential
to screen for genetic mutations that reveal a specific phe-
notype in the presence of the drug (gene-environment
interactions). Raible and colleagues extended their chem-
ical screening to identify genetic mutations that protect
against the effects of neomycin induced hair cell death
(Owens et al. 2008). Five recessive loci that were either
specific to neomycin resistance or have additional pheno-
types were identified. One mutant, called sentinel, had a
mutation in a novel and conserved gene that had not pre-
viously been functionally studied in an animal system.
Notably, neither PROTO-1 nor sentinel could protect
against another ototoxic compound, cisplatin, suggesting
that PROTO-1 and sentinel act specifically to prevent
aminoglycoside toxicity. Hearing loss is variable in the
human population, and polymorphisms are associated
with familial, environmental and drug induced adult-
onset hearing loss [55-57]. Through screening, zebrafish
have a unique role in the identification of chemical and
genetic modifiers of drug-induced hearing loss. Already,
additional screening of an FDA-approved small molecule
library for those that protect zebafish lateral lines hair
cells has identified tacrine as a drug that protects the
mouse utricle from neomycin induced hair cell death
[52,58].
Screening for new applications of clinical 
compounds: hematopoietic stem cells
There are now numerous examples of small molecules
that show effects in zebrafish and have relevant bioactiv-
ity in mammalian cells. But will the knowledge gained in
the zebrafish system be directly translatable to the clinical
setting? Zon, North and colleagues have used chemical
screening in the developing zebrafish to identify small
molecules that modify hematopoietic stem cell (HSC)
number in vivo [59]. Definitive HSCs develop in the
aorta-gonad-mesonephros (AGM) region, and then colo-
nize the hematopoietic organs [60]. In zebrafish and
mammals, runx1 and cmyb genes are expressed in the
AGM and are required for HSC formation. Small mole-
cules were screened by RNA in situ hybridization for
those that altered runx1 and cmyb expression in the
AGM (Figure 2D). Of 2480 compounds screened, 82
compounds were identified that affected HSC number,
and of these ten were small molecules with known effects
in the prostaglandin pathway [59]. The prostaglandins are
evolutionarily conserved lipid signaling molecules that
are derived from arachidonic acid, that are first processed
by the cyclooxygenases (COXs) and then further by pros-
taglandin synthases (PGEs) to generate the effector pros-
taglandins, such as PGE2 [61]. PGE2 signals through G-
protein coupled receptors and plays an important physio-
logical role in smooth muscle contraction and relaxation,
pain, inflammation and blood clotting. COX inhibitors
are widely used as non-steroidal anti-inflammatory
drugs, the most common being aspirin and ibuprofen.
Confirming the targets of the small molecules identified
in the screen, morpholino oligonucleotide knockdown of
cox1 and cox2 reduced HSC formation, an effect that
could be rescued by the addition of a long acting deriva-
tive of PGE2 (dmPGE2). Likewise, knockdown of the
PGE2 receptors diminished HSC runx1 and cmyb expres-
sion.
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trol in embryos, Zon and colleagues then wanted to
establish if prostaglandin signaling was effective in adult
fish and conserved in mammals (Figure 2D). In adult
zebrafish, the site of hematopoiesis is in the kidney, and
dmPGE2 was shown to be effective at stimulating HSC
dependent kidney marrow recovery in irradiated wild
type fish [59]. Next, in mice, whole bone marrow (WBM)
was stimulated ex vivo by dmPGE2 before being trans-
planted into irradiated recipients, and was found to
increase hematopoietic progenitor formation. Adminis-
tration of dmPGE2 also enhanced bone marrow recovery
after 5-fluorouracil induced bone marrow injury, and
conversely, administration of COX inhibitors diminished
WBM and blood recovery. In this way, these studies have
found an important and druggable regulator of HSC
homeostasis that is conserved in vertebrates. Patients
that have depleted HSCs may benefit from dmPGE2
stimulated cord blood transplants as a therapy to expand
HSCs and enhance engraftment [61]. Based on these
studies, dmPGE ex vivo treatment is currently in clinical
trial for patients receiving cord blood transplants [61];
L.I. Zon, personal communication).
The versatility of the zebrafish assay and the evolution-
ary conservation of zebrafish biology has allowed further
work using prostaglandin chemical modulators to tease
apart the developmental pathways that reguate HSCs.
Wnt signalling is critical for development, regeneration
and stem cells [62-64]. Using a transgenic β-catenin-
responsive reporter line, dmPGE2 treatment increased
Wnt actvity in the AGM that co-localized with HSCs
[62]. Further detailed studies using a combination of
chemical modulators, the β-catenin-responsive reporter
line, and fish and mouse adenomatosis polyposis coli
(APC) mutants strongly supported a conserved PGE2-
Wnt signalling axis in development of HSCs. This axis
also appears to play a critical role in liver regeneration in
both adult fish and mice, and may be a general coordi-
nated proliferative / anti-apoptotic response to wound
healing [62]. In vitro experiments also suggest a close
relationship between Wnt signalling and PGE2 in cellular
proliferation and onocogenesis in colon cancer cell lines
[65,66]. These results bear clinical significance because
COX inhibitors, such as aspirin, reduce PGE2 levels, and
also are known to reduce the number and size of colorec-
tal adenomas in colon cancer patients [67].
Heartbeat and circulation is present in early developing
zebrafish embryos, despite sufficient oxygen supply by
difussion. North et al. (2009) used chemical biology in
zebrafish to show that the blood circulation itself is
required at these early stages for HSC development.
Returning to the other chemicals identified in the HSC
screen, several compounds were found to be modulators
of heartbeat and blood flow (North et al., 2009). While a
chemically diverse set of compounds, in general, com-
pounds that increased blood flow through vasodilation
increased HSC formation, and compounds that
decreased blood flow through vasoconstriction
decreased HSC formation. Emphasizing the importance
of vigorous blood circulation on HSC formation, the
zebrafish silent heart mutant that lacks a heartbeat and
bloodflow, had reduced HSC formation. While chemi-
cally enhanced blood flow can increase HSC formation,
only one compound, the nitric oxide (NO) donor S-
nitroso-N-acetyl-penicillamine (SNAP) could increase
HSC formation before the onset of blood flow. Likewise,
treatment before the onset of blood flow with the NO ini-
hibitor N-nitro-L-arginine methyl ester (L-NAME)
reduced HSC formation. NO is a gaseous signaling mole-
cule that regulates angiogenesis and vascular tone, and is
a toxic antibiotic secreted by phagocytes in the immune
response [68]. NO production increases in response to
sheer stress and blood flow [69], and remarkably, SNAP
treatment of silent heart mutant zebrafish embryos could
rescue HSC development. Importantly, the role of NO in
HSCs is conserved in mice, and loss of Nos3 reduces
HSCs and transplantable HSCs [70]. These studies have
direct relevance for clinical patients undergoing stem cell
transplants: enhanced blood flow or increased NO sig-
naling might enhance HSC production and engraftment,
improving the outcome for transplant patients.
Screening for chemical modifiers of oncogene-
induced cell fate changes
Many chemotherapeutic drugs target the proliferating
bulk of a cancer cells. However, even with intense chemo-
therapy many cancers return, suggesting that there is a
less proliferative cancer cell population that can survive
treatment. For the majority of patients with acute myel-
ogenous leukemia (AML) the disease recurs within two
years of treatment, and less than 10% of adults with AML
patients will survive beyond five years http://www.can-
cerhelp.org.uk/. AML can be caused by the oncogene
fusion AML1-ETO (AE), and AE redirects cells from an
erythrocytic fate to a granulocytic blast cell fate [71].
Small molecules that suppress the action of this AE-
induced fate change may enhance the effects of chemo-
therapy when combined with anti-proliferative drugs.
Peterson and colleagues developed a transgenic line that
expressed AE from the heatshock inducible promoter,
and screened for small molecules that suppressed the
action of AE on the erythrocytic cell lineage [72]; Figure
2E). When grown at 28.5°C, the hsp:AML1-ETO trans-
genic fish had normal blood development, and expressed
gata1 in the posterior blood island [72]. When shifted to
40°C, AML1-ETO was expressed, and within an hour
after heatshock, gata1 was no longer detectable by RNA
in situ hybridization. After screening 2000 bioactive com-
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restored gata1 expression without affecting the expres-
sion of the transgene. Inihibition of COX enzymes both
enhanced gata1 expression (erythrocyte lineage), and
decreased the AE driven mpo expression (granulocytic
lineage). Notably, these effects could be reversed by the
addition of dmPGE2, the major effector metabolite of
COX in zebrafish. Peterson and colleagues then used
morpholino oligonucleotides to directly test the genetic
role of the COX enzymes. Interestingly, the AE cell fate
change was strongly affected by the specific loss of the
COX-2 proteins, suggesting that COX-2 is essential for
the AE oncogene-induced cell fate change. This effect
may be via transcriptional control, as AE expression in
human myelogenous leukemia cells is almost five times
higher than in control cells, and the cells preferentially
differentiate into the myeloid lineage: an effect that can
be prevented upon addition of a COX-2 inhibitor.
Because PGE2 is important in stimulating β-catenin
expression in the pathogenesis of cancers, such as colon
cancers, the effects of AE were tested on ß-catenin
expression. Importantly, AE expression dramatically
enhanced β-catenin expression in human myelogenous
leukemia cells, an effect that could be suppressed by
chemical inhibition of COX-2. This pathway is conserved
in zebrafish, as knockdown of β-catenin genes in
zebrafish embryos compromised the AE differentiation
activity, while treatment with a β-catenin activator, an
inhibitor of the GSK-3β, enhanced the AE differentiation
activity. Taken overall, this study identifies COX-2 small
molecule modifiers of the AE oncogene driven cell fate
changes, and identifies an AE induced COX-2-PGE2-β-
catenin pathway that contributes to dysregulated
hematopoietic differentiation [72]. The conservation of
this pathway in fish and human cells, suggests that this
pathway may be relevant to target in AML pre-clincial
mammalian models.
Using cancer drugs to restore developmental 
processes: Cardio-facio-cutaneous syndrome
Rare developmental disorders are unlikely to attract drug
development programmes. However, if the developmen-
tal mutation is in a pathway that is mutated in common
diseases, such as cancer, there may be the potential to test
available drugs in the context of developmental diseases.
Children with germ-line mutations in KRAS, BRAF,
MEK1 and MEK2 develop Cardio-facio-cutaneous syn-
drome (CFC), characterized by abnormal heart, craniofa-
cial, and skin development. Activation by the fibroblast
growth factors (FGFs) leads to activation of the RAS-
RAF-MEK-ERK (MAPK) pathway kinases, ultimately
directing the cellular action, including proliferation,
apoptosis, differentiation or senescence [73]. The MAPK
pathway is one of the most frequently mutated pathways
in cancer, and is the focus of intense drug development
[74]. Intriguingly, the BRAF CFC syndrome mutations
are both kinase-active and kinase impaired in vitro. Our
laboratory recently expressed a panel of CFC syndrome
and melanoma alleles in the developing zebrafish, and
found that all alleles are gain of function mutations in
vivo, and promote an early cell movement phenotype
[75]. The highly specific and clinically active MEK inhibi-
tor, CI-1040 was able to suppress the cell movement
defect in early embryogenesis caused by CFC kinase
mutations. CI-1040 is a non-ATP-competitive inhibitor,
that selectively inhibits the activity of MEK1 and MEK2
in in vitro and in vivo mouse tumor models [76]. Unlike in
cancer cells, a developing animal requires MAPK signal-
ing in specific cell types, within discrete time points in
development. Therefore, despite the gain of function
mutations in CFC syndrome, it would not be desirable to
completely inhibit MAPK signaling in the developing
embryo. Indeed, treatment with CI-1040 can restore cell
movements in gastrulation, but causes severe effects later
in development. Treating CFC-zebrafish embryos within
a specific one-hour treatment window early in zebrafish
gastrulation restored normal cell movements without
additional drug induced developmental defects [75]. This
work highlights the intrinsic value of the zebrafish system
to test drugs designed for common diseases, such as can-
cer, within a different disease context.
Finding novel small molecule modulators of the 
FGF-MAPK pathway in zebrafish
Uncontrolled MAPK pathway activation is associated
with disease and abnormal development, and the path-
way is carefully attenuated by phosphatases that limit sig-
nalling. One phosphatase, the dual-specificity
phosphatase (Dusp) 6 specifically dephosphorylates the
extracellular signal-related kinase (ERK). Using a trans-
genic line that allows for visualization of dusp6 expres-
sion as a biosensor for FGF signalling, Tsang and
colleagues screened for small molecules that enhanced
FGF signalling in the developing embryo [77]. One com-
pound, called BCI, caused an increase in dusp6-GFP
expression that was dependent on the activity of FGF8
signalling. As described below BCI directly inhibits
Dusp6, and notably, BCI was also active in human cells,
supporting conservation between the human and
zebrafish MAPK pathway and its regulatory enzymes. In
mice, loss of dusp6 leads to an enhanced heart size, but
the mechanism behind this heart size control is unknown
[78]. In zebrafish, knockdown of dusp6 in development
leads to early embryonic defects, which obscures the
study of dusp6 in the heart. With a Dusp6 inhibitor in
hand, the timing and cellular action of Dusp6 in heart
development could be carefully studied and mapped. BCI
treatment at the one to eight somite stage of development
Taylor et al. Cell Communication and Signaling 2010, 8:11
http://www.biosignaling.com/content/8/1/11
Page 10 of 14led to the expansion of myocardial progenitors, coupled
with a reduction of the endothelial lineages [77]. Thus,
live embryo screening of a transgenic zebrafish line has
identified a specific inhibitor of the Dusp6 phosphatase
and can reveal novel insight into the role of MAPK sig-
nalling during development, and possibly MAPK dis-
eases.
Screening for new small molecules that control 
zebrafish behaviour
By 2020, it is projected that major depression will become
the disease responsible for the most years of disability
worldwide, with bipolar disorder sixth and schizophrenia
ninth (Lopez and Murray, 1998). Many behaviour-alter-
ing drugs were discovered by chance in the 1940s and
50s, and have become the prototypes for newer analogues
used today [79]. There is an unmet clinical need for new
classes of neuroactive molecules to treat the range of
mental illnesses, and chemical tools to explore neurobiol-
ogy research [79]. One of the reasons for the lack of
newer neuroactive drugs comes from the lack of available
relevant model systems for screening large numbers of
active compounds. The complex networks of the brain
cannot be modelled in vitro, and the expense and ethical
issues surrounding mice and rats do not make them easily
amenable to high throughput screening [79]. In the first
high-throughput chemical screens for behaviour pheno-
types, Peterson, Schier and colleagues have developed
screening platforms that allow for high throughput
screening of known and novel small molecules for behav-
ioural phenotypes in living zebrafish embryos [80-82].
The rest/wake cycle is established as early as four-days
post-fertilization in the developing larvae [81]. Like
humans and other animals, zebrafish have wake and
sleep-like states characterized by periods of activity and
rest [81,83]. In the day, zebrafish display increased loco-
motor activity for longer periods, while night activity is
characterized by short bouts of infrequent movements
[81]. Using a tracking device, detailed measurements of
zebrafish movement behaviour, including quantitative
measurements of the frequency and duration of rest and
waking activity, and the latency between states, was
recorded for individual zebrafish larvae over three days
each when exposed to one of over 5600 chemicals [82].
The multifactorial nature of the quantitative measure-
ments could be organized into a profile for each treat-
ment, called behavioural profiling. Hierarchical
clustering of the profiles clustered the small molecules
into two broad states, arousing and sedative. These stud-
ies in zebrafish are relevant to our understanding of
human biology because arousing and sedative drugs gen-
erally showed a conserved neuropharmacology between
zebrafish and mammals. Compounds that shared profiles
often shared target pathways or therapeutic applications,
indicating that behavioural profiling in zebrafish can
identify and group bioactively similar compounds.
Importantly, by virtue of the shared profiles with well-
characterized drugs, the mode of action for poorly char-
acterized compounds could be predicted. Behavioural
profiling also identified new pathways that govern rest/
wake behaviours, including a new role for the inflamma-
tory signalling pathways and the Ether-a-go-go-related
gene (ERG) potassium channel blockers. In this way, a
systems biology approach to rest/wake neuropharmacol-
ogy in zebrafish may be directly applicable to the devel-
opment of new drugs for the proportion of the
population (> 10%) who suffer from chronic sleep distur-
bances.
In another study, Peterson and colleagues have discov-
ered a novel phenotype in zebrafish that display stereo-
typic motor behaviours before, during and after exposure
to a high-intensity light stimulus, called the photomotor
response (PMR) [80]. Using tracking devices, the PMR
and an embryonic touch response (ETR) were analysed
for behavioural phenotypes when exposed to 14,000 dif-
ferent small molecules. Behavioural information could be
quantified, and organised into behavioural "barcodes".
Hierarchical clustering of the barcodes revealed groups of
compounds that induced similar phenotypes, called phe-
noclusters. Often, phenoclusters were enriched for com-
pounds of a similar chemical class, and point to the
cellular targets within a pathway. As with the chemical
screening for changes in the rest/wake cycle, hierarchical
clustering of the PMR and ETR phenotype could also
reveal the mode-of-action for uncharacterized com-
pounds, and provide testable hypotheses about the target
identification for that compound. For example, two unre-
lated compounds, STR-1 and STR-2 have no known
activity in mammals, and have the same behavioural bar-
code profile as compounds known to inhibit acetylcholin-
esterase (AchE). In vitro, STR-1 could inhibit AchE, but
STR-2 required bioactivation in the embryo to inhibit
AchE. Thus, phenoclustering revealed novel compounds,
and accurately predicted their mechanism of action.
Importantly, molecules that require activation within the
context of the animal would have been missed in in vitro
designed screens. Finally, high throughput behavioural
screening may also be able to identify compounds that
alter a chemical or genetic behavioural phenotype. As an
example, small molecules that cause paralysis or excita-
tion in the zebrafish embryo could be treated with chemi-
cal antidotes to restore normal behaviour. Given the
unmet need for new drugs to treat mental illness and the
quantity of information obtained for thousands of com-
pounds on just a few zebrafish behaviours, high through-
put behavioural screening in zebrafish has the potential
to reveal important new drug leads and targetable path-
ways for these and more complex behaviours.
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While many currently used clinical drugs have no known
target [3], target identification remains an important
aspect of chemical biology. For example, to identify the
target of the small molecule BCI described above, Tsang
and collegues used purified Dusp6 to directly test for in
vitro ERK phosphatase assays in the presence or absence
of BCI. Computational BCI docking simulations showed
an accessible crevise in Dusp6 but not Dusp5, and by
binding this site, BCI acts via an allosteric mechanism to
prevent the shift from low to high enzyme activity upon
ERK binding [77]. In other examples, a systems approach
led to the identification of the mode of action for novel
neurobiological compounds [80,82]. Hierarchical cluster-
ing of the behaviour phenotypic profiles enriches for
compounds that act on a similar target or target pathway,
and targets of previously uncharacterized compounds
have been identified by virtue of their similar behavioural
phenotype with well characterized compounds. In
another systems approach, we are using a combined yeast
and zebrafish approach to identify the intended and unin-
tended targets of small molecules in vivo (Ishizaki et al.,
DMM, in press).
Affinity chromatography using immobilised small mol-
ecules is another method for target identification. How-
ever, immobilisation of a small molecule through the
attachment of an adequate linker can often unintention-
ally cause reduced activity of the compound. To address
this issue, Chang and colleagues designed a 1536 triazine-
tagged compound library, incorporating the linkers prior
to screening to provide a straightforward method of iso-
lation of the target compound [84]. In one screen, a triaz-
ine-tagged library was screened for enhanced
pigmentation in developing zebrafish [85,86]. A com-
pound called PPA was identified that could enhance pig-
mentation in both the fish embryo and also in human
albino melanocytes [85,86]. Affininty chromatography
identified the F1F0-ATPase as a cellular target of PPA.
Notably, although PPA was identifed in the zebrafish sys-
tem, it is also effective in a range of mammalian melano-
cyte and melanoma cells. Ion gradients appear to play a
role in pigmentation, and PPA may prove a valuable
research tool to study how mitochondrial ATPases con-
trol melanin in both zebrafish and mammalian melano-
cyte cells.
Zebrafish can play an important role in the drug devel-
opment process by testing for action in vivo, and in struc-
ture-activity profiling. For example, Lum and colleagues
screened 200,000 chemicals for Wnt/β-catenin pathway
modulators using a Wnt pathway responsive reporter
construct expressed in mouse L cells [64]. One class of
compounds, called inhibitors of the Wnt response (IWR),
specifically reduced β-catenin levels and stabilized a
component of the β-catenin destruction complex, called
Axin. Wnt signaling is required for zebrafish tail fin
regeneration, and to test the activity of the IWR com-
pounds in vivo, adult zebrafish tail fins were clipped, and
treated with IWR compounds. The IWR compounds pre-
vented tail fin regeneration as well as decreased prolifera-
tion in the gastrointestinal crypt cells, showing that Wnt
signaling is critical for stem cell activities in vivo. Almost
all colorectal cancers have activated Wnt signaling caused
by mutations in the Wnt suppressors, adenomatosis poly-
posis coli gene or axin, or activating mutations in β-
catenin, but there are currently no Wnt inhibitors in clin-
ical trials. Novel Wnt inhibitors such as these may pro-
vide therapeutically relevant compounds, and zebrafish
are playing a central role in determining their in vivo effi-
cacy, structure-activity relationships, and tissue specific
sensitivity [64,87].
Finally, zebrafish can provide new insight into how
drugs work in an organism. Thalidomide was widely pre-
scribed in the 1950s and 1960s in many countries, includ-
ing Canada and the United Kingdom, to pregnant women
suffering from morning sickness. This resulted in the
birth of over ten thousand children with serious develop-
mental birth defects, including severe shortening or
absence of limbs, ear defects and other heart and gastro-
intestinal abnormalities. While the teratogenicity of thali-
domide is well established, the mechanism behind the
developmental defects is unknown. This is important
because thalidomide is still used today as a treatment for
multiple myeloma and as an immune suppressant for
treating the painful leprosy asssociated erythema nodo-
sum leprosum. Handa and colleagues identified cereblon
(CRBN) and DNA binding protein 1 (DDB1) as binding
partners of thalidomide in cancer cell extracts [88]. Using
biochemical techniques, Handa and colleagues showed
that CRBN forms a functional E3 ubiquitin ligase com-
plex with Cullin (Cul) 4 and DDB1; importantly, thalido-
mide binding to CRBN inhibits E3 function. Ultimately,
thalidomide may have multiple targets in a developing
organism, but chemical and genetic approaches in
zebrafish showed CRBN to be a relevant in vivo target of
thalidomide in limb outgrowth. Unlike mice and rats, that
are insensitive to thalidomide teratogenicity, zebrafish
embryos treated with thalidomide show otolith and
angiogenic deficiencies and fail to develop outgrowth of
pectoral fins [88,89]. Gene knockdown of crbn or cul4 in
zebrafish caused a loss of the developing fin, and fin
development could be rescued by a thalidomide-insensi-
tive mutant form of crbn. Together, this evidence points
to the binding and inhibition of Crbn as the casue of the
teratogenic effect of thalidomide in the ears and limbs.
The E3 targets of Crbn are unknown, but expression of
Fgf8 at the apical ectodermal ridge of the zebrafish fin
bud was dramatically reduced upon thalidomide treat-
ment, a phenotype that could also be rescued by the thal-
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thalidomide-Crbn-Fgf8 pathway is conserved in the chick
limbs, providing evidence that the zebrafish limb pheno-
types are relevant in other species. Identification of the
dangerous teratogen targets can aid in generation of thal-
idomide deriviatives that no longer inhibit Crbn E3 activ-
ity, and the sensitivity of zebrafish to thalidomide will be a
valuable living tool for screening new thalidomide derivi-
atives.
Conclusions
The combination of genetic and developmental features
places zebrafish small molecule screening at the cutting
edge of chemical biology. Ten years after the first small
molecule screen in zebrafish, we have examples of how
small molecules can lead to fundamental insight into
developmental and behavioural processes, to new clinical
strategies, and to understanding of the action of currently
used drugs. In addition to the chemical biology examples
presented here, other important screens in zebrafish have
identified the first regulators of the BMP pathway [90,91],
regulators of TGFβ signaling [92], histone deacetylase
inhibitors that can suppress models of polycystic kidney
disease [93] and cancer cell radiosensitizers [94], among
others. We are only just beginning to understand how
small molecules act within living animals and the trans-
parent nature of the zebrafish embryo may facilitate
future visualization and understanding of how chemicals
act upon targets within cells. As high throughput screen-
ing becomes more accessible, a greater range of chemical
space within biological systems can be explored. Finally,
sharing of chemical libraries between zebrafish research-
ers with diverse biological interests should lead to an
unprecedented wealth of new insight into chemical biol-
ogy within a whole animal system [95].
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Summary
Small molecules complement genetic mutants and can be used to probe pigment cell biology by inhibiting
specific proteins or pathways. Here, we present the results of a screen of active compounds for those that
affect the processes of melanocyte and iridophore development in zebrafish and investigate the effects of a
few of these compounds in further detail. We identified and confirmed 57 compounds that altered pigment
cell patterning, number, survival, or differentiation. Additional tissue targets and toxicity of small molecules
are also discussed. Given that the majority of cell types, including pigment cells, are conserved between ze-
brafish and other vertebrates, we present these chemicals as molecular tools to study developmental pro-
cesses of pigment cells in living animals and emphasize the value of zebrafish as an in vivo system for testing
the on- and off-target activities of clinically active drugs.
Introduction
Zebrafish have three pigment cell types: melanocytes,
xanthophores, and iridophores, which produce black
melanin, yellow pteridine, and reflective crystalline guan-
ine, respectively (Kelsh et al., 2009). Combinations of
these cells create a stereotypical pigmentation pattern
in the embryo that is maintained until metamorphosis,
when the fish develops the bluish-black and yellowish-
silver striped adult pattern (Rawls et al., 2001). Melano-
cytes (often called melanophores in fish) are dendritic
cells that become visible from prim-12 stage (28 h post-
fertilization; hpf); iridophores become visible as shiny,
oval cells under incident light from high-pec stage
(42 hpf), and are often associated with melanocytes;
and xanthophores, also dendritic, become most visible
by 5 days post-fertilization (dpf). Within each of the pig-
ment cell types, pigment is contained within mem-
brane-bound organelles (melanosomes, reflecting
platelets, and pteridine granules, respectively). During
zebrafish embryonic development, pigment cells
become specified from multipotent progenitors through
combinations of intrinsic factors such as Sox10 (Dutton
et al., 2001) with extrinsic factors, including Wnt (mela-
nocytes) and Ltk signaling (iridophores) (Dorsky et al.,
1998; Lopes et al., 2008) that together promote expres-
sion of cell-type-specific transcription factors such as
Mitfa (melanocytes) (Lister et al., 1999). These cell-type-
Significance
Small molecules are bioactive tools to probe pigment cell biology within specific developmental time
windows and at different dose concentrations. While some of the compounds directly link the cellular
phenotype to a known molecular mechanism, others reveal new pathways for the control of pigment cell
biology. Thus, the zebrafish system is a valuable, rapid, and inexpensive system for screening small
molecules and gaining new insight into pigment cell processes in vivo.
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specific transcription factors then coordinate expression
of the whole suite of genes required for full expression
of the differentiated characteristics of the pigment cells.
As in the zebrafish and the mouse, human skin mela-
nocytes are derived from the neural crest lineage, and
many of the melanocyte molecular factors such as
Sox10, Mitf, tyrosinase, Dct, and SLC25A4 are highly
conserved between species (Levy et al., 2006; Lin and
Fisher, 2007). Human skin is pigmented by melanocytes
that produce and distribute melanin to surrounding
keratinocytes, thereby coloring human skin and playing
an important role in protection from the damaging
effects of UV-light (Tran et al., 2008). In contrast, fish
change color by altering pigment location and reflectivity
during background adaptation or stress (Logan et al.,
2006; Richardson et al., 2008). Many of the human
melanocyte pigmentation and disease states can be
modeled using zebrafish genetics, including skin color,
albinism, Waardenburg Syndrome, vitiligo, nevi, and
melanoma (Ceol et al., 2008; Ishizaki et al., 2010; Lama-
son et al., 2005; Navarro et al., 2008; Patton et al.,
2005, 2010; Richardson et al., 2011; Schonthaler et al.,
2008; Taylor et al., 2010; White and Zon, 2008). Thus, a
detailed understanding of pigment cell biology in zebra-
fish is relevant to mammalian melanocyte biology.
Genetic screens in zebrafish and medaka have identi-
fied genes that control pigment cell processes, many of
which are conserved and relevant to other animal spe-
cies (Kelsh et al., 1996, 2004; Odenthal et al., 1996;
Rawls and Johnson, 2003). These genetic tools have
been complemented by efforts to identify small mole-
cules affecting melanocyte pigmentation, distribution,
survival, and stem cells (Hultman et al., 2009; Ishizaki
et al., 2010; Jung et al., 2005; Mendelsohn et al., 2006;
O’reilly-Pol and Johnson, 2008, 2009; Sheets et al.,
2007; White et al., 2011; Yang and Johnson, 2006). The
small size of the zebrafish embryo, coupled with the
optical transparency and homologous target pathways in
human cells, has made zebrafish an advantageous
model organism for screening small molecules in vivo
(Taylor et al., 2010; Zon and Peterson, 2005, 2010). An
important aspect of chemical biology in zebrafish is the
ability to alter time and dose of the compound, to iden-
tify discrete time of action of a specific pathway, and
the ability to simultaneously target multiple members of
a given protein family (Taylor et al., 2010; Zon and
Peterson, 2005, 2010). Chemical biology in zebrafish
can also contribute to the identification of the mode of
action as well as unknown target pathways of small
molecules in vivo (Ishizaki et al., 2010; Kokel et al.,
2010; Rihel et al., 2010).
To expand the available molecular tools to probe pig-
ment cell biology, we have performed a screen for small
molecules that alter iridophore and melanocyte develop-
ment in zebrafish embryos. Here, we present the pig-
ment cell-specific compounds identified from the Sigma
LOPAC library, the Enzo Life Sciences Screen-WellTM
Kinase Inhibitor Library, and Enzo Life Sciences Screen-
WellTM Phosphatase Inhibitor Library. Some have been
identified in previous studies (Ishizaki et al., 2010; Men-
delsohn et al., 2006; Sheets et al., 2007), but others pro-
vide new insight into developmental processes and
should prove to be a useful resource to study both funda-
mental aspects of pigment cell development and models
of pigment cell disease.
Results
We screened for compounds that caused specific pig-
ment cell phenotypes or altered the pigment cells in
addition to targeting other tissue structures (Figure 1A,
B). Zebrafish embryos were collected, and five embryos
were arrayed at sphere stage (4 hpf) in each well of a
24-well plate. This developmental stage is well before
neural crest development, which arises during the seg-
mentation period at about 10 hpf. Screening in 24-well
plates provided ample space for manipulation of the live
embryos to visualize as much of the pigmentation as
possible, while keeping only five embryos per well
helped prevent a decrease in water quality from embryo
crowding during the screen. Each well contained 10 lM
of a compound from the Sigma LOPAC collection (1280
bioactive compounds), or the Enzo Life Sciences
Screen-WellTM Kinase and Phosphatase libraries (80 and
33 compounds, respectively). Many of the compounds
are active in other systems at 10 lM (e.g. cell cultures)
and are expected to be stable for the duration of the
screen, although the activity of the compounds may
diminish over time (for example, see roscovitine below).
The developing fish were screened under the dissecting
microscope for changes in iridophore and melanocyte
number, location, and pigmentation ⁄ iridescence at long-
pec stage (48 hpf), protruding mouth stage (72 hpf), and
larval day 4 stage (96 hpf). We initiated screening at
long-pec stage (48 hpf) because both melanocytes and
iridophores are clearly visible in a stereotypic pattern at
this time. To facilitate screening of iridophores, we
screened independently both AB wild-type and mitfa
mutant embryos with each compound. General toxicity
phenotypes (e.g. necrotic tissue and general delay)
were observed with 81 compounds and were eliminated
from the screen. To confirm the effects of those com-
pounds that had a more specific effect, we re-tested
compounds from the screening plate at three different
concentrations and confirmed their phenotype (Table 1
and Table S1, see Supporting Information; shaded text).
For some compounds, we obtained fresh supplies and
re-tested to confirm the phenotype (Table 1 and Table
S1, see Supporting Information; black text). We also
performed targeted retesting of compounds identified
from the literature that were not confirmed in the sec-
ond round of rescreening, most likely due to lower than
expected concentrations in the screening plates (Table 1
and Table S1, see Supporting Information; asterisk).
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Phenotypes were classified using the scheme for the
large-scale genetic screen in zebrafish (Kelsh et al.,
1996). This phenotypic classification is based on four
broad categories: reduced chromatophore numbers
(Class I–III), abnormal chromatophore distribution (Class
IV, V), reduced chromatophore pigmentation (Class VI.A–
J), and abnormal chromatophore morphology (Class
VII.A–D). Fifty-seven compounds were confirmed in our
screen that produced reproducible melanocyte pheno-
type (Figure 2) and iridophore phenotype (Figure 3;
Table 1 and Table S1, see Supporting Information).
Class I–III: Reduced chromatophore numbers
We screened for changes in melanocyte and iridophore
development and did not screen for changes in xantho-
phores; thus, unlike in the genetic mutant screen (Kelsh
et al., 1996), we did not identify compounds that
affected all three cell types (Class I). However, we did
identify 13 compounds that affected iridophore number
(Class II) and five compounds that affected melanocyte
number (Class III). Small molecules that affected mela-
nocyte number included leflunomide that has recently
been described as affecting transcription of neural crest
genes and is effective against melanoma xenografts
(White et al., 2011).
Of particular interest, we found that zebrafish
embryos treated with roscovitine had fewer visible
melanocytes than DMSO control-treated embryos
(Figure 4, Table 1 and Table S1, see Supporting Infor-
mation) Zebrafish melanocytes first become visible at
about 25 hpf, and by 60 hpf, there are about 460 pig-
mented melanocytes that make up the pattern of the
embryo (Yang and Johnson, 2006). Fewer observed
melanocytes could be due to roscovitine promoting
melanocyte cell death, modulation of proliferation of
melanocyte precursors, or clustering of melanocytes
so that they cannot be distinguished as separate units.
We treated 3 and 4 dpf embryos (with fully pigmented
melanocytes) with roscovitine and found no evidence
of cell death (e.g. fragmentation of melanin or extru-
sion of pigmented cell fragments; data not shown;
Yang and Johnson, 2006). To define the phenotype
more precisely, we next examined the concentration
and time of action window for roscovitine in melano-
cyte development. We found roscovitine to be a rela-
tively unstable compound, which needed to be
refreshed daily in the water. A 20 lM roscovitine con-
tinuous treatment from prim-5 stage (24 hpf) allowed
the embryo to develop without obvious general devel-
opmental defects. However, although melanocytes of
the roscovitine-treated fish were darkly pigmented and
appeared in the correct spatial location, they were
reduced in total number and some of the melanocytes
appeared to have a short dendrites compared with
control-treated zebrafish (Figure 4A, B). Higher concen-
trations of roscovitine caused non-specific toxicity in
the zebrafish embryo, including heart edema and brain
necrosis (data not shown). To quantitate the observed
melanocyte effect at 20 lM, we defined a region of
the head of an immobilized embryo and counted the
number of melanocytes in the dorsal stripe (Richard-
son et al., 2008; Figure S1). Roscovitine caused a sig-
nificantly reduced number of melanocytes in the
developing zebrafish, compared with control-treated
fish (Figure 4C, D). Melanocyte loss was not restricted
to the head region and caused fewer melanocytes
over the entire body of the 4 dpf zebrafish embryo
[28% reduction in melanocyte number: control mean:
300.8 (SD = 53.53, n = 5); roscovitine 20 lM mean:
217.2 (SD = 15.90, n = 6) two-sample unpaired t-test
P = 0.0051]. Thus, roscovitine appears to affect total












II Reduced number of iridophores
III Reduced number of melanocytes











Figure 1. Screen for small molecules that modulate pigment cell biology in zebrafish. (A) Adult zebrafish were bred, embryos collected and
arrayed in 24-well plates, each well with a compound at 10 lM dissolved in DMSO and E3 embryo medium. Zebrafish embryos were
screened at long-pec stage (48 hpf), protruding mouth stage (72 hpf), and larval day 4 (96 hpf) for melanocyte and iridophore phenotypes and
classified, where possible, based on the phenotypic analysis used to characterize genetic mutations altering pigment cell biology (Kelsh et al.,
1996). (B) Pie-chart showing the range and distribution of phenotypes observed in the screen. Numbers of chemicals identified for each
phenotypic category are indicated.
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Class IV: Melanocyte pattern abnormal
Neural crest-derived melanocytes in zebrafish embryos
undergo extensive migration from their neural crest
origin to generate a highly stereotypical pattern of four
stripes (dorsal, lateral, ventral, and yolk sac) (Kelsh et al.,
2009). We identified five compounds that affected pig-
Table 1. Results of screening small molecules for pigment cell phenotypes
Pigment cell phenotypea Compoundb Reported target pathway
Reduced chromatophore numbers
II. Reduced number of iridophores (-)-Eseroline fumarate Cholinesterase
4-Chloromercuribenzoic acid Carboxy- and aminopeptidase
Cyclosporin A PP2B
Ellipticine P450 and topoisomerase II
Genistein Tyrosine kinases
Nalidixic acid sodium salt DNA gyrase
PKC 412 PKC
PQ 401 IGF-1R
Tyrphostin AG 825 HER 1-2
Tyrphostin AG 1296 PDGFRK
Tyrphostin AG 1478 EGFRK ⁄ ERB
Rapamycin mTOR
SU 1498 Flk1
III. Reduced number of melanocytes Clotrimazole Ca2+-activated K+ channel
Leflunomide* Dihydrooroate dehydrogenase and tyrosine kinases
Rapamycin mTOR
Roscovitine CDK (see Table S2, Supporting Information)
SU4312 Flk1
Abnormal chromatophore distribution
IV. Melanocyte pattern abnormal Emodin p56 LCK
LY294002 P13K
Retinoic acid RAR agonist
Tyrphostin AG 1296 PDGFRK ⁄ c-kit (see Table S2, Supporting Information)
Tyrphostin AG 1478 EGFRK ⁄ ERB
V. Ectopic chromatophores (-)-Eseroline fumarate Cholinesterase
Budesonide Glucocorticoid




VI.A. Pale melanin 4-Chloromercuribenzoic acid Carboxy- and aminopeptidase
b-Estradiol Steroid
CCG4986 RGS4
CGP 13501 GABAB receptor
CinnGel PTP1B
Clotrimazole Ca2+-activated K+ channel











Sanguinarine chloride Mg2+ and Na+ ⁄ K+-ATPase
SP 600125 JNK
SU 1498 Flk1
Tyrphostin AG 126 IRAK
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ment cell pattern, defined by an absence of part of the
normal pigmentation pattern (Class IV). These com-
pounds all affected the normal melanocyte pattern and
included inhibitors of PI3-kinase signaling (LY294002),
p56LCK signaling (Emodin), ERB signaling (Tyrphostin
AG1478), and retinoic acid signaling. One kinase inhibi-
tor, Tyrphostin AG1296, caused a strong melanocyte
migration delay in the zebrafish embryo (Figure 5A, B).
Tyrphostin AG1296 treatment from bud stage (10 hpf)
permitted melanocyte specification and pigmentation,
but their migration remains incomplete, so that cells
remain clustered around the ear and in dorsal regions of
the embryo and fail to cover the yolk sac and yolk sac
extension (Figure 5A). Treatment with Tyrphostin
AG1296 was dosage dependent, with the strongest
defect seen at 20 lM (Figure 5C). The time of addition
was also important: later addition of the compound could
produce intermediate phenotypes in which melanocytes
at the anterior of the fish had migrated correctly while
the posterior had not (data not shown). Tyrphostin
AG1296 is a PDGFR and c-kit receptor inhibitor, and we
find inhibitory effects on other kinases such as Aurora B
by in vitro kinase profiling (Table S2, see Supporting
Information). The receptor tyrosine kinase c-kit is critical
for melanocyte migration, and mutations in this gene
lead to white midline spots in mice and piebaldism in
humans (Lamoreux et al., 2010). In zebrafish, there are
two kit genes (kita ⁄ sparse and kitb), and kita is required
Table 1. (Continued)
Pigment cell phenotypea Compoundb Reported target pathway
VI.C. Melanophore degeneration 5-Bromo-2-deoxyuridine Thymidine analog
Budesonide Glucocorticoid




Tyrphostin AG 126 IRAK
VI.I. Dull iridophores Emodin p56 LCK
Fiduxosin a1-Adrenoceptor
Fusaric acid Dopamine b-hydroxylase
Tyrphostin AG 126 IRAK
Abnormal chromatophore morphology
VII.A. Spindly melanophores 3-alpha,21-dihydroxy-5alpha-pregnan-20-one GABAA receptor activator
5-N-methyl carboxamido adenosine Adenosine receptor agonist





Nalidixic acid sodium salt DNA gyrase
Nimesulide COX2
Progesterone Steroid
Valproic acid sodium Anti-convulsant








Sanguinarine chloride Mg2+ and Na+ ⁄ K+-ATPase
Su1498 Flk1
VII.D. No background adaptation Felodipine Ca2+ channel
Forskolin Adenylate cyclase inhibitor
Nocodozole Tubulin polymerization
by re-ordering the compound and testing in a dose curve series; *Phenotype is confirmed in the literature.
aPhenotypic categories are as described by Kelsh et al. (1996). Only pigment cell phenotypes that were identified in the chemical screen are
presented here. No compounds were found that caused I. No chromatophores because changes in xanthophore development were not
screened.
bShaded phenotypes were identified in the screen and confirmed by the compound in the screening plate; Bold phenotypes were confirmed
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for melanocyte migration and survival (Parichy et al.,
1999; Rawls and Johnson, 2003). Based on the similar
phenotypes between the zebrafish kit mutant (Parichy
et al., 1999) and Tyrphostin AG1296 chemical treatment,
we suggest that the primary target of Tyrphostin









Figure 3. Small molecules that modulate
iridophore biology in zebrafish. Images of
zebrafish embryos treated with small
molecules identified in the screen (A¢–D¢)
or DMSO as a control (A–D, respectively).
Phenotype examples include dull
iridophores (fiduxosin), reduced numbers
of iridophores (ellipticine), and ectopic
iridophores (CyPPA). CyPPA treatment
most likely causes an indirect effect on
iridophore location because of a notochord
defect (arrowhead). All panels except C,








Figure 2. Small molecules that modulate melanocyte biology in zebrafish embryos. Images of zebrafish embryos treated with small
molecules identified in the screen or DMSO as a control. Embryos (prim-25 stage; 36 hpf) treated with DMSO (A, A¢), ellipticine (B, B¢, C, C¢),
or sanguinarine (D, D¢) reveal examples of wild type, spindly morphology, and pale and small melanocytes, respectively. A¢, B¢, and D¢ are
enlarged images to show phenotypic detail. Melanocyte fragmentation is indicated (arrow). Dorsal view of DMSO (C) and ellipticine (C¢)-
treated embryos show the spindly morphology of the melanocytes (arrow). (E, E¢, F, F¢) Pec-fin stage embryos (60 hpf) treated with DMSO,
AG1478 (20 lM) or hydroquinone (40 lM) reveal examples of wild type, an abnormal melanocyte pattern, and reduced pigmentation. Arrow
indicates reduced numbers of melanocytes at the ventral stripe; asterisks indicate accumulation of melanocytes at the dorsal stripe.
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Class V: Ectopic chromatophores
Five compounds were identified that caused ectopic
chromatophores, defined as ectopic chromatophores in
addition to the wild-type zebrafish pattern. One com-
pound, CyPPA, caused clusters of iridophores associated
with a buckling and wavy notochord (Figure 3). This phe-
notype is similar to the phenotype caused by copper
deficiency (Ishizaki et al., 2010). We found this pheno-
type could be prevented with the addition of copper
chloride to the water (data not shown), suggesting that
the appearance of ectopic iridophores in CyPPA-treated
embryos is most likely due to the structural changes
within the embryo affecting iridoblast migration, rather
than a direct change in iridophore development.
Class VI: Reduced chromatophore pigmentation
Pale melanin (VI.A) was the most commonly altered
characteristic identified in the screen, with 23
compounds affecting pigment synthesis and ⁄ or inten-
sity. For some compounds, we understand the mode of
interference with pigmentation, for example by disrupt-
ing copper metabolism and ⁄ or tyrosinase activity (e.g.
PTU, U0126, and hydroquinone). While we attempted to
remove compounds that simply caused general toxicity,
for other compounds, we note that pale pigmentation is
often associated with general developmental delay
and ⁄ or reduced fitness, and therefore, some of the
compounds identified may not reflect direct interference
with pigment synthesis.
We identified four compounds that affected iridophore
pigmentation, such that iridophores were present, but
were dull and lacked reflective properties (Class VI.I).
While melanin synthesis is well understood, much less
is known about iridophore pigmentation. Iridophores in
some fish species can respond to transmitter release by





Figure 4. Roscovitine alters melanocyte
cell number in zebrafish embryos. (A, B)
Images of 5-day old zebrafish embryos
treated with DMSO or 20 lM roscovitine.
(C, D) Box and whisker plots of the
number of melanocytes in the head region
(Figure S2) in DMSO-treated embryos
compared with embryos treated with
roscovitine from prim-5 stage (24 hpf) until
(C) 4 dpf and (D) 5 dpf. Standard mean is









Figure 5. Tyrphostin AG1296 alters
melanocyte movement in zebrafish
embryos. (A, B) A prim-25 stage (36 hpf)
zebrafish embryo treated with DMSO as a
control or 20 lM of Tyrphostin AG1296
from the 2 to 4 somite stage (10.7–
11.3 hpf). Treated embryos develop
melanocytes, but the melanocytes are
clustered behind the ear (asterisk; A¢, B¢)
and have been retarded in their migration
along the medial migration pathway (red
arrow; A’’, B’’). Melanocytes also fail to
populate the yolk sac and yolk sac
extension (black arrows). (C) Embryos
treated with 12 lM Tyrphostin AG1296
(C¢) show reduced numbers of
melanocytes at yolk extension and ventral
stripe compared with embryos treated
with 20 lM Tyrphostin AG1296 (C’’;
arrows).
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Iga, 1992; Mathger et al., 2003; Nagaishi and Oshima,
1989). For example, motile iridophores have been
described in adult zebrafish blue stripes that can change
from a blue to yellow color via a norepinephrine-alpha-
adrenoreceptor response (Oshima, 2002), and earlier
studies have shown that adrenoreceptor signaling may
promote changes to reflecting platelet dispersion in
some species of fish (Matsuno and Iga, 1989). In our
study of zebrafish embryonic iridophores, we find no
evidence of motility in the light-reflecting platelets of
the iridophores (S. Colanesi and R. N. Kelsh, unpub-
lished observations). Thus, it was unexpected that we
identified fiduxosin as a potent inhibitor of iridophore
reflection in zebrafish development (Figure 6). Fiduxosin
is an alpha-adrenoreceptor antagonist that blocks G-pro-
tein-coupled signaling through the catecholamine adren-
ergic receptors (Hancock et al., 2002). Previous work
has associated alpha-adrenoceptor signaling with pig-
ment aggregation (Fujii, 2000), yet in our screen, this
effect was not seen with fiduxosin. In contrast, fiduxo-
sin interfered with iridophore reflectiveness in a dose-
dependent manner, with complete loss of iridophore
reflection at 15 lM (Figure 6A). Iridophores were still
present, however, as indicated by expression of the
iridophore gene, leukocyte tyrosine kinase (ltk, Lopes
et al., 2008) by RNA in situ hybridization (Figure 6A).
This suggests that fiduxosin may interfere with irido-
phore light-reflective properties or directly with an irido-
phore differentiation program.
If fiduxosin disrupts the iridophore reflective capacity
by altering the reflective plates, we would expect the
effects to be rapidly reversible upon drug ‘wash-out’
(transfer to fresh water). For example, in the tropical par-
adise whiptail fish, the rapid changes to iridophore reflec-
tivity from blue to red occur within seconds to minutes
and are reversible (Mathger et al., 2003). Likewise, in ze-
brafish melanocytes, melanin distribution in response to
background color or epinephrine is rapid and readily
reversible (Logan et al., 2006; Richardson et al., 2008;
Sheets et al., 2007). In contrast to our experience with
melanin distribution, we found very slow recovery
(requiring at least 24 h) of iridophore reflectivity after
‘wash-out’ of fiduxosin (data not shown), suggesting
Fiduxosin alters the formation of the guanine plates.
To examine the effects of fiduxosin in more detail,
we examined expression at prim-25 (36 hpf), long-pec
stage (48 hpf), and protruding mouth stage (72 hpf) of
two iridoblast markers, ltk and endothelin receptor B
A
B
Figure 6. Fiduxosin treatment affects
reflective properties of iridophores. (A)
Fiduxosin causes a dose-dependent loss
of iridophore reflectivity (left panel, close
up of dorsal stripe at 72 hpf, incident
light), while still expressing the iridophore-
specific marker ltk (right panel, close up of
corresponding area of dorsal stripe at
72 hpf). (B) Fiduxosin disrupts
pigmentation of iridophores. Fiduxosin-
treated embryos maintain expression of
early markers of the iridophore lineage, ltk
and ednrb1, but show reduced expression
of a late iridophore differentiation marker,
cb632 (also called gmps).
Colanesi et al.
138 ª 2012 John Wiley & Sons A/S
(ednrb1), and the iridophore marker guanine mono-
phosphate synthetase (gmps; also known as cb632,
http://zfin.org/) in embryos treated with 10 lM fiduxosin
from 20 hpf. Expression of ednrb1 and ltk at prim-25
stage (36 hpf) and long-pec stage (48 hpf) in the distinc-
tive pattern of iridophores demonstrates that specifica-
tion and early differentiation of the iridophore lineage
has occurred normally (Figure 6B). In contrast, these
cells did not express the gmps gene (Figure 6B), which
is required for guanine platelet formation in the irido-
phore (Ng et al., 2009). Thus, we suggest fiduxosin
directly interferes with the iridophore differentiation pro-
gram resulting in a failure to express gmps at the levels
required for guanine platelet formation.
Class VII: Abnormal chromatophore morphology
We identified 11 compounds that resulted in pale, spin-
dly melanocytes (VII.A) and nine compounds that
caused small, rounded melanocytes (VII.B). Strikingly,
three cyclooxygenase (COX) inhibitors – ibuprophen,
indomethacin, and nimesulide – caused melanocytes to
have a spindly morphology at lower-dose treatments
and to be small and spot-like at higher concentration
treatments (Figure 7). Progesterone and the GABAA
receptor activator were also identified in both catego-
ries. We did not identify any compounds that affected
iridophore shape, or compounds that caused stellate
chromatophores (VII.C). Finally, while we did not
actively screen for alterations in melanocyte background
adaptation (VII.D), we identified three compounds that
had fully expanded, darkly pigmented melanocytes. In
zebrafish, pigment in melanocytes is motile, and the
melanin area can expand or contract within the cell in
response to hormones and catecholamines via a cyclic
AMP (cAMP) response signaling pathway (Fujii, 2000;
Logan et al., 2006; Richardson et al., 2008; Sheets
et al., 2007). Two of the identified compounds, forskolin
and nocodozole, are known to affect melanin distribu-
tion in background adaptation (Logan et al., 2006; Rich-
ardson et al., 2008; Sheets et al., 2007) and were also
confirmed in our screen (VII.D; Table 1, data not
shown).
Discussion
Small molecules provide a means for controlling pig-
ment cell development that complements the wealth of
genetic mutations identified in nature and in the labora-
tory. The zebrafish is an advantageous system for pig-
ment cell chemical biology because the embryos are (i)
transparent, (ii) develop ex vivo, and (iii) small enough
for multiple embryos to be immersed in relatively little
total compound. By screening a small series of libraries,
we have identified more than 50 compounds that affect
a range of pigment cell processes including specifica-
tion, migration, pigmentation, and differentiation. A
number of the compounds identified are consistent with
known processes both in zebrafish and in other melano-
cyte systems. For example, forskolin and nocodozole
were identified as causing no background adaptation
(VII.D), consistent with the known role of cAMP signal-




D D’Figure 7. COX inhibitors cause spot-like
melanocytes. Images of long-pec stage
(48 hpf) embryos treated with (A, D)
DMSO, (B, B¢) nimesulide, (C, C¢)
indomethacin, or (D¢) ibuprophen.
Melanocytes with a spindly morphology
(black arrow) or spot-like (red arrow) are
indicated.
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zebrafish melanocytes (Logan et al., 2006; Richardson
et al., 2008; Sheets et al., 2007). Also, the melanocyte
migration phenotype caused by the c-kit inhibitor
AG1296 corresponded well to that expected based upon
the known pharmacology of the compound.
Many compounds affected more than one biological
process. This is likely to reflect the repeated use of
biochemically similar activities, such as intracellular
signaling pathways, in different biological processes. As
demonstrated in the literature and confirmed by our in
vitro kinase profiling analysis of AG1296 and roscovitine
(Table S2, see Supporting Information), many kinase
inhibitors target more than one kinase. Thus, the pheno-
types we observe may, unlike genetic mutations, reflect
inhibition of multiple kinases. Indeed, we hypothesize
that the iridophore phenotype of AG1296 indicates inhi-
bition of leukocyte tyrosine kinase (Ltk; Lopes et al.,
2008). Furthermore, some compounds are designed to
target a class of kinases, such as MEK inhibitors that
target both MEK1 and MEK2 (Barrett et al., 2008).
In many cases, the link between the characterized
pharmacological target of the compound and the pig-
ment phenotype observed is unknown. For example,
how fiduxosin inhibits iridophore pigmentation is
unknown, indicating a possible new pathway in pigment
cell biology. Alternatively, there may be additional unex-
pected targets of the compounds that affect known pig-
ment cell biology regulators. This is seen with both
U0126 and CyPPA that prevent melanin synthesis and
alter iridophore location by an indirect effect on copper
metabolism required for tyrosinase activity and noto-
chord development (Figure 3C; Ishizaki et al., 2010). We
speculate that an unexpected target may also be
responsible for the small and pale melanocytes caused
by the VEGF inhibitor SU1498, a phenotype not
detected in treatments with other VEGF inhibitors such
as SU4312 (Figure S2).
Some phenotypes were difficult to assign unambigu-
ously to specific categories. For example, it was not
always easy to distinguish between reduced number of
iridophores (II) and dull iridophores (VI.I) phenotypes
based on visualization by incident light because dull
iridophores may be present but not clearly visible and ⁄ or
the intrinsic variability in appearance of these cells
dependent upon the angle of incidence of illumination.
Likewise, depending on the phenotype, it was some-
times difficult always to accurately assign phenotypes
to the melanocyte pattern abnormal (IV) or reduced
number of melanocytes (III) classes. Nonetheless, we
have made a first attempt to characterize the pheno-
types, but appreciate that future detailed studies of the
compounds in zebrafish development may indicate addi-
tional or different classifications.
Roscovitine, fiduxosin, and COX inhibitors were of
particular interest from our screen, not least because
they are all currently used in humans to treat a range of
conditions. We identified roscovitine as a compound
that specifically interfered with the numbers of melano-
cytes in the developing embryo (Figure 4). Roscovitine
(Seliciclib) is a cyclin-dependent kinase (CDK) inhibitor
that has activity against CDK2 ⁄ 7 ⁄ 9 and is being devel-
oped as an anti-cancer, anti-viral, and anti-inflammatory
drug. Roscovitine also effectively inhibits ERK8 and
DYRK1A in our kinase profiling assays (Table S2, see
Supporting Information). CDK2 appears to play a specific
role in melanoma as a transcriptional target of Mitf, and
CDK2 expression levels in melanoma lines correlate
with sensitivity to roscovitine treatment (Du et al.,
2004). A specific role for CDKs in melanocyte develop-
ment has not been previously shown, in part, because
mice deficient for CDK2 have normal coat color (Berthet
et al., 2003; Ortega et al., 2003). Roscovitine is also a
potent activator of p53, possibly by inhibition of a CDK-
dependent mechanism (Lu et al., 2001). While the
molecular mechanism underlying the roscovitine pheno-
type is unknown, roscovitine treatment reveals a novel
zebrafish pigmentation phenotype, distinct from those
defined genetically to date.
Fiduxosin is used as a muscle relaxant for symptomatic
treatment of benign prostatic hyperplasia. We identified
fiduxosin as a compound that specifically interferes with
an iridophore differentiation transcriptional program (Fig-
ure 6). Currently, we know almost nothing about the tran-
scriptional basis for iridophore differentiation, so
identifying the target inhibited by fiduxosin might be very
informative. While fiduxosin is an alpha-adrenoreceptor
antagonist, however, it is not clear whether this is the tar-
get in iridophore differentiation. As a practical application,
fiduxosin may be a useful tool for removing iridophore
pigmentation and autofluorescence, in just the way that
PTU is useful for preventing melanin synthesis.
Finally, COX inhibitors are non-steroidal anti-inflam-
matory drugs commonly used in people to treat pain,
reduce heart disease, and more recently shown to
affect cord blood stem cells (North et al., 2007). We
found COX inhibitors to cause spindly melanocytes at
lower concentrations, and distinctive small, spot-like
melanocytes at higher concentrations (Figure 7). COX
enzymes produce prostaglandins that can increase dif-
ferentiation of epidermal melanocytes. In human skin,
keratinocytes are thought to produce the prostaglandin
PGE2 as a pro-inflammatory mediator after erythema
caused by excessive UV exposure. More recently,
prostaglandin synthesis enzymes have been identified
in melanocytes, and prostaglandins have been shown
to be a UV irradiation-inducible autocrine factor for epi-
dermal melanocytes that can stimulate tyrosinase activ-
ity (Gledhill et al., 2010; Masoodi et al., 2010; Scott
et al., 2005; Starner et al., 2010). In our screen, the
identification of three small molecules with the same
target and same phenotype is compelling evidence that
COX inhibition (and not an alternative target) is directly
responsible for the melanocyte phenotypes in zebra-
fish. This may provide a useful in vivo system to
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address how prostaglandins interact with the pigmenta-
tion response, cAMP signaling, and alpha-MSH signal-
ing (Gledhill et al., 2010; Masoodi et al., 2010; Scott
et al., 2005; Starner et al., 2010). Notably, COX inhibi-
tors, such as aspirin, can decrease the incidence of
colorectal cancer. Thus, a target for COX inhibitors in
zebrafish melanocyte homeostasis may provide insight
when applied to the study of prostaglandins in mela-
noma (Fricke et al., 2010).
In conclusion, we have identified small molecules that
promote phenotypes that mirror some of the zebrafish
genetic pigment cell mutants as well as identify new
pigment cell pathways and phenotypes. Small mole-
cules often have unintended targets in vivo, and addi-
tional efforts are required to determine the direct target
within the pigment cell. However, testing multiple inhibi-
tors that target the same pathway will help to identify
both the target pathway of interest within the pigment
cell as well as unintended targets specific to a particular
compound. Many of the compounds identified here
have been effective in other melanocyte contexts (e.g.
melanoma and melanocytes in culture), underscoring
the value of the approach. Importantly, we have identi-
fied compounds and phenotypes not previously
reported, providing new resources for exploring melano-
cyte and iridophore development in detail.
Methods
Zebrafish husbandry
Zebrafish care and procedures were approved by the University of
Edinburgh veterinary staff and Ethics committee and the University
of Bath Ethical Review Committee, and in compliance with the Ani-
mals Scientific Procedures Act 1986 of the UK. Fish were housed
in fish facilities at the Universities of Edinburgh (MRC funded) and
Bath (Wellcome Trust funded). Embryos were acquired by breeding
wild-type strains AB, AB · TL or mitfa mutant zebrafish lines.
Chemical screening
The chemical libraries screened were the Sigma LOPAC collection
(1280 bioactive compounds), the Enzo Life Sciences Screen-WellTM
Kinase (80 compounds), and the Enzo Life Sciences Screen-WellTM
Phosphatase libraries (33 compounds). Five sphere stage (4 hpf)
embryos were arrayed in 24-well plates (Corning, Amsterdam, Neth-
erlands) containing 10 lM of compound in 1% DMSO in 1 ml of E3
embryo medium. Embryos were assessed for phenotypic changes
under standard and incident light conditions at long-pec stage
(48 hpf), protruding mouth stage (72 hpf), and larval day 4 (96 hpf).
In situ hybridization
In situ hybridization with hydrolized RNA probes was performed as
described Thisse & Thisse (2008). Probes were labeled with digoxi-
genin using the DIG RNA Labeling Kit (Roche, Mannheim, Ger-
many) and detected with the appropriate antibody. The signal was
detected by incubating the whole-mount samples in BMPurple AP
Substrate (Roche).
Kinase profiling
Kinase profiling was performed at the International Centre for
Kinase Profiling, MRC Protein Phosphorylation Unit, Dundee (http://
www.kinase-screen.mrc.ac.uk/). Compounds were supplied in
DMSO and screened in duplicate against a panel of 131 protein kin-
ases, using a radioactive (33P-ATP) filter-binding assay, as described
in detail in Bain et al. (2007).
Melanocyte counting assay
Embryos were assessed for melanocyte cell number by first expos-
ing the zebrafish to light to contract the melanin within the melano-
cyte and then fixed in 4% paraformaldehyde and imaged.
Melanocytes were counted within a defined head region (Richard-
son et al., 2008) in photographs by two observers, or over the
entire body.
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Understanding how drugs work in vivo is critical for
drug design and for maximizing the potential of
currently available drugs. 5-nitrofurans are a class
of prodrugs widely used to treat bacterial and
trypanosome infections, but despite relative speci-
ficity, 5-nitrofurans often cause serious toxic side
effects in people. Here, we use yeast and zebrafish,
as well as human in vitro systems, to assess the
biological activity of 5-nitrofurans, and we identify
a conserved interaction between aldehyde dehydro-
genase (ALDH) 2 and 5-nitrofurans across these
species. In addition, we show that the activity of
nifurtimox, a 5-nitrofuran anti-trypanosome prodrug,
is dependent on zebrafish Aldh2 and is a substrate
for human ALDH2. This study reveals a conserved
and biologically relevant ALDH2-5-nitrofuran interac-
tion that may have important implications for
managing the toxicity of 5-nitrofuran treatment.
INTRODUCTION
Drugs often have multiple targets in vivo that can lead to unin-
tended side effects. Identifying unintended drug targets and their
in vivo relevance is a fundamental challenge in chemical biology.
5-Nitrofurans are a class of drugs that save thousands of lives as
front-line treatments for parasitic trypanosome infections in Latin
America and Africa, and they are also effective antibiotics in
human and veterinary medicine (Castro et al., 2006; Coura and
Viñas, 2010; Nussbaum et al., 2010; Priotto et al., 2009). 5-Nitro-
furans are of such importance to human health that the World
HeathOrganization deems the 5-nitrofuran, nifurtimox, an essen-Chemistry & Biology 19,tial medicine and Bayer HealthCare provides nifurtimox free of
charge for trypanosome infections. 5-Nitrofurans are prodrugs,
and their relative specificity comes from parasitic and bacteria-
specific nitroreductases (NTRs) that reduce the 5-NO2 functional
group to a toxic anion radical, therebygenerating reactiveoxygen
species and inducing cell death. Despite their widespread use,
5-nitrofurans have serious toxic side effects (Castro et al.,
2006). For nifurtimox, toxic side effects lead to treatment cessa-
tion in over 30%ofpatientswithChagasdisease,which is caused
by Trypanosoma cruzi infection (Castro et al., 2006). Clinical side
effects are complex and can vary between populations, but they
include polyneuropathy, depression, forgetfulness, alcohol intol-
erance, and headaches, as well as gastrointestinal complica-
tions. There is currently no treatment strategy available to reduce
the off-target toxic side effects of 5-nitrofurans.
Over decades of research, scientists have identified multiple
human enzymes capable of 5-nitrofuran reduction in vitro, in
cells or tissues (Dubuisson et al., 2001; Rao et al., 1987; Rao
and Mason, 1987). However, the question of whether these
enzymes are relevant to 5-nitrofuran side-effect activity and
the potential for therapeutic intervention to inhibit their off-target
activity in vivo is unanswered. Drug mechanism of action is
readily examined in the zebrafish model system, in which clini-
cally active compounds can be directly assayed in the trans-
parent embryo (Zon and Peterson, 2005). Within 2 to 5 days of
development in zebrafish, most tissues and organs have formed,
thereby enabling the identification of tissue-specific drug activi-
ties and/or bioactivation. These features allow facile phenotypic
chemical screens within the whole animal. Phenotypic small-
molecule screens in zebrafish have enabled the identification
of new biological pathways, novel bioactive chemicals, and
unexpected potential for known drugs (Taylor et al., 2010). Drugs
often have multiple targets in vivo, and examining the effects of
small molecules on the developing zebrafish can also identify
unintended drug targets (Ishizaki et al., 2010; Ito et al., 2010;
Laggner et al., 2012; Rihel et al., 2010).883–892, July 27 , 2012 ª2012 Elsevier Ltd All rights reserved 883
Figure 1. 5-Nitrofurans Promote Melanocytotoxicity in Zebrafish
(A and B) Examples of zebrafish embryos treated at 2 dpf for 48 hr with DMSO as a control, plus 5 mM NFN1 and 5 mM NFN1.1 (A) or 50 mM nifurtimox (B). Black
melanocytes (red arrows) and melanocyte detritus (blue arrows) are indicated.
(C) Chemical structures of the four 5-nitrofurans (NFN1–4 [Maybridge compounds BTB05727, SEW00138, BTB13657, and BR00087]) identified in a chemical
screen for modulators of melanocyte development. The 5-NO2-furan functional group shared between the 5-nitrofurans, including nifurtimox, is indicated in red.
The chemical structure of NFN1.1. is identical to that of NFN1 but lacks the 5-NO2 functional group required for activity (blue).
See also Figure S1 and Movie S1.
Table 1. Derivatives of 5-Nitrofurans and Their Activity in
Zebrafish
Compound 0.2 mM 0.4 mM 0.8 mM 1.6 mM
NFN1 No activity No activity + +++
NFN1.1 No activity No activity No activity No activity
NFN5 No activity + ++ ++++
NFN5.1 No activity + ++ ++
NFN5.2 No activity + ++ ++++a
+Some melanocytes become dendritic, few are fragmented.
++Some punctate and fragmented melanocytes.
+++All melanocytes are punctate, many clearly fragmented, pigment
remains in eye.
++++All melanocytes are fragmented, with almost complete loss of
pigment in body and eye.
aAdditional nonspecific toxicity.
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ALDH2 Mediates 5-Nitrofuran ActivityHere, we use a multispecies approach to identify ALDH2 as
a mediator of 5-nitrofuran toxicity in yeast and zebrafish, and
we show that 5-nitrofurans are substrates for human ALDH2
in vitro. In a zebrafish phenotypic screen, we found that 5-nitro-
furans are melanocytotoxic. We exploited this highly visible
in vivo activity to generate a 5-nitrofuran probe, identify ALDH2
as a 5-nitrofuran target, and validate the interaction in vivo.
This interaction is conserved from yeast to human, and is also
relevant for the clinically active 5-nitrofuran nifurtimox. We
propose that this new interaction may be relevant to some of
the 5-nitrofuran toxicity observed in the clinic.
RESULTS
5-Nitrofurans Are Active in Zebrafish
Melanocytes are pigment-producing cells that generate black
melanin, and pigmented melanocytes are clearly visible in the
developing zebrafish beginning at 28 hr postfertilization (hpf;
Figure 1A). We identified four 5-nitrofuran compounds, NFN1
(Maybridge BTB05727), NFN2 (SEW00138), NFN3 (BTB13657),
and NFN4 (BR00087), in a chemical screen for modulators of
melanocyte development in zebrafish embryos (Figures 1A and
1C; see Methods). We also found that zebrafish were sensitive
to the clinically active 5-nitrofuran nifurtimox (Figures 1B and
1C). 5-Nitrofuran treatment directly affected the melanocyte
andmelanocyte progenitor viability in a dose-dependent manner
and was independent of tyrosinase activity (Figure S1 available
online; Movie S1). Thus, 5-nitrofurans are melanocytotoxic in
zebrafish, and unlike prodrugs that are bioactivated by pigmen-
tation enzymes (Jawaid et al., 2009; Yang and Johnson, 2006),
their activity is independent of tyrosinase. Altered pigmentation
is not a feature of 5-nitrofuran toxicity in humans, but melanocyte
specificity in zebrafish provided a rapid, convenient, and highly884 Chemistry & Biology 19, 883–892, July 27 , 2012 ª2012 Elseviervisible assay to study 5-nitrofuran activity in an animal model,
independent of trypanosome infection.
5-Nitrofuran Activity Requires the 5-NO2 Moiety
5-Nitrofurans are prodrugs, and the 5-NO2moiety is essential for
bioactivation in parasites and bacteria (Maya et al., 2007). We
modified NFN1 by replacing the NO2 moiety with a hydrogen
atom (Figure 1C, NFN1.1; Table 1; Supplemental Information).
In contrast to treatment with NFN1, NFN1.1 had no effect on
zebrafish melanocytes, and the melanocyte remained pig-
mented and intact (Figure 1A; Table 1). Nitrofuran activity in
melanocytes is therefore dependent upon the 5-NO2 functional
group. As in humans, zebrafish do not have NTRs (which are
present in trypanosomes) to process the 5-NO2 functional group,
and thus, the effects of NFN1 on zebrafish melanocytes mayLtd All rights reserved
Figure 2. 5-Nitrofurans Bind Aldh2 in Zebrafish
(A) Biotinylated probes linked to a 5-nitrofuran (Pr-NFN)
and a control furan (Pr-FN). Biotin is labeled in blue and the
5-nitro or modification moiety in red.
(B) Silver stain of protein bands identified using Pr-NFN
probe, or streptavidin beads alone as a control (No Probe).
The red box indicates the region of the gel that was iso-
lated for mass spectrometry analysis (arrow) at 57 kD.
(C) Western blot of zebrafish protein bound to the no-
probe control, the furan (Pr-FN) control, or the 5-nitrofuran
probe (Pr-NFN), and probed with zebrafish anti-Aldh2
antibodies. A band corresponding to 57 kDa is indicated
(arrow). MW, molecular weight.
See also Figure S2 and Table S1.
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processing.
Nitrofurans Bind ALDH2 in Zebrafish
To identify the possible targets of the 5-nitrofurans, we per-
formed affinity purification to capture 5-nitrofuran interacting
proteins in zebrafish extracts. First, we generated a series of
5-nitrofuran derivatives and tested their activity in zebrafish
(Table 1; Supplemental Information). Importantly, 5-nitrofuran
derivatives containing a phenyl ring (NFN5, NFN5.1, NFN5.2)
effectively targeted zebrafishmelanocytes (Table 1). As substitu-
tion at the para position of the phenyl ring in NFN5.1 and NFN5.2
was tolerated, a 5-nitrofuran probe was generated by linking
to biotin through the para position of the phenyl ring (Pr-NFN;
Figure 2A). Next, the 5-nitrofuran probe was bound to streptavi-
din beads, and protein complexes captured from zebrafish
extract derived from 3-day embryos were subjected to tandem
mass spectrometry. A 57-kD binding protein was identified
as aldehyde dehydrogenase (Aldh) 2b (Figure 2B; Table S1).
Zebrafish have two aldh2 (Lassen et al., 2005; Song et al.,
2006) genes (a and b) that are orthologs of human ALDH2 (Fig-
ure S2); aldh2b is expressed in neural crest derived cells,
including presumptive melanocytes (Thisse et al., 2001). To
confirm the identity of the 57-kD protein, we repeated our affinity
purification protocol and performed western blotting with anti-
Aldh2 zebrafish antibodies raised against both a and b forms
of Aldh2 (Lassen et al., 2005) (Figure 2C). As a control, we gener-
ated a furan probe that was identical to the nitrofuran probe
except that it lacked the 5-NO2 functional group (Pr-FN; Fig-
ure 2A). Aldh2 (either a or b) bound more strongly to the 5-nitro-
furan probe than to the control probe, and not to streptavidin
beads alone (Figure 2C). These experiments validate Aldh2 as
a 5-nitrofuran binding protein.
Aldh2 Is Required for 5-Nitrofuran Activity in Zebrafish
Aldh2 catabolizes toxic aldehydes in the liver after alcohol
consumption (Druesne-Pecollo et al., 2009), in the heart after
ischemia (Chen et al., 2008), and in dopamine metabolism (Yao
et al., 2010). We asked if 5-nitrofuran toxicity was dependent
on Aldh2 in zebrafish. The natural product daidzin, found in the
Kudzu vine (Pueraria lobata), is a potent and specific inhibitor
of human ALDH2 and has long been used in traditional medi-
cines as an antidipsotropic (Keung and Vallee, 1993a, 1993b;
Lowe et al., 2008). More recently, ALDH2 inhibitors have beenChemistry & Biology 19,shown to reduce anxiety associated with treatment of cocaine
and alcohol addiction (Arolfo et al., 2009; Yao et al., 2010). We
reasoned that ALDH2 inhibitors were likely to prevent the toxicity
of 5-nitrofurans in zebrafish because (1) human ALDH2 is closely
related to zebrafish Aldh2 (a and b forms) (Figure S2), and (2)
computational modeling of zebrafish Aldh2b bound to daidzin
suggests that critical drug-protein interactions are conserved
between species (Figure 3A). Treatment of zebrafish embryos
with daidzin protected melanocytes from the cytotoxicity of the
coadministered 5-nitrofuran NFN1 (Figure 3B), as well as the
clinically active 5-nitrofuran nifurtimox (Figure 3C). Thus, coad-
ministration of the Aldh2 inhibitor daidzin abrogates the activity
of NFN1 and nifurtimox in zebrafish.
To provide additional evidence that the action of daidzin was
by inhibition of Aldh2 and not an additional unintended target,
zebrafish embryos were cotreated with NFN1 and a second
ALDH1/2 inhibitor, disulfiram (DSF). DSF, also called Antabuse
and Antabus, is used to treat chronic alcoholism by preventing
the ALDH2-dependent metabolism of alcohol and producing
enhanced sensitivity to alcohol. DSF also chelates copper, and
we and others have found that DSF prevents pigmentation of
zebrafish melanocytes prior to melaninization, most likely due
to inhibition of copper-dependent pigmentation enzymes (Fig-
ure S3; O’Reilly-Pol and Johnson, 2008). DSF treatment of
embryos 3 days postfertilization (dpf) that had fully pigmented
melanocytes had no effect on melanocyte integrity, while DSF
prevented melanocyte toxicity upon cotreatment with NFN1
(Figure 3B). Taken together, these experiments with two chemi-
cally independent ALDH2 inhibitors support a biological role for
Aldh2 in the bioactivation of 5-nitrofuran melanocytotoxicity in
zebrafish.
ALDH2 is regulated in a tissue-specific manner, and in partic-
ular, εPKC can directly modulate ALDH2 during ischemic pre-
conditioning in the heart (Chen et al., 2008, 2010). We identified
the PKC inhibitors PKC412 and Ro318220 as chemical suppres-
sors of 5-nitrofuran activity in zebrafish by screening a library
of 80 known kinase inhibitors. Treatment of 3 dpf zebrafish
embryoswith PKC412 or Ro318220 had no effect onmelanocyte
viability (Figure 3B). However, treatment with PKC412 or
Ro318220 prevented NFN1 activity in melanocytes (Figure 3B).
We tested a third PKC inhibitor, GF109203X, that can inhibit
ethanol or dopamine D2 receptor agonist NPA-induced intracel-
lular translocation of εPKC (Yao et al., 2008). GFX109203X had
no effect on melanocytes alone, but we found that it could also883–892, July 27 , 2012 ª2012 Elsevier Ltd All rights reserved 885
Figure 3. Aldh2 Is Responsible for 5-Nitrofuran Activity in Zebrafish
(A) A predicted model of daidzin binding to zebrafish ALDH2b, based on key residues involved in the human ALDH2-daidzin (PDB 2vle) protein-ligand interaction
(Lowe et al., 2008). The equivalent residues in zebrafish Aldh2b are shown. Human ALDH2/Zebrafish Aldh2 2b (Phe-459/Phe-457; Phe-170/Phe-186;
Trp-177/Trp-193; Val-120/Val-136; Phe-296/Phe-312; Phe-292/Ile-308; Asp-457/Asn-473; Cys-303/Cys-319).
(B) Aldh2 and PKC inhibitors prevent 5-nitrofuran activity in zebrafish. Examples of zebrafish embryos treated at 2 dpf with 20 mM of the ALDH inhibitors daidzin
or DSF for 1 hr, or with 20 mM of the PKC inhibitors PKC412 or Ro318220, and then treated with 5 mM NFN1 or 0.1% DMSO alone for 2 days. Experiments were
repeated at least three times, with n > 10 embryos per condition.
(C) Examples of 2 dpf zebrafish embryos pretreated with DMSO, 30 mM of daidzin, or the PKC inhibitor GFX 109203X for 1 hr, and then treated with 50 mM
nifurtimox for 7 hr. Punctatemelanocytes are indicated. Experiments were repeated at least three times (n = 5–10 embryos per condition) and treatment-condition
cohorts blind scored.
(D) Daidzin alters background adaptation in zebrafish embryos. (Left) Images of fixed zebrafish embryos (5 dpf) treated with 0.1% DMSO or 10 mM daidzin, and
shifted from a dark environment to a light environment (light), or vice versa (dark). The average percentage of melanin coverage (within the area indicated by the
red dotted outline) for each treatment condition ± SD is indicated. (Right) Box plot of melanin coverage (y axis) for each embryo in different treatment conditions
(x axis). Individual values taken from one of three experiments are shown as red circles. The box depicts the lower quartile and the upper quartile, with the median
depicted by the intersecting line. Whiskers extend between the minimum and maximum of all the data. In DMSO-treated embryos, melanocytes are significantly
contracted in the light and expanded in the dark (p < 0.001, n = 20 for each condition; ANOVA, 95% confidence interval [CI] 11.081[5.966, 16.195]). Zebrafish
treatedwith daidzin contract their melanin in response to light environment but do not significantly expand their melanin in response to dark environments (95%CI
0.563[4.552, 5.677]). The experiment was repeated three separate times with embryos at 5 dpf (n = 5–20 embryos per condition) and once with embryos at 4 dpf
(n = 10 embryos per condition).
See also Figure S3.
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was also effective at preventing the activity of nifurtimox in
zebrafish melanocytes (Figure 3C). Although we do not know if886 Chemistry & Biology 19, 883–892, July 27 , 2012 ª2012 ElsevierPKC directly enhances Aldh2b activity or expression in zebra-
fish, these results suggest that PKC activity is important for
5-nitrofuran cytotoxicity within the melanocyte.Ltd All rights reserved
Figure 4. Cross-Species Conservation of 5-Nitrofuran-ALDH2 Interaction in Yeast
(A) Yeast cultures were treated with NFN1 (red) or NFN1.1 (blue). OD values were normalized against DMSO-treated controls. The mean of two experiments with
three replicates is shown; error bars represent the SE.
(B) Daidzin-NFN1 drug interaction was assessed by combination matrix assays in 96 well plates. Cultures were treated with NFN1 (red) or with daidzin in the
absence (blue) or presence (black) of 50 mM NFN1. The average normalized growth of three experiments is shown; error bars represent the SE.
(C) Normalized growth in the presence of NFN1 was determined for wild-type (blue) and the Dald6 strain (red). Data points are the mean of four replicates; error
bars represent the SE.
(D) NFN1 dose response curves for Dald2Dald3 (red) and the Dald2Dald3Dald6 (black) strains, as well as wild-type control (blue), were generated and normalized
against DMSO-treated controls. The average of three replicates is shown; error bars represent the SE.
(E) Control (n = 24) or aldh2b splice-site morphants (n = 62) at 3 dpf without NFN1 treatment (left) or with 0.8 mMNFN1 treatment (right). Embryos were scored as
class I (strong) or class II (mild) sensitivity to NFN1 (bar graph). aldh2bmorphant embryos were less sensitive to NFN1 treatment compared to control morphants
(p = 0.007; 95% CI [0.139, 0.528]; Fisher’s exact test).
See also Figure S4.
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in Zebrafish Melanocytes
We wanted to understand why zebrafish melanocytes were
sensitive to 5-nitrofuran treatment, when this is not a feature of
5-nitrofuran toxicity in patients. Unlike human melanocytes,
zebrafish melanocytes respond to environmental conditions by
concentrating or dispersing their melanosomes in light or dark
conditions, respectively (Logan et al., 2006). This effect is termed
background adaptation and is a dopaminergic response (Logan
et al., 2006). A role of Aldh2 in zebrafish background adaptation
has not been previously identified, but aldh2b is specifically
expressed in developing pigment cells (Thisse et al., 2001),
and ALDH2 is required for dopamine metabolism in mammals
(Chen et al., 2010). We tested the effects of ALDH2 inhibition
on background adapation in zebrafish and found that daidzin
treatment blocked dispersal of melanin in zebrafish melanocytes
in the dark (Figure 3D). These observations suggest that Aldh2
activity is required for regulation of zebrafish background adap-
tation, and they may explain the sensitivity of zebrafish melano-
cytes to 5-nitrofurans.
Multispecies Conservation of the 5-Nitrofuran-ALDH
Interaction
Chemical-genetic and chemical-chemical interactions identified
in yeast are often conserved in multicellular species including
zebrafish and mammals (Ishizaki et al., 2010). Budding yeast
have five ALDH genes (ALD2–6) that all share 42%–48% simi-
larity with human ALDH 1/2 (Figure S2). Yeast also have two
fungal-specific nitroreductase-like proteins, but these share little
similarity with the nitroreductases that are known to reduce nitro-
furans (de Oliveira et al., 2007). To establish that 5-nitrofuransChemistry & Biology 19,also showed activity in yeast, liquid cultures were treated with
increasing concentrations of NFN1 (Figure 4A). Yeast were highly
sensitive to NFN1, which inhibited growth even at submicromo-
lar concentrations. In contrast, treatment with the control furan
compound, NFN1.1, had no effect on yeast growth, even at
100 mM. These data indicate that the toxicity of 5-nitrofurans in
yeast is dependent on the 5-NO2 moiety. To test whether
NFN1 toxicity was dependent on ALDH activity, we tested
drug combinations in yeast cultures. Increasing concentrations
of daidzin rescued the effects of 50 mM NFN1 on the yeast
growth rate in a dose-dependent fashion, whereas daidzin alone
had no effect on growth (Figure 4B).
Mutations that render yeast resistant to a specific compound
can provide direct links to the target pathway (Ishizaki et al.,
2010). We determined whether yeast strains bearing deletions
in each of the ALD genes (orthologs of human and zebrafish
ALDH1/2) were resistant to 5-nitrofuran treatment. The ald2D,
ald3D, ald4D, and ald5D deletion strains each exhibited the
same sensitivity to NFN1 as wild-type (data not shown). In con-
trast, an ald6D strain was significantly less sensitive to NFN1
treatment, as was an ald2Dald3D double-deletion strain (Figures
4C and 4D). These effects of different aldmutations appeared to
be additive, as a triple ald2Dald3Dald6D deletion strain was
almost completely resistant to 50mMNFN1 treatment (Figure 4D).
Once activated, 5-nitrofurans cause DNA damage, and consis-
tent with this observation, we find that chemical-genetic profiles
in yeast indicate that disruption of DNA damage repair pathways
causes hypersensitivity to 5-nitrofurans (Figure S4).
To further validate the genetic dependence of 5-nitrofuran
bioactivity on Aldh2, we used morpholino oligonucleotides
(MOs) to knockdown aldh2b in zebrafish. Single-cell embryos883–892, July 27 , 2012 ª2012 Elsevier Ltd All rights reserved 887
Figure 5. 5-Nitrofurans Bind and Are Substrates for Human ALDH2 In Vitro
(A) Binding of purified human ALDH2 by 5-nitrofuran probe (Pr-NFN), a furan control probe (Pr-FN), or streptavidin beads alone (No Probe). Arrow indicates
ALDH2 protein, ALDH2 input lane (0.5 mg).
(B) Schematic overview of chemical reaction used to monitor recombinant human ALDH2 activity and experimental design. In experiment C (red arrow), ALDH2
was incubated with 1% DMSO, NFN1, and NFN1.1 or Nifurtimox for 10 min., and then ALDH2 activity was assessed. In experiment D (red + blue arrows), ALDH2
was incubated with 1% DMSO, NFN1, or Nifurtimox for 10 min., incubated with 0.5 mM TCEP or buffer alone for a further 15 min., and then ALDH2 activity was
assessed.
(C) Bar graph of spectrophotometric analysis of the rate of production of NADH (monitored at 341 nm) by ALDH2 (expressed as a percentage of DMSO control
treatment) with DMSO, NFN1, NFN1.1, and Nifurtimox.
(D) Bar graph of spectrophotometric analysis of the rate of production of NADHby ALDH2 after combined treatment of DMSO, NFN1, and Nifurtimoxwith TCEP or
buffer. Enzyme buffer = 50 mM sodium phosphate (pH 7.4). Error bars are SD; experiments were repeated in triplicate.
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were treated with NFN1. PCR analysis of the splice-site MO indi-
cated that aldh2b morphants had reduced levels of correctly
spliced aldh2b transcript in addition to a misspliced transcript,
indicating that the aldh2b morphants are hypomorphic for
aldh2b (Figure S4). We consistently found that the splice-site-
blocking aldh2b MO conferred partial resistance to a low treat-
ment dose (0.8 mM) of NFN1 melanocytotoxicity (Figure 4E). An
aldh2b-translation-block MO also conferred partial resistance
to a short NFN1 treatment (Figure S4). We conclude that there
is a genetic dependence on Aldh2b for 5-nitrofuran activation
in zebrafish, in line with genetic studies in yeast.
5-Nitrofurans Are Substrates for Human ALDH2
There are 19 ALDH enzymes in humans, each with specific
targets and additional activities (Marchitti et al., 2008). To deter-
mine whether the 5-nitrofuran-ALDH2 interaction is conserved in
humans we asked whether human ALDH2 could bind 5-nitrofu-
rans directly. Purified human ALDH2 was added to the 5-nitro-
furan probe (Pr-NFN), a furan control probe (Pr-FN), or streptavi-
din beads alone. In an analogous manner to the experiments
using zebrafish extracts, human ALDH2 binding was strongly
enriched in association with the 5-nitrofuran, while the control
furan and the streptavidin beads alone did not bind ALDH2
(Figure 5A).
Given our results with daidzin in yeast and zebrafish, we
proposed that NFN1 was probably a substrate of ALDH
enzymes. ALDH2 enzymes have reducing potential as well as888 Chemistry & Biology 19, 883–892, July 27 , 2012 ª2012 Elsevierdehydrogenase activity (Chen et al., 2002; Marchitti et al.,
2008), and it has been shown that in the absence of a reducing
agent, ALDH2 inactivates itself during the bioactivation of sub-
strates such as nitroglycerine (GTN) (Chen et al., 2010; Wenzel
et al., 2007). Consistent with this, we found that in the absence
of a reducing agent, NFN1, but not the no-nitro NFN1.1, inacti-
vated recombinant human ALDH2 in vitro (Figures 5B–5D). Like-
wise, we found that ALDH2 activity was reduced by 39.6%,
77.6%, and 96.5% following 10 min incubation with 5 mM nifurti-
mox, 16.7 mM nifurtimox, and 50 mM nifurtimox, respectively
(Figure 5C). Importantly, as with the zebrafish studies, these
experiments were performed with nifurtimox at concentrations
that are within the range of those recorded in the serum of
nifurtimox-treated patients (Paulos et al., 1989; Saulnier Sholler
et al., 2011). For both NFN1- and nifurtimox-inactivated ALDH2,
the subsequent addition of a reducing agent (TCEP) led to partial
reactivation of the enzyme, in line with literature studies using
the accepted substrate, GTN (Figure 5D). We observe that the
NFN1-ALDH2 interaction is stronger than the nifurtimox-ALDH2
in zebrafish and in our biochemical assay. This raises the
possibility that the mechanism of action of nifurtimox is more
complex than that of NFN1, or that NFN1 may in fact be a more
effective 5-nitrofuran substrate of ALDH2 than nifurtimox.
Daidzin Does Not Affect Nifurtimox Trypanocidal
Activity
In an attempt to develop a clinically testable hypothesis, we
examined the genome sequence of the trypanosomatids toLtd All rights reserved
Figure 6. ALDH2 in Trypanosomes
(A) Schematic of a 5-nitrofuran-daidzin combi-
nation-treatment strategy. ALDH2 can cause
5-nitrofuran bioactivtion in ALDH2-expressing
cells (e.g., zebrafish melanocytes), but not in
trypanosomes because they lack ALDH2 (see also
Figure S2). We propose that cotreatment with an
ALDH2 inhibitor such as daidzin could limit
5-nitrofuran toxicity without interfering with anti-
trypanosome activity.
(B) Viability of Trypanosoma brucei (bloodstream
form) at 37C after 72 hr treatment with increasing concentrations of nifurtimox in the absence or presence of daidzin (100 mM). Experiments were conducted
twice in replicates of four; a representative set of data from one experiment containing four replicates is shown. ED, effective dose.
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Leishmania (Figure S2) (Aslett et al., 2010; Cross, 2005; Lowe
et al., 2008; Marchitti et al., 2008; Sobreira et al., 2011). Given
the absence of an obvious ALDH2 in Trypanosoma we hypothe-
sized that while Aldh2 inhibition would protect the zebrafish
melanocytes and yeast cells from 5-nitrofuran activity, ALDH2
inhibitors might not protect trypanosomes from 5-nitrofuran
sensitivity (Figure 6A). We grew the bloodstream-form T. brucei
(strain 427) in HMI9 media and determined the trypanocidal
activity of nifurtimox in the absence and presence of daidzin.
Trypanosomes were stained with an Alamar Blue vital dye as
an indicator of Trypanosoma survival. We found that nifurtimox
was equally effective in the absence (ED50 = 2.12 ± 0.17 mM;
slope 1.00) and presence (ED50 = 2.18 ± 0.10 mM; slope 0.98)
of daidzin (Figure 6B). The trypanocidal effect of nifurtimox
against bloodstream T. brucei obtained in these assays was
comparable to previously observed effects (Priotto et al., 2009;
Sokolova et al., 2010). Daidzin treatment alone showed no trypa-
nocidal effect up to 100 mM (data not shown). We conclude that
daidzin does not interfere with 5-nitrofuran trypanocidal activity,
consistent with a lack of an ALDH2 in trypanosomes.
DISCUSSION
We have used a multispecies, chemical-biology approach to
identify 5-nitrofurans as substrates for ALDH2. We have identi-
fied a series of 5-nitrofuran compounds by phenotypic screening
in zebrafish and have shown that 5-nitrofuran-specific melano-
cytotoxicity in vivo is mediated at least in part by Aldh2 (Figures
1 and 3). Zebrafish gene products are usually conserved in
humans and are often sensitive to clinically active drugs at phys-
iological concentrations (Zon and Peterson, 2005). As shown
here, phenotypic chemical screens in zebrafish are effective
because (1) the rapid and cell-type-specific toxicity of 5-nitrofu-
rans can be visualized in real time (Movie S1), (2) the whole
animal is amenable to pharmacological studies (Figures 1A and
1B), and (3) initial structure activity relationships can be deter-
mined to enable the design of biologically relevant probes for
affinity purification (Figure 2; Table 1).
Despite the benefits of phenotypic screens in zebrafish, target
identification remains a challenge in chemical biology (Laggner
et al., 2012; Taylor et al., 2010; Zon and Peterson, 2005). Here,
we use parallel approaches to enable identification of an impor-
tant target of 5-nitrofurans. First, we used affinity chromatog-
raphy to identify Aldh2 as a 5-nitrofuran binding partner and
confirmed the dependence on the 5-NO2 functional group usingChemistry & Biology 19,an inactive furan probe (Figure 2). Second, we used computa-
tional modeling to predict that the ALDH2 inhibitor daidzin would
be active in zebrafish (Figure 3A), and used two chemically
distinct ALDH2 inhibitors (daidzin and DSF) to confirm the bio-
logical relevance of the 5-nitrofuran-Aldh2 interaction in vivo
(Figures 3B and 3C). Third, we showed cross-species conserva-
tion of the drug-drug interactions in the evolutionarily distant
budding yeast system (Figures 4A and 4B). Fourth, we used
genetic mutants in yeast and gene knockdowns in zebrafish to
validate a genetic dependence on ALDH activity for 5-nitrofuran
activity in vivo (Figures 4C–E). Fifth, we showed that the 5-nitro-
furan-ALDH2 interaction is maintained with human ALDH2 (Fig-
ure 5A). Finally, using a literature-precedent method, we showed
that 5-nitrofurans are direct substrates of human ALDH2 (Figures
5B–5D).
We find that zebrafishmelanocytes are sensitive to the 5-nitro-
furans because unlike human melanocytes, zebrafish melano-
cytes use ALDH2 to elicit a melanocyte background adaptation
response (camouflage; Figure 3D). While additional host
enzymes, possibly including other ALDHs, may bioactivate
5-nitrofurans in patients, we speculate that, in line with our
studies in zebrafish and yeast, daidzin may protect cells that
specifically express ALDH2, such as the liver and dopaminergic
neuronal cells (Figure 6A). Although 500million individuals world-
wide have an ALDH2-inactive variant (Druesne-Pecollo et al.,
2009), it is unknown whether these genetic variants contribute
to the variability of 5-nitrofuran-associated side effects; our
chemical-genetic data in yeast and zebrafish (Figure 4) suggest
that this hypothesis could be examined in the clinic. 5-Nitrofu-
rans have also recently become anticancer agents, and nifurti-
mox is currently in clinical trials for relapsed/refractory pediatric
neuroblastoma and medulloblastoma (Saulnier Sholler et al.,
2011). It is possible that 5-nitrofuran bioactivation by ALDH2
explains the sensitivity of these dopaminergic cancers to nifurti-
mox. We find that human melanoma cells are also sensitive to
nitrofurans, that DNA damage occurs, and that this activity is
dependent on the NO2 functional group present in NFN1 (Fig-
ure S4). Taken together with the hypersensitivity of yeast DNA-
damage mutants to NFN1, these results suggest that once acti-
vated, the cytotoxic effects of 5-nitrofurans arise through a
similar DNA-damage-dependent mechanism across species,
although it is unclear at this time whether NTR- and ALDH2-
mediated activation of 5-nitrofurans leads to exactly the same
toxic intermediates.
We argue that NFN1, but not the no-nitro NFN1.1, is a
substrate for recombinant human ALDH2 in vitro (Figure 5).883–892, July 27 , 2012 ª2012 Elsevier Ltd All rights reserved 889
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tion of nitroglycerin (Chen et al., 2010; Wenzel et al., 2007),
thereby raising the interesting question of how 5-nitrofurans
are bioactivated by ALDH2. ALDH2 enzymes have reducing
potential as well as dehydrogenase activity (Chen et al., 2002;
Marchitti et al., 2008), and we envision that ALDH2 may reduce
the nitro group of 5-nitrofurans, potentially generating nitroso-,
hydroxylamine, and/or amine intermediates with concomitant
oxidation of the enzyme. Interestingly, dithiothreitol (DTT) can
react with 5-nitrofurans, leading to oxidation of DTT to the corre-
sponding disulfide (L.Z. and N.W., unpublished data). As DTT
contains two thiols in close proximity, in an analogous manner
to the active site of ALDH2, we suggest that the reactions of
5-nitrofurans with ALDH2 and DTT may be linked by a common
mechanism.
5-Nitrofurans are important therapeutic agents, yet many
patients suffer from unacceptable drug-induced toxic side
effects. One approach to solving this problem is to identify new
antitrypanosome drug targets, such as the recently identified
N-myristoyltransferase inhibitors (Frearson et al., 2010) that
have been validated in mouse trypanosomiasis models. Based
on our studies in model systems and in vitro, we propose
a complementary approach that involves targeting and mini-
mizing the toxic side effects of current therapies, thereby allow-
ing more patients to benefit from approved treatment regimes
that are already available (Figure 6A). If the 5-nitrofuran-ALDH2
interaction is conserved in patients, then combination therapy
to treat 5-nitrofuran toxic side effects may be testable, because
(1) ALDH2 is a targetable enzyme; (2) the ALDH2 inhibitors daid-
zin and DSF are both currently available at low cost and show
activity in humans with limited toxicity; and (3) our analysis indi-
cates that T. brucei and T. cruzi do not have a close ALDH2
homolog (Figure S2), nor is T. brucei protected from nifurtimox
by daidzin (Figure 6B). Our findings provide impetus for address-
ing the role of ALDH2 in 5-nitrofuran activation in the preclinical
and clinical setting.
SIGNIFICANCE
Discovering how drugs work in vivo and identifying unin-
tended drug targets is a fundamental challenge in chemical
biology. Nifurtimox is one of only two drugs used to treat
Chagas disease, caused by Trypanosoma cruzi infection,
which is estimated to affect over 10 million people per year
and kills between 15,000 and 50,000 annually. Like other
5-nitrofurans, nifurtimox is a prodrug that is activated by
parasite-specific nitroreductases to a toxic form. Despite
the absence of nitroreductases in humans, 5-nitrofurans
cause significant clinical off-target toxic side effects that
interfere with patients’ ability to complete the treatment
course. There has been no significant improvement in
trypanosome disease treatment for 40 years, and there is
currently no treatment strategy in patients to reduce the
burden of these toxic side effects of existing drugs.
Here, we use model organism chemical genetics to
explore the basis for this toxicity. We use the zebrafish
model (1) to identify toxic effects of 5-nitrofuran compounds;
(2) as a platform for structure-activity relationships and
target identification; and (3) to show that the toxicity of890 Chemistry & Biology 19, 883–892, July 27 , 2012 ª2012 Elsevier5-nitrofurans in zebrafish can be prevented by cotreatment
with aldehyde dehydrogenase 2 (ALDH2) inhibitors. We
then show that the ALDH2-5-nitrofuran interaction is
conserved in yeast and with human ALDH2 and argue that
5-nitrofurans are a direct substrate of human ALDH2. We
extend these findings to show that the 5-nitrofuran nifurti-
mox also has Aldh2-dependent activity in zebrafish, and
that it is a direct substrate of human ALDH2. Thus, we
show in model systems that drug treatments combining
ALDH2 inhibitors with 5-nitrofurans block the 5-nitrofuran
unintended biological activity, and we propose that similar
treatments based on a readily available combination of inex-
pensive approved drugs may prevent some of the clinical
side effects caused by 5-nitrofurans.
EXPERIMENTAL PROCEDURES
Zebrafish Small-Molecule Screens and Treatments
All zebrafish work was done in accordance with United Kingdom Home Office
Animals (Scientific Procedures) Act (1986) and approved by the University of
Edinburgh Ethical Review Committee. The chemical library was a collection
of 1576 Maybridge compounds (Ishizaki et al., 2010). Two 4 hpf embryos
were arrayed in 96 well plates containing 10 mM of compound in 1% DMSO
in 300 ml of E3 embryo medium. Embryos were assessed and imaged for
phenotypic changes at 28, 36, 48, and 56 hpf. For the screening of The
Screen-Well Kinase Inhibitor Library (Enzo Life Sciences), five embryos
(24 hpf) were placed into each well of a 24 well plate (Corning) containing
20 mM NFN1 (BTB05727, Maybridge Screening compounds) and 5, 10, or
20 mM of a corresponding compound (total volume 1 ml per well). For cotreat-
ment experiments, five 36–48 hpf embryos were arrayed in 24 well plates in
600 ml to 1 ml of E3 embryo medium and pretreated with ALDH or PKC inhib-
itors (1–7 hr), and then treated with 0.5–5 mM NFN1 or 50 mM nifurtimox.
Affinity Purification and Coimmunoprecipitation
with 5-Nitrofuran Beads
Lysate was generated from approximately 900 3 dpf zebrafish in 300 ml of
RIPA buffer (2 M Tris pH 7.5, 5 M NaCl, 1% NP40, Na-deoxycholate, 10%
SDS, 0.5 M NaF, 1 M b-glycosyl phosphate and protease-inhibitor cocktail
tablet [Roche]), centrifuged at 4C (25 min), transferred to a new tube, and
kept on ice. Protein capture was performed using a pull-down biotinylated
protein:protein interaction kit (Pierce) using the biotinylated chemical probe
(5 ml 10 mg/ml DMSO solution), and bead complexes were washed with
0.1 M NaCl TBS buffer four times to reduce nonspecific binding. Beads
were boiled in 33 Laemmli buffer with DTT for 5 min and run on 10% SDS-
PAGE gel for electrophoresis. Captured proteins were visualized with a
Silverquest silver-staining kit and/or Colloidal blue-staining kit (Invitrogen).
Themass spectroscopy was analyzed in the University of Dundee FingerPrints
Proteomics Facility. For western blotting, protein was detected using rabbit
anti-zebrafish Aldh2 (1:1000) and goat anti-rabbit antibody (1.5:5000;
Calbiochem).
In Vitro Binding Assay
ALDH2 human recombinant protein (ProSpec) was added to 4 ml 10 mg/ml of
chemical probe with 100 ml TBS buffer and incubated at room temperature for
1 hr. Streptavidin bead suspension (50 ml) was added to the mixture (room
temperature; 1 hr), the supernatant was removed, and beads were washed
with 4 3 0.1 M NaCl TBS buffer, boiled in 33 Laemmli buffer with DTT for
5 min, and run on 10% SDS-PAGE gel for electrophoresis. The bands were
detected by silver staining (Invitrogen).
Molecular Modeling
Using methods analogous to those used previously (Medda et al., 2009), the
zebrafish Aldh2b homology model was generated using the Swiss model
server using bovine ALDH2 (PDB code 2AG8). The daidzin structure was
generated using the PRODRG server. The docking studies were performedLtd All rights reserved
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Pymol.
Yeast Growth Assays
Overnight S. cerevisiae BY4741 cultures in SC media were diluted
(OD600 0.025) and dispensed into 96 well Corning Costar assay plates. Quan-
titative growth curves were generated in Tecan Sunrise plate readers at 30C
564 rpm with automated absorbance reads every 15 min. Growth-curve data
were used to determine when control cultures reached late log phase, and OD
values of the entire plate at that time point were used to calculate normalized
growth values. Data were analyzed with custom R scripts to generate plots.
For the deletion-strain growth curves, normalization was performed against
control wells for each strain.
Trypanocidal Studies
The trypanocidal activity of nifurtimox in the absence and presence of daidzin
(100 mM) against Trypanosoma brucei bloodstream form (strain 427) were
cultured at 37C in HMI9 medium supplemented with 2.5 mg ml–1 G418, and
viability was determined using the Alamar Blue test, as described previously
(Mikus and Steverding, 2000). The data were fitted using GraFit software to
obtain ED50 ± SD and slope factors.
Supplemental Experimental Procedures
The synthesis of all theNFNs andNFN-based affinity probes is described in the
Supplemental Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, one table, Supplemental
Experimental Procedures, and one movie and can be found with this article
online at http://dx.doi.org/10.1016/j.chembiol.2012.05.017.
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The coordination of cell proliferation with differentiation is
important for both developmental and cancer biology. In some
well-studied systems, proliferation and differentiation are mutually
exclusive. For example, haematopoietic stem cells give rise to
committed progenitor cells that produce mature, highly specialized
and terminally differentiated blood cells. This is exploited in
differentiation therapy, a successful treatment strategy for acute
promyelocytic leukaemia, by promoting cancer cell maturation
with the concomitant loss of proliferative capacity (de The and
Chen, 2010). However, the coupling of differentiation to cell cycle
arrest can be cell type specific, and some dividing cells can
maintain differentiated characteristics, such as pancreatic -cells,
horizontal neurons in the retina and specific neural cell types in the
spinal cord (Ajioka et al., 2007; Barnabe-Heider et al., 2010;
Brennand et al., 2007; Davis and Dyer, 2010; Dor et al., 2004).
For melanocytes, differentiation involves cell shape changes, the
expression of pigmentation enzymes and the generation of
melanins to colour the skin, hair and eyes (Kelsh et al., 2009; Levy
et al., 2006). In mouse development, unpigmented melanoblasts
first undergo extensive proliferation in the dermis prior to
migration into the epidemis, followed by rapid expansion in the
epidermis before localizing to the hair follicle (Jordan and Jackson,
2000; Mackenzie et al., 1997; Nishikawa et al., 1991). At the hair
follicle, unpigmented melanocyte stem cells (MSCs) in the bulge
region undergo transient amplification to generate pigmenting
melanocytes with each hair cycle and so colour the hair shaft
(Nishimura et al., 2005; Nishimura et al., 2002). Differentiation
seems to preclude proliferation in these MSCs because DNA
damage appears to trigger differentiation and MSC pigmentation
resulting in loss of melanocyte renewal (Inomata et al., 2009). Skin
melanocyte numbers also expand following ultraviolet radiation
exposure, and in the mouse these cells appear to arise from
proliferative undifferentiated melanoblasts (Kawaguchi et al., 2001;
van Schanke et al., 2005; Walker et al., 2009). In zebrafish, most
embryonic melanocytes are directly derived from the neural crest,
and adult melanocytes are added to the embryonic melanocyte
pattern by an expansive wave of development from
undifferentiated melanocyte progenitors or MSCs (Hultman et al.,
2009; Parichy, 2003; Yang and Johnson, 2006). Thus, in
developing animals, melanocyte population numbers are achieved
primarily by proliferation of unpigmented melanocyte precursor
cells and pigmentation is associated with differentiation without
evidence of cell division.
In contrast to the observations in development, pigmented
primary melanocytes and melanoma cells retain the potential for
division in culture (Bennett, 1983; Bennett, 1989; Bennett et al.,
1985). Time-lapse imaging of melanoma cell culture have captured
cell division of pigmented melanoma cells in mitosis, and normal
diploid pigmented human melanocytes can divide as quickly as
unpigmented cells. Numerous pigmented mouse and human
melanocyte and melanoma cell lines have been described in
culture, supporting the notion that melanocyte differentiation
features do not necessarily preclude the potential for cell division.
Development 138, 3579-3589 (2011) doi:10.1242/dev.064014
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SUMMARY
Coordination of cell proliferation and differentiation is crucial for tissue formation, repair and regeneration. Some tissues, such as
skin and blood, depend on differentiation of a pluripotent stem cell population, whereas others depend on the division of
differentiated cells. In development and in the hair follicle, pigmented melanocytes are derived from undifferentiated precursor
cells or stem cells. However, differentiated melanocytes may also have proliferative capacity in animals, and the potential for
differentiated melanocyte cell division in development and regeneration remains largely unexplored. Here, we use time-lapse
imaging of the developing zebrafish to show that while most melanocytes arise from undifferentiated precursor cells, an
unexpected subpopulation of differentiated melanocytes arises by cell division. Depletion of the overall melanocyte population
triggers a regeneration phase in which differentiated melanocyte division is significantly enhanced, particularly in young
differentiated melanocytes. Additionally, we find reduced levels of Mitf activity using an mitfa temperature-sensitive line results
in a dramatic increase in differentiated melanocyte cell division. This supports models that in addition to promoting
differentiation, Mitf also promotes withdrawal from the cell cycle. We suggest differentiated cell division is relevant to melanoma
progression because the human melanoma mutation MITF4T2B promotes increased and serial differentiated melanocyte division
in zebrafish. These results reveal a novel pathway of differentiated melanocyte division in vivo, and that Mitf activity is essential
for maintaining cell cycle arrest in differentiated melanocytes.
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In humans, a small percentage of melanocytes appear to divide in
skin homeostasis (Jimbow et al., 1975) and differentiated
melanocytes may contribute to re-pigmentation in wound-healing
and vitiligo, although the primary melanocyte reservoir is thought
to be from undifferentiated melanocytes (Cui et al., 1991;
Falabella, 2009; Falabella and Barona, 2009; Hirobe, 1988;
Tanimura et al., 2011). Many aggressive melanomas, including
BRAFV600E melanomas, maintain differentiation characteristics in
situ (Broekaert et al., 2010; Ohsie et al., 2008).
The apparent differences in the described potential for
pigmented melanocytes to divide prompted us to revisit the fate of
differentiated melanocytes in situ. The zebrafish system permits
visualization of differentiating melanocytes in the natural context
of the developing whole animal because the embryos are fertilized
outside the mother, sustained by a yolk sac and are transparent.
Developing zebrafish embryos can be imaged in real-time,
allowing for the visualization of melanin and transgenic fluorescent
reporters in melanocytes. Continuous imaging of differentiated
melanocytes in living animals has not been previously reported. We
used live-cell imaging of developing zebrafish embryos to address
three questions: (1) does differentiated cell division play a role in
zebrafish pigmentation?; (2) what controls cell cycle arrest in
differentiated cells?; and (3) is differentiated cell division relevant
for melanocyte regeneration or melanoma?
MATERIALS AND METHODS
Time-lapse Imaging of zebrafish
Zebrafish were cared for by standard procedures, as described (Westerfield,
2000). De-chorionated embryos were immobilized in a solution of 1.2%
agarose, onto a six-well black polystyrene borosilicate glass-bottomed plate
(IWAKI). Agarose around the head and tail of the embryo was removed to
allow for growth of the embryo, and E3 embryo medium was added to
each well. Time-lapse imaging took place on the Live Cell Imaging
System, comprising a Zeiss Axiovert 200 fluorescence microscope
equipped with 20/1.5 EC plan neofluar, 10/0.45 and 5/0.16 plan
apochromat objectives (Carl Zeiss, Welwyn, UK), a Lambda LS 300 W
Xenon source with liquid light guide and 10-position excitation, and neutral
density and emission filterwheels (Sutter Instrument, Novato, CA)
containing #86000 Sedat Quad filter set (Chroma Technology,
Rockingham, VT). For zebrafish work, the system was equipped with a
Solent Scientific incubation chamber with CO2 enrichment (Solent
Scientific, Segensworth, UK). Temperature was monitored by using an EL-
USB-1 temperature sensor (Lascar Electronics, Hong Kong). Image
capture was performed using MetaMorph software (Molecular Devices,
Sunnyvale, CA). Time-lapse was set to capture an image every 20 minutes.
Images were captured in bright field at 20 ms exposure and, when required,
under FITC fluorescence at 500 ms exposure for Tyrp1-GFP respectively.
Z-stacks of images were taken over a 120 m z range with a slice interval
of 20 m or 30 m as appropriate, to enable selection of the best plane of
focus. For accurate lineage analysis in the tyrp1-GFP embryos, the seven
z-stacks with seven 20 m slices were compressed into a z-projection. Cell
division events were defined as cells that clearly separated into two cells
and migrated away from each other, remaining separated for the time-lapse
analysis.
Drug treatment
The nitrofuran BTB05727 (Maybridge; referred to as NFN1 by H.I.,
K.L.T., Z.Z., S. Johnson, M. Tyers and E.C.P., unpublished) was dissolved
in dimethyl sulphoxide (DMSO; Sigma) to make a stock solution of 10
mM and stored at –20°C. Embryos were incubated at 28.5°C in six-well
plates with 20 m BTB05727 dissolved in E3 embryo media (Westerfield,
2000). Upon washout into embryo media, embryos were allowed a 1-hour
recovery before being immobilized in agarose for time-lapse microscopy.
Transgenic expression of MITF
The human MITF (wild type and mutant 4T2B) cDNA (Cronin et al.,
2009) and zebrafish mitfa cDNA were placed under the minimal 836 bp
zebrafish mitfa promoter in the Gateway compatible Tol2 vector pT2Kmin-
NP or the Gateway Tol2 vector pDestTol2CG2, respectively (J.A.L.,
unpublished) (Kwan et al., 2007). DNA constructs were injected into
mitfavc7 (temperature sensitive) (Johnson et al., 2011) or mitfaw2 (nacre)
(Lister et al., 1999) mutant embryos at approximately the one- to two-cell
stage with Tol2 transposase RNA (Kwan et al., 2007). Each embryo was
injected with ~2 nl of mixed plasmid and RNA. The final concentrations
of plasmid and RNA were 25 and 35 ng/l, respectively. After injection,
the nacre mutant embryos were incubated at 28.5°C, while the mitfa ts
mutants were kept at 30-32°C to inhibit activity of endogenous mitfa.
Melanocyte counting
Embryos were dechorionated at 3 dpf, anesthetized in 160 g/ml of tricaine
and imaged under the stereomicroscope. After imaging, the embryos were
fixed and stored in 4% paraformaldehyde (PFA, sigma) for melanocyte
counting.
RESULTS
Time-lapse imaging of direct-developing
melanocytes
We sought to establish whether cell division of pigmented cells
contributes to the pigmentation pattern of the developing fish.
Zebrafish melanocytes pigment the fish in two waves of
development. First, during embryogenesis, most melanocytes are
derived directly from the neural crest cells (NCCs; direct-
developing melanocytes). During this period, quiescent adult
melanocyte stem cells (MSCs) are also established and these cells
primarily populate the adult stripe pattern in a second wave at
metamorphosis (beginning at 15 dpf; stem-cell derived
melanocytes) (Hultman et al., 2009; Parichy, 2003).
Zebrafish melanocytes first become visible at about 28 hpf with
the formation of melanin. To visualize the differentiation of direct-
developing melanocytes by time-lapse imaging, we embedded
embryos in an imaging chamber at 28.5°C, and followed the
development of melanocytes using pigment as a marker. We
imaged the head of developing embryos because we could
consistently image the same region in each fish, and because early
and late developing melanocytes in the head appear to originate
from direct-developing melanocytes (Fig. 1A) (Hultman and
Johnson, 2010). Images were taken every 20 minutes, and
individual melanocytes were followed from their first appearance
to ~92 hpf in nine embryos, and from 72 hpf to ~116-144 hpf in
another 10 embryos. We could clearly detect individual
melanocytes emerging de novo in the dorsal head as very lightly
pigmented cells that then rapidly darkened (Fig. 1A; see Movie 1
in the supplementary material). Cells were initially highly motile
and then became mostly stationary by 72 hpf. Melanocytes were
continually added to the pattern on the head from ~25 hpf until 96
hpf, although the majority of melanocytes appeared established by
72 hpf, consistent with previous reports (Yang and Johnson, 2006).
Crucially, we also noticed a previously undescribed population of
melanocytes arising through division of pigmented cells (Fig.
1A,B). Cell division events were rare (n8/174; 4.6%), but seen in
five of the nine embryos that were followed to ~90 hpf on the head
region. In zebrafish, the distribution of melanin within a
melanocyte can be altered (Logan et al., 2006), and thus the ability
to analyze each frame in detail to follow each cell through time and
position (z-stacks) was an important feature of our approach as it
minimized the possibility of mis-scoring the division events.
Melanocyte division also occurred outside the head region, as rare
melanized cells in the yolk and embryonic body stripes were
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Fig. 1. Melanocytes develop from undifferentiated precursor cells and from pigmented melanocytes. (A)Still images of time-lapse
microscopy at the onset of melanocyte differentiation. Melanocytes emerge in the dorsal head as highly dendritic and pigmenting cells. Most
melanocytes arise de novo from the neural crest and do not divide (melanocytes b,c). A few pigmented melanocytes divide (melanocyte a),
becoming rounded before division (to become two cells: a.i, a.ii), which then move away from each other. Scale bar: 100m. (B)High-
magnification image of pigmented melanocyte a division during a 1.3 hour interval, with cells outlined (broken yellow lines depict the approximate
outline of the cells as analyzed through all z-stacks using enhanced contrast techniques). (C)Quantitative analysis of melanocyte development in
individual fish (labelled i-ix) over 1-4 dpf show the majority of melanocytes are derived de novo from unpigmented precursor cells (n166; grey
diamonds) and a subpopulation of melanocytes derived from cell division events (n8; yellow diamonds). Division events were charted for ten other
fish examples (fish x-xix) from 3 to 5/6 dpf. Only three new melanocytes were identified during this time, two of which were from division events.











positive for the late-G2- and M-phase cell cycle marker phospho-
histone H3 (see Fig. S2 in the supplementary material). These
results identify a subpopulation of melanocytes that is added to the
zebrafish pattern via division of differentiated melanocytes.
Dividing embryonic melanocytes give rise to
pigmented dendritic cells
As part of the differentiation programme, melanocytes express
pigmentation enzymes, including tyrosinase related protein (Tyrp)
1 (Braasch et al., 2009; Smyth et al., 2006; Steel et al., 1992). We
analyzed developing melanocytes in the zebrafish j900 line that
expresses GFP from the fugu tyrp1 promoter in the neural crest-
derived melanocytes (Hultman and Johnson, 2010). Expression of
GFP could be seen prior to the first faint appearance of melanin
(Fig. 2A; see Fig. S3 in the supplementary material). GFP
expression was present throughout the cell, but in fully pigmented
cells melanin obscured much of the GFP (Fig. 2A) (Zou et al.,
2006). As in the wild-type zebrafish, rare cell division events were
observed, with the GFP expression clearly showing the single cell
becoming two cells in a rapid cell division of less than 20 minutes
(Fig. 2A). The characteristically dendritic cells rounded up just
prior to division, then resumed a dendritic shape immediately
afterwards. Both mother and daughter melanocytes were always
both pigmented, and we did not detect pigmented cells giving rise
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Fig. 2. Visualization of the differentiation marker tyrp1-GFP during cell division. (A)Expression of tyrp1-GFP in the developing melanocyte
allows for visualization of the melanocyte cytoplasm and precedes pigment formation (83.3 hpf, thin white box and inset). Continued monitoring
of this cell reveals pigmentation (85.3 hpf), followed by rounding (88.7 hpf) and division (89.0 hpf). Two cells with distinct cytoplasm are visible
(89.0 hpf) that migrate apart and become dendritic (93.0 hpf). (B)A single albino tyrp1-GFP cell (73.3 hpf) clearly revealed the presence of two











to GFP+ unpigmented cells. We did not see evidence of de-
differentiation in dividing cell; however, this could be due to the
stability of melanin or GFP preventing our ability to visualize
dedifferentiation. No obvious differences were detected between
the differentiation features, motility or distance to neighbouring
melanocytes (data not shown) of the cells that divided and those
that did not.
Because melanin obscured many of the intracellular features of
the melanocyte during division, we also followed development of
melanocytes in the j900 line crossed into an albino fish, which
develop melanocytes but do not generate melanin (Hultman and
Johnson, 2010). As with the pigmented fish, we did not detect
division events in cells expressing tyrp1-GFP prior to 72 hpf in the
head region. GFP expression was present throughout the cell and
strongest in the nucleus (Fig. 2B). During cell division, two clear
nuclear signals could be detected followed by rapid separation of
the cells (Fig. 2B, 73.7 hpf and 74.0 hpf). Taken together with the
observations described above, we conclude that a subpopulation of
differentiated melanocytes have cell division potential in normal
development.
Enhanced differentiated cell division during
melanocyte regeneration
Having shown that differentiated melanocytes have the potential
to divide, we next wanted to establish whether regenerating
melanocytes derived from the MSCs also repopulate the
embryonic pigment pattern by cell division. Recruitment of the
MSC into differentiated melanocytes can be induced in
embryogeneis during melanocyte repopulation after chemical or
genetic ablation (Hultman et al., 2009; Parichy, 2003; Yang and
Johnson, 2006). Yang and Johnson (Yang and Johnson, 2006)
have previously shown that treatment of zebrafish embryos with
MoTP, a phenol derivative, will specifically kill differentiated
melanocytes and committed melanoblasts expressing tyrosinase
(Yang and Johnson, 2006). After MoTP treatment, zebrafish
regenerate melanocytes primarily from undifferentiated
precursor cells. Following on from this, we have recently
identified a series of nitrofuran compounds that also kill
undifferentiated and differentiated melanocytes, depending on
treatment dose (H.I., K.L.T., Z.Z., S. Johnson, M. Tyers and
E.E.P., unpublished). We challenged the zebrafish embryo with
a short nitrofuran treatment to kill melanocytes (~30-50 hpf) and
followed the repopulation of the melanocytes using time-lapse
imaging (Fig. 3A,B; see Fig. S4A,B and Movie 3 in the
supplementary material). Melanocyte cell division events were
observed in seven of the nine fish imaged (Fig. 3C). Notably,
these differentiated cell division events were more common in
repopulating melanocytes (n21/132; 15.9%; Fig. 3C,D)
compared with embryonic development of the melanocytes
[P0.001; 95% CI (0.043, 0.18); binomial test of comparison of
proportions].
We next examined the role of division of differentiated cells
in another melanocyte regeneration model. Microphthalmia-
associated transcription factor (Mitf) is highly conserved and
essential for melanocyte development in humans, mice and
zebrafish; animals with mutations in mitf lack melanocytes or
show hypopigmentation. Zebrafish have two Mitf genes (mitfa
and mitfb) (Johnson et al., 2011; Lister et al., 2001), and all
neural crest derived melanocytes require the activity of mitfa
(Lister et al., 1999). A mitfa temperature-sensitive mutant line
(mitfavc7, generating an intron 6 splice site mutation) has recently
been described and re-establishment of Mitfa activity by shifting
to the permissive temperature at 48 hpf allows for melanocyte
regeneration from the presumed MSCs (Johnson et al., 2011).
We grew mitfavc7 embryos at 32°C from ~4-48 hpf so that
melanocytes did not develop in the embryo (Fig. 3E,F), although
the unpigmented MSCs are established (Johnson et al., 2011).
Embryos were then shifted to 23-24°C and imaged (Fig. 3E,F;
see Fig. S4C in the supplementary material). As with the
nitrofuran-treated embryos, there was an increased proportion of
cell divisions in the regenerating melanocytes compared with
direct-developing melanocytes in normal development
[n29/243; 11.9%; Fig. 3G,H; P0.009; 95% CI (0.022, 0.12);
binomial test]. Thus, both chemical and genetic approaches to
stimulate melanocyte repopulation from unpigmented
progenitors or MSCs result in an increase in the proportion of
pigmented cell divisions from differentiated melanocytes,
suggesting cell division may be a regulated process and used
where necessary to achieve completion of the melanocyte
pattern.
Regenerating melanocytes are younger when
they divide
Next, we asked whether the increased number of pigmented cell
divisions was associated with a change in the time period from
cell differentiation to division. Using time-lapse movies, we
measured the time interval from onset of earliest visible
pigmentation (or differentiation; TEVD) (Bennett, 1983) to cell
separation. During normal development, there was a long latency
between the TEVD and cell division, and dividing cells were
pigmented for an average of 43 hours before division (Fig. 4).
Analysis of the regenerating melanocytes in the nitrofuran-
treated embryos and in the mitfavc7 mutant embryos revealed that
the average time of initial pigmentation to cell division was
significantly reduced, especially in the mitfavc7 regenerating
melanocytes. In contrast to the direct-developing melanocytes,
younger stem-cell derived melanocytes that had only been
pigmented for an average of 12 hours were capable of division
in the mitfavc7 mutant embryo (Fig. 4). In addition, regenerating
melanocytes in the nitrofuran-treated embryos were pigmented
for an average of 15 hours prior to division, also a significant
reduction in the time from pigmentation to division compared
with normal development. We suggest that, after melanocyte
loss, the rapid division of differentiated melanocytes, in
combination with the described expansion and differentiation of
unpigmented precursors cells (Yang and Johnson, 2006),
contributes to melanocyte repopulation in zebrafish.
Mitfa hypomorphic melanocytes undergo serial
differentiated cell divisions
In melanocytes, Mitf controls both differentiation and cell cycle
progression. MITF stimulates expression of differentiation genes
(such as TYR encoding tyrosinase) and cell cycle regulators that
both stimulate the cell cycle (e.g. CDK2) and inhibit cell cycle
progression (e.g. p21) (Levy and Fisher, 2011). In melanoma,
MITF has been proposed to act as a ‘rheostat’: low levels of Mitf
promote stem-like invasiveness, moderate levels stimulate
proliferation, and high levels cause differentiation with cell cycle
arrest (Hoek and Goding, 2010; Khaled et al., 2010). Much of
this work has been done in cell lines and in cancer cells. The
effects of reduced Mitf in differentiated cells has been difficult
to study in animals because Mitf first affects melanocyte
specification and survival (Hornyak et al., 2001; Lister et al.,
1999; Opdecamp et al., 1997).












We hypothesized that reduced Mitf activity would cause division
in differentiated melanocytes. We followed the development of the
temperature-sensitive mitfavc7 embryos by time-lapse imaging from
30 hpf-151 hpf at a low (<24°C), intermediate (25-26.5°C) and
high temperature (28.5°C). No melanocytes developed at the high
temperature, consistent with the temperature-sensitive nature of the
allele (Johnson et al., 2011). At low temperatures (<24°C), mitfavc7
mutants develop melanocytes but have somewhat compromised
activity (Johnson et al., 2011). We found melanocytes developed
and many of the differentiated melanocytes divided at low
permissive temperatures (Fig. 5). In a few cases, the daughter
melanocyte was also capable of additional divisions (Fig. 5; serial
cell division). By contrast, at intermediate temperatures, most
differentiated cells divided, and, surprisingly, many differentiated
cells underwent serial cell division. Serial cell divisions
significantly contributed to the pattern of the zebrafish. In one
example, 12 differentiated melanocytes were derived from a single
differentiated melanocyte (Fig. 5A). In the same embryo, of the
final 39 melanocytes in the head region at 114 hpf, seven
melanocytes were directly derived from undifferentiated precursor
cells and 32 were from differentiated cells (Fig. 5A). The
differences in differentiated melanocyte divisions were due to
alterations in the temperature-sensitive nature of the allele (and not
temperature itself) because wild-type fish grown at similar
temperatures showed neither the high numbers of differentiated cell
divisions, nor successive differentiated cell divisions (data not
shown). Similarly, we attribute the increased differentiated
melanocyte divisions to altered Mitf activity (and not to an
unknown additional mutation) because we see a statistically
significant difference between the low and intermediate
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Fig. 3. Melanocyte division events are enhanced during melanocyte regeneration. (A)Workflow of nitrofuran treatment from ~30 hpf to
50 hpf to promote loss of differentiated melanocytes. After washout (grey bar), the embryos were immobilized in agarose and imaged by time-
lapse microscopy (black bar). (B)Images of control and nitrofuran-treated embryos at the time of embedding in agarose and at the end of the time-
lapse imaging. (C,D)Quantitative analysis of melanocytes derived de novo from unpigmented cells (grey diamonds; n111) and from division of
pigmented cells (yellow diamonds; n21) in nine different zebrafish (i-ix). (E)Workflow of mitfavc7 temperature-sensitive experimental conditions.
Zebrafish embryos with the mitfavc7 mutation grown at 32°C from 4 hpf until ~48 hpf (yellow bar) do not develop ontogenic melanocytes. Upon
shifting to the permissive conditions (grey bar), the embryos are immobilized in agarose and imaged by time-lapse microscopy (black bar). (F)Images
of wild type and mitfavc7 embryos at the time of embedding in agarose and at the end of the time-lapse imaging. No neural crest-derived
melanocytes are visible at 48 hpf (although non-neural crest pigmented cells in the eye remain pigmented) and melanocytes have repopulated the
animal by 150 hpf. (G,H)Quantitative analysis of melanocytes derived de novo from unpigmented cells (grey diamonds; n214) and from division of











temperatures (Fig. 5B,C). Thus, sustained reduction of Mitf activity
in the developing embryo can permit appropriate melanocyte
specification, differentiation and survival, but is not sufficient to
inhibit cell cycle division in differentiated cells.
One possibility for the differentiated cell divisions in the mitfavc7
mutants is that the cue for cell division arose from a change in the
embryonic environment, rather than from within the melanocyte
itself. The mitfavc7 mutant embryos have fewer melanocytes when
grown at the intermediate temperature compared with the lower
temperature (Johnson et al., 2011). Therefore, differentiated cell
division in the mitfavc7 mutants could be an indirect response to a
reduction in the melanocyte population rather than a direct
response of reduced Mitf activity. To test this idea, we rescued
melanocytes in melanocyte-deficient embryos and assessed their
cell division potential. Single-cell embryos (mitfavc7 at 30-32°C)
were injected with DNA encoding zebrafish mitfa expressed from
the mitfa promoter, and the embryos were grown for 3 dpf (Fig.
6A). In 31 injected zebrafish, one developed a single melanocyte
and seven developed between two and 17 melanocytes (Fig. 6B).
Uninjected control embryos (n50) or embryos injected with a
construct with GFP expressed from the mitfa promoter did not
develop melanocytes (n43). We imaged seven individual
transgenic fish with one to a few melanocytes on the head by time-
lapse microscopy (30-126 hpf; total 11 melanocytes). All
melanocytes were derived from undifferentiated precursor cells,
with no evidence of cell division. Taken together, we suggest that
the increased melanocyte division in mitfvc7 (>24°C) is due to
changes in Mitf activity, rather than to a reduced total number of
melanocytes in the embryo.
Human melanoma MITF4T2B stimulates
differentiated cell division
MITF somatic mutations are found in human melanoma (Cronin et
al., 2009). Because Mitf mutations in zebrafish could promote
differentiated cell division, we asked whether human melanoma
MITF mutations have the potential to promote differentiated cell
division. First, we established whether human MITF could replace
zebrafish mitfa function. As above, nacre (mitfa loss of function)
or mitfavc7 (temperature sensitive grown at the restrictive
temperature 30-32°C) were injected at the single-cell stage with a
transgene expressing human MITF from the zebrafish mitfa
promoter. Differentiated melanocytes were detected in nacre
(n22/55; see Fig. S6 in the supplementary material) and mitfa ts
injected embryos (n8/89; Fig. 6), whereas no melanocytes were
seen in the uninjected controls. Thus, human MITF is functional in
zebrafish, and can replace loss of mitfa function in neural crest
melanocytes. We imaged eight individual transgenic fish with one
to a few melanocytes on the head by time-lapse microscopy (30-
126 hpf; total 27 melanocytes), and we did not observe the division
of differentiated cells.
Second, we addressed the potential for a human melanoma
mutation to rescue the melanocytes in the nacre and mitfavc7 mutant
zebrafish. The human melanoma MITF4T2B mutation is a splice
variant that results in the loss of exon 2B (Cronin et al., 2009).
Notably, compared with wild-type human MITF mutations, 4T2B
has increased transcriptional activity of the differentiation gene
tyrosinase but reduced transcriptional activity of the cell cycle
inhibitor p21 (Cronin et al., 2009). We expressed MITF4T2B in
zebrafish melanocytes from the mitfa promoter, and found that
MITF4T2B rescued zebrafish melanocyte development with a
striking enhancement in total numbers of melanocytes (n36/41 in
nacre; n35/61 in mitfavc7; Fig. 6; see Fig. S6 in the supplementary
material).
Finally, we imaged ten embryos expressing melanocytes
MITF4T2B by time lapse microscopy (30-126 hpf) in mitfavc7
mutant zebrafish at 30°C. MITF4T2B embryos had between one
and 22 melanocytes in the head region, and a total of 75
melanocytes were imaged. No melanocytes were seen in mitfavc7
uninjected controls. In five embryos, melanocytes developed from
undifferentiated precursor cells and did not divide. By contrast, in
the other five embryos, two showed differentiated cell division and
three showed serial differentiated cell division. Remarkably, in one
example, a differentiated melanocyte gave rise to 18 differentiated
cells. These data indicate that the melanoma mutation MITF4T2B
has the potential to both promote melanocyte cell division and
differentiation.
DISCUSSION
Much of the extensive expansion required to populate the skin and
hair in development is from undifferentiated melanocyte precursor
cells. We were prompted by previous observations, that
differentiated melanocytes in culture and in melanoma maintain
proliferative capability, to examine closely the potential of
differentiated zebrafish melanocytes to divide in situ. We find a
subpopulation of differentiated melanocytes has cell division
potential during melanocyte development and regeneration in
zebrafish, and that Mitf activity is required to maintain cell cycle
arrest in differentiated cells. The finding that a human melanoma
MITF mutation permits cell division in differentiated cells
underscores the importance of MITF anti-proliferative activity in
vivo.
High or low levels of MITF activity in cell culture leads to G1
arrest with differentiation or invasion, respectively (Carreira et al.,
2005; Carreira et al., 2006; Goodall et al., 2008). MITF also
promotes the cell cycle in melanoma (Carreira et al., 2005; Du et
al., 2004; Garraway et al., 2005; Widlund et al., 2002), and graded
changes in MITF activity are thought to switch melanoma cells
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Fig. 4. Time of earliest visible differentiation (pigmentation) to
cell division is reduced in regeneration. Time of earliest visible
differentiation (TEVD) until cell division was calculated for dividing
melanocytes in development and regeneration conditions. During
development, the average time of pigmentation to division is 43 hours
(n10 cell divisions; the origin and age of the dividing melanocyte in
fish xii is unknown and has been excluded from the analysis). In
regeneration, either after mitfavc7 or nitrofuran treatment, cell division
occurred in younger melanocytes (12 hours or 15 hours post
pigmentation, respectively). Data are mean±s.e.m. Significance is
observed within the dataset (P<0.001); analysis of variance (ANOVA).
Post-hoc analysis shows significance between TEVD of wild-type and
nitrofuran treatment [mean and 95% confidence interval of
differences; 26.81 (16.11; 37.52)] and between wild type and mitfavc7












phenotypically from a proliferative to an invasive stem-cell like
state or vice versa (the MITF rheostat model) (Hoek and Goding,
2010). Consistent with this idea, transient silencing of MITF
generates invasive cells with stem-like properties that have
increased efficiency of tumour initiation (Cheli et al., 2011;
Carreira et al., 2006; Goodall et al., 2008; Pinner et al., 2009).
It is less clear how the rheostat model applies to melanocytes.
TGF signalling maintains melanocyte stem cells in the hair
follicle in mice, which is associated with low Mitf levels
(Nishimura et al., 2010), and in zebrafish and frogs, loss of Mitf
causes altered differentiation characteristics in shape and melanin
distribution (Johnson et al., 2011; Kawasaki et al., 2008). The
impact of altered MITF on the cell cycle in differentiated cells in
animals has been difficult to study because the first role of MITF
is in melanocyte specification and survival (Hornyak et al., 2001;
Lister et al., 1999; Opdecamp et al., 1997). The development of
mitfa temperature-sensitive lines in zebrafish (Johnson et al., 2011)
is essential in order to address this issue because we can now assess
the effects of graded Mitf activity during melanocyte development
in vivo, and zebrafish are amenable to sustained live time-lapse
imaging.
Our observations in live animals show that, during normal
development, Mitf maintains cell cycle arrest in differentiated
melanocytes (Figs 5, 6), and that differentiation is not
necessarily terminal (Figs 1-3). Although our observations are
consistent with the Mitf rheostat model that altered levels of Mitf
promote different phenotypic outcomes in melanoma, they differ
by suggesting that in some contexts melanocytes can be both
differentiated and proliferative. In particular, differentiation and
proliferation are frequency uncoupled in regenerating wild-type
melanocytes (Fig. 3). How melanocytes in regeneration regulate
differentiated cell division is unknown, but given our results that
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Fig. 5. Hypomorphic Mitf activity enhances differentiated cell division. (A)Schematic representation of melanocyte development in embryos
imaged by time-lapse microscopy. Two embryos are represented for each treatment condition. Wild-type or mitfavc7 mutant embryos were grown at
28.5°C for ~20 hours, embedded in agarose, shifted to temperatures below 24°C (23-24°C) or over 24°C (25°C, 25.5°C or 26.0°C), and imaged by
time-lapse microscopy until ~108-151 hpf. All melanocytes begin as undifferentiated (grey) melanoblasts that become differentiated (black).
Lineage is represented by broken lines: vertical broken lines indicate relative time between division events. The approximate order of melanocyte
development is represented along the horizontal axis. Final total number of melanocytes in imaged region is indicated. (B)Stacked bar graph
indicating the proportion of melanocytes that arise from differentiated or undifferentiated cells in wild type (n9; 16/174 melanocytes) and mitf vc7
mutants grown at below 24°C (n7; 82/210 total melanocytes) or over 24°C (n13; 168/256 total melanocytes). The proportion of melanocytes
arising from a differentiated cell is significantly greater in mitfvc7 mutants at below 24°C and over 24°C compared with wild-type fish; P<0.001;
95% CI (0.22, 0.38) and P<0.001; 95% CI (0.49, 0.64) respectively; binomial test of comparison of proportions. Additionally, the proportion of
melanocytes arising from a differentiated cell between mitfvc7 mutants at below 24°C and over 24°C is significant; P<0.001; 95% CI (0.18, 0.36);
binomial test of comparison of proportions. Datasets include only mitfavc7 time-lapse analysis that is longer than 108 hpf. (C)Bar graph indicating
the proportion of mitfavc7 melanocytes that undergo serial division at below 24°C (n7; 27/82) compared with those grown at over 24°C (n13;
84/168). P0.014, binomial test of comparison of proportions; 95% CI (0.04, 0.30). Datasets include only mitfavc7 time-lapse analyses that were











Mitf activity is required to maintain cell cycle arrest of
differentiated cells in development, Mitf activity may be
regulated during regeneration to permit cell division in
differentiated cells. Additional factors may be involved,
however, because from our initial experiments we do not see an
enhancement of differentiated cell division in mitfavc7-
regenerating melanocytes compared with melanocytes
regenerating after nitrofuran treatment (Fig. 3E-H). For example,
Kit signalling may be important in regulation of differentiated
cell division (Rawls and Johnson, 2003). Our initial experiments
also suggest a reduced number of melanocytes in the embryo is
not sufficient to stimulate cell division in a differentiated cell
(Fig. 6A), although transgenic melanocytes dependent on a
fragment of the mitfa promoter may have less potential to
respond to environmental stimuli than wild-type melanocytes. In
vitro, the potential for both proliferation and differentiation in
melanocytes is illustrated by the MITF4T2B allele that has
increased transcriptional activity of differentiation genes coupled
with reduced expression of the cell cycle inhibitor p21 in vitro
(Cronin et al., 2009). In zebrafish, we find that human
MITF4T2B has increased differentiated cell cycle division
potential compared with wild-type human MITF in zebrafish
(Fig. 6). We speculate that MITF4T2B uncoupling of
differentiation and cell cycle arrest in development may be
relevant to the oncogenesis of MITF4T2B mutant melanoma.
How melanocytes fine-tune Mitf activity in a temporal- and
spatial-specific manner is a complex challenge in melanocyte
biology (Levy and Fisher, 2011), and includes coordination of
extrinsic signals, transcriptional regulation (Levy et al., 2006),
interactions with related transcription factors (Hemesath et al.,
1994), chromatin modifiers (de la Serna et al., 2006; Keenen et al.,
2010; Price et al., 1998; Sato et al., 1997) and direct protein
interactions (Bismuth et al., 2005). Our work illustrates the
importance of fine tuning Mitf activity in melanocytes because
Mitf activity that is sufficient for specification and differentiation
is not sufficient for cell cycle arrest. Unlike in mammals, zebrafish
maintain the potential for extensive regeneration in many tissues
(O’Reilly-Pol and Johnson, 2009; Poss, 2007), and it is possible
that differentiated melanocyte division is specific to zebrafish.
Nonetheless, the molecular machinery that controls melanocyte
development is highly conserved (Kelsh et al., 2009) and suggests
that our observations in zebrafish may be relevant to stem cell and
differentiation-based therapy in melanoma, and in melanocyte
regeneration in vitiligo.
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MITF4T2B; 95% CI; 16.04 (3.65, 28.43). (C)Schematic representation of melanocyte cell lineage analysis (as described in Fig. 5) for four embryos
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